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Complicated urinary tract infections (cUTIs) are a major cause of hospital admissions 
and are associated with significant morbidity and health care costs. Knowledge of 
baseline risk of urinary tract infection can help clinicians make informed diagnostic 
and therapeutic decisions. Prevalence rates of UTI vary by age, gender, race, and 
other predisposing risk factors. In this regard, this book provides comprehensive 
information on etiology, epidemiology, immunology, pathology, pathogenic mechanisms, 
symptomatology, investigation and management of urinary tract infection. Chapters 
cover common problems in urinary tract infection and put emphasis on the importance 
of making a correct clinical decision and choosing the appropriate therapeutic approach. 
Topics are organized to address all of the major complicated conditions frequently seen in 
urinary tract infection. The authors have paid particular attention to urological problems 
like the outcome of patients with vesicoureteric reflux, the factors affecting renal 
scarring, obstructive uropathy, voiding dysfunction and catheter associated problems. 
This book will be indispensable for all professionals involved in the medical care of 
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Preface 
Complicated urinary tract infections (cUTIs) are a major cause of hospital admissions 
and are associated with significant morbidity and health care costs. Knowledge of 
baseline risk of urinary tract infection can help clinicians to make informed diagnostic 
and therapeutic decisions. Prevalence rates of UTI vary by age, gender, race, and other 
predisposing risk factors. In this regard, this book provides comprehensive infor-
mation on etiology, epidemiology, immunology, pathology, pathogenic mechanisms, 
symptomatology, investigation and management of urinary tract infection. The chap-
ters cover common problems in urinary tract infection and put emphasis on making 
the correct clinical decision and choosing the appropriate therapeutic approach. 
Topics of Chapters are organized to address all of the major complicated conditions
frequently seen in urinary tract infection. The authors have paid particular attention to
urological problem like the outcome of patients with vesicoureteric reflux, the factors 
affecting renal scarring, obstructive uropathy, voiding dysfunction and catheter asso-
ciated problems.  
This book will be indispensable for all professionals involved in the medical care of
patients with urinary tract infection. 
My sincere thanks to all expert contributors from different countries because of the
recommended therapeutic approachs which will be gauged at an international stand-
ard applicable to most regional referral centers. 
Ahmad Ali Nikibakhsh
Health Science Center Motahari Hospital 
Pediatric Department Urmia, 
IRAN
Preface 
Complicated urinary tract infections (cUTIs) are a major cause of hospital admissions 
and are associated with significant morbidity and health care costs. Knowledge of 
baseline risk of urinary tract infection can help clinicians to make informed diagnostic 
and therapeutic decisions. Prevalence rates of UTI vary by age, gender, race, and other 
predisposing risk factors. In this regard, this book provides comprehensive infor-
mation on etiology, epidemiology, immunology, pathology, pathogenic mechanisms, 
symptomatology, investigation and management of urinary tract infection. The chap-
ters cover common problems in urinary tract infection and put emphasis on making 
the correct clinical decision and choosing the appropriate therapeutic approach.  
Topics of Chapters are organized to address all of the major complicated conditions 
frequently seen in urinary tract infection. The authors have paid particular attention to 
urological problem like the outcome of patients with vesicoureteric reflux, the factors 
affecting renal scarring, obstructive uropathy, voiding dysfunction and catheter asso-
ciated problems.  
This book will be indispensable for all professionals involved in the medical care of 
patients with urinary tract infection. 
My sincere thanks to all expert contributors from different countries because of the 
recommended therapeutic approachs which will be gauged at an international stand-
ard applicable to most regional referral centers. 
Ahmad Ali Nikibakhsh 
Health Science Center Motahari Hospital 
Pediatric Department Urmia, 
IRAN 
Part 1 
Epidemiology of Urinary Tract Infection 
Part 1 
Epidemiology of Urinary Tract Infection 
 1 
Epidemiology and Control of Urinary Tract 
Infections in Intensive Care Patients 
Antonella Agodi and Martina Barchitta 
Department GF Ingrassia,  
University of Catania 
Italy 
1. Introduction 
Healthcare-associated infections (HAIs) are one of the most common complications in 
hospitalized patients, leading to increased hospitalization, morbidity and mortality and 
associated with additional costs (Geffers and Gastmeier, 2011).  
Urinary tract infection (UTI) is common in hospitalized patients. It has been reported that in 
U.S. hospitals, among adults and children outside of the intensive care units (ICUs), the 
urinary tract is the most common site of HAI, accounting for 36% of infections, followed by 
surgical site infections (20%), bloodstream infections and pneumonia (11%, each) and other 
infection types (all 22%) (Klevens et al., 2007).  
Almost all healthcare-associated UTIs are caused by instrumental urinary tract 
procedures. In fact, the presence of a foreign body in the urinary tract predisposes the 
patient to UTI and alters the body’s ability to eradicate bacteria (Gray et al., 2010). It has 
been estimated that more than 80% of UTIs are associated with an indwelling catheter 
(Anderson et al., 2007) and notably, catheter-associated UTI (CAUTI) has been related 
with such complications that prolonged hospital stay, and increased cost, morbidity and 
mortality (Gould et al., 2009). 
Urologic patients should be considered at high risk for a healthcare-associated UTI, 
because they are usually exposed both to urethral catheterization and instrumentation of 
the urinary tract. In a surveillance study conducted in an urologic clinic of an Italian 
university hospital  the incidence of symptomatic UTIs was 1.4 per 1000 patient-days 
(Agodi et al., 2007).  
1.1 Epidemiology of UTI in intensive care units 
Since of intrinsic (such as, severity of illness or impaired immunity) and extrinsic (such as, 
devise exposure: mechanical ventilation, urinary and central line catheterization) risk 
factors, patients admitted in ICUs are at high risk of HAIs (Lambert et al., 2011). 
Particularly, in Europe, the Annual Epidemiological Report on Communicable Diseases in Europe 
of the European Centre for Disease Prevention and Control (ECDC, 2009), show that 3% of 
patients staying more than two days in ICUs, acquire bloodstream infections, and 6.2% of 
patients acquire pneumonia. 
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UTI is one of the most common infection in ICU. The mean incidence density of UTI in 
patients admitted in European ICUs is 5.4 UTI episodes per 1000 patient-days. The majority 
of UTI (96.2%) are associated with the use of a urinary catheter (HELICS, 2005), that is the 
most important risk factor for development of UTI (Meddings et al., 2010). It has been 
reported that about 15% - 25% of patients may be exposed to short-term indwelling urinary 
catheters (Warren JW, 2001) and in several cases, catheters are placed for inappropriate 
indications.   Urinary catheters are used frequently in ICUs for correct monitoring of urinary 
output, but, once inserted, catheters tend to remain in place until appropriate indications for 
their use end and thus CAUTI incidence increases as the duration of catheter use increases. 
Use of urinary catheters in the ICU causes breaches in the mucosa or may provide a surface 
for colonization, thus, increasing the incidence of CAUTI. The risk for infection is at least 5% 
per day of catheterization (Tissot et al., 2001; Elpern et al., 2009).   
Other factors have been reported as potential risk factors for CAUTI including constitutional 
factors such as female gender, pregnancy and older age and potential modifiable factors 
such as poor nutrition, fecal incontinence, use of systemic antibiotics, severity of illness, 
impaired immune system function, and elevated creatinine level (Gray, 2010).  
A recent multicenter study was conducted in a cohort of patients from 10 countries 
(Argentina, Brazil, Colombia, Greece, India, Lebanon, Mexico, Morocco, Peru, and Turkey) 
to estimate the excess length of stay (LOS) and mortality in ICU due to CAUTI. Results 
show that CAUTI lead to a small increase LOS in ICU, particularly, prolonging length of 
ICU stay by an average of 1.59 days, but CAUTI increase the risk of death by 15% (Rosenthal 
et al., 2011). 
Thus, it is necessary to implement every possible preventive measure that have proven 
useful in the prevention of CAUTI. 
Furthermore, UTIs are often underdiagnosed due the lack of physician requesting 
systematic laboratory tests and urine cultures (Agodi et al., 2007). Diagnosis, particularly in 
the ICU setting, is very difficult, as asymptomatic bacteriuria may be hard to be 
differentiated from symptomatic UTI (Shuman and Chenoweth, 2010).  
The National Healthcare Safety Network (NHSN) is a system for the surveillance of HAI 
that aggregates data of surveillance, reported by hospitals participating in the network, into 
a single national database (Edwards et al., 2007). In the framework of the “Patient Safety 
component” of the NHSN, data are collected using standardized methods and definitions 
and are grouped into specific module protocols. Particularly, in the device-associated 
module infection control professionals collect data on CAUTIs that occur in patients staying 
in a patient care location such as an ICU, specialty care area, or ward. Indicators are 
calculated in terms of urinary catheter associated infection rate and urinary catheter 
utilization ratio (Table 1).  
 
Indicator  
Urinary catheter associated 
infection rate  
Number of urinary catheter-associated UTI  x 1000 
Number of urinary catheter-days  
Urinary catheter utilization 
ratio 
Number of urinary catheter-days 
Number of patient-days 
Table 1. Calculation of urinary catheter-associated infection rate and urinary catheter 
utilization ratio. 
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The NHSN reports that in 2006 pooled mean urinary catheter utilization ratios in ICU and 
non-ICU wards ranged from 0.23 in inpatient medical/surgical ward to 0.91 in trauma ICU. 
The pooled mean of CAUTI rates ranged from 3.1 infections per 1000 catheter-days in 
medical/surgical ICU to 7.5 infections per 1000 catheter-days in burn ICUs.  
In Europe, the German National Reference Centre for surveillance of nosocomial infections 
was started in 1997 creating a nationwide surveillance system: the Krankenhaus Infektions 
Surveillance System (KISS) (Gastmeier et al., 2008). The surveillance methods of the 
National Nosocomial Infections Surveillance (NNIS) System (Garner et al. 1988; Emori et al., 
1991) were used and for diagnosing HAIs the definitions of the CDC were adopted. 
Surveillance data obtained from January 2005 to December 2009 in German ICUs, report an 
urinary catheter utilization ratio of 0.81 and a CAUTI rate of 1.97 per 1000 device-days 
(Geffers and Gastmeier, 2011).  
1.2 Case definitions of UTI  
Major challenges in appraising the quality of evidence in the CAUTI literature are 
represented by the limitations due to heterogeneity of definitions of UTI used in various 
published studies. Researchers have often used numerous different definitions for UTI, 
ranging from simple bacteriuria to symptomatic infection defined by combinations of 
bacteriuria and various signs and symptoms. Furthermore, the heterogeneity of definitions 
may reduce the quality of evidence for a given intervention and often precludes meta-
analyses (Gould et al., 2009). 
Case definition of UTI proposed by the Hospitals in Europe Link for Infection Control 
through Surveillance (HELICS) system is reported in Table 2 (HELICS-ICU, 2004). 
Particularly, in the HELICS protocol three different types of UTIs are identified and 
defined: microbiologically confirmed symptomatic UTI (UTI-A), not microbiologically 
confirmed symptomatic UTI (UTI-B) and asymptomatic bacteriuria (UTI-C) (HELICS-ICU, 
2004). Of note is that UTIs may be added or not, optionally, in the HELICS protocol 
surveillance.  
The case definitions of UTI by the HELICS are similar to the case definition by the Centers 
for Disease Control and Prevention/National Healthcare Safety Network (CDC/NHSN) 
(NHSN Manual; Horan et al., 2008), where CAUTIs are classified into two groups with 
specific sets of criteria for each: symptomatic urinary tract infections (SUTI) and 
asymptomatic bacteriuria (ASB). The only difference is that, in the HELICS, asymptomatic 
bacteriuria is defined as the subcategory UTI-C, and not as a separate category. Otherwise, 
the subcategories UTI-A and UTI-B are the same as respectively criterion 1 and 2 of the 
CDC/NHSN definition of symptomatic urinary tract infection. NHSN in January 2009 has 
revised the UTI definition criteria. Among the changes are removal of the ASB criterion and 
refinement of the criteria for defining symptomatic SUTI. The time period for follow-up 
surveillance after catheter removal also has been shortened from 7 days to 48 hours to align 
with other device-associated infections (NHSN Manual).  
1.3 Pathogenesis of UTIs 
Microorganisms causing CAUTI can be acquired by an endogenous source (such as, via 
meatal, rectal, or vaginal colonization) or an exogenous one (such as, via contaminated 
hands of healthcare personnel or devices).     
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Patient has no fever (>38°C), urgency, frequency, dysuria, or 
suprapubic tenderness 
and either of the following criteria: 
1. Patient has had an indwelling urinary catheter within 7 
days before urine is cultured  
and 
Patient has a urine culture, that is,  ≥105 microorganisms per 
ml of urine with no more than two species of microorganisms.  
2. Patient has not had an indwelling urinary catheter within 
7 days before the first positive culture 
and 
Patient has had at least two positive urine cultures ≥105 
microorganisms per mm3 of urine with repeated isolation of 
the same microorganism and no more than two species of 
microorganisms 
Table 2. Case definition of Urinary Tract Infection (HELICS-ICU, 2004). 
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The NHSN reported that between 2006-2007, the most frequent pathogens associated with 
CAUTI were Escherichia coli (21.4%) and Candida spp. (21.0%), followed by Enterococcus spp. 
(14.9%), Pseudomonas aeruginosa (10.0%), Klebsiella pneumoniae (7.7%), and Enterobacter spp. 
(4.1%). A smaller proportion of CAUTI was caused by other gram-negative bacteria or by 
Staphylococcus spp. (Hidron et al., 2008).  
Finally, it is important to underline that bacteriuria associated to CAUTI commonly leads to 
antimicrobial use, that would have been avoidable, as well as to urinary drainage systems 
that are often reservoirs for multidrug-resistant bacteria and a potential source of 
transmission to other patients (Gould et al., 2009). 
As reported in the Annual Epidemiological Report on Communicable Diseases in Europe (ECDC, 
2010), the antimicrobial resistance of microorganisms is to be considered the most important 
disease threat. In 2008 a Europe-wide increase of resistance to all antibiotic classes under 
surveillance was observed for the most common Gram-negative bacteria – E. coli - 
responsible for bacteraemia and UTIs.  
1.4 Prevention of CAUTI 
CAUTIs are generally considered an avoidable complication. It has been estimated that 
between 17% and 69% of all observed CAUTIs may be prevented by implementation of an 
evidence based prevention program that is particularly important in the ICU setting with a 
high prevalence of urinary catheterization and a high percentage of patients with 
comorbidities (Gould et al., 2009).  
The CDC/Healthcare Infection Control Practices Advisory Committee (HICPAC) published 
a specific document - Guideline for Prevention of Catheter-associated Urinary Tract Infections – 
that addresses the prevention of CAUTI for patients with short- or long-term urinary 
catheterization admitted in any type of healthcare facility and evaluates the evidence for 
several options of methods of urinary drainage, including intermittent catheterization, 
external catheters, and suprapubic catheters (Gould et al., 2009). The guideline is based on a 
specific systematic review of the best available evidence on CAUTI prevention; it uses the 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
approach (Atkins et al., 2004; Guyatt et al., 2008a; Guyatt et al. 2008b) in order  to provide 
clear links between the available evidence and the resulting recommendations. 
Particularly, in this document, recommendations include: i) appropriate urinary catheter 
use; ii) proper techniques for urinary catheter insertion; iii) proper techniques for urinary 
catheter maintenance; iv) quality improvement programs; v) administrative infrastructure; 
and vi) surveillance.  
As suggested by the Authors of this guideline further research in order to prevent CAUTIs 
should focuse on catheter materials (antimicrobial and antiseptic-impregnated catheters and 
standard catheters), appropriate urinary catheter use (in incontinent patients and 
appropriate indications for continued use in postoperative patients), use of antiseptics (for 
periurethral cleaning prior to catheter insertion and  to prevent CAUTI), alternatives to 
indwelling urethral catheters and bag drainage (suprapubic catheters, urethral catheters, use 
of catheter valves and other alternative methods of urinary drainage), optimal methods for 
preventing encrustation in long-term catheterized patients, other prevention measures and 
prevention of transmission of pathogens colonizing urinary drainage systems.  
A specific recommendation for the appropriate urinary catheter use (category IB) is: 
“Minimize urinary catheter use and duration of use in all patients, particularly those at 
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higher risk for CAUTI or  mortality from catheterization such as women, the elderly, and 
patients with impaired immunity” (Gould et al., 2009). 
In this contest, a recent study (Elpern et al., 2009) has been conducted in a medical ICU in 
order to implement and evaluate the efficacy of an intervention, based on the decreasing use 
of urinary catheters, to reduce CAUTI. Results of this study report that the implementation 
of an intervention targeting the appropriate use of indwelling urinary catheters may result 
in a significant reduction in the duration of catheterization as well as in the occurrences of 
CAUTIs. 
A systematic literature review and meta-analysis was performed to evaluate the effect of 
interventions that remind clinicians of the presence of urinary catheters to prompt the 
timely removal of catheters during hospitalization. Results of the meta-analysis report that 
the rate of CAUTI was significantly reduced by 52% with the use of a reminder or stop 
order. Furthermore, the mean duration of catheterization decreased by 37%. Thus, 
interventions to routinely prompt physicians or nurses to remove unnecessary urinary 
catheters appear to reduce the rate of CAUTI and should be strongly considered to enhance 
the safety of hospitalized patients (Medding et al., 2010). 
The Institute for Health Care Improvement (IHI) developed the model of “bundles” to help 
health care workers more consistently deliver the best possible care for patients undergoing 
particular treatments (Institute for Health Care Improvement, 2006). “A bundle is a 
structured way of improving the processes of care and patient outcomes: a small, 
straightforward set of evidence-based practices — generally three to five — that, when 
performed collectively and reliably, have been proven to improve patient outcomes” (Resar 
et al., 2005).  
A recent observational study (Venkatram et al., 2010) was conducted in order to study the 
effect of bundle strategies on the device use adjusted rate of HAI in adult medical ICU, to 
prevent HAIs associated with endovascular catheters, mechanical ventilation, and urinary 
tract catheters. Particularly, the UTI bundle regards the use of antimicrobial catheters, closed 
drainage systems, and daily assessment for removal. During the study period, HAIs 
declined from 47 in 2004 to 3 in 2007. Particularly, CAUTI decreased from 6.23 to 0.63 per 
1000 device-days. However, the decline in infection rates cannot be accounted by the decline 
in device use by itself, in fact, when adjusted to device use, the decrease in HAI rates still 
showed statistical significance. Therefore, it is not easy to attribute this decline to any one 
component of the bundle. Results of this study demonstrate that best practices using a 
multidisciplinary bundle strategy including device use can lead to optimal outcomes with 
respect to HCAI rates. 
2. Surveillance of urinary tract infections in ICUs 
Epidemiologic surveillance of HAI in ICUs is an important tool of internal quality 
management in the hospital setting (Zuschneid et al., 2010), and together with appropriate 
infection control activities, can decrease infection rates significantly (Haley et al., 1985).  
A specific recommendation, of category II, included in the CDC/HICPAC Guideline for 
Prevention of Catheter-associated Urinary Tract Infections is: “Consider surveillance for CAUTI 
when indicated by facility-based risk assessment”. Particularly, it is recommended to 
identify the patient groups or units on which to conduct surveillance based on frequency of 
catheter use and potential risk of CAUTI and to use standardized methodology for 
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performing CAUTI surveillance (Category IB). Furthermore, providing regular feedback of 
CAUTI rates to the staff  should be also considered (Gould et al., 2009). 
In order to explore the epidemiologic scenario and control of UTIs in intensive care patients, 
surveillance of HAI was performed on three Sicilian ICUs participating in the first two 
edition of the SPIN-UTI (Sorveglianza Prospettica delle Infezioni Nosocomiali nelle Unità di 
Terapia Intensiva) project.  
2.1 Methods of surveillance 
The Italian Nosocomial Infections Surveillance in ICUs, SPIN-UTI project, established in 
Italy by the Italian Study Group of Hospital Hygiene (GISIO) of the Italian Society of 
Hygiene, Preventive Medicine and Public Health (SItI) (Agodi et al., 2010), started the first 
edition in 2006 - 2007, the second edition of the project was implemented in 2008 – 2009, and 
the third, in 2010 – 2011 is in progress.  
The methodology of surveillance are describes in great details elsewhere (Agodi et al., 2010) 
and is based on the HELICS-ICU protocol, in order to participate in the European 
benchmark (HELICS-ICU, 2004; Suetens et al., 2007). The enrollment of patients was 
prospective, and data regarding ICU stay, patient’s risk factors including exposure to 
invasive devices (such as intubation, central venous catheter and urinary catheter), were 
collected using a web-based data collection procedure for each patient staying longer than 
two days in the ICU (Figure 1).  
The definitions of HAI used in the SPIN-UTI project are the same proposed by the HELICS-
ICU protocol for pneumonia, bloodstream infections (BSIs), central venous catheter-related 
bloodstream infections (CRIs) and UTIs (HELICS-ICU, 2004; Suetens et al., 2007). UTI data 
collection was mandatory. 
The indicators included cumulative incidence and, to adjust for length of stay, incidence 
density. Furthermore, device-associated infection rates and device utilization ratios were 
also calculated as the number of infections per 1000 device-days and the number of days 
with the device divided for the number of patient-days.  
2.2 Web-based data collection and statistical analysis 
Surveillance data collection was performed from all patients enrolled in the project using four 
electronic data forms – designed using SPSS "Data Entry Enterprise Server" - as instruments 
for data collection. Particularly, the following data forms were used: 1) ‘Characteristics of 
hospital and of ICU’, 2) ‘Patient’, 3) ‘Infection’ and 4) ‘Microorganism’ (Figure 1). The 
electronic forms were characterized by functional instruments. Using these electronic forms 
data are entered via Web and each record is sent to the server, where it is automatically routed 
to the appropriate database. Cleaning and analyses were performed using SPSS for Windows 
(version 14.0): univariate analyses and the above reported indicators were calculated. 
Furthermore, categorical variables were compared using the chi-square-test, and continuous 
variables by Student’s t-test; p < 0.05  was considered statistical significant. 
3. Results of surveillance 
3.1 ICU setting 
The study was conducted at three Sicilian ICUs participating in the first two edition of the 
SPIN-UTI Project. The ICU identified as ICU 1 is a 12-bed interdisciplinary ICU, from a 700-
bed acute care hospital; the ICU identified as ICU 2 is a 7-bed interdisciplinary ICU, from a 
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830-bed tertiary care hospital; the ICU identified as ICU 3 is a 6-bed interdisciplinary ICU, 
from a 200-bed tertiary care hospital. 
3.2 Patient’s characteristics and device usage 
A total of 501 patients with length of stay >2 days, for a total of 9681 patient-days, were 
admitted in the three ICUs during the two edition of the SPIN-UTI project and thus were 
enrolled in the study. A summary of patient characteristics and urinary catheter use is 
shown in Table 3.  
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Table 3. Main characteristics of patients included in the study. 
Particularly, in the first edition of the project a total of 280 patients for a total of 3611 patient-
days and a total of 221 patients for a total of 3669 patient-days in the second edition, were 
admitted. During the two edition of the project, a significant reduction of the proportion of 
patients with urinary catheter was observed (chi-square test, p <0.05). Particularly, in the 
first edition the overall proportion of patients with urinary catheter was 96.4% (range: 93.2% 
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- 99.0%) and in the second edition was 77.4% (range: 72.0 – 82.4%). Furthermore, in the first 
edition the total length of urinary catheterization was 3257 days (mean: 12.2 days; range: 1-
79) and increased significantly (comparison between means, Student’s t test, p <0.05), in the 
second edition where was 3575 days (mean 16.4 days; range: 3-106 days).   
Considering all three ICUs, an increase of urinary catheter utilization ratio, from 0.90 to 0.97, 
was observed in the second edition of the project. 
3.3 Infection’s indicators 
Table 4 reports infection’s indicators. Considering all ICUs, in the first edition of the SPIN-
UTI project, the most frequently reported ICU-acquired infection type was pneumonia 
(38.2%) followed by bloodstream infections (30.9%), urinary tract infections (20.9%) and 
central venous catheter-related bloodstream infections (10.0%). In the second edition, the 
most frequently reported ICU-acquired infection type was bloodstream infections (43.7%) 
followed by urinary tract infections (29.1%), pneumonia (23.2%) and central venous 
catheter-related bloodstream infections (4.0%). Thus, in the last edition of the SPIN-UTI 
project an increase of the proportion of infections due to bloodstream infections and to 
urinary tract infections were registered, both considering all ICUs and each ICU separately. 
Instead, a decrease of the proportion of infections due to pneumonia infections and to 
central venous catheter-related bloodstream infections were registered, both considering all 
ICUs and each ICU separately. 
The risk of ICU-acquired infections for all sites was estimated by computing the cumulative 
incidence: 39.3 per 100 patients in the first edition and 68.3 per 100 patients in the second 
one; and the incidence density: 30.5 per 1000 patient-days in the first edition and 41.2 per 
1000 patient-days in the second one. Particularly, the cumulative incidence and the 
incidence density of UTI were increased in the second edition compared with the first one 
(Table 4). 
Notably, in the two edition of the project, all UTIs were related to the presence of urinary 
catheter.  
Urinary catheter-associated UTI rates (i.e. the number of urinary catheter-associated UTI per 
1000 urinary catheter-days) was 7.1 per 1000 urinary catheter-days in the first edition and 
12.3 per 1000 urinary catheter-days in the second edition.  
3.4 Microorganisms associated to HAI 
Considering all infection sites, relative frequencies of the five most common isolated 
microorganisms in ICU-acquired infections are reported in Table 5. 
Despite difference among ICUs (data not shown), in the first edition of the SPIN-UTI project, 
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1st microorganism (n; %) P. aeruginosa (21; 18.1) A. baumannii (36; 20.3) 
2nd microorganism (n; %) A. baumannii (18; 15.5) K. pneumoniae (28; 15.8) 
3rd microorganism (n; %) S. epidermidis (17; 14.7) P. aeruginosa (22; 12.4) 
4th microorganism (n; %) K. pneumoniae (9; 7.8) S. epidermidis (12; 6.8) 
5th microorganism (n; %) E. coli (8; 6.9) E. coli (8; 4.5) 
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A. baumannii and C. glabrata 





Table 6. Relative frequencies of the isolated microorganisms in UTIs. 
4. Discussion 
In several high-income countries, device-associated HAI surveillance in the ICU plays a 
considerable role in hospital infection control and quality assurance (Edwards et al., 2009).  
A recent study was performed in the framework of the German KISS with the aim of 
investigating whether surveillance of CAUTI in ICUs leads to reduced infection rates. When 
comparing the symptomatic CAUTI rates in the third and first years of the surveillance, a 
significant reduction in CAUTI was shown. However, before-and-after studies are limited 
by confounding variables such as the difficulties of ICU patients in recognizing and 
reporting UTI symptoms, that leads to the availability of microbiological reports as a major 
criterion for diagnosing symptomatic UTI. Thus, in the case of CAUTI diagnosis, 
microbiological reports may have decreased over time and  have influenced reduction of 
CAUTI rates (Gastmeier et al., 2011).  
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In the same study, it has been reported that the overall surveillance effect was highest for 
ventilator-associated pneumonia and central venous catheter bloodstream infection. This 
could be explained by the perception of the clinicians that ventilator-associated pneumonia 
and central venous catheter bloodstream infection are more serious infections demanding 
more effective responses rather than CAUTI. However, CAUTI may also lead to sepsis, and 
changes in CAUTI rate over time, with consistent microbiology diagnostic procedures, may 
lead to the introduction of appropriate infection control measures (Gastmeier et al., 2011). 
The SPIN-UTI project was implemented to create a HAI surveillance network of Italian ICUs 
(Agodi et al., 2010). The validation study of the SPIN-UTI project has showed a high 
sensitivity, specificity, and positive and negative predictive values of surveillance data 
(Masia et al., 2010). 
Comparison of results of the two editions of the SPIN-UTI project revealed that, the risk of 
ICU-acquired infections for all sites, estimated by computing the cumulative incidence and 
the incidence density, increased in the second edition compared to the first one.  
Differences were presented considering infection by site. In the second edition of the project 
a decrease of the proportion of infections due to pneumonia and to CRIs were registered. On 
the contrary, an increase of the proportion of infections due to BSIs and to UTIs were 
observed, either considering all ICUs or each ICU separately. Particularly, after comparing 
results of the two studies, in the second edition a higher proportion of the patients acquired 
a UTI in ICU than in the first edition. The cumulative incidence of UTI increased from 8.2 
per 100 patients to 19.9 per 100 patients. The incidence density also increased from 6.4 per 
1000 patient-days to 12.0 per 1000 patient-days. 
Hospital wide prevalence rates for indwelling catheterization vary from 25% to 35% (Haley 
et al., 1981; Junkin & Selekof, 2007). Prevalence rates in ICU are substantially higher at 67% 
to 76% (Huang et al., 2004; Gray, 2010). In our study, a high proportion of patients were 
with urinary catheter (range: 72.0%- 99.0%), and although a significant reduction of the 
proportion of exposed patients was observed in the second edition of the project an increase 
of the mean length of urinary catheterization from 12.2 days to 16.4 days was observed. 
Furthermore, urinary catheter utilization ratio was significantly higher in the second edition 
compared with the first edition (from 0.90 to 0.97).   
Notably, in the two edition of the project, all UTIs were related to the presence of urinary 
catheter. Urinary catheter-associated UTI rates increased from 7.1 per 1000 urinary catheter 
days in the first edition and 12.3 per 1000 urinary catheter days in the second edition.  
It is advised that device-associated infection rates and device utilization ratios should be 
examined together so that preventive measures may be appropriately targeted. Since 
urinary catheter use is a significant risk factor for UTI, efforts must be redirected to reducing 
their use or limiting the duration with which they are used and to addressing the best 
consensus guidelines and recommendations in their insertion and maintenance (Edwards et 
al., 2007). In fact, it has been reported that targeted strategies for prevention of UTI include 
limiting the use and duration of urinary catheterization, using aseptic technique for catheter 
insertion, and adhering to proper catheter care (Shuman and Chenoweth, 2010).  
The most frequently isolated microorganisms causing CAUTI in the ICU setting are enteric 
Gram-negative bacilli, enterococci, Candida species, and P. aeruginosa (Shuman and 
Chenoweth, 2010). Microorganisms are often multidrug resistant probably following the 
increasing use of broad-spectrum antibiotics in hospitals and this is a considerable problem 
in ICU.  
In our surveillance survey, despite difference among ICUs, in the first edition of the project, 
the most frequently reported microorganism associated to UTI was P. aeruginosa, in the 
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second one, K. pneumoniae (22.2%) was the first species isolated. Notably, in the second 
edition an increase of K. pneumoniae isolation and a decrease of P. aeruginosa isolation were 
observed.    
5. Conclusion 
Our study represents a contribution to improve the quality of care in the ICU setting. A 
major item was identified for planning future intervention: focusing on the appropriate 
urinary catheter use. HAIs can be prevented by constant use of “bundles” of simple and 
effective measures, including the monitoring of device use, recommended by CDC and IHI 
(Institute for Health Care Improvement, 2006; Gould et al., 2009). To improve patient safety, 
an integrated, multimodal and comprehensive “bundles” approach is the means to reducing 
the impact of HAI. 
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1. Introduction 
The first beta- lactamases were identified in a species of E.coli in 1940 (1). However, the 
ability of bacteria to produce enzymes that destroy the b-lactam ring was noted even before 
penicillin was developed. In fact, many of the gram-negative bacteria possess 
chromosomally mediated b- lactamases, which help the bacteria find a niche when faced 
with competition from other bacteria that naturally produce b-lactams. 
In 1965, the first plasmid mediated beta- lactamases was discovered. This occurred in a 
strain of E.coli isolated from the blood culture of a patient from Greece whose name was 
Temoniera.  The beta -lactamases was named TEM-1 after the patient’s name from whom it 
was isolated. (2) This strain soon spread to other members of the Enterobacteriaceae species, 
Hemophilus influenza, Neisseria gonorrhoeae and Pseudomonas aeruginosa due to the plasmid 
mediated transfer. 
Around the same time a second plasmid mediated beta-lactamases was found in Klebsiella 
pneumonaie and E.coli. This was called SHV-1 (sulfhydryl variable) (3).  The advent of the b- 
lactam class of antibiotics was influenced largely by the discovery of these enzymes. An 
example of this was the development of oxyimino-cephalosporin, which showed good 
stability against the TEM-1 and SHV-1 b-lactamases (4). This class of antibiotics soon became 
the workhorse for these types of serious infections.  
Unfortunately, resistance to this class soon became evident in 1985 with beta-lactamases 
showing the ability to hydrolyze these compounds in K.pneumoniae  (5). Because this enzyme 
was noted to be active against expanded spectrum b-lactams these enzymes were labeled as 
“extended spectrum beta-lactamases” –ESBL. 
Several b-lactamases have continued to be with over 130 TEMS types and over 50 SHV types 
known to date. These are mainly found in E.coli, K.pneumoniae and P.mirabilis, but have also 
been found in other species of the Enterobacteriacae family and even in some nonenteric 
bacteria such as Acinetobacter species. 
Shortly after the introduction of new broad-spectrum cephalosporins such as cefotaxime 
and ceftazidime, non-TEM and non SHV ESBL’s were discovered. This new class of ESBL’s 
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has been called CTX-M in reference to the potent hydrolytic activity of these enzymes 
against cefotaxime(6). There are over 40 of these enzymes reported.  CTX-M producing 
ESBL pathogens usually have cefotaxime in the resistant range (MIC>64).   
More recently, and of greater concern is the occurrence of carbapenemases which show 
activity against oxyimino-cephalosporins and cephamycins but also against carbapenems 
(7). There are two major groups in this class called metallo-b-lactamases (Verona integron 
encoded metallo b lactamases) (VIM) and carbapenemases. Structural studies of ESBL 
indicate that active site expansion and remodeling are responsible for the extended 
hydrolytic activity (8).These enzymes are globally present and appear to cause clinically 
significant disease such as urinary tract infections, abscesses and bacteremia.  
With the advent of the ESBL pathogens, there has been a significant increase in the 
morbidity and mortality related to these infections. If the number of carbapenemase- 
producing organisms continues to increase, the treatment options will be seriously 
compromised. 
In addition, ESBL producing pathogens are not only resistant to penicillin and 
cephalosporins but also to trimethoprim-sulphamethoxazole and fluroquinolones which can 
compromise the treatment of both nosocomial and community acquired infections caused 
by Enterobacteriaceae and other species (9). 
One of the major clinical problems has been the recognition of both nosocomial and 
community acquired urinary tract infections resulting from ESBL pathogens. The treatment 
options for these infections are limited, especially in the out patient setting.  
This chapter will review the epidemiology, risk factors, clinical features and therapeutics 
options for ESBL-induced infections of the urinary tract. 
2. Recent epidemiological data 
ESBL producing organisms have been implicated in nosocomial infections. Over the last 
decade, there has been a steady increase of these infections in the community.  
In fact, a recent study from Spain suggest there was been an increase in ESBL E.coli 
producers from 0.3% to 4.8% between 1995 and 2002. (10) Interestingly, during this same 
period there was a drop in the rate of ESBL producing K.pneumoniae following the control of 
nosocomial transmission of this pathogen. These K. pneumoniaie were mostly clonally related 
and produced SHV and TEM.  
In contrast, the ESBL E.coli strains were not clonally related and the predominant strain was 
a CTX-M. In addition, half of these strains were isolated from outpatients (10,11). 
France was one of the first countries to report an outbreak of ESBL infections in 1986. In this 
study, 30% of Enterobacter aerogenes isolates in 2000 were ESBL producers (12). Since that 
time, virtually every country in Europe has reported ESBL producers with considerable 
geographical variability in the occurrence of ESBL’s. Examples of this include a prevalence 
rate of ESBLs  
K. pneumoniaie in Sweden of 3% to 34% in Portugal (13). In one study done in France, it was 
noted that intestinal carriage prevalence of ESBL-E.coli was 8.0%, mainly the CTX-M type. 
At the same time, it was noted that there was an increase in antibiotic usage, especially the 
beta-lactams. This variability probably occurred because of the repeated introduction of new 
strains and plasmids and from inter-individual dissemination (14) 
In Central and South America ESBL, rates in Klebsiella varied from 30 to 60% in countries 
such as Brazil, Columbia and Venezuela (15). The ESBL strains included SHV-2, 5, CTX-M 
and even non-TEM and non-SHV with no geographical predilection. (16, 17) 
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In Africa and the Middle East there has been a number of outbreaks of ESBL producing 
infections from South Africa to northern Africa. The rates of ESBL were variable depending 
on the country (18 19) . 
In North America the first case of an ESBL producer was in 1988and since then a variety of 
infections produced by TEM strains, SHV type and CTM-X have been reported.  In fact, in a 
recent survey it was noted that non-susceptibility to third generation cephalosporin’s may 
be as high as 13 %.( 20,21). In the outpatient, setting 1.8% of k.pneumoniae and 0.4% were 
ceftazidime resistant (22) 
In Asia, there seems to be a larger proportion of ESBL pathogens. Studies from several 
countries, including China, India, Japan, Korea, and Malaysia showed ranges from 30% to 
40 % (23,24). Reports of a possible predominant CTM-X ESBL in countries like India, China 
Korea, Japan and Taiwan indicate that there may be a dominant ESBL type in Asia (25,26). 
More recently, there have been studies showing increasing numbers of carbapenemase 
producing pathogens, which is of increasing clinical importance due to the lack of effective 
antimicrobial therapy. (27-31). 
Current data suggest that the incidence of ESBL producing infections is on the rise globally 
resulting in increasing difficulty in the diagnosis and treatment of these infections. 
3. In vitro resistance studies for ESBL 
In- vitro susceptibility testing of cephalosporins for ESBL producing enterobacteriacae can be 
misleading. Testing may suggest that an isolated strain is susceptible to a given 
cephalosporin, but the drug may not be effective when used to treat a serious infection 
caused by the organism. Thus, CLSI guidelines recommend that laboratories report ESBL 
producing isolates as resistant to all penicillin’s, cephalosporins and aztreonam irrespective 
of in vitro results. (32). 
In vitro studies performed in Turkey found that E.coli isolated from CA-UTI infections had 
simultaneous resistance to trimethoprim-sulphamethaxazole, ciprofloxacin, and gentamicin 
in 4.6% of an ESBL negative group and 39.2% in the ESBL positive group. 90% of these ESBL 
isolates were found to have CTX-M 15. (33). This data is worrisome as therapeutic options 
are limited when oral antibiotics are used. 
 In Taiwan, Lau and colleagues looked at 201 patients with and without bacteremia in CA-
ESBL UTI. They found that e.coli was the most common pathogen and was more frequent in 
the bacteremic than non-bacteremic group. Non-E.coli isolates such as K.pneumoniae, 
Morganella morganii etc were more common in the non-bacteremic group. E.coli isolates had 
a high rate of resistance to ampicillin (80%), gentamicin (29%) trimethoprim-
sulphamethaxazole (56%). (34). Similar findings have been documented from other parts of 
the world such as Saudi Arabia  (35). 
Detection of ESBL’s is based on the fact that ESBL producers should be reported as resistant 
to all penicillin’s, cephalosporins (except cephamycins) and aztreonam irrespective of 
routine antimicrobial susceptibility testing. (32) 
Both broth dilution and disk diffusion can be used for the screening of ESBL producers. 
Specific phenotypic confirmatory tests should be done if the E.coli, K.pneumoniae, show 
MIC’s>8ug/ml for cefpodoxime or MIC’s >2 ug/ml against ceftazidime, cefotaxime or 
aztreonam. (36,37) 
The E-test can also be used in the detection of ESBL. Automated methods for bacterial 
identification and susceptibility testing are also used in the detection of ESBL producing 
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organisms. These include the BD Phoenix system, Vitek 2 system and the Micoscan 
Walkway -96 system.   
4. Risk factors for colonization /infection with ESBL 
There have been several case controlled studies looking at the risk factors for colonization 
with or without infection due to ESBL producers. However, the results are conflicting due to 
study populations, geographical areas, selection of cases and controls and sample size. (38-
48). 
Despite these statistical differences, some generalizations can be made. (Table 1) 
 
Diabetes mellitus 
Previous antimicrobial exposure (quinolones, third generation cephalosporins, penicillin) 
Previous hospital admissions 
Older age 
Male patients 
Table 1. Risk factors for the Development of Community ESBL Infections. 
Some of these risk factors include seriously ill patients with prolonged hospital stays (11-67 
days) who have usually had multiple invasive devices and co-morbidities such as urinary 
catheters, central lines, nasogastric tubes, jejunostomy tubes, arterial lines, total parental 
administration, recent surgery, decubitus ulcers, hemodialysis catheters and poor 
nutritional status.   
The use of previous antibiotics such as third generation cephalosporins, quinolones, 
trimethoprim-sulphamethoxazole, aminoglycosides and metronidazole have also been 
implicated in several studies. (38,42,45,49,44,50,47, 48,51).  
5. Community –acquired infections involving ESBL pathogens 
In a large French study in 1993, looking at E.coli, K.pneumoniae and P .mirabilis (2500 isolates) 
from non-hospitalized patients, there was no evidence of community acquired ESBL 
infections (52). Since then, there have been several studies of true community acquired ESBL 
infections. These involved patients with diarrheal diseases such as Shigella, Salmonella, Vibrio 
cholerae and E. coli. (53-56) 
The prevalence of colonization with enterobacteria is unknown.  The percentage of ESBL 
producing Enterobacteria faecal carriers in Spain increased from 2.1% to 7.5% IN 2002. (57) . 
The most frequent types of ESBL were CTX-M, followed by SHV. In India, the rate of fecal 
carriage was 7% in a sample of healthy adults (60). In Canada, Pitout found 5.5 cases per 
100,000 populations with 69% being community acquired. (59) 
Three case controlled studies looking at risk factors for ESBL E.coli outpatient infections 
found that diabetes mellitus, previous use of antibiotics such as quinolones and 
cephalosporins, recurrent urinary tract infections, prior hospital admissions and older age 
were independent risk factors (59,60). However, infections due to ESBL producing E.coli in 
patients can occur without obvious risk factors. This may be related to the increase in 
healthy carriers colonized with this pathogen.  
Colodoner et al evaluated 128  cases of UTI caused by ESBL E.coli and K. pneumoniae and 
found that age >60 years, male sex, previous use of quinolones or cephalosporins, previous 
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hospitalization, and previous infections caused by K. pneumoniae were independent risk 
factors.(61) 
In community- acquired urinary tract infection (CA-UTI), the rate of ESBL associated UTI’s 
varied from 1.4% in Spain up to 3.3% in the Gaza strip (60,62,63). 
In the last 7 years, there have been an increasing number of publications from several 
countries showing and increase of community acquired ESBL infections, mainly in urinary 
tract. (64,65,61,57,30,59,60,31) Most of these patients had urinary tract infections (UTI’s) with 
genes encoding for CTM-X type of ESBL’s (60). Recently, there has been an increase in the 
diagnosis of infections caused by ESBL E.coli producers diagnosed in the outpatient’s 
setting.(59,60,30)  
Romero et al showed an increase from 0.3% in 1995 to 4.8% in 2002 in community acquired 
ESBL E.coli producers. (10). These ESBL E.coli producing strains were not clonally related 
with the majority belonging to the CTX-M family and more than 50% were isolated in the 
outpatient setting. (10, 11) 
In one study in Spain up to 6.5% of community, acquired bacteremia was associated with 
ESBL E.coli UTI (60).  
In summary, ESBL infections can range from colonization to carriage to true infections 
involving sepsis syndromes and bacteremia.  
6. Clinical features of CA-UTI infections caused by ESBL pathogens 
Several studies have described the microbiological features of ESBL producing organisms in 
the outpatient setting. However, very few studies have correlated the microbiological 
findings with that of the clinical features and prognosis of these CA-UTI ESBL infections. 
Therefore, one may only draw some tentative conclusions from these studies.   
In urinary tract infections, the majority of ESBL’s isolated, not surprisingly, have been ESBL 
E.coli. This organism has also been isolated from other sources such as wounds, sputum, and 
occasionally blood. (59,60,11,) 
In the United States, Chao Qi et al evaluated 193 single patient ESBL isolates in outpatient 
urine cultures during a 5-year period. 3% of E.coli had ESBL and this was noted to have 
increased 14 times from 2003 to 2008. This increase may have been in part due to the 
dissemination of CTX-M type of ESBL. (66) This was also noted in another study from 
nursing homes and out patient clinics. (67) . Resistance to ciprofloxacin and trimethoprim-
sulphamethaxazole was much higher as well. 
In another study of 49 patients with ESBL E.coli infections, ESBL E.coli was isolated from 
urine in 47 of the cases and from blood in 6 of the patients. Thirty-seven (76%) of these 
patients were considered to have symptomatic infections and 11 (22%) asymptomatic 
bactiuria. 1 patient also had cholangitis and 6 (13.5%) of these patients were bacteremic. In 
this same study, 10 of the 28 patients who received antibiotics actually received an 
appropriate agent to which the organism was susceptible in vitro. 13% of these patients had 
a UTI relapse. There were no deaths in this study (60). It appears that the complication rate 
with CA-ESBL UTI’s may not be higher than that associated with routine non-ESBL 
pathogens, although further studies are still needed. The main predictor of mortality caused 
by ESBL E.coli is probably inadequate initial antimicrobial therapy. In comparison, ESBL-EC 
associated mortality for hospitalized patients with serous infections such as bacteremia and 
sepsis was about 25%-31%. This was also associated with inadequate empiric antibiotic 
therapy. (68,69). 
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The most frequent cause of community-acquired bacteremia is E.coli (70,71) and currently 
available antibiotics such as quinolones, beta-lactams and third generation cephalosporins 
are commonly used to treat them. This may need to change with the advent of increasing 
antimicrobial resistance and increasing mortality associated with these CA-ESBL infections 
(44,59). Rodriguez-Bano examined CA-ESBL associated bacteremia and its features and 
found that in 95 patients with blood stream infections 7.3% were due to E.coli. The majority 
belonged to the CTX-M family of ESBL and was clonally unrelated. The risk factors 
associated with these patients included urinary foley catheter use and previous 
antimicrobial exposure (60). The sources of bacteremia were the urinary tract, intra-
abdominal sites and respiratory tract. Interestingly, mortality associated with blood stream 
infections due to ESBL-E.coli was lower among patients who received empirical therapy 
with beta-lactam or it combinations or carbapenems than among those that received 
quinolones. In addition, higher mortality was associated with inappropriate empirical 
therapy in patients with bacteremia due to E.coli. (72) 
In patients with solid organ transplants and renal transplants, the major site of infection was 
the urinary tract in 72% of the cases, with ESBL .K. pneumoniae being more common in renal 
transplant patients ( 73). 
Geriatric patients with ESBL UTI’s pose an unusual clinical problem. These patients may be 
chronically colonized in either the gastrointestinal tract or the skin and reinfection is a 
possibility. In addition, many of these patients are asymptomatic and do not present with 
the classic symptoms of dysuria, frequency of urination, fever or leukocytosis. In general, 
one may not need to treat asymptomatic ESBL infections. If there is a change in the clinical 
status such as fever, leukocytosis or altered mental status then treatment options should be 
considered. Numerous outbreaks have been reported of patients with ESBL infections. 
Much of the spread is plasmid mediated and is therefore through direct and indirect 
transmission. Contact isolation should be instituted in patients with ESBL infections. 
In summary, ESBL infections can present from simple colonization to active UTI’s and to 
serious bacteremia associated with sepsis syndrome.  
7. Treatment options for ESBL UTI infections 
Treatment options for ESBL infections are the same for both nosocomial and community 
acquired infections. The major problem at this time is the lack of effective oral antibiotics for 
the treatment of outpatient ESBL infections.  
7.1 Overview of available antibiotics 
ESBL’s hydrolyze aztreonam, penicillin and cephalosporins (with the exception of 
cephamycins) with varying degrees of hydrolytic activity. Usually the TEM and SHV type 
ESBL’s have greater hydrolytic activity for ceftazidime than for cefotaxime (74). Therefore, 
ESBL producing organisms may appear susceptible to some of the above-mentioned 
antibiotics in vitro. In addition, there is frequent co –expression of resistance by these 
organisms to classes of antimicrobial agents other than those hydrolyzed by the ESBL’s. This 
has been documented for quinolones, aminoglycosides, tetracycline’s (excluding 
glycylcycline) and trimethoprim-sulphamethoxazole (59) 
Some of the other antibiotic classes used to treat  ESBL infections include beta lactam/beta-
lactamases inhibitors. The level of activity for these agents varies by the type of inhibitor 
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and by the class of ESBL. For example, tazobactam appears to be more effective than 
clavulanic acid against certain types of CTX-M type ESBL’s and both of these agents are 
more effective than sulbactam in inhibiting TEM and SHV type ESBL. (75,76). This data is 
mainly from in-vitro studies. Clinical information is sparse in regards to beta-lactam and 
inhibitor combinations, but some favorable outcomes have been reported with 
pipercillin/tazobactam. However, it is important to note that favorable results have not 
been consistently reported (74,77). One possible oral option may be amoxicillin/clavulanate, 
which has shown some activity in CA-ESBL Enterobacteriaceae UTI infections (60,78) 
Few studies have evaluated cephalosporins in the treatment of both bacteremic and non-
bacteremic ESBL infections. The results have been equivocal when ceftazidime or cefepeme 
were compared to Imipenem in e. coli bacteremia and in ICU patients with 
Enterobacteriaceae infections. (79,80). In vitro data also suggests suboptimal outcomes when 
the cephalosporins were used to treat ESBL infections. Thus, most experts’ advise against 
using cephalosporins in the treatment of ESBL associated infections.(79,80) 
Cephamycins have not been well studied in the treatment of ESBL associated infections. In 
one small retrospective study,  there was no obvious difference in the mortality rates 
between the cephamycins and carbapenems. Recent studies have documented resistance to 
the cephamycins (49,74). 
The glycylcycline class of antibiotics, specifically tigecycline, thus far evaded the common 
mechanisms of resistance in both gram positive and gram-negative pathogens. It has 
excellent in vitro activity against ESBL-E.coli and K. pneumoniae. However, clinical data is 
sparse in the treatment of ESBL UTI’s and bacteremia. In addition, only a fraction of the 
drug is excreted in the urine as unchanged drug. In addition, tigecycline does not achieve 
high concentrations in the blood,  casting doubts on its potential effectiveness in the 
treatment of bacteremia.(81)  
Fosfomycin has been used in Europe but is not available in most parts of the world. It is a 
phosphor derivative of streptomycin and inhibits cell wall synthesis and impairs adherence 
to urogenital mucosa. A study in Spain found that the resistance rate to fosfomycin of  
ESBL-EC was 0.3%. (82). It has been used in cystitis and asymptomatic UTI in pregnancy. 
(82,83). In the United States 90% of the isolates in one study were susceptible to fosfomycin 
and to a combination of cefdinir plus amoxicillin-clavulanate. (84,85) 
Pivmecillinam is a beta lactam antibiotic, which binds penicillin-binding protein 2 (PBP-2) 
and inhibits cell wall synthesis. This drug has been used in the treatment of cystitis due to 
Enterobacteriaceae. (86). 
Nitrofurantoin is a bactericidal drug, which acts by altering bacterial ribosome’s proteins 
and can be used for UTI as well. 
Finally, carbapenems are considered the drug of choice for ESBL infections. All the drugs in 
the class appear to have the same efficiency in the treatment of ESBL. Ertapenem, is the only 
drug in this class that can be administered once a day. It can be used in the outpatient 
setting as long as the in vitro activity is similar to imipenem, doripenem or 
meropenem.(87,88). However, recent reports of carbapenem resistance have emerged and 
the spread of resistance is of concern. One possible option might  be to add amikacin to the 
empiric regimen in community-acquired sepsis originating in the urinary tract since 
amikacin resistance among CTX-M isolates is relatively low. 
The treatment for upper UTI’s may have to be limited to the intravenous antibiotics 
mentioned above especially as the patients tend to be sicker and may present with systemic 
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inflammatory response syndrome and occasionally bacteremia. These should include 
carbapenems. Occasionally, ampicillan-sulbactam and tigecycline may be alternate therapies 
although data on these drugs in the treatment of ESBL  UTI infections is sparse. 
In lower UTI‘s, some of the oral antibiotics such as nitrofurantoin, fosphomycin, amoxicillin-
clavulanate and trimethoprim-sulphamethaxazole may be used if the pathogen is 
susceptible to them. 
8. Conclusion 
Antimicrobial resistance has become a global problem of increasing importance. It is now 
essential that laboratories be able to rapidly identify and characterize resistant organisms.  
This is, of even more importance, in ESBL producing organisms that clearly have a higher 
morbidity and mortality associated with their infections. There is also increasing evidence, 
that ESBL organisms frequently possess resistance factors to other classes of other 
antimicrobials, like the aminoglycosides and quinolones. ESBL producing bacteria are being 
found both in the hospital and in the community, especially the CTX-M beta –lactamases. 
The increasing number of community isolates, especially E. coli producing CTX-M-15 have 
become global and now are being seen in the hospital as well. It is thought that the CTX-M -
15 producing E.coli is mostly due to a single clone named ST131, which appears to have 
originated in the Indian sub-continent. In addition, the increasing number of 
carbapenemases could also seriously compromise our treatment options. Therefore, empiric 
antimicrobial coverage may need to be modified in patients who present with serious sepsis 
syndromes, especially,  after travel to countries that are high risk for this clone. 
Treatment of ESBL infections requires the use of carbapenems in seriously ill patients. 
Imipenem, meropenem, doripenem are all viable alternatives. Ertapenem can be used in the 
out patient setting, in the absence of Pseudomonas aeruginosa. Agents such as fosfomycin, 
nitrofurantoin, amoxicillin/clavulanic acid, pivemecillinam, temocillin can be alternate 
drugs in uncomplicated UTI’s and in patients with drug allergies to the carbapenems. 
Salvage therapy using tigecycline and colistin can be used in seriously ill patients who are 
CTX-M producers and Amp-C producing isolates.  
In addition to understanding the complex mechanisms involved in ESBL infections, strict 
antimicrobial stewardship, appropriate infection control measures and aggressive treatment 
of seriously ill patients is necessary in reducing the mortality and morbidity associated with 
these infections. 
9. References 
[1] Abraham EP, Chain E(1940): An enzyme from bacteria able to destroy penicillin (letter). 
Nature ;146:837 
[2] Datta N, Kontomichalau P(1965): Penicillinase synthesis controlled by infectious R 
factors in Enterobacteriaceae. Nature ;208:239-44 
[3] Pitton JS (1972): Mechanism of bacterial resistance to antibiotics. Rev. Physiol Biochem 
Pharmacol.;65:15-93 
[4] Neu HC (1982). The new beta-lactamase stable cephalosporins. Ann Intern Med ;97:408-
19 
[5] Kiebe C et al (1985): Evolution of plasmid coded resistance to broad-spectrum 
cephalosporins. Antimicrobial Agents chemotherar .28:302-7 
The Changing Epidemiology of Extended Spectrum Beta-Lactamases (ESBL)  
Infections of the Urinary Tract Focusing on Clinical Resistance and Therapeutic Options 
 
27 
[6] Bonnet R (2004). Growing extended spectrum of beta lactamases: the CTX-M 
enzymes.Antimicrob Agents Chemother;48:1-14 
[7] Nordmann P, Poirel L (2002): Emerging carbapenemases in gram-negative aerobes. Clin 
Microbiol Infect;8:321-31 
[8] Perez F et al (2007): The continuing challenges of ESBL’S. Curr Opin Pharmacol  oct 
7(5):459-469. 
[9] Paterson DL et al (2001). Outcome of cephalosporins treatment for serious infections due 
to apparently susceptibility organism producing extended spectrum beta 
lactamases: implications for the clinical microbiology laboratory. J Clin 
Microbiol;39:2206-12 
[10] Romero L et al (2005) A: long-term study of the frequency of ESBL producing e.coli and 
Klebsiella pneumonia isolates. Clin Microbiol Infect. 11;625-631 
[11] Hernandez JR et al (2005) A. Spanish Group for nosocomial infections . Nationwide  
study of Escheria coli and Klebsiella pneumoniae producing extended spectrum 
beta lactamases in Spain. Antimicrobial Agents Chemother. ;49;2122-2125 
[12] Albertini Mt et al (2002). Surveillance of methicillin resistant staphylococcus aureus and 
enterobacteriacae producing extended spectrum beta lactamases (ESBL) in 
Northern France. A 5-year multicentre study. . J hosp Infec;52:107-113. 
[13] Handberger H et al(1999): Antibiotic susceptibility among gram negative bacilli in 
intensive care units in 5 European countries. French and Portuguese ICU study 
groups. .JAMA 281:67-71 
[14] Woerther PL et al (2010). Emergence and dissemination of extended spectrum beta 
lactamases producing Escherichia coli in the community: lessons from the study of 
a remote and controlled population.  J Infect Dis. Aug 15;(4):515-23 
[15] Mendes C et al (2000): evaluation of the in vitro activity of 9 antimicrobials against 
bacterial strains isolated from patients in the intensive care units in Brazil. MYSTIC 
antimicrobial surveillance Program.2000. Braz J Infect Dis. 4:236-244 
[16] Casellas JM, Quinteros MG . A Latin American point de vu on the epidemiology, 
control and treatment options of infections caused by extended spectrum beta-
lactamase producers. In Anabile-cuevas CF. editor. Antimicrobial resistance in 
bacteria. Wymondham Horizon bioscience. 99-122 
[17] Bauernfeind A et al (1992). A new plasmidic cefotaximase from patients infected with 
salmonella typhimurium . Infection .20:158-163 
[18] Aitmhand R et al (2002). Plasmid mediated TEM 3 extended spectrum beta lactamase 
production in salmonella typhimurium in Casablanca.  J Antimicrobial 
Chemother.49;169-179 
[19] Barguellil F et al (1995). In vitro acquisition of extended spectrum beta lactamases in 
salmonella enteritis during antimicrobial therapy. Eur j Clin Microbiol Infect Dis.  
14:703-706 
[20] Neuwirth CS et al (2001). TEM 89 beta lactamase produced by a Proteus mirabilis 
clinical isolate. New complex mutant with mutations in both TEM 59 and TEM 3. . 
Antimicrobial Agents Chemother 45:3591-3594 
[21] Myers KS et al (1993): Nosocomial outbreak of Klebsiella infection resistant late 
generation cephalosporin’s. . Ann Intern Med. 119:353-358 
 
Clinical Management of Complicated Urinary Tract Infection 
 
26
inflammatory response syndrome and occasionally bacteremia. These should include 
carbapenems. Occasionally, ampicillan-sulbactam and tigecycline may be alternate therapies 
although data on these drugs in the treatment of ESBL  UTI infections is sparse. 
In lower UTI‘s, some of the oral antibiotics such as nitrofurantoin, fosphomycin, amoxicillin-
clavulanate and trimethoprim-sulphamethaxazole may be used if the pathogen is 
susceptible to them. 
8. Conclusion 
Antimicrobial resistance has become a global problem of increasing importance. It is now 
essential that laboratories be able to rapidly identify and characterize resistant organisms.  
This is, of even more importance, in ESBL producing organisms that clearly have a higher 
morbidity and mortality associated with their infections. There is also increasing evidence, 
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The increasing number of community isolates, especially E. coli producing CTX-M-15 have 
become global and now are being seen in the hospital as well. It is thought that the CTX-M -
15 producing E.coli is mostly due to a single clone named ST131, which appears to have 
originated in the Indian sub-continent. In addition, the increasing number of 
carbapenemases could also seriously compromise our treatment options. Therefore, empiric 
antimicrobial coverage may need to be modified in patients who present with serious sepsis 
syndromes, especially,  after travel to countries that are high risk for this clone. 
Treatment of ESBL infections requires the use of carbapenems in seriously ill patients. 
Imipenem, meropenem, doripenem are all viable alternatives. Ertapenem can be used in the 
out patient setting, in the absence of Pseudomonas aeruginosa. Agents such as fosfomycin, 
nitrofurantoin, amoxicillin/clavulanic acid, pivemecillinam, temocillin can be alternate 
drugs in uncomplicated UTI’s and in patients with drug allergies to the carbapenems. 
Salvage therapy using tigecycline and colistin can be used in seriously ill patients who are 
CTX-M producers and Amp-C producing isolates.  
In addition to understanding the complex mechanisms involved in ESBL infections, strict 
antimicrobial stewardship, appropriate infection control measures and aggressive treatment 
of seriously ill patients is necessary in reducing the mortality and morbidity associated with 
these infections. 
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1. Introduction  
Escherichia coli (E. coli) is a very diverse bacterial species found naturally in the intestinal 
tract of humans and many other animal species. Even though E. coli is known to be part of 
the normal gut microbiota, some strains – that are pathogenic – cause a wide variety of 
different intestinal and extraintestinal diseases (Marrs et al., 2005). Typical extraintestinal 
infections due to E. coli include urinary tract infections (UTI), diverse intra-abdominal 
infections, pneumonia, surgical-site infection, meningitis, osteomyelitis, soft-tissue 
infections, bacteremia (Russo & Johnson, 2006).  
UTIs are one of the most frequently acquired bacterial infections and E. coli accounts for as 
many as 90% of all community-acquired UTIs. Approximately 50% of all women have had a 
UTI by their late 20s. About 20–30% of women with first UTI will have two or more 
infections; while 5%, will develop chronic recurring infections which greatly disrupt a 
woman’s life (Marrs et al., 2005). In Slovenia E. coli is the causative agent of approximately 
80% of uncomplicated UTIs (Lindič, 2005). 
E. coli isolates that cause UTI exhibit a number of specific characteristics and are classified, 
as uropathogenic E. coli (UPEC), a subgroup of extraintestinal pathogenic E. coli (ExPEC) 
(Russo & Johnson, 2000). UPEC strains mainly belong to the B2 phylogenetic group and to a 
lesser extent to the D group, while commensal strains belong to groups A and B1 (Picard et 
al., 1999). Further, some O-antigens (O1, O2, O4, O6, O7, O18 and O83) are more prevalent 
among uropathogenic E. coli strains and are therefore associated with UTI (Moreno et al. 
2006). In comparison to commensal E. coli strains, UPEC possess an array of virulence 
factors namely, adhesins, toxins, polysaccharide coatings, invasins, iron uptake systems and 
systems to evade host immune responses (Oelschlaeger et al., 2002).  
Of serious concern and an increasing health problem, on a global scale, is the appearance 
and spread of antimicrobial resistance. One of the major health care concerns is emergence 
of multidrug resistant bacteria and clinical microbiologists increasingly agree that multidrug 
resistant Gram-negative bacteria pose the greatest risk to public health (Kumarasamy et al., 
2010). Therefore, it is essential to determine susceptibility of pathogenic strains for 
antimicrobial agents and association of antimicrobial resistance with virulence genes.  
One of the means for acquiring specific virulence factor genes and antimicrobial resistance 
genes, is via mobile DNA (e. g. conjugal plasmids, transposons/integrons) (Alekshun & 
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Levy, 2007; Boerlin & Reid-Smith, 2008; Dobrindt et al., 2010). Hence, determining the 
prevalence of mobile elements and examining the correlation of antimicrobial 
resistance/virulence factor genes with mobile elements among UPEC is of great 
significance. 
The search for alternative antibacterial agents is of great importance and colicins, toxic, 
narrow killing spectrum exhibiting proteins produced by colicinogenic E. coli, exhibit great 
potential as an alternative approach in the battle against microbes. It has been reported that 
colicins are effective against intestinal and UPEC strains (Rijavec et al., 2007; Schamberger et 
al., 2004; Stahl et al., 2004), and that they prevent colonization of urinary catheters (Trautner 
et al., 2005). To evaluate the potential of colicins as antimicrobial agents, studies on the 
prevalence of colicins and colicin resistance are needed. 
In summary, to diminish the burden of UPEC, using effective preventive measures, data on 
phylogenetic groups, serogroups, virulence factor prevalence, antimicrobial resistance, 
presence of mobile DNA, colicin production and colicin resistance among E. coli isolates 
from different geographic regions must be assessed.  
In Slovenia in 2002, we collected 110 E. coli isolates from humans with community-acquired 
urinary tract infections at the Institute of Microbiology and Immunology, Medical Faculty, 
Ljubljana, Slovenia. Isolation was performed according to standard laboratory protocols and 
UPEC were isolates from > 105 colony-forming units (CFU) (Rijavec et al., 2006). These 
isolates were studied in order to obtain an extended characterisation, including 
phylogenetic groups, serogroups, virulence factor prevalence, antimicrobial resistance, 
presence of mobile DNA and colicinogeny and colicin resistance (Rijavec et al., 2006; Starčič 
Erjavec et al., 2006; Starčič Erjavec et al., 2007; Starčič Erjavec & Žgur-Bertok, 2008; Starčič 
Erjavec et al., 2008; Starčič Erjavec et al., 2009; Starčič Erjavec et al., 2010). 
2. Phylogenetic groups and subgroups 
E. coli strains can be assigned to one of four main phylogenetic groups: A, B1, B2, and D. The 
four groups were identified on the basis of allelic variation at enzyme-encoding genes 
detected by multilocus enzyme electrophoresis (Ochman et al., 1983, Whittam et al., 1983). 
Clermont et al. (2000) established the method of rapid and simple determination of the E. 
coli phylogenetic groups by a triplex PCR. This genotyping method is based on the 
amplification of a 279 bp fragment of the chuA gene; a 211 bp fragment of the yjaA gene; and 
a 152 bp fragment of TSPE4.C2, a noncoding region of the genome. The presence or absence 
of combinations of these three amplicons is used to assign E. coli to one of the four 
phylogenetic groups. However, to increase the discriminative power of phylogenetic group 
analysis, Escobar-Paramo et al. (2004) proposed the introduction of phylogenetic subgroups. 
They defined (Figure 1), apart from the phylogenetic group B1 (lacking chuA and yjaA and 
having Tspe4.C2), the following six subgroups: in the phylogenetic group A, subgroupA0 
(lacking chuA, yjaA, and Tspe4.C2) and subgroup A1 (lacking chuA, having yjaA, and lacking 
Tspe4.C2); in the phylogenetic group B2, subgroup B22 (having chuA and yjaA and lacking 
Tspe4.C2) and subgroup B23 ( having chuA, yjaA, and Tspe4.C2); in the phylogenetic group 
D, subgroup D1 (having chuA and lacking yjaA and Tspe4.C2) and subgroup D2 (having 
chuA, lacking yjaA, and having Tspe4.C2), Fig. 1. 
Analysis of our collection of 110 UPEC isolates showed that 55 (50%) belonged to group B2, 
28 (25%) to A, 21 (19%) to D, and 6 (5%) to the B1 group (Rijavec et al., 2006). When 
subgroups were considered the distribution of the isolates was: 4 (4%) of the studied isolates 
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belonged to the subgroup A0, 24 (22%) to A1, 6 (5%) to B22, 49 (45%) to B23, 16 (15%) to D1 
and 5 (5%) to D2 (our unpublished data).  
 
 
Fig. 1. Diagram of phylogenetic (sub)group determination. 
The obtained distribution of the studied isolates into the phylogenetic groups, with the large 
majority classifying to the B2 group was expected since, it is known that ExPEC isolates 
mainly belong to the B2 phylogenetic group (Picard et al., 1999) however, the 
disproportionate distribution into the B22 (5%) and B23 (45%), and A0 (4%) and A1 (22%) 
subgroups was surprising. 
3. Serogroups 
Serotyping of E. coli isolates is an often used method for distinguishing possible pathogenic 
E. coli from commensal E. coli. It is complex since among E. coli 173 O-antigens, 80 K-
antigens, and 56 H-antigens can be found. The O-, K-, and H-antigens can occur in many 
possible combinations therefore, the final number of E. coli serotypes is very high, 50,000-
100,000 or more. However, the number of frequent pathogenic serotypes is limited. Two 
main groups of frequent serotypes are: (i) serotypes from diarrhoeal disease and (ii) 
serotypes from extraintestinal disease (Orskov & Orskov, 1992). 
Serotyping of the 110 uropathogenic strains revealed that 77 (70%) were O-antigen typable, 
19 (17%) were O-nontypable, and 14 (12.7%) were rough. Sixty-three (57%) of the examined 
strains were H-antigen typable, 41 (37%) were H-antigen negative, and 6 (5%) were H-
antigen nontypable. The O-typable strains were distributed into 31 serogroups. 
Nevertheless, the most frequent were O2 (9 isolates) and serotype O6:H1 (10 isolates). Five 
common serotypes were identified in three or more strains: O2:HNT (n = 3), O2:H6 (n = 3), 
O6:H1 (n = 10), O7:HNT (n = 3), and O74:H39 (n = 4) accounting for 30% of the serotypable 
isolates. A number of other serotypes were detected in one or two strains (Rijavec et al., 
2006). 
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subgroups were considered the distribution of the isolates was: 4 (4%) of the studied isolates 
 
Extended Characterization of Human Uropathogenic Escherichia coli Isolates from Slovenia 
 
37 
belonged to the subgroup A0, 24 (22%) to A1, 6 (5%) to B22, 49 (45%) to B23, 16 (15%) to D1 
and 5 (5%) to D2 (our unpublished data).  
 
 
Fig. 1. Diagram of phylogenetic (sub)group determination. 
The obtained distribution of the studied isolates into the phylogenetic groups, with the large 
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mainly belong to the B2 phylogenetic group (Picard et al., 1999) however, the 
disproportionate distribution into the B22 (5%) and B23 (45%), and A0 (4%) and A1 (22%) 
subgroups was surprising. 
3. Serogroups 
Serotyping of E. coli isolates is an often used method for distinguishing possible pathogenic 
E. coli from commensal E. coli. It is complex since among E. coli 173 O-antigens, 80 K-
antigens, and 56 H-antigens can be found. The O-, K-, and H-antigens can occur in many 
possible combinations therefore, the final number of E. coli serotypes is very high, 50,000-
100,000 or more. However, the number of frequent pathogenic serotypes is limited. Two 
main groups of frequent serotypes are: (i) serotypes from diarrhoeal disease and (ii) 
serotypes from extraintestinal disease (Orskov & Orskov, 1992). 
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19 (17%) were O-nontypable, and 14 (12.7%) were rough. Sixty-three (57%) of the examined 
strains were H-antigen typable, 41 (37%) were H-antigen negative, and 6 (5%) were H-
antigen nontypable. The O-typable strains were distributed into 31 serogroups. 
Nevertheless, the most frequent were O2 (9 isolates) and serotype O6:H1 (10 isolates). Five 
common serotypes were identified in three or more strains: O2:HNT (n = 3), O2:H6 (n = 3), 
O6:H1 (n = 10), O7:HNT (n = 3), and O74:H39 (n = 4) accounting for 30% of the serotypable 
isolates. A number of other serotypes were detected in one or two strains (Rijavec et al., 
2006). 
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Serotype analysis of the studied strains revealed that they belonged to diverse serogroups. 
However, the most frequent were O2 and O6, which are well established as associated with 
urinary tract infections. The large majority, 96%, of the O2 and O6 isolates were assigned to 
the B2 phylogenetic group (Rijavec et al., 2006). 
4. Virulence factors 
Any component of a microbe that is required for, or potentiates its ability to cause disease is 
designated as a virulence factor. Many different virulence factors exist however, they can all 
be placed in one of the four major groups of virulence factors: adhesins, toxins, iron uptake 
systems and host immunity evading systems. Hence, virulence factors facilitate colonization 
and invasion of the host, avoidance or disruption of host defence mechanisms, injury to host 
tissue, and/or stimulation of a noxious host inflammatory response (Johnson and Steel, 
2000). 
4.1 Adhesins 
Among the first virulence factors that come into play during establishment of an infection 
are adhesins. Besides their primary role as adhesin molecules, they can also function as 
invasins, promoters of biofilm formation and transmitors of signals to epithelial cells 
resulting in inflammation. Various adhesins have been identified and studied (Zhang & 
Foxman, 2003). In our analysis we focused on the four mostly studied: type 1 fimbriae, P 
fimbriae, S fimbriae and the Afa/Dr family of adhesins (Starčič Erjavec & Žgur-Bertok, 
2008). 
Type 1 fimbriae are the most common adhesive organelles of E. coli strains. They are 
encoded by the vast majority of uropathogenic E. coli (UPEC) isolates and many other 
pathogenic and commensal isolates (Bower et al., 2005). Receptors for type 1 fimbriae are 
present on erythrocytes, buccal epithelial cells, intestinal cells, vaginal cells and uroepithelial 
cells (Johnson, 1991). The fimH gene that was tested in our study (Starčič Erjavec & Žgur-
Bertok, 2008), encodes the minor subunit protein FimH that mediates binding to the 
receptor. FimH has several variants: UPEC strains have a FimH that binds both 
monomannose and trimannose containing glycoprotein receptors, while commensal E. coli 
isolates typically show high affinity binding to only trimannose residues (Bower et al., 2005). 
Type 1 fimbriae function not just as adhesins, but also as invasins for bladder epithelial cells 
(Martinez et al., 2000).  
P fimbriae are among the best studied fimbrial adhesive fibres of UPEC strains. The P 
fimbrial adhesin molecule (PapG) recognizes globoseries of glycolipids as receptors (Zhang 
& Foxman, 2003). In our study the papC, papGII and papGIII genes were included (Starčič 
Erjavec & Žgur-Bertok, 2008). The papC gene encodes the outer membrane usher protein that 
is required for ordered P fimbriae assembly (Thanassi et al., 1998). Many studies showed 
that P fimbriae occur more frequently among UPEC than fecal isolates. Based on binding 
specificities, P fimbriae are grouped into three major classes: I, II and III (Zhang & Foxman, 
2003). 
S fimbriae bind to sialyl galactosides. Studies showed that E. coli UTI isolates were at least 
two times more likely to carry S fimbriae genes (sfa operon) than fecal strains (Zhang & 
Foxman, 2003). In our study the fimbriae typical gene sequence sfa/foc was investigated 
(Starčič Erjavec & Žgur-Bertok, 2008). 
The Afa/Dr family consists of 13 known adhesins that all bind to the Dra blood group 
antigen present on the complement regulatory molecule CD55, also known as decay-
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accelerating factor (DAF) (Bower et al., 2005). The E. coli strains harbouring these adhesins 
have been found to be associated with UTIs and also with various enteric infections (Servin, 
2005). 
Among the tested adhesin genes in the studied UPEC isolates (Table 1), the type 1 fimbriae 
were the most prevalent - the fimH gene nucleotide sequences were detected in 107 strains 
(97%). The P fimbriae were also abundant, the papC encoding gene sequence was found in 
54 strains (49%), 37 strains (34%) harboured the class II papG adhesin sequence and 14 
strains (13%) harboured the class III papG adhesin. Twenty-six (24%) possessed the S 
fimbriae typical gene sequence sfa/foc. Only 2 strains (2%) harbored afa/dra sequences (Starčič 
Erjavec & Žgur-Bertok, 2008). 
Analysis of the distribution of adhesin gene sequences among phylogenetic groups revealed 
that adhesin gene sequences were differently distributed (Table 1): fimH sequences were 
found with similar prevalence in strains of all four phylogenetic groups, papC sequences 
were found in all phylogenetic groups, but they were most prevalent (65%) among B2 group 
strains. The association of papC with the B2 group was statistically significant. Nevertheless, 
papGII sequences were found in all phylogenetic groups, in contrast, papGIII adhesin 
sequences were exclusively found among strains of the B2 group. 
Further, a very high, statistically significant, prevalence of S fimbriae in the B2 group was 
detected, 45% of the strains belonging to the B2 group harboured sfa/foc sequences (Starčič 
Erjavec & Žgur-Bertok, 2008). 
4.2 Toxins 
Toxins affect an astonishing variety of fundamental eukaryotic processes and thereby harm 
the host (Kaper, 2004) and are important virulence factors in a variety of E. coli mediated 
diseases – in UTI the production of toxins by colonized E. coli may cause an inflammatory 
response that leads to the UTI symptoms (Zhang & Foxman, 2003).  
In pathogenic E. coli strains several important toxins have been identified, the best known, 
associated with UPEC strains, are alpha hemolysin (HlyA) and cytotoxic necrotizing factor 1 
(CNF1) (Zhang & Foxman, 2003).  
Well known toxins are also invasins, the Ibe proteins that help E. coli strains to invade the 
human brain microvascular endothelial cells (Xie et al., 2004). The presence of IbeA protein 
is statistically significantly higher in strains causing cystitis and/or pyelonephritis (Johnson 
et al., 2005). The gene for the uropathogenic specific protein (USP) that was found as a 
homologue of the Vibrio cholerae zonula occludens toxin encoding gene (Kurazono et al., 
2000), has been significantly more often detected in UPEC strains than in fecal strains from 
healthy individuals (Bauer et al., 2002). 
Among the screened toxin encoding genes in the studied UPEC isolates (Table 1), the usp 
gene had the highest prevalence as usp specific nucleotide sequences were detected in 48 
strains (44%). The prevalence of hlyA and cnf1 was similar, 28 (25%) and 25 strains (23%), 
respectively, possessed the tested nucleotide sequences. Only 10 strains (9%) harboured ibeA 
sequences (Starčič Erjavec et al., 2008). 
Analysis of the distribution of toxin encoding genes among the determined phylogenetic 
groups of studied strains (Table 1) revealed that the tested toxin encoding genes hlyA, cnf1, 
ibeA and usp were mostly harboured by UPEC strains belonging to the B2 phylogenetic 
group, as 26 (93%) of the strains harbouring hlyA belonged to the B2 group, 25 (100%) 
harbouring cnf1, 9 (90%) harbouring ibeA and 42 (88%) harbouring usp belonged to the B2 
phylogenetic group (Starčič Erjavec et al., 2008). 
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accelerating factor (DAF) (Bower et al., 2005). The E. coli strains harbouring these adhesins 
have been found to be associated with UTIs and also with various enteric infections (Servin, 
2005). 
Among the tested adhesin genes in the studied UPEC isolates (Table 1), the type 1 fimbriae 
were the most prevalent - the fimH gene nucleotide sequences were detected in 107 strains 
(97%). The P fimbriae were also abundant, the papC encoding gene sequence was found in 
54 strains (49%), 37 strains (34%) harboured the class II papG adhesin sequence and 14 
strains (13%) harboured the class III papG adhesin. Twenty-six (24%) possessed the S 
fimbriae typical gene sequence sfa/foc. Only 2 strains (2%) harbored afa/dra sequences (Starčič 
Erjavec & Žgur-Bertok, 2008). 
Analysis of the distribution of adhesin gene sequences among phylogenetic groups revealed 
that adhesin gene sequences were differently distributed (Table 1): fimH sequences were 
found with similar prevalence in strains of all four phylogenetic groups, papC sequences 
were found in all phylogenetic groups, but they were most prevalent (65%) among B2 group 
strains. The association of papC with the B2 group was statistically significant. Nevertheless, 
papGII sequences were found in all phylogenetic groups, in contrast, papGIII adhesin 
sequences were exclusively found among strains of the B2 group. 
Further, a very high, statistically significant, prevalence of S fimbriae in the B2 group was 
detected, 45% of the strains belonging to the B2 group harboured sfa/foc sequences (Starčič 
Erjavec & Žgur-Bertok, 2008). 
4.2 Toxins 
Toxins affect an astonishing variety of fundamental eukaryotic processes and thereby harm 
the host (Kaper, 2004) and are important virulence factors in a variety of E. coli mediated 
diseases – in UTI the production of toxins by colonized E. coli may cause an inflammatory 
response that leads to the UTI symptoms (Zhang & Foxman, 2003).  
In pathogenic E. coli strains several important toxins have been identified, the best known, 
associated with UPEC strains, are alpha hemolysin (HlyA) and cytotoxic necrotizing factor 1 
(CNF1) (Zhang & Foxman, 2003).  
Well known toxins are also invasins, the Ibe proteins that help E. coli strains to invade the 
human brain microvascular endothelial cells (Xie et al., 2004). The presence of IbeA protein 
is statistically significantly higher in strains causing cystitis and/or pyelonephritis (Johnson 
et al., 2005). The gene for the uropathogenic specific protein (USP) that was found as a 
homologue of the Vibrio cholerae zonula occludens toxin encoding gene (Kurazono et al., 
2000), has been significantly more often detected in UPEC strains than in fecal strains from 
healthy individuals (Bauer et al., 2002). 
Among the screened toxin encoding genes in the studied UPEC isolates (Table 1), the usp 
gene had the highest prevalence as usp specific nucleotide sequences were detected in 48 
strains (44%). The prevalence of hlyA and cnf1 was similar, 28 (25%) and 25 strains (23%), 
respectively, possessed the tested nucleotide sequences. Only 10 strains (9%) harboured ibeA 
sequences (Starčič Erjavec et al., 2008). 
Analysis of the distribution of toxin encoding genes among the determined phylogenetic 
groups of studied strains (Table 1) revealed that the tested toxin encoding genes hlyA, cnf1, 
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 Prevalence (N, [%]) 
  Phylogenetic group 









Virulence factors      
Adhesins      
fimH 107 (97) 28 (26) 5 (5) 53 (50) 21 (20) 
papC 54 (49) 8 (15) 1 (2) 35 (65) 10 (19) 
papGII 37 (34) 5 (14) 1 (3) 21 (57) 10 (27) 
papGIII 14 (13) 0 (0) 0 (0) 14 (100) 0 (0) 
sfa/foc 26 (24) 1 (4) 0 (0) 25 (96) 0 (0) 
afa/dra 2 (2) 1 (50) 0 (0) 1 (50) 0 (0) 
Toxins      
hlyA 28 (25) 1 (4) 0 (0) 26 (93) 1 (4) 
cnf 25 (23) 0 (0) 0 (0) 25 (100) 0 (0) 
ibeA 10 (9) 0 (0) 0 (0) 9 (90) 1 (10) 
usp 48 (44) 1 (2) 0 (0) 42 (88) 5 (10) 
Iron uptake systems      
iucD 46 (42) 8 (17) 0 (0) 27 (59) 11 (24) 
iroCD (=iroN) 51 (46) 9 (18) 0 (0) 41 (80) 1 (2) 
ireA 22 (20) 4 (18) 0 (0) 12 (55) 6 (27) 
fyuA 84 (76) 17 (20) 3 (4) 49 (58) 15 (18) 
Host immunity evading systems      
K1 6 (5) 1 (17) 1 (17) 4 (67) 0 (0) 
K5 11 (10) 2 (18) 1 (9) 8 (73) 0 (0) 
traT 63 (57) 20 (32) 4 (6) 29 (46) 10 (16) 
tcpC 23 (21) 0 (0) 0 (0) 23 (100) 0 (0) 
Antimicrobial susceptibility      
Ampicillin 57 (52) 12 (21) 5 (9) 32 (56) 18 (32) 
Ciprofloxacin 99 (90) 23 (23) 5 (5) 52 (53) 19 (19) 
Chloramphenicol 50 (45) 7 (14) 3 (6) 32 (64) 8 (16) 
Kanamycin 95 (86) 20 (21) 5 (5) 51 (54) 19 (20) 
Mezlocillin 59 (54) 12 (20) 5 (8) 34 (58) 8 (14) 
Nalidixic acid 64 (58) 12 (19) 3 (5) 38 (59) 11 (17) 
Norfloxacin 99 (90) 23 (23) 5 (5) 52 (52) 19 (19) 
Streptomycin 69 (63) 15 (22) 5 (7) 40 (60) 9 (13) 
Sulfamethoxazole-Trimethoprim 87 (79) 18 (21) 6 (7) 49 (56) 14 (16) 
Tetracycline 47 (43) 6 (13) 4 (9) 33 (70) 4 (9) 
Trimethoprim 72 (65) 14 (19) 6 (8) 41 (57) 11 (15) 
Mobile genetic elements      
RepFIA 20 (18) 7 (35) 0 (0) 10 (50) 3 (15) 
RepFIB 57 (52) 18 (32) 2 (4) 26 (46) 11 (19) 
RepFIIA 24 (22) 7 (29) 0 (0) 15 (63) 2 (8) 
Integron 34 (31) 12 (35) 1 (3) 12 (35) 9 (26) 
Colicinogenity 42 (38) 12 (29) 3 (7) 20 (48) 7 (17) 
Table 1. Characterized traits in studied UPEC isolates – prevalence and distribution among 
phylogenetic groups. 
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4.3 Iron uptake systems 
Iron is an essential cofactor for many basic metabolic pathways and bacteria have developed 
specialized iron uptake systems to capture iron. The most prominent are the siderophores, 
iron-binding molecules that are taken up by special siderophore receptors and ATP-
consuming porin-like transporters in the bacterial outer membrane (Schaible & Kaufmann, 
2004). Siderophores can be classified into three groups: (i) the catecholate type (enterobactin, 
salmochelin = enterochelin), (ii) hydroxamate type (aerobactin) and (iii) a mixed type - a 
combination of both (yersiniabactin) (Grass, 2006; Schaible & Kaufmann, 2004). In addition 
to siderophore synthesis strains can use siderophores produced and released into the 
extracellular medium by other bacteria and even fungi. In the host, bacteria may use iron 
sources such as heme, hemoglobin, hemopexin, and iron bound to transferrin and 
lactoferrin (Braun & Braun, 2002). Apart from the siderophores and their receptors, 
autotransporters, virulence-associated proteins in gram-negative bacteria, can also play a 
role in obtaining iron for example, the hemoglobin protease Hbp (Otto et al., 2002). All 
autotransporter proteins are energy-independent secreted via a type 5 secretion system and 
possess an overall unifying structure, comprising (i) an amino-terminal leader peptide (for 
secretion across the inner membrane), (ii) the secreted mature protein (or passenger 
domain), and (iii) a dedicated C-terminal domain, which forms a pore in the outer 
membrane through which the passenger domain passes to the cell surface (Henderson & 
Nataro, 2001).  
In our study the following iron uptake systems genes were investigated (Table 1): iucD for 
aerobactin, iroCD and iroN for salmochelin, fyuA for yersiniabactin and ireA of a putative 
TonB-dependent siderophore receptor. The iron uptake system with the highest prevalence 
was yersiniabactin, the fyuA gene coding for the ferric yersiniabactin receptor was found in 
84 strains (76%). The salmochelin uptake system genes iroN, coding for the catecholate 
siderophore receptor, and iroCD coding for proteins needed in salmochelin transport, were 
found in 51 (46%) of studied strains. The aerobactin iron uptake system gene iucD, coding 
for lysine:N6-hydroxylase needed in aerobactin biosynthesis, was detected in 46 strains 
(42%) and the ireA gene was harboured by 22 studied strains (20%) (our unpublished data). 
Analysis of the distribution of iron uptake systems encoding genes among the determined 
phylogenetic groups of studied strains (Table 1) revealed that all of the studied iron uptake 
systems were mostly harboured by UPEC strains belonging to the B2 phylogenetic group, as 
41 (80%) of the strains harbouring iroCD and iroN belonged to the B2 group, 49 (58%) 
harbouring fyuA, 27 (59%) harbouring iucD and 12 (55%) harbouring ireA belonged to the B2 
phylogenetic group (our unpublished data). 
4.4 Host immunity evading systems 
Pathogenic microbes avoid host defences using a wide array of virulence factors, ranging 
from polysaccharide capsules, serum resistance proteins to immune system modulating 
agents (Kaper et al., 2004).  
Capsules are the discrete structural layers of extracellular polysaccharides that envelope the 
cell and allow the bacteria to evade or counteract the host immune system (Roberts, 1996). 
Capsules protect pathogens from assaults such as opsonophagocytosis and complement-
mediated killing (Roberts, 1995); and in case of acidic capsules they can act as “sponges” to 
sequester and neutralize antimicrobial peptides (Llobet et al., 2008). Virtually all UPEC have 
a K-type polysaccharide capsule. Most UPEC express Group 2 or 3 capsules on their 
surfaces (Goller and Seed, 2010) and the K-antigens K1, K5, K30 and K92 are the most 
prevalent among UPEC (Johnson, 1991). 
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phylogenetic group (our unpublished data). 
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agents (Kaper et al., 2004).  
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mediated killing (Roberts, 1995); and in case of acidic capsules they can act as “sponges” to 
sequester and neutralize antimicrobial peptides (Llobet et al., 2008). Virtually all UPEC have 
a K-type polysaccharide capsule. Most UPEC express Group 2 or 3 capsules on their 
surfaces (Goller and Seed, 2010) and the K-antigens K1, K5, K30 and K92 are the most 
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TraT, the surface exclusion protein of the plasmid transfer system, has been implicated in 
increased serum resistance (Binns et al., 1979). TraT is one of the most prevalent virulence 
factors in pathogenic E. coli isolates, as traT sequences have been found in 50% of E. coli 
isolates from sepsis (Ananias & Yano, 2008), in 68% of uroseptic E. coli (Johnson & Stell, 
2000), and in 65% of UPEC isolates from cystitis, pyelonephritis, prostatitis (Johnsons et al., 
2005a). 
Recently, TcpC, a Toll/interleukin-1 receptor (TIR) domain–containing protein of 
uropathogenic E. coli inhibiting Toll-like receptor (TIR) and MyD88-specific signaling, 
impairing the innate immune response was described (Cirl et al, 2008). The tcpC 
homologous sequences were found in about 40% of E. coli isolates from individuals with 
pyelonephritis, in 21% cystitis isolates, in 16% asymptomatic bacteriuria and in only 8% of 
commensal isolates therefore, TcpC is implicated in the severity of urinary tract infections 
(UTI) in humans (Cirl et al., 2008). 
Among the 110 studied UPEC isolates (Table 1) 6 (5%) had the K1-capsule and 11 (10%) had 
the K5-capsule (Starčič Erjavec et al., 2007). The traT sequences were found in 63 (57%) 
(Rijavec et al., 2006) and the tcpC sequences were found in 23 (21%) (Starčič Erjavec et al., 
2010) of studied UPEC isolates. 
Analysis of the distribution of the studied immune system evading characteristics among 
the determined phylogenetic groups (Table 1) showed that, isolates with K1- and K5-
capsules were the most prevalent in the B2 group, 4 (67%) and 8 (73%), respectively 
however, capsule possessing isolates also belonged to the A and B1 group, albeit at low 
prevalence. One (17%) K1-capsule coated strain was found in the A and one in the B1 group 
and 2 (18%) K5-capsule coated strains in the A group and one (9%) in the B1 group. The traT 
sequence was more evenly distributed among all four phylogenetic groups A, B1, B2 and D 
– the prevalence was 20 (32%), 4 (6%), 29 (46%) and 10 (16%), respectively. On the other 
hand, the tcpC-encoding strains were found only in the B2 group.  
5. Antimicrobial susceptibility 
An important task in clinical microbiology is the performance of antimicrobial susceptibility 
testing in order to detect possible drug resistance in common pathogens and to assure 
susceptibility to drugs of choice for particular infections (Jorgensen & Ferraro, 2009). 
Therefore, several studies on the subject of antimicrobial susceptibility and E. coli isolates 
from UTI have been performed (e. g. Karlowsky et al., 2003; Kahlmeter & Menday, 2003; 
Yilmaz et al., 2009). 
In the year 2002, when the studied isolates were collected, treatment of UTI in outpatients in 
Slovenia was as follows: a course of antibiotics (therapy of choice - trimethoprim 160 mg or 
trimethoprim/sulfamethoxazole 160 mg/800 mg twice daily for 3 days) and advice to 
consume sufficient quantities of liquids (2–3 l per day) (Car et al., 2003).  
The studied uropathogenic strains were screened for susceptibility to the following 
antibiotics: ampicillin, chloramphenicol, kanamycin, streptomycin, tetracycline, 
trimethoprim, trimethoprim-sulfamethoxazole, ciprofloxacin, norfloxacin, nalidixic acid, 
mezlocillin, amikacin, cefotaxime, cefotiame, cefoxitin, ceftazidime, and gentamicin. 
Susceptibilities to the tested antibiotics ranged from 109 (99%) susceptible to amikacin, 
cefotaxime, ceftazidime, to 47 (43%) susceptible to tetracycline. Antibiotics with the highest 
prevalence of susceptibility, apart from amikacin, cefotaxime, ceftazidime, were to 
cefotiame, cefoxitin, and gentamicin as 108 (98%), 103 (94%), and 101 (92%) of the studied 
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strains, respectively, were susceptible. Antibiotics with the lowest prevalence of 
susceptibility, apart from tetracycline, were to chloramphenicol, ampicilin, mezlocillin and 
nalidixic acid, as 50 (45%), 57 (52%), 59 (54%) and 64 (58%), respectively, were susceptible 
(Rijavec et al., 2006). 
Forty-six (42%) of the studied strains were resistant to more than three classes of the tested 
antimicrobial agents—beta lactams, quinolone/fluoroquinolone, trimethoprim/ 
trimethoprim-sulfamethoxazole, tetracycline, chloramphenicol, aminoglycosides 
(streptomycin, kanamycin)—and were designated as multidrug resistant (MDR). 
Subsequently, the association between MDR and the phylogenetic group was examined. A 
statistically significant correlation between non-MDR and the B2 group was determined and 
a significant correlation between MDR and the D phylogenetic group was found. On the 
other hand, there were no statistically significant correlations between MDR or non-MDR 
strains and the A or B1 groups (Rijavec et al., 2006). 
6. Mobile genetic elements 
The loss and gain of mobile genetic elements has a pivotal role in shaping the genomes of 
pathogenic bacteria. Horizontal gene transfer is an important mechanism that rapidly 
disseminates new traits to recipient organisms. Acquiring these new traits is crucial in 
promoting the fitness and survival of a pathogen while it coevolves with its host (Croxen & 
Finlay, 2010).  
Bacterial plasmids, self-replicating, extrachromosomal elements are key agents of change in 
microbial populations. They promote the dissemination of a variety of traits, including 
virulence, enhanced fitness, resistance to antimicrobial agents, and metabolism of rare 
substances (Johnson & Nolan, 2009). E. coli strains possess a variety of plasmid types, of 
different sizes, usually ranging in size from approximately 300 bp to 2400 kbp nevertheless, 
each plasmid must harbour a replication region (Kado, 1998). Plasmids are classified into 
incompatibility groups mostly on the basis of the replication region (Couturier et al., 1988).  
Integrons are assembly platforms that incorporate exogenous open reading frames by site-
specific recombination and convert them to functional genes by ensuring their correct 
expression. Integrons are composed of three key elements necessary for the capture of 
exogenous genes: a gene (intI) encoding an integrase belonging to the tyrosine-recombinase 
family; a primary recombination site (attI); and an outward-orientated promoter (Pc) that 
directs transcription of the captured genes. At present, five classes of mobile integrons are 
distinguished. These classes have been historically defined based on the sequence of the 
encoded integrases, which show 40–58% identity. All five classes are physically linked to 
mobile DNA elements, such as insertion sequences, transposons and conjugative plasmids, 
all of which can serve as vehicles for intraspecies and interspecies transmission of genetic 
material. Class 1 integrons are associated with functional and non-functional transposons 
derived from Tn402 that can be embedded in larger transposons, such as Tn21. Class 2 
integrons are exclusively associated with Tn7 derivatives and class 3 integrons are thought 
to be located in a transposon inserted in a plasmid. The other two classes of mobile 
integrons, class 4 and class 5, have been associated only with Vibrio species; class 4 is a 
component of a subset of SXT elements found in Vibrio cholerae, and class 5 is located in a 
compound transposon carried on a plasmid in Vibrio salmonicida (Mazel, 2006). 
The studied UTI strains were screened for replication regions of IncFI and IncFII plasmids. 
We found (Table 1) a high (62 strains, 56%) incidence of rep IncF sequences among the 
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a significant correlation between MDR and the D phylogenetic group was found. On the 
other hand, there were no statistically significant correlations between MDR or non-MDR 
strains and the A or B1 groups (Rijavec et al., 2006). 
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Finlay, 2010).  
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different sizes, usually ranging in size from approximately 300 bp to 2400 kbp nevertheless, 
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expression. Integrons are composed of three key elements necessary for the capture of 
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encoded integrases, which show 40–58% identity. All five classes are physically linked to 
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material. Class 1 integrons are associated with functional and non-functional transposons 
derived from Tn402 that can be embedded in larger transposons, such as Tn21. Class 2 
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to be located in a transposon inserted in a plasmid. The other two classes of mobile 
integrons, class 4 and class 5, have been associated only with Vibrio species; class 4 is a 
component of a subset of SXT elements found in Vibrio cholerae, and class 5 is located in a 
compound transposon carried on a plasmid in Vibrio salmonicida (Mazel, 2006). 
The studied UTI strains were screened for replication regions of IncFI and IncFII plasmids. 
We found (Table 1) a high (62 strains, 56%) incidence of rep IncF sequences among the 
 
Clinical Management of Complicated Urinary Tract Infection 
 
44
examined UPEC strains. Particularly prevalent were RepFIB sequences that were detected in 
57 (52%) of the strains while RepFIA and RepFIIA were found in 20 (18%) and 24 (22%) 
strains, respectively. rep sequences were found in all four phylogenetic groups. Of the 62 
isolates harbouring at least one of the tested IncF replicons, 20 belonged to group A, 2 to B1, 
27 to B2, and 13 to group D (Rijavec et al., 2006). 
Since only class 1, 2 and 3 of integrons were shown to be associated with pathogenic E. coli 
in our study we focused only on these three classes. Analysis (Table 1) revealed that 29 
(26%) of the strains harboured a class 1 integron, 1 strain (1%) contained a class 1 and a class 
2 integron, and 4 strains (4%) a class 2 integron. Analysis of the distribution of integrons 
with regard to the phylogenetic group showed that integron sequences were found in all 
four groups. Of the 34 isolates harbouring integron sequences, 12 belonged to group A, 1 to 
B1, 12 to B2, and 9 to group D (Rijavec et al., 2006). 
7. Colicins 
Colicins are bacteriocins produced by E. coli strains. As other bacteriocins, colicins are 
extracellular bacterial toxic proteins that are active against the same, or closely related 
species as the producer cell (Daw & Falkiner, 1996). The mechanism of action of these 
compounds involves adsorption to specific receptors located on the external surface of 
sensitive bacteria followed by killing via one of three primary mechanisms: i) formation of 
channels in the cytoplasmic membrane, ii) degradation of cellular DNA or iii) inhibition of 
protein synthesis (Riley & Gordon, 1999). Because of their narrow range of activity, it has 
been proposed that the primary role of bacteriocins is to mediate intraspecific, or population 
level, interactions (Riley, 1998) however, bacteriocins have also been implicated in virulence 
determination, since many pathogenic strains harbour plasmid-encoded bacteriocins, for 
example the ColV plasmid of UPEC isolates (Johnson & Nolan, 2009). Typically, 25–50% of 
E. coli isolates are colicinogenic and usually, the percentages are higher among pathogenic 
than commensal strains (Riley & Gordon, 1996). Due to high levels of colicinogenity in 
natural E. coli populations, high levels of colicin resistance are known to occur (Feldgarden 
& Riley, 1998). 
 
 
Fig. 2. A colicinogenic uropathogenic strain was stab inoculated on 4 points on an agar plate 
and overlaid with a sensitive E. coli strain. 
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Among the studied UPEC isolates 42 (38%) exhibited colicinogenic activity (Starčič Erjavec 
et al., 2006). Each of the 110 UPEC strains was resistant to at least 3 colicinogenic strains 
from Pugsley's collection of colicinogenic strains (Pugsley & Oudega, 1987), 23 UPEC strains 
(21%) were resistant to all 20 tested Pugsley's strains (our unpublished data). Colicinogenic 
strains were found in all four phylogenetic groups (Table 1) however, most colicinogenic 
strains, 20 (48%) belonged to the B2 group (our unpublished data). 
8. Conclusion 
Our investigation of UPEC isolates from Slovenia revealed a high prevalence of drug 
resistance and multidrug resistance. The virulence profile of the examined strains was 
comparable to that of strains from other geographic regions. 
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Group B streptococcus (GBS), also known as Streptococcus agalactiae is a Gram-positive, β-
hemolytic, chain-forming bacterium and a commensal within the genital tract flora in 
approximately 25% of healthy adult women (Campbell et al., 2000). The organism is a 
leading cause of serious infection in newborns, pregnant women, and older persons with 
chronic medical illness (Baker et al., Edwards&Baker, 2005). In neonates GBS infection most 
commonly causes pneumonia, meningitis, and sepsis. In addition to maternal 
cervicovaginal colonization and neonatal infection that can result from vertical transmission 
of GBS from mothers to their infants, the bacterium can also cause urinary tract infection 
(UTI). The spectrum of GBS UTI includes asymptomatic bacteriuria (ABU), cystitis, 
pyelonephritis, urethritis, and urosepsis (Bronsema et al., 1993, Edwards&Baker, 2005, 
Farley et al., 1993, Lefevre et al., 1991, McKenna et al., 2003, Munoz et al., 1992, Ulett et al., 
2009). GBS ABU is particularly common among pregnant women, although those most at 
risk for cystitis due to GBS appear to be elderly individuals (Edwards&Baker, 2005, Falagas 
et al., 2006, Muller et al., 2006). In addition to acute and asymptomatic UTI other invasive 
diseases caused by GBS infection include skin infections, bacteraemia, pneumonia, arthritis, 
and endocarditis (Liston et al., 1979, Patil&Martin, 2010, Tissi et al., 1997, Trivalle et al., 
1998). Thus, GBS is considered unique in terms of its ability to cause a spectrum of diseases 
in newborns and adult humans and its ability to colonize the genital tract of healthy women 
in a commensal-type manner. In contrast to GBS disease conditions resulting from neonatal 
infection, the clinical and microbiological features of GBS UTI and asymptomatic genital 
tract colonization are not well characterized. Moreover, the risk factors for the various 
diseases caused by GBS including UTI and the pathogenesis of the different diseases caused 
as a result of GBS infection are not well defined. 
Recent advances in the awareness, diagnosis and treatment of GBS infections, particularly in 
relation to vertical transmission and neonatal infection, have significantly reduced mortality 
in the newborn population. Establishment of preventative and treatment guidelines by the 
Centres for Disease Control (CDC) beginning in the 1990s has resulted in a reduction in 
mortality rates due to acute GBS infection in newborns from approximately 30-50% to 4–5% 
(Dermer et al., 2004). Guidelines for the prevention of GBS infections in newborns first 
published in 1992 and revised in 1997 include surveillance programs and administration of 
antibiotics during labour (intrapartum antibiotic chemoprophylaxis) (1992, 1997). Since the 
mid-1990s, most pregnant women in the United States have been screened for infection by 
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GBS and the success of intrapartum antibiotic chemoprophylaxis for the prevention of 
vertical transmission of GBS has been noted (Verani et al., 2010). However, preventive 
strategies to identify at-risk individuals are controversial and the rates of GBS-related 
stillbirths, prematurity, and late onset disease (LOD) have not decreased (Gibbs et al., 2004). 
The incidence of morbidities in newborn survivors of acute GBS infection ranges from 20–
60% and includes neurological sequelae (Gibbs et al., 2004, Lukacs et al., 2004). The manner 
in which specific preventative strategies are implemented may also affect disease prevalence 
due to GBS in some areas (Krasnianin et al., 2009, Rausch et al., 2009). Thus, infections due 
to GBS and the ensuing diseases that result remain a significant cause of morbidity and 
mortality in newborns as well as healthy adults (Berner, 2004, van der Poll&Opal, 2008). 
In addition to representing a major infection risk for neonates and pregnant women GBS is 
also a prominent pathogen of the elderly, immunocompromised, and individuals with 
diabetes and malignancies. These populations are particularly at risk for invasive GBS 
infection (Edwards&Baker, 2005, Farley, 2001). The manifestations of GBS infection in these 
populations are highly varied; however, some of the most common clinical presentations 
include skin and soft tissue infections, bacteraemia, pneumonia, arthritis, UTI, and 
endocarditis (Baker, 1997, Farley, 2001, Lee et al., 2007, Trivalle et al., 1998). The case fatality 
rate for GBS infection in elderly adults was estimated to be approximately 15% in the United 
States between 2001 and 2005 (Edwards&Baker, 2005, Farley, 2001). Importantly, there is no 
vaccine currently available to prevent GBS disease in neonates or adults despite a 
substantial research effort in identifying potential immunogens as vaccine candidates in 
immunization strategies (Doro et al., 2009).  
The recent emergence of GBS strains that are resistant to multiple antibiotics represents a 
significant concern in the treatment of these infections in adults and children (Andrews et 
al., 2000, Bland et al., 2001, Dahesh et al., 2008, Heelan et al., 2004, Kimura et al., 2008, 
Nagano et al., 2008, Simoes et al., 2004). Penicillin-derived antibiotics remain the drugs of 
choice for treatment of GBS infections in infants and adults (Sendi et al., 2008, 
Verani&Schrag, 2010). These antibiotics inhibit cell wall synthesis during active growth of 
the bacteria. Vancomycin, cefezolin, clindamycin and telavancin are also used for the 
treatment of GBS infections. Trends of increasing antibiotic resistance (Edwards, 2006) may 
reflect clonal dissemination and horizontal transfer of resistance genes, which occurs among 
some GBS isolates (Puopolo et al., 2007). In addition, the identification of GBS strains 
resistant to penicillin, clindamycin and erythromycin represents a significant concern for the 
treatment of infections (Andrews et al., 2000, Bland et al., 2001, Dahesh et al., 2008, Heelan et 
al., 2004, Kimura et al., 2008, Nagano et al., 2008, Simoes et al., 2004). A large number of 
microbiological studies on GBS infection over the past two decades have underscored the 
importance of GBS as a major public health concern and a need for improvements in 
preventative and therapeutic strategies. An improved understanding of the mechanisms of 
GBS disease pathogenesis is vital for such strategies. 
1.1 Host range and GBS serotypes 
GBS was once seen only as a veterinary pathogen. The organism was originally isolated 
from cattle in the 1930s and prior to the 1980s was regarded as a prominent cause of bovine 
mastitis in dairy cows. Indeed, the species name, agalactiae, translates to "no milk" and 
reflects this history. Subsequently, epidemiology and prevalence studies indicated that GBS 
was associated with disease in neonates and the bacterium was increasingly recognized 
beginning in 1977 as a major cause of postpartum infection in human newborns (Ferrieri et 
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al., 1977). GBS is now universally accepted as among the most common causes of neonatal 
sepsis and meningitis. Research in the mid-1980s demonstrated that GBS was carried in the 
genital tract and the gastrointestinal flora in up to 30% of healthy adult women, which 
reflected intermittent, transient, or persistent colonization (Boyer et al., 1983, Dillon et al., 
1982). Over the last fifteen years studies have demonstrated that GBS is a significant cause of 
serious disease in non-pregnant adults including elderly people and immunocompromised 
individuals. Emerging trends in GBS disease incidence and prevalence strongly suggest that 
changes in the recognition and treatment of GBS infections are impacting the types of 
individuals affected by the bacterium and invasive disease in adults is now more common 
than in neonates (Baker, 2000. , Falagas et al., 2006, Muller et al., 2006).  
There are ten different capsular serotypes of GBS, namely Ia, Ib, and II-IX. These are based 
on the structure of the surface polysaccharide capsule of the bacterium. Nontypeable GBS 
also exist and are associated with some infections in humans including UTI (Baker&Barrett, 
1974, McKenna et al., 2003, Persson et al., 1985). Capsular serotyping of GBS can be 
performed by latex agglutination using commercial antisera (Slotved et al., 2003), which 
differentiates the major Lancefield groups (Facklam, 2002) based on serotype-specific 
antibody-based binding. Molecular serotyping (MS) methods have gained popularity and 
can provide additional insight into serotype traits that are not able to be derived from 
antisera-based approaches, possibly as a result of limited antigen expression in some strains 
(Ferrieri et al., 2004, Kong et al., 2002, Manning et al., 2008, Ramaswamy et al., 2006, Wen et 
al., 2006). MS identification of all ten serotypes is possible (MS Ia, Ib, and II-IX) with the use 
of a multiplex PCR and reverse line blot hybridization assay targeting a GBS species-specific 
gene (cfb) and serotype-specific sequences in various other capsular loci genes (Kong et al., 
2005). Among the ten different types, the serotypes most frequently associated with serious 
disease are serotypes Ia, II, III, and V (Edwards&Baker, 2005). There is some evidence to 
suggest that switching can occur between capsular types in GBS (Martins et al., 2010). 
1.2 GBS disease spectrum and Co-morbidities 
GBS is a frequent cause of puerperal infections including pneumonia, sepsis, meningitis, 
amnionitis and endometritis. These infections are common in newborns, pregnant women, 
and adults with underlying medical conditions (Nizet et al., 2000, Pass et al., 1982). Diabetes 
mellitus and malignancy are among the most common underlying conditions associated 
with these GBS infections (Huang et al., 2006). Other co-morbidities that have been 
associated with GBS disease in adults include cardiovascular abnormalities, genitourinary 
disorders, neurologic deficits, cirrhosis, steroid use, AIDS, renal dysfunction, and peripheral 
vascular disease. Relapse of GBS disease in affected individuals is not uncommon, with 
approximately 5% of non-pregnant adults experiencing a second episode of GBS disease 
after resolution of the primary infection (Sendi et al., 2008). The pathogenic basis of this 
recurrence is unknown but it is nonetheless an important consideration clinically.  
The nature of GBS as a frequent constituent of the resident vaginal bacterial microflora in 
healthy adult women means that the bacterium is regarded as a normal commensal under 
these circumstances. Colonized women often carry GBS for long periods of time and usually 
do not show clinical symptoms as a result of persistent genital tract infection. On the other 
hand, conditions during pregnancy may lead to increased GBS multiplication in the 
urogenital tract and GBS can grow to high numbers in human amniotic fluid. This may lead 
to serious consequences for both the colonized mother and the infant. Between 15%-45% of 
pregnant women harbour GBS in the gastrointestinal and or genitourinary tracts (Schuchat, 
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1998); neonates acquire the bacteria at birth from their asymptomatically colonized mothers 
in approximately 1% of all live births (Baker, 2000. , Nandyal, 2008, Schuchat, 1998). The 
neonatal lung can receive a substantial inoculum from infected amniotic fluid at birth (Nizet 
et al., 2000). In addition, GBS may be acquired by the growing fetus prior to birth in utero, 
which can trigger adverse pregnancy outcomes. Thus, GBS continues to be an important 
perinatal pathogen but causes a wide spectrum of diseases that is associated with various 
co-morbidities.  
1.3 Detection and identification of GBS 
The majority of GBS infections can be diagnosed through routine laboratory testing of 
clinical samples such as blood, cerebrospinal fluid, or aspirates from sites of local 
suppuration. In the majority of cases isolates are rapidly identified by typical colony 
morphology on agar medium such as tryptic soy agar-5% sheep blood, and are tested for 
catalase, which streptococci do not express. Isolates are grouped into the Lancefield B group 
(Facklam, 2002) using commercial typing antisera for latex agglutination assays. GBS 
antigens can occasionally be detected in blood, cerebrospinal fluid, and urine but are not 
routinely tested for in any diagnostic assays. A Gram stain of a clinical specimen can be 
useful in the detection of infection but is not specific and therefore not definitive for 
identification. Polymerase chain reaction and optical immunoassay may, on the other hand, 
provide rapid and specific results for the detection of GBS infection; however, optimization 
and validation of these assays to ensure sensitivity and specificity has limited their 
widespread application in the clinical laboratory (Daniels et al., 2009, Schwope et al., 2010).  
1.4 GBS virulence factors and host cell responses 
A number of GBS virulence factors that contribute to disease and infection in the host have 
been discovered. The role of these GBS virulence factors in UTI remains unexplored. A 
number of exotoxigenic virulence factors are produced by GBS, including hyaluronate lyase, 
Christine Atkins Munch Peterson (CAMP) factor, superoxide dismutase, proteases, 
nucleases, platelet-activating factor, collagenase/oligopeptidase, protein c, RIB, R protein, 
and C5a peptidase (Lindahl et al., 2005, Liu&Nizet, 2004, Nizet et al., 2000). The functions 
and structures of several of these virulence factors are reviewed elsewhere (Liu&Nizet, 
2004). One of the major GBS virulence factor is the sialic acid-rich capsular polysaccharide, 
which has been extensively studied as a virulence factor for many years (Slotved et al., 
2007). Capsular polysaccharide is anti-phagocytic and influences the pathogenicity of GBS 
by mediating evasion of phagocytes (Adderson et al., 2000). GBS lipotechoic acid (LTA) is 
another key virulence factor that contributes to successful infection in the host. GBS LTA is 
cytotoxic to human monocytes and induces inflammation including the production of pro-
inflammatory cytokines such as TNF-α (Berner, 2002). Cytotoxicity including the ability to 
induce programmed cell death (PCD) in host cells may contribute to disease by promoting 
adhesion, invasion, and host immune-evasion (Nizet et al., 2000). β-hemolysin is produced 
in varying amounts by virtually all clinical isolates of GBS and has several known roles in 
virulence including cytotoxicity (Liu&Nizet, 2004, Nizet et al., 2000). β-hemolysin is 
expressed on the surface of GBS and is responsible for the characteristic β-hemolytic activity 
on blood agar (Nizet, 2002, Nizet et al., 2000). β-hemolysin has a role in early but not late 
PCD and its expression is abolished by glucose (Fettucciari et al., 2000, Ulett et al., 2003). 
Several virulence factors of GBS including LTA, β-hemolysin, C5a peptidase and the R 
protein/antigen are involved in recognition by host cells and inducing or evading immune 
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responses (Cheng et al., 2001, Fasola et al., 1996, Henneke et al., 2005, Liu et al., 2004). The 
proficiency of GBS recognition by macrophages is considered a crucial component of early 
immune responses against the bacteria (Chattopadhyay et al., 2011, Franke-Ullmann et al., 
1996, Jonsson et al., 1985, Sherman et al., 1992, Sibille&Reynolds, 1990). However, GBS are 
able to persist inside macrophages for an extended period of time after nonopsonic 
phagocytosis and eventually trigger death of the host cell (Cornacchione et al., 1998, 
Fettucciari et al., 2000, Ulett et al., 2003, Valenti-Weigand et al., 1996). Intracellular 
persistence and manipulation of death pathways in macrophages may represent a virulence 
mechanism whereby GBS contributes to the characteristically poor inflammatory response 
in the neonatal lung. GBS-induced cell death is also a prominent feature of hepatocytes in a 
rabbit model of GBS sepsis (Ring et al., 2002) and in neurons of the dentate gyrus in GBS 
meningitis (Bogdan et al., 1997).  
2. Bacterial UTI: general aspects 
Ten to forty percent of adult women will contract at least one UTI in their lifetime, and 
approximately 3% will experience more than one infection per year (Andriole&Patterson, 
1991, Patton et al., 1991, Foxman, 2002). UTI are the second most common infectious 
diseases in humans after respiratory tract infections, and contribute to approximately 60 
million hospital visits per year. The costs to health care systems have been estimated at over 
$2 billion annually (Andriole&Patterson, 1991, Barnett&Stephens, 1997, Hooton&Stamm, 
1997, Patton et al., 1991). Chronic UTI are difficult to prevent and treat, and infections are 
often recurrent. Over 80% of UTI are caused by uropathogenic Escherichia coli (UPEC) 
(Ronald, 2002). Approximately 2% of UTI are caused by GBS. Among an estimated 40% of 
all adult women who will experience a UTI episode in their lifetime almost 1% will suffer 
UTI caused by GBS (Foxman, 2002). The urinary tract is a distinct mucosal surface of the 
body and bacterial colonization of the uroepithelium is unique compared to other mucosal 
surfaces. Colonizing bacteria must overcome the normal flushing actions of urine flow and 
the physical barrier of the uroepithelial lining. This lining embodies a tightly interlaced 
latticework of proteins called uroplakins (Apodaca, 2004). These are closely associated with 
a collection of lipids, sphingolipids, and cholesterol referred to as lipid rafts that 
cumulatively constitute a surface that is highly impregnable to urine, solutes, and potential 
pathogens such as UPEC and GBS (Apodaca, 2004). 
2.1 Prevalence of GBS in the urinary tract 
The spectrum of UTI caused by GBS includes ABU, cystitis, pyenorephritis, urethritus, and 
urosepsis (Bronsema et al., 1993, Farley et al., 1993, Lefevre et al., 1991, McKenna et al., 2003, 
Munoz et al., 1992). In many cases, GBS colonization of the urinary tract in women probably 
occurs by an ascending route from the vagina, where GBS can persist asymptomatically. 
GBS is cultured from approximately 2% of all UTI cases (de Mouy et al., 2007, Munoz et al., 
1992, Persson et al., 1988). In the most recent single-centre analysis of adult patients in the 
United States GBS was cultured from urine during routine assessment for UTI in 2% of 
patients; most of these represented ABU (Ulett et al., 2009). This is consistent with findings 
in other studies (Aungst et al., 2004, Le et al., 2004). However, several studies have reported 
high rates of GBS UTI in non-pregnant adults (Edwards&Baker, 2005, Falagas et al., 2006, 
Muller et al., 2006, Toumi et al., 2006). In one study, GBS was cultured from 39% of all cases 
of symptomatic UTI among nursing home residents >70 years of age (Trivalle et al., 1998). 
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1998); neonates acquire the bacteria at birth from their asymptomatically colonized mothers 
in approximately 1% of all live births (Baker, 2000. , Nandyal, 2008, Schuchat, 1998). The 
neonatal lung can receive a substantial inoculum from infected amniotic fluid at birth (Nizet 
et al., 2000). In addition, GBS may be acquired by the growing fetus prior to birth in utero, 
which can trigger adverse pregnancy outcomes. Thus, GBS continues to be an important 
perinatal pathogen but causes a wide spectrum of diseases that is associated with various 
co-morbidities.  
1.3 Detection and identification of GBS 
The majority of GBS infections can be diagnosed through routine laboratory testing of 
clinical samples such as blood, cerebrospinal fluid, or aspirates from sites of local 
suppuration. In the majority of cases isolates are rapidly identified by typical colony 
morphology on agar medium such as tryptic soy agar-5% sheep blood, and are tested for 
catalase, which streptococci do not express. Isolates are grouped into the Lancefield B group 
(Facklam, 2002) using commercial typing antisera for latex agglutination assays. GBS 
antigens can occasionally be detected in blood, cerebrospinal fluid, and urine but are not 
routinely tested for in any diagnostic assays. A Gram stain of a clinical specimen can be 
useful in the detection of infection but is not specific and therefore not definitive for 
identification. Polymerase chain reaction and optical immunoassay may, on the other hand, 
provide rapid and specific results for the detection of GBS infection; however, optimization 
and validation of these assays to ensure sensitivity and specificity has limited their 
widespread application in the clinical laboratory (Daniels et al., 2009, Schwope et al., 2010).  
1.4 GBS virulence factors and host cell responses 
A number of GBS virulence factors that contribute to disease and infection in the host have 
been discovered. The role of these GBS virulence factors in UTI remains unexplored. A 
number of exotoxigenic virulence factors are produced by GBS, including hyaluronate lyase, 
Christine Atkins Munch Peterson (CAMP) factor, superoxide dismutase, proteases, 
nucleases, platelet-activating factor, collagenase/oligopeptidase, protein c, RIB, R protein, 
and C5a peptidase (Lindahl et al., 2005, Liu&Nizet, 2004, Nizet et al., 2000). The functions 
and structures of several of these virulence factors are reviewed elsewhere (Liu&Nizet, 
2004). One of the major GBS virulence factor is the sialic acid-rich capsular polysaccharide, 
which has been extensively studied as a virulence factor for many years (Slotved et al., 
2007). Capsular polysaccharide is anti-phagocytic and influences the pathogenicity of GBS 
by mediating evasion of phagocytes (Adderson et al., 2000). GBS lipotechoic acid (LTA) is 
another key virulence factor that contributes to successful infection in the host. GBS LTA is 
cytotoxic to human monocytes and induces inflammation including the production of pro-
inflammatory cytokines such as TNF-α (Berner, 2002). Cytotoxicity including the ability to 
induce programmed cell death (PCD) in host cells may contribute to disease by promoting 
adhesion, invasion, and host immune-evasion (Nizet et al., 2000). β-hemolysin is produced 
in varying amounts by virtually all clinical isolates of GBS and has several known roles in 
virulence including cytotoxicity (Liu&Nizet, 2004, Nizet et al., 2000). β-hemolysin is 
expressed on the surface of GBS and is responsible for the characteristic β-hemolytic activity 
on blood agar (Nizet, 2002, Nizet et al., 2000). β-hemolysin has a role in early but not late 
PCD and its expression is abolished by glucose (Fettucciari et al., 2000, Ulett et al., 2003). 
Several virulence factors of GBS including LTA, β-hemolysin, C5a peptidase and the R 
protein/antigen are involved in recognition by host cells and inducing or evading immune 
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responses (Cheng et al., 2001, Fasola et al., 1996, Henneke et al., 2005, Liu et al., 2004). The 
proficiency of GBS recognition by macrophages is considered a crucial component of early 
immune responses against the bacteria (Chattopadhyay et al., 2011, Franke-Ullmann et al., 
1996, Jonsson et al., 1985, Sherman et al., 1992, Sibille&Reynolds, 1990). However, GBS are 
able to persist inside macrophages for an extended period of time after nonopsonic 
phagocytosis and eventually trigger death of the host cell (Cornacchione et al., 1998, 
Fettucciari et al., 2000, Ulett et al., 2003, Valenti-Weigand et al., 1996). Intracellular 
persistence and manipulation of death pathways in macrophages may represent a virulence 
mechanism whereby GBS contributes to the characteristically poor inflammatory response 
in the neonatal lung. GBS-induced cell death is also a prominent feature of hepatocytes in a 
rabbit model of GBS sepsis (Ring et al., 2002) and in neurons of the dentate gyrus in GBS 
meningitis (Bogdan et al., 1997).  
2. Bacterial UTI: general aspects 
Ten to forty percent of adult women will contract at least one UTI in their lifetime, and 
approximately 3% will experience more than one infection per year (Andriole&Patterson, 
1991, Patton et al., 1991, Foxman, 2002). UTI are the second most common infectious 
diseases in humans after respiratory tract infections, and contribute to approximately 60 
million hospital visits per year. The costs to health care systems have been estimated at over 
$2 billion annually (Andriole&Patterson, 1991, Barnett&Stephens, 1997, Hooton&Stamm, 
1997, Patton et al., 1991). Chronic UTI are difficult to prevent and treat, and infections are 
often recurrent. Over 80% of UTI are caused by uropathogenic Escherichia coli (UPEC) 
(Ronald, 2002). Approximately 2% of UTI are caused by GBS. Among an estimated 40% of 
all adult women who will experience a UTI episode in their lifetime almost 1% will suffer 
UTI caused by GBS (Foxman, 2002). The urinary tract is a distinct mucosal surface of the 
body and bacterial colonization of the uroepithelium is unique compared to other mucosal 
surfaces. Colonizing bacteria must overcome the normal flushing actions of urine flow and 
the physical barrier of the uroepithelial lining. This lining embodies a tightly interlaced 
latticework of proteins called uroplakins (Apodaca, 2004). These are closely associated with 
a collection of lipids, sphingolipids, and cholesterol referred to as lipid rafts that 
cumulatively constitute a surface that is highly impregnable to urine, solutes, and potential 
pathogens such as UPEC and GBS (Apodaca, 2004). 
2.1 Prevalence of GBS in the urinary tract 
The spectrum of UTI caused by GBS includes ABU, cystitis, pyenorephritis, urethritus, and 
urosepsis (Bronsema et al., 1993, Farley et al., 1993, Lefevre et al., 1991, McKenna et al., 2003, 
Munoz et al., 1992). In many cases, GBS colonization of the urinary tract in women probably 
occurs by an ascending route from the vagina, where GBS can persist asymptomatically. 
GBS is cultured from approximately 2% of all UTI cases (de Mouy et al., 2007, Munoz et al., 
1992, Persson et al., 1988). In the most recent single-centre analysis of adult patients in the 
United States GBS was cultured from urine during routine assessment for UTI in 2% of 
patients; most of these represented ABU (Ulett et al., 2009). This is consistent with findings 
in other studies (Aungst et al., 2004, Le et al., 2004). However, several studies have reported 
high rates of GBS UTI in non-pregnant adults (Edwards&Baker, 2005, Falagas et al., 2006, 
Muller et al., 2006, Toumi et al., 2006). In one study, GBS was cultured from 39% of all cases 
of symptomatic UTI among nursing home residents >70 years of age (Trivalle et al., 1998). 
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Other studies have reported that GBS UTI may account for up to one-third of all invasive 
infections due to GBS in elderly adults (Falagas et al., 2006, Hernaiz et al., 2004, Lefebvre et 
al., 2007, Munoz et al., 1992) and up to 7% of late-onset disease in neonates (Yagupsky et al., 
1991). Urinary tract abnormalities, chronic renal failure (Munoz et al., 1992), 
diabetes mellitus (Ronald, 2003), corticosteroid use (Falagas et al., 2006), and prior UTI (Ulett 
et al., 2009) are among risk factors for GBS UTI.  
2.2 GBS ABU and UTI in pregnancy 
While the overall prevalence of GBS UTI remains unclear, GBS bacteriuria during pregnancy 
occurs at rates of between 1 and 3.5% (Baker, 1997, McKenna et al., 2003, Whitney et al., 
2004). Approximately 2-7% of pregnant women exhibit ABU caused by GBS and GBS ABU 
during pregnancy is considered a surrogate marker for heavy maternal genital tract 
colonization (Liston et al., 1979, McKenna et al., 2003, Moller et al., 1984, Persson et al., 
1986a, Wood&Dillon, 1981) and is indicated for intrapartum antibiotic chemoprophylaxis 
(McKenna et al., 2003, Schrag et al., 2002). In addition, up to 7% of pregnancies may be 
complicated by GBS UTI, and GBS reportedly accounts for approximately 10% of all cases of 
pyelonephritis during pregnancy (Muller et al., 2006, Persson et al., 1986a, Persson et al., 
1986b). GBS UTI may also contribute to chorioamnionitis (Anderson et al., 2007), premature 
onset of labour (Moller et al., 1984), and an increased risk of vertical transmission of GBS  
(Persson et al., 1985, Wood&Dillon, 1981). Stemming from this, maternal GBS ABU 
(including pure and predominant growth of GBS in the urine) has been associated with 
vertical transmission and an increased risk for early-onset disease (EOD) in newborn infants 
(Heath et al., 2009, Liston et al., 1979, Moller et al., 1984, Persson et al., 1986a, Persson et al., 
1985, Wood&Dillon, 1981). One study found an elevated risk for EOD among infants born to 
women with low colony-count GBS ABU compared with mothers who did not have GBS 
ABU (Weng et al., 2010). However, studies have also demonstrated that some women with 
GBS ABU during the first trimester of pregnancy may not exhibit vaginal-rectal colonization 
at 35-37 weeks gestation (McKenna et al., 2003) or at the time of delivery (Edwards et al., 
2002). Thus, while maternal ABU does not necessarily lead to vertical transmission, ABU at 
any point during pregnancy may be a risk factor for neonatal EOD and has therefore been 
an indication for intrapartum antibiotic chemoprophylaxis since 1996 (Schrag et al., 2002, 
Yancey et al., 1996). ABU may also be an indicator of potential preterm labour (Schrag et al., 
2002, Yancey et al., 1996). The American College of Obstetricians and Gynecologists (ACOG) 
and CDC guidelines recommend the evaluation of pregnant women at 35-37 weeks 
gestation and antibiotic therapy for women with positive cultures for GBS ABU. The 1996 
ACOG and CDC guidelines do not specify a colony-count threshold for defining GBS ABU. 
However, the 2002 and more recent guidelines recommend reporting of GBS at any 
concentration in urine (Lin&Fajardo, 2008). Finally, although pregnant women may receive 
antibiotics to treat GBS ABU this therapy may not eliminate GBS from the genitourinary 
tract, and recolonization after a course of antibiotics can occur (Baecher&Grobman, 2008, 
Gardner et al., 1979, Hall et al., 1976). 
Most data on the risk for EOD among infants born to women with GBS ABU are derived 
from studies using thresholds >105 cfu/ml despite lower counts of 103 cfu/ml having been 
associated with acute GBS UTI (Persson et al., 1986b, Persson et al., 1985, Ulett et al., 2009, 
Wood&Dillon, 1981). Although low concentrations (103-104 cfu/ml) of GBS in urine can be 
associated with colonization (Centelles-Serrano et al., 2009) limited data support the risk for 
EOD among infants born to women with low colony-count GBS ABU (Persson et al., 1986a). 
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The recommendation to report any colony count of GBS in urine represents increased 
workload for clinical laboratories, which generally do not report bacterial growth in urine of 
other pathogens at concentrations <104 cfu/ml (McCarter et al., 2009) and rarely know 
whether urine samples are from pregnant women. In the context of universal late antenatal 
GBS  screening, it is unclear how much EOD is prevented by screening for low colony-count 
GBS ABU and whether identification of low colony-count bacteriuria is cost-effective. 
2.3 Diagnosis of GBS UTI 
Diagnostic strategies for UTI vary substantially between clinicians (Hay&Fahey, 2002, 
Kaufmann&Modest, 2002, Libbus, 2002); however, patients with a combination of symptoms 
have a high probability of UTI (Bent et al., 2002, Nicolle, 2008). Pyuria concurrently with 
bacteriuria constitutes diagnostic criteria in some settings (Shaikh et al., 2007), although 
what constitutes clinically significant bacteriuria is not strictly defined; colony counts 
>103 cfu/ml of a uropathogen is however, now widely accepted diagnostic criteria for 
cystitis (Nicolle, 2008, Rubin et al., 1992). Clinically, UTI due to GBS may be 
indistinguishable from UTI caused by other uropathogens (Muller et al., 2006). A recent 
study of multiple uropathogens highlighted unique frequencies of host characteristics in UTI 
groups defined by the causal organism (Tabibian et al., 2008). This suggests that the clinical 
and microbiological features of UTI may differ depending on the infecting pathogen and the 
most ideal diagnostic approaches may depend on the causal organism. In one study the 
investigators regarded single-organism GBS bacteriuria and at least one UTI symptom as 
being a probable case of UTI  and used urinary leukocyte esterase with pyuria as 
confirmatory for diagnosis (Ulett et al., 2009). Here, a provisional diagnosis was defined by 
the presence of single-organism GBS bacteriuria (>104 cfu/ml) with at least one symptom 
that included dysuria, increased urinary frequency and/or urgency, fever of >38°C, flank 
pain, and/or lumbar tenderness. In cases where urinalysis (UA) was performed, UTI was 
confirmed on the basis of positive urinary leukocyte esterase and significant pyuria 
(≥107 white blood cells/high-power field; non-spun). These are the generally accepted 
criteria for the diagnosis of UTI (Hay&Fahey, 2002, Kaufmann&Modest, 2002, Libbus, 2002) 
although inclusion of bacteriuria counts of >103 cfu/ml may provide additional clinical 
relevance. In this study group, patients were grouped into probable GBS UTI where UA was 
not performed and confirmed cases where (positive) UA data were available. Individuals 
defined as having GBS isolated from urine incidentally were selected on the basis of low-
grade GBS bacteriuria (<104 cfu/ml) in the absence of symptoms. In this study, multiple 
patients were identified who had symptoms of UTI and positive UA findings but had GBS 
bacteriuria counts between 103-105 cfu/ml, which is consistent with reports that up to 30% of 
women with cystitis present with bacteriuria of <105 cfu/ml. Thus, the level of bacteriuria in 
GBS UTI may not correlate well with acute disease. The serotypes of GBS associated with 
UTI have not been well defined; however it appears that most serotypes can cause acute 
UTI. MS and antisera-based serotyping was used in one study to identify the serotypes 
associated with UTI (Ulett et al., 2009), and demonstrated a predominance of serotypes Ia, II, 
III, and V in patients with acute UTI. Other studies demonstrated that nontypeable GBS also 
cause acute UTI (McKenna et al., 2003, Persson et al., 1985).  
2.4 How does GBS colonize the urogenital tract?  
GBS infection often begins with binding to epithelial cells at mucosal surfaces, such as those 
lining the respiratory or urogenital tracts. GBS are able bind to human vaginal epithelial 
cells under low pH conditions, which are characteristic of vaginal mucosa. These 
 
Clinical Management of Complicated Urinary Tract Infection 
 
56
Other studies have reported that GBS UTI may account for up to one-third of all invasive 
infections due to GBS in elderly adults (Falagas et al., 2006, Hernaiz et al., 2004, Lefebvre et 
al., 2007, Munoz et al., 1992) and up to 7% of late-onset disease in neonates (Yagupsky et al., 
1991). Urinary tract abnormalities, chronic renal failure (Munoz et al., 1992), 
diabetes mellitus (Ronald, 2003), corticosteroid use (Falagas et al., 2006), and prior UTI (Ulett 
et al., 2009) are among risk factors for GBS UTI.  
2.2 GBS ABU and UTI in pregnancy 
While the overall prevalence of GBS UTI remains unclear, GBS bacteriuria during pregnancy 
occurs at rates of between 1 and 3.5% (Baker, 1997, McKenna et al., 2003, Whitney et al., 
2004). Approximately 2-7% of pregnant women exhibit ABU caused by GBS and GBS ABU 
during pregnancy is considered a surrogate marker for heavy maternal genital tract 
colonization (Liston et al., 1979, McKenna et al., 2003, Moller et al., 1984, Persson et al., 
1986a, Wood&Dillon, 1981) and is indicated for intrapartum antibiotic chemoprophylaxis 
(McKenna et al., 2003, Schrag et al., 2002). In addition, up to 7% of pregnancies may be 
complicated by GBS UTI, and GBS reportedly accounts for approximately 10% of all cases of 
pyelonephritis during pregnancy (Muller et al., 2006, Persson et al., 1986a, Persson et al., 
1986b). GBS UTI may also contribute to chorioamnionitis (Anderson et al., 2007), premature 
onset of labour (Moller et al., 1984), and an increased risk of vertical transmission of GBS  
(Persson et al., 1985, Wood&Dillon, 1981). Stemming from this, maternal GBS ABU 
(including pure and predominant growth of GBS in the urine) has been associated with 
vertical transmission and an increased risk for early-onset disease (EOD) in newborn infants 
(Heath et al., 2009, Liston et al., 1979, Moller et al., 1984, Persson et al., 1986a, Persson et al., 
1985, Wood&Dillon, 1981). One study found an elevated risk for EOD among infants born to 
women with low colony-count GBS ABU compared with mothers who did not have GBS 
ABU (Weng et al., 2010). However, studies have also demonstrated that some women with 
GBS ABU during the first trimester of pregnancy may not exhibit vaginal-rectal colonization 
at 35-37 weeks gestation (McKenna et al., 2003) or at the time of delivery (Edwards et al., 
2002). Thus, while maternal ABU does not necessarily lead to vertical transmission, ABU at 
any point during pregnancy may be a risk factor for neonatal EOD and has therefore been 
an indication for intrapartum antibiotic chemoprophylaxis since 1996 (Schrag et al., 2002, 
Yancey et al., 1996). ABU may also be an indicator of potential preterm labour (Schrag et al., 
2002, Yancey et al., 1996). The American College of Obstetricians and Gynecologists (ACOG) 
and CDC guidelines recommend the evaluation of pregnant women at 35-37 weeks 
gestation and antibiotic therapy for women with positive cultures for GBS ABU. The 1996 
ACOG and CDC guidelines do not specify a colony-count threshold for defining GBS ABU. 
However, the 2002 and more recent guidelines recommend reporting of GBS at any 
concentration in urine (Lin&Fajardo, 2008). Finally, although pregnant women may receive 
antibiotics to treat GBS ABU this therapy may not eliminate GBS from the genitourinary 
tract, and recolonization after a course of antibiotics can occur (Baecher&Grobman, 2008, 
Gardner et al., 1979, Hall et al., 1976). 
Most data on the risk for EOD among infants born to women with GBS ABU are derived 
from studies using thresholds >105 cfu/ml despite lower counts of 103 cfu/ml having been 
associated with acute GBS UTI (Persson et al., 1986b, Persson et al., 1985, Ulett et al., 2009, 
Wood&Dillon, 1981). Although low concentrations (103-104 cfu/ml) of GBS in urine can be 
associated with colonization (Centelles-Serrano et al., 2009) limited data support the risk for 
EOD among infants born to women with low colony-count GBS ABU (Persson et al., 1986a). 
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The recommendation to report any colony count of GBS in urine represents increased 
workload for clinical laboratories, which generally do not report bacterial growth in urine of 
other pathogens at concentrations <104 cfu/ml (McCarter et al., 2009) and rarely know 
whether urine samples are from pregnant women. In the context of universal late antenatal 
GBS  screening, it is unclear how much EOD is prevented by screening for low colony-count 
GBS ABU and whether identification of low colony-count bacteriuria is cost-effective. 
2.3 Diagnosis of GBS UTI 
Diagnostic strategies for UTI vary substantially between clinicians (Hay&Fahey, 2002, 
Kaufmann&Modest, 2002, Libbus, 2002); however, patients with a combination of symptoms 
have a high probability of UTI (Bent et al., 2002, Nicolle, 2008). Pyuria concurrently with 
bacteriuria constitutes diagnostic criteria in some settings (Shaikh et al., 2007), although 
what constitutes clinically significant bacteriuria is not strictly defined; colony counts 
>103 cfu/ml of a uropathogen is however, now widely accepted diagnostic criteria for 
cystitis (Nicolle, 2008, Rubin et al., 1992). Clinically, UTI due to GBS may be 
indistinguishable from UTI caused by other uropathogens (Muller et al., 2006). A recent 
study of multiple uropathogens highlighted unique frequencies of host characteristics in UTI 
groups defined by the causal organism (Tabibian et al., 2008). This suggests that the clinical 
and microbiological features of UTI may differ depending on the infecting pathogen and the 
most ideal diagnostic approaches may depend on the causal organism. In one study the 
investigators regarded single-organism GBS bacteriuria and at least one UTI symptom as 
being a probable case of UTI  and used urinary leukocyte esterase with pyuria as 
confirmatory for diagnosis (Ulett et al., 2009). Here, a provisional diagnosis was defined by 
the presence of single-organism GBS bacteriuria (>104 cfu/ml) with at least one symptom 
that included dysuria, increased urinary frequency and/or urgency, fever of >38°C, flank 
pain, and/or lumbar tenderness. In cases where urinalysis (UA) was performed, UTI was 
confirmed on the basis of positive urinary leukocyte esterase and significant pyuria 
(≥107 white blood cells/high-power field; non-spun). These are the generally accepted 
criteria for the diagnosis of UTI (Hay&Fahey, 2002, Kaufmann&Modest, 2002, Libbus, 2002) 
although inclusion of bacteriuria counts of >103 cfu/ml may provide additional clinical 
relevance. In this study group, patients were grouped into probable GBS UTI where UA was 
not performed and confirmed cases where (positive) UA data were available. Individuals 
defined as having GBS isolated from urine incidentally were selected on the basis of low-
grade GBS bacteriuria (<104 cfu/ml) in the absence of symptoms. In this study, multiple 
patients were identified who had symptoms of UTI and positive UA findings but had GBS 
bacteriuria counts between 103-105 cfu/ml, which is consistent with reports that up to 30% of 
women with cystitis present with bacteriuria of <105 cfu/ml. Thus, the level of bacteriuria in 
GBS UTI may not correlate well with acute disease. The serotypes of GBS associated with 
UTI have not been well defined; however it appears that most serotypes can cause acute 
UTI. MS and antisera-based serotyping was used in one study to identify the serotypes 
associated with UTI (Ulett et al., 2009), and demonstrated a predominance of serotypes Ia, II, 
III, and V in patients with acute UTI. Other studies demonstrated that nontypeable GBS also 
cause acute UTI (McKenna et al., 2003, Persson et al., 1985).  
2.4 How does GBS colonize the urogenital tract?  
GBS infection often begins with binding to epithelial cells at mucosal surfaces, such as those 
lining the respiratory or urogenital tracts. GBS are able bind to human vaginal epithelial 
cells under low pH conditions, which are characteristic of vaginal mucosa. These 
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interactions occur via low avidity interactions of cell-wall-associated LTA and via higher-
affinity interactions mediated by hydrophobic GBS surface proteins (Tamura et al., 1994). 
Many of these host-cell interactions involve attachment of GBS to extracellular matrix 
molecules such as fibronectin, fibrinogen and laminin, which in turn bind host-cell-surface 
proteins such as integrins (Maisey et al., 2008). For example, ScpB, which is a GBS cell-
surface protein previously characterised for its ability to cleave the complement-derived 
chemoattractant C5a (Beckmann et al., 2002), can bind fibronectin (Cheng et al., 2002). ScpB 
can bind to integrins, which may promote both binding to host cells and complement 
proteolysis (Brown et al., 2005). Naturally occurring ScpB variants with a deletion that 
destroys peptidase function retain the capacity to bind fibronectin (Cleary et al., 2004, 
Tamura et al., 2006). GBS attachment to fibrinogen is mediated by the surface-anchored 
protein FbsA (Schubert et al., 2004), and adherence to laminin involves the adhesin Lmb 
(Spellerberg et al., 1999). The serine-rich repeat domain protein Srr-1 binds human keratin 4 
(Samen et al., 2007) and the GBS surface protein LrrG, containing the leucine-rich-repeat 
motif found in many invasins, binds to epithelial cells, suggesting that it serves as an 
adhesin during GBS infection (Seepersaud et al., 2005). In each of these examples, these 
binding interactions probably promote GBS adherence to epithelial cells.  
GBS were also recently shown to express pili (Lauer et al., 2005), which typically facilitate 
Gram-negative bacterial attachment to host cells (Sauer et al., 2000). Among eight sequenced 
GBS genomes, two genetic loci encoding pili were identified, the second existing in one of 
two variants, although not all genomes contain both loci (Rosini et al., 2006). GBS pilus 
island 2’ includes the genes encoding PilB, an LP(x)TG-motif-containing protein that 
polymerises to form a pilus backbone, and accessory pilus proteins PilA and PilC (Dramsi et 
al., 2006, Maisey et al., 2007). Epithelial cell adherence is reduced in isogenic GBS mutants 
lacking PilA or PilC, but not those lacking PilB (Dramsi et al., 2006). The role of GBS pili in 
binding in the urogenital tract is unknown.  
2.5 Modeling GBS UTI from clinical studies   
Uropathogenic GBS (UPGBS) have been shown to bind to both murine and human bladder 
uroepithelium in in vivo (Figure 1) and in vitro (Figure 2) studies. These models were 
developed to study the pathogen-host interaction underlying GBS UTI. UPGBS bind more 
efficiently to bladder epithelial mucosa when compared with non-UPGBS (Ulett et al., 2010). 
Binding models of GBS UTI to study host cell interactions in vivo and in vitro have been 
derived from clinical studies conducted in the past five years. The largest of these clinical 
studies of GBS UTI to date was performed in the United States using a cohort of 387 patients 
with positive GBS cultures in urine. This study investigated the traits of UPGBS that cause 
acute UTI and ABU using detailed analysis of patients groups alongside serotyping 
comparisons, and risk factor analysis. The study also investigated the demographic data 
alongside standard diagnostic microbiological measures for the defined patient groups, 
which are summarized in Table 1. In this study, a total of 62 patients of the 387 patients with 
positive GBS urine culture had single-organism bacteriuria >104 cfu/ml concurrent with at 
least one UTI symptom and were defined as having probable GBS UTI. The most prevalent 
serotypes of GBS causing UTI in this study according to MS were serotypes V, Ia, and III, as 
shown in Table 2. Together, these serotypes accounted for 76% of GBS UTI cases. Serotype 
III GBS was the only serotype that was more frequently isolated from UTI case patients 
than from controls. Thus, in this study GBS UTI occurred mostly as uncomplicated cystitis in 
middle-aged women (>50 yrs) in the absence of chronic underlying disease but was 
associated with a prior history of UTI.  
 











Fig. 1. UPGBS bound to bladder uroepithelium in a murine model of GBS cystitis (A–C, 
flattened bladder; D, native conformation). The arrows in panel D show bound UPGBS  
between folds of bladder uroepithelium. Panel E illustrates better bind of UPGBS to bladder 
mucosa compared with non-UPGBS although binding is not as efficient as uropathogenic 
Escherichia coli (UPEC) and levels of bacteriuria are simiular (F). Reproduced, along with 
Figure 2, with permission from (Ulett et al., 2010) courtesy of Oxford Journals. 
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Fig. 2. UPGBS (green) bound to human bladder cells (blue, nuclei; red F-actin) at 
multiplicities of infection of 50 (A) and 5 (B). Uninfected cells in (C). Measures of binding of 
UPGBS and non-UPGBS to T24 (D) and 5637 (E) cells shows higher binding of UPGBS.  
 





















Age (mean years; range) 46; 18-95 54; 19-82 52; 19-93 53; 19-93 30; 18-64 < 0.001g 
Female sex 322 (83) 25 (81) 27 (87) 52 (84) 46 (90) 0.002h 
Symptoms   
 
- Dysuria 68 (17.6) 18 (58.1) 17 (54.8) 35 (56.5) 0 (0) ND 
- Frequency 57 (14.7) 11 (35.5) 12 (38.7) 23 (37.1) 0 (0) ND 
- Flank pain 35 (9.0) 7 (22.6) 7 (22.6) 14 (22.6) 0 (0) ND 
- Fever 15 (4.0) 4 (13.0) 2 (6.0) 6 (10.0) 0 (0) ND 
- C/W cystitise 130 (33.6) 25 (80.6) 24 (77.4) 50 (81.0) 0 (0) ND 
- C/W pyleonphritisf 65 (16.8) 6 (19.4) 7 (22.6) 12 (19.0) 0 (0) ND 
Pregnant 99 (30.1) 1 (4) 5 (18.5) 6 (11.5) 35 (76)  
Possible Risk factors  
- Limited mobility 13 (3.4) 1 (3.2) 0 (0) 1 (1.6) 0 (0) 1.000 
- Diabetes mellitus 91 (23.5) 5 (16.1) 4 (12.9) 9 (14.5) 9 (17.6) 0.651 
- Chronic kidney disease 72 (18.6) 4 (12.9) 0 (0) 4 (6.5) 7 (13.7) 0.219 
- Indwelling urinary catheter 4 (1.0) 0 (0) 0 (0) 0 (0) 0 (0) ND 
- Altered mental status 14 (3.6) 3 (9.7) 2 (6.5) 5 (8.1) 0 (0) 0.063i 
- Prior History of UTI 76 (19.6) 9 (29.0) 9 (29.0) 18 (29.0) 6 (11.8) 0.032j 
Pure GBS isolated 207 (53.5) 31 (100) 31 (100) 62 (100) 15 (29.4) ND 
GBS count >107 cfu/L 319 (82.4) 31 (100) 31 (100) 62 (100) 0 (0) ND 
Mean GBS count (x 107/L) 4.7  3.6 7.4  3.5 6.1  3.1 6.7  3.4 0.5  0.3 ND 
UA done 210 (54.3) 31 (100) 0 (0) 31 (50) 9 (17.3) ND 
- Pyuria 114 (54.3) 31 (100) ND 31 (100) 0 (0) ND 
- Leukocyte esterase 122 (58.1) 31 (100) ND 31 (100) 0 (0) ND 
- Hematuria 74 (35.2) 21 (67.7) ND 21 (67.7) 2 (22) ND 
- +ve and C/W UTId-f 91 (43.3) 31 (100) ND 31 (100) 0 (0) ND 
 
 
Table 1. Patients who had GBS  isolated from urine during routine assessement for UTI at 
University of Alabama Hospital between August 2007-2008. NOTE. Data are no. (%) of 
patients, unless otherwise indicated; a. Consecutive urine specimens sent for culture, from 
which GBS  was isolated; b. Patients with ≥1 symptom(s) of UTI and pure growth of GBS  
>107 cfu/L; c. UA: +ve (consistent with UTI) positive leukocyte esterase and pyuria; ND not 
done; d. Subjects without symptoms from whose urine GBS  was isolated in counts <107/L; e. 
Symptoms consistent with (C/W) cystitis: dysuria and/or frequency; f. Symptoms C/W 
pyelonephritis: dysuria and/or frequency plus flank pain and/or fever >38ºC; g. By Mann–
Whitney U test; h. By Pearson 2 analysis. Gender comparisons performed using population 
data (equal group sizes) from the US Census Bureau for Birmingham (male-female ratio 
85.7); i. By Fisher’s exact test; j. By forward stepwise logistic regression subsequent to 
Pearson 2 analysis; Reproduced, with Table 2, with permission from (Ulett et al., 2009) 
courtesy of The American Society for Microbiology. 
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  n (%)   n (%)   n (%)   n (%)   n (%)
Ia 81 (21) 6 (19) 8 (26) 14 (23) 8 (16)
Ib 31 (8) 2 (7) 3 (10) 5 (8) 5 (10)
II 69 (18) 5 (16) 3 (10) 7 (11) 12 (24)
III 48 (12)e 8 (26) 5 (16) 13 (21)e 5 (10)
IV 24 (6) 2 (7) 1 (3) 3 (5) 5 (10)
V 125 (32) 8 (26) 12 (37) 20 (32) 10 (20)
VI 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
VII 0   (0) 0 (0) 0 (0) 0 (0) 0 (0)
VIII 2 (1) 0 (0) 0 (0) 0 (0) 1 (2)
NTf 7 (2) 0 (0) 0 (0) 0 (0) 5 (10)
IX 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
  
Table 2. Molecular serotypes of GBS that cause UTI, from the largest study of 387 patients 
with positive urine cultures for GBS to date. NOTE. Data are no. (%) of GBS  isolates, unless 
otherwise indicated; a. Consecutive urine specimens sent for culture, from which GBS  was 
isolated; b. Patients with ≥1 symptom(s) of UTI and pure growth of GBS  >107 cfu/L; c. UA: 
+ve (consistent with UTI) positive leukocyte esterase and pyuria; ND not done; d. Subjects 
without symptoms from whose urine GBS  was isolated in counts <107/L; e. Difference 
between the prevalence of serotype III among all GBS  UTI case patients and all other non-
GBS  UTI cases (n=325), significant by Pearson 2 analysis (P=0.026); f. Isolates were 
identified using antisera as: NT (3), II (2), IV (1) and V (1). 
3. Conclusions 
In summary, GBS is an important pathogen that causes serious infections in newborns, 
pregnant women, and elderly people with chronic illness. While early diagnosis and 
management of GBS among pregnant women can reduce the incidence of neonatal infection 
the prevalence of GBS disease in adult populations emphasizes the need for additional 
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preventative and therapeutic measures. Moreover, the emergence of antibiotic-resistant 
strains of GBS imposes a significant threat to the successful treatment of these infections. 
This is particularly relevant to GBS UTI, which is associated with relatively high rates of 
treatment failure and poor clinical outcomes (Munoz et al., 1992). Screening pregnant 
mothers for GBS ABU appears to be important in relation to the vertical transmission of GBS 
to infants however more research is needed to clarify this aspect of GBS UTI. An 
overarching and intriguing theme with GBS infection in humans is that GBS can efficiently 
colonize the genital tract of healthy adult women long-term without triggering apparent 
disease but, on the other hand, can also cause acute disease in some individuals. How this 
occurs is unknown.  
Research efforts to understand GBS pathogenesis should focus on the different strains of 
GBS that cause distinct clinical conditions of UTI such as ABU and cystitis in order to 
analyse the virulence traits that are associated with these infections. How these infections 
progress to disease in some individuals is completely unknown but acute inflammation in 
GBS UTI appears to differ mechanistically compared to that which occurs in other Gram-
negative UTI. Further longer-term surveillance studies of GBS UTI and ABU will help to 
better define the clinical features and serotypes associated with these infections. The 
question of how GBS might adapt to the niche environment of the urinary tract is another 
intriguing and unanswered question. A better understanding of the molecular mechanisms 
used by GBS to colonise uroepithelium and persist in the bladder will be an important area 
for future investigation. Broader utilization of appropriate in vivo and in vitro models 
beyond those already characterized will help to answer these questions. One area for 
investigation, for example, would be to use human urine as a growth medium to study 
fitness traits of UPGBS as has been performed for other uropathogens to discover key 
elements of UTI disease pathogenesis and how some successful uropathogens persist within 
the urinary tract in the absence of direct binding to cellular targets. Such studies will pave 
the way to develop new preventive and perhaps therapeutic strategies for GBS UTI. While 
many of the current strategies have focused on the development of vaccines for prevention 
of GBS disease (Maione et al., 2005) their potential for reducing GBS disease burden due to 
UTI is unknown. Identification of alternate drug targets would also be a goal of future 
research. Elucidation of the mechanisms that underlie GBS disease pathogenesis is pivotal 
for the identification of such alternate drug targets and also in the development of novel 
vaccines. A better  understanding of how GBS  regulates expression of its virulence survival 
factors is imperative. Finally, the underlying phenotypic basis for UPGBS could be gained 
by comparing GBS isolated from asymptomatic infection to cystitis strains by comparative 
genome sequencing approaches. Discoveries from such research may challenge the existing 
paradigms and reveal surprising insights into the versatile nature of this important human 
pathogen. 
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1. Introduction 
The Chlamydiae belongs to the order Chlamydiales with one family Chlamydiaceae one 
genus Chlamydia and three species that infect man Chlamydia trachomatis, Chlamydia psittacci 
and Chlamydia pneumoniae (Thylefers et al. 1987; Zhang and Stephens, 1992; Peeling et al. 
1998).  Chlamydiae were first cultured in the 1950s. The wide spread importance and 
frequencies of genital tract Chlamydia infections were first appreciated in the 1960s. 
Chlamydia were first thought to be viruses and were referred to as large viruses (Peeling et 
al. 1998). They look like bacteria by having cell wall which lack muramunic acid and are like 
viruses by being filterable (Koh et al. 2002).   
Chlamydia includes organisms previously called the psittacisis- lymphogranuloma 
venereum-trachoma group (PLT organisms) or the trachoma-inclusion conjunctivitis (TRIC 
organisms). Chlamydia are non-motile, coccoid looking like gram-negative bacteria ranging 
in size from 0.2 to 1.5. For years Chlamydia were considered to be viruses but they are now 
considered to be a special kind of Gram negative bacteria. They also differ from viruses by 
containing both DNA and RNA (Strickland, 1994). They can only reproduce in the 
cytoplasmic vesicle of the host cell by a unique developmental life cycle involving the 
formation of elementary and reticulate bodies (Miyuashita et al. 1993). 
Chlamydia are rapidly inactivated by heat. They lose their infectivity completely after 10 
minutes at 60oC and partly after 3 to 12 hours at 37oC. They can maintain infectivity for 
years at 5oC and 7oC. During the process of freeze-drying, much of the infectivity is lost, but 
successfully lyophylised preparations are stable for a long period. Chlamydiae are rapidly 
inactivated in the presence of phenols (Koh et al. 2002). 
Chlamydia psittaci is a diverse species that has poorly been characterized. Strains that infect 
psittacine birds seem to differ from those that infect poultry. Several mammals and 
marsupials have species-specific strains (Prescott et al. 1999). Generally humans are not 
susceptible to infection with most mammalian strains of Chlamydia psittaci. A major problem 
with Chlamydia psittaci is that it is zoonotic in nature. In birds Chlamydia psittaci may present 
as an upper respiratory infection with nasal and ocular discharge, diarrhea or a combination 
of both. In some cases birds may be infected with no sign. These cases are of importance 
because birds are carriers and shed the organism. Psittacosis in humans can result in mild 
and severe disease. In several cases, humans that are infected often have severe fever with 
night sweats leading to pneumonia. It is very important that pet birds owners and handlers 
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of poultry become aware of this disease in order to prevent outbreak (McPhee and 
Harrignton, 1987). 
The first Chlamydia pneumoniae case which was formally called Taiwanese acute respiratory 
(TWAR) agent strain was first cultured in 1960s in chick embryo sac but was thought to be a 
member of the species Chlamydia psittaci. Chlamydia pneumoniae as an important respiratory 
pathogen has led to the reappraisal of our concept chlamydia respiratory infections 
(Grayston et al. 1990 and Grayston, 1992). Chlamydia pneumoniae is mainly unique to man 
and in man infection may vary from mild to severe cases. Result of surveys indicated that 
sub clinical chlamydial infections occur, which often remains undiagnosed because of their 
similarity to other respiratory infections. The onset of pneumonia may be sudden with 
chills, fever, anorexia, sore throat, severe headache and photophobia or the disease may 
develop gradually. In severe cases, nausea, vomiting and diarrhea or constipation may be 
observed. The fever remains high in severe cases while it may fall to normal within a week 
in milder cases. Cyanoids and low blood pressure may be observed. Generally, Chlamydia 
pneumoniae causes pneumonia, bronchitis and pharyngitis in school children (Karvonem et 
al. 1992). Some physicians have reported Chlamydia pneumoniae infection in patients with 
asthma. 
A mention of Chlamydia is often referred to a disease caused by Chlamydia trachomatis. 
Chlamydia trachomatis infections are mainly spread through sexual contact and most times 
neonatal. This includes from penis to vagina, penis to rectum and also from mother to child 
during birth (Lin et al. 1992) the sexually transmitted disease usually comes with no clear-
cut symptoms. Chlamydia trachomatis threatens to cause reproductive damage and infertility 
in as many as 3 to 5 million people in America alone each year (Lin et al. 1992). This makes 
Chlamydia trachomatis the most prevalent sexually transmitted diseases worldwide 
(Macaulay et al. 1990; Azenabor and Eghafona, 1997; Azenabor et al. 2007). Due to its latent 
infection Chlamydia trachomatis is rarely diagnosed especially in developing countries, which 
is why this study sought to establish the prevalence of Chlamydia trachomatis in non-specific 
urethritis.  Chlamydia trachomatis still remains ahead of gonorrhea and syphilis in the list of 
most commonly transmitted sexual disease. Chlamydia trachomatis may result in urethritis, 
epididymitis, cervicitis, pelvic inflammatory disease (PID) and other conditions. Men and 
women infected with Chlamydia may have discharge from the penis or vagina and may 
notice burning urination. Infections in the rectum may cause problems or pains. In many 
instances, both men and women will not notice any symptoms (50% of women and 25% of 
men). If symptoms do occur, they usually show up within 1 to 2 weeks after been exposed. 
A person can be infected at any age, the age group been mostly affected being 15-19 years of 
age but Okoror et al. (2008) reported age group 30-36 being mostly exposed but this they 
attributed to the fact that they sampled only women of child bearing age and their spouses. 
Okoror et al. (2007) also reported that Chlamydia trachomatis infect all age groups. The 
discrepancies in their reports would have been because of difference in the populations 
sampled. Johnson et al. (Johnson et al. 1994) reported that the adolescents are at high risk. In 
a study by Agbonlahor et al. (2009) in North West zone of Nigeria, 75% of the total samples 
cultured were positive to Chlamydia trachomatis although the diseases were not stratified. 
They also reported that most of the subjects whose samples were positive had difficulty 
urinating and that most of the positive women had symptoms looking like that of PID as 
confirmed by a clinician. They also confirmed the endemicity of Chlamydia trachomatis in the 
population studied. However, there could be prevalence of Chlamydia trachomatis in 
asymptomatic individuals. Baud et al. (2008) reported low prevalence of Chlamydia 
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trachomatis in asymptomatic Swiss males. They also reported that the prevalence of 
Chlamydia trachomatis is low compared to other countries.  
Urinary tract infections (UTI) could be defined as the persistent presence within the urinary 
tract of actively multiplying microorganisms. UTI implies both microbial colonization of the 
urine and invasion of the lower or upper urinary tract by microorganisms (Reld and Spied, 
1987). It is an infection with more than 100,000 organisms per millilitres in the mid-stream 
samples of urine (Macleod et al., 1984).  
Urinary tract infection is the most common disease of the urinary tract and it is a major 
cause of morbidity in both the hospital and the community (Hannan et al., 1993). The most 
common cause of UTI are bacteria, and less often viruses, yeasts or other intracellular 
microorganisms (Cattell, 1985). According to Bohnson (1986), bacteriuria may be completely 
asymptomatic or remain localised in the bladder without the development of renal infection. 
Urine secreted by normal kidney is sterile and remain so while it travels to the bladder, 
however, normal urine is known to have a microbial flora and any voided urine in normal 
persons may therefore contain thousands of bacteria per millilitre derived from this normal 
flora. In other to differentiate this smaller number of microorganisms from the larger 
number of microorganisms commonly found in infections of the urinary tract, it is essential 
to count the number of bacteria present in fresh properly collected specimens by 
appropriate methods (Schroeder, et al., 1990).   
In Nigeria, UTI is prevalent among men and women, but more common among women, 
especially during pregnancy (Eke et al., 1987). Unrecognised UTI in infancy and childhood 
may have serious long-term effects and chronic pyelonephritis may occur in adults. 
However, the infection occurs in all persons regardless of sex or age with particular impact 
on the young and the very elderly (Rubin et. al., 1986). Sexually active females are also 
predisposed to UTI than their male counterparts (Wiswell and Smith, 1985; Johnson et al., 
1995). In later life, UTI is more among men until the age of prostatic hypertrophy (above 40 
years of age) (Schroeder et al., 1990). 
For many years, pathogens associated with uncomplicated UTI have remained constant, 
with E. coli identified as the etiological agent in about 75-90% of infections (Hooton and 
Stamm, 1997). Five to ten percent of uncomplicated cases are caused by S. saprophyticus 
(Gupta et al., 1999) with Klebsiella, Proteus, Enterococcus and Pseudomonas species seen in 
much smaller percentages. (Kahlmeter, 2001; Gupta., 2001; Wright et. al., 2000).  
In women, signs can include unusual vaginal discharge or bleeding, burning during 
urination or lower abdominal pain. Men like women, may in addition to pain during 
urination develop swellings in the testicles. Without treatment 40% of infected women 
develop pelvic inflammatory disease (PID) which affects the fallopian tubes and causes 
damage to the ovaries (Delpiano et al. 1994). Chlamydia trachomatis have human as their only 
natural host primates may be susceptible to experimental infection (Orienston, 1998) . 
Chlamydia trachomatis causes about 40% non-gonococcal urethritis in men and occur 
concurrently with Niesseria gonorrheae in as many as 50% of the later in women. Chlamydia 
trachomatis causes muco-purulent cervicitis, urethritis, endometritis, salpingitis, perihepatitis 
and later post partum endometritis (Okoror, 2010). At least a third of infected females have 
no symptom (Orienston, 1998). Young children are particularly vulnerable to the infection. 
Transmission is usually by contact with formitis where it causes pharyngitis in children. 
Approximately 75% of neonates born by vaginal infected mothers become infected. The 
infection may remain latent for several months after birth (Schachter and Dawson, 1978). 
Less commonly infants born with caesarian sections may also be infected. The anatomic sites 
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of poultry become aware of this disease in order to prevent outbreak (McPhee and 
Harrignton, 1987). 
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Okoror et al. (2007) also reported that Chlamydia trachomatis infect all age groups. The 
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cultured were positive to Chlamydia trachomatis although the diseases were not stratified. 
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trachomatis in asymptomatic Swiss males. They also reported that the prevalence of 
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much smaller percentages. (Kahlmeter, 2001; Gupta., 2001; Wright et. al., 2000).  
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urination develop swellings in the testicles. Without treatment 40% of infected women 
develop pelvic inflammatory disease (PID) which affects the fallopian tubes and causes 
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Less commonly infants born with caesarian sections may also be infected. The anatomic sites 
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most commonly infected in infants are the conjunctiva which often manifest as purulent 
conjunctivitis and nasopharynx. Serious manifestation of post-natal chlamydial infection is 
pneumonia, which may range in severity. Reports have it that the male urethral and the 
female cervix serves as a reservoir for Chlamydia trachomatis  (Chernesky et al. 1994) and that 
if symptoms are present in the lower urinogenital genital tract they are expressed as 
cervicitis or urethritis. A major involvement of Chlamydia trachomatis in urethritis was 
studied by Chernesky et al. (1994b) when they tested first void urine in both males and 
females in Canada using the Ligase Chain reaction of which 6% females and 18.4% males 
were positive to Chlamydia trachomatis.  
 
Age groups Total Tested Number Positive (%) Total Positive Male Female Male Female 
10-15 10 15 2 (8) 6 (24) 8 (32) 
16-21 72 108 49 (27.2) 69 (38.3) 118 (65.6) 
22-27 56 99 52 (35.5) 54 (34.8) 106 (68.4) 
28-33 49 71 33 (27.5) 40 (33.3) 73 (60.8) 
34-39 40 71 23 (20.7) 40 (36) 63 (56.8) 
40-45 42 66 25 (23.1) 37 (34.3) 62 (57.4) 
46-51 32 59 20 (22) 26 (28.6) 46 (50.5) 
52-57 29 42 19 (26.8) 24 (33.8) 43 (60.6) 
58-63 36 38 22 (29.7) 23 (31.1) 45 (60.8) 
64-69 29 40 18 (26.1) 19 (27.5) 37 (53.6) 
Total 395 (39.3) 609 (60.7) 263 (43.8) 338 (56.2) 601 (59) 
Table 1. Distribution of subjects tested for multiple infection (non-specific urethritis) with 
bacteria associated with UTI. 
This study sought to establish the involvement of Chlamydia trachomatis in non-specific 
urethritis so as to make treatment of the disease easier and quicker by knowing the likely 
organisms that are involved in urethritis especially when multiple organisms are involved 
which might make treatment and management of disease more complex. 
2. Materials and methods 
2.1 Sample collection 
Mid urine samples (1004) were collected from both male (467) and females (537) as well as 
urethral swabs were from males and endocervical and high vaginal swabs from females 
visiting various clinics for cases of urethritis. Blood samples were also collected from all the 
patients. The blood samples were aseptically collected into sterile vacutaniers, centrifuged at 
3000 rpm (hetituch), sera separated, collected into sterile vials and stored at -20oC until used. 
The endocervical swab and the urethral swabs were collected into modified Ringer’s 
solution as transport medium. Ringer’s solution has been modified by the addition of calf 
serum and addition of vancomycin, streptomycin and nystatin. The samples were then 
transported to the laboratory. Clinical information of the patients sampled were collected 
which included pain during urination, penal and vaginal discharge, urethral and vaginal 
itching, foul vaginal smell and urethral irritation. Only those samples that gave a growth of 
more than one bacteria were further screened for Chlamydia trachomatis. Sample size was 
calculated using the online sample size calculator from sample survey network using the 
2005 National Census figure available in the Nigerian Population Commission.  
 




The urine samples were immediately cultured onto, Nutrient agar, McConkey agar, Blood 
agar, Chocolate agar, Mannitol salt agar, Thayer Martins media and CLED agar plates 
(Oxoid). All the samples were cultured in duplicates and incubated both aerobically an 
anaerobically at 370C (Gallenkamp, UK) for 24 hours. Bacterial count and identification were 
done according to the standard methods of Bergey’s manual (1997), Harrigan and McCane 
(1976) and Cowan and Steel (1993). Endocervical swabs and urethral swabs were cultured 
into the yolk sac of chicken’s embryonated eggs (Krivoshein 1998). The blood samples were 
analysed using the complement fixation test (Okoror, 2010) using the positive culture 
material from embryonated eggs as antigen. The antigen was then titetrated to the required 
concentration. The sheep red blood cells used was obtained by bleeding the jugular vein of a 
sheep and then washed in Alseveir’s solution. The sheep red blood cells were stored at 4oC 
until used. Guinea pig serum was obtained by cardiac puncture of guinea pigs to obtain 
blood and the blood centrifuged to obtain the serum which was later mixed with required 
concentration of streptomycin and stored at 4oC until used as complements. Sheep red blood 
cells was used to vaccinate rabbit for at least two weeks, the blood of the rabbit was 
obtained by jugular vein, centrifuged and titerated to the required concentration and used 
as heamolytic serum. The swabs were emulsified in sterile phosphate buffered saline before 
inoculating into yolk sac of 7 days old chicken’s embryonated eggs as described by 
Krivoshein (1998). The eggs were harvested after 10 days of incubation. The eggs were 
candled before and after incubation prior to harvesting. Upon harvesting a portion of the 
harvest materials were fixed with pure ethanol on a clean grease free slide, Romanoesky-
Giemsa staining technique carried out and observed for species-specific inclusion bodies 
under the oil immersion objectives. Statistical analysis was done using the SPSS version 17 
by carrying out the regression analysis using the total positive result as the dependent 
variable and other individual results (CCFA, Culture into chicken’s embryonated eggs and 
monoclonal antibody tests) as the explanatory variable.       
3. Results 
Of the 1004 mid stream urine samples collected from patients with symptoms of urethritis in 
Nigeria and tested for bacteria involved in urethritis, only 601 were positive for multiple 
infections with UTI organisms. This included 56 samples positive for Pseudomonas aeruginosa 
and Staphyloccocus aureus, 129 positive for Proteus mirabilis, Pseudomonas aeruginosa, Staph 
aureus and E. coli. 97 were positive for Klebsellia sp and Pseudomonas sp, 21 for Enteroccocus sp 
and Staph aureus, 102 for E. coli and Staph aureus while 196 were positive for E. coli, Staph 
aureus, Streptoccocus sp and Proteus sp. From the 601 positive for different UTI organisms, 
263 (43.8%) were males while 338 (56.2%) were females. Age group distribution shows that 
age group 16-21 had the highest number of individuals visiting hospitals for UTI cases 
which was followed by 22-27 with the highest number of individuals positive to non-
specific urethritis (Table 1). A total of 395 (39.3%) males and 609 (60.7%) females visitied the 
hospitals for UTI.  The 601 positive samples for non-specific urethritis were screened for 
Chlamydia complement fixing antibody (CCFA) with 205 (34.1%) positive for males and 278 
(46.3%) positive for females. Distribution of CCFA according to age group (table 2) shows 
that age group 22-27 had the highest positive case which was closely followed by 16-21. 
More females had the CCFA (272) as compared to males (227). Females also had the highest 
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most commonly infected in infants are the conjunctiva which often manifest as purulent 
conjunctivitis and nasopharynx. Serious manifestation of post-natal chlamydial infection is 
pneumonia, which may range in severity. Reports have it that the male urethral and the 
female cervix serves as a reservoir for Chlamydia trachomatis  (Chernesky et al. 1994) and that 
if symptoms are present in the lower urinogenital genital tract they are expressed as 
cervicitis or urethritis. A major involvement of Chlamydia trachomatis in urethritis was 
studied by Chernesky et al. (1994b) when they tested first void urine in both males and 
females in Canada using the Ligase Chain reaction of which 6% females and 18.4% males 
were positive to Chlamydia trachomatis.  
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The endocervical swab and the urethral swabs were collected into modified Ringer’s 
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serum and addition of vancomycin, streptomycin and nystatin. The samples were then 
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which included pain during urination, penal and vaginal discharge, urethral and vaginal 
itching, foul vaginal smell and urethral irritation. Only those samples that gave a growth of 
more than one bacteria were further screened for Chlamydia trachomatis. Sample size was 
calculated using the online sample size calculator from sample survey network using the 
2005 National Census figure available in the Nigerian Population Commission.  
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positive individuals across the age groups with the exception of 22-27 age groups where 
more males had the CCFA.  
 
Age groups Number positive (%) Total Males Females 
10-15 2 5 7 
16-21 33 56 89 
22-27 50 47 97 
28-33 31 46 77 
34-39 30 45 75 
40-45 17 30 47 
46-51 16 26 38 
52-57 17 24 41 
58-63 17 25 42 
64-69 14 14 28 
Total 227 272 541 
Table 2. Distribution of samples positive to CCFA across the age groups. 
Antibody titeration shows that 66% of the subjects positive to CCFA had antibody titre 
higher than 1:16. Age group 16-21 had the highest number of subjects with anti body titre 
higher than 1:16 Culture of samples into chicken’s embryonated eggs shows that 499 of the 
total samples positive to CCFA were positive to Chlamydia trachomatis specific inclusion 
bodies with age groups 16-21 and 22-27 having the highest positive results. Also the result 
from the embryonated eggs culture was 31 less than those CCFA with antibody titre of 1:16 
and above. Regression analysis showed that there was no significant (t=0.111, p=0.915, -
18.797-20.587; CI=99%) difference between the result obtained by culture into chicken’s 
embryonated eggs and CCFA as well as test using the monoclonal antibodies kits (CCFA 
t=1.176, p=0.284, -2.756-7.854; Culture t=2.410, p=0.053, -0.122-16.282; Monoclonal antibody 
t=-1.921, p=0.103, -21.415-2.576; CI=99%) however, the monoclonal antibody kits varied 
differently while culture into chicken’s embryonated eggs and CCFA varied in the same 
direction (table 5). ANOVA reveal a significant difference within groups of all the positive 





1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1024 Total 
10-15 - 2 2 2 1 - - - 7 
16-21 20 20 13 11 9 10 6 - 69 
22-27 31 19 42 - - - 5 - 66 
28-33 11 29 17 5 5 5 - 5 66 
34-39 21 18 13 3 10 5 5 - 54 
40-45 5 5 10 11 13 1 - 2 42 
46-51 3 8 8 5 5 4 4 1 35 
52-57 21 9 10 10 - - - - 30 
58-63 5 32 3 - 1 1 - - 37 
64-69 3 3 3 1 6 6 6 - 25 
Total 120 145 121 48 50 32 26 9 431 
Table 3. Antibody titeration of sera positive to CCFA. 
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Age Groups Test Performed CFT Culture Monoclonal 
10-15 7 6 7 
16-21 89 80 82 
22-27 97 89 91 
28-33 77 66 69 
34-39 75 67 71 
40-45 47 47 47 
46-51 38 38 38 
52-57 41 38 39 
58-63 42 40 40 
64-69 28 28 28 
Total  499 501 
Table 4. Distribution of Chlamydia in different test performed (CFT, Culture and Monoclonal 
antibodies). 
4. Discussion  
Infection of the genital with Chlamydia trachomatis cannot be overemphasized. Reports have 
it that the organism has been involved in both female and male urinogenital infection with 
the females worse hit in both mild and chronic infections [Okoror et al 2008). Chlamydia 
trachomatis have also been reported to cause about 40% non-gonoccocal urethritis and occur 
concurrently with about 25% cases with Niesseria gonorrheae with sparse report of Chlamydia 
trachomatis in non-specific urethritis especially in developing countries where Chlamydia 
trachomatis is not currently been screened for in the day to day clinical diagnosis (Okoror, 
2010). Reports also has it that relative frequency of Chlamydia trachomatis infections in 
developing countries is sparse and that infections could be higher than have been reported 
which is largely due to lack of diagnosis for Chlamydia trachomatis in developing countries 
which justifies this study. The lack of information on relative frequencies of Chlamydia 
trachomatis infection have let to lack of diagnosis in routine clinical diagnosis and therefore 
difficulty in treatment of Chlamydia trachomatis diseases like urethritis. This study is 
particularly concerned with the involvement of Chlamydia trachomatis in non-specific 
urethritis.  
The lack of treatment of Chlamydia trachomatis infections may be the reason why there was a 
high positive result for Chlamydia trachomatis in this study (59.9%) which is similar to earlier 
reports but the percentage positivity was far higher than an earlier report by Chernesky et 
al. (1994) This could be because Chernesky et al. (1994) carried out their study in Canada a 
developed country with routine clinical diagnosis for Chlamydia as opposed to this study in 
Nigeria where there is no routine clinical diagnosis for Chlamydia and hence no opportunity 
for treatment of the infection except the infection has come up with serious sequelae. Other 
bacteria involved in UTI were identified in order to establish the fact that infection were 
actually caused by multiple organism. De Jongh et al. (2009) screened 253 males with 
urethritis using PCR for Chlamydia trachomatis, Neisseria gonorrheae and Trichomonas vaginalis 
where they reported 15% positive samples for Chlamydia trachomatis and 7.5% co-infection 
with Neisseria gonorrheae in South African males a result similar with the one observed in 
this study though with a higher positive result which is also a reflection of lack of screening 
for Chlamydia trachomatis and most probably because they screened only males. Complement 
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positive individuals across the age groups with the exception of 22-27 age groups where 
more males had the CCFA.  
 
Age groups Number positive (%) Total Males Females 
10-15 2 5 7 
16-21 33 56 89 
22-27 50 47 97 
28-33 31 46 77 
34-39 30 45 75 
40-45 17 30 47 
46-51 16 26 38 
52-57 17 24 41 
58-63 17 25 42 
64-69 14 14 28 
Total 227 272 541 
Table 2. Distribution of samples positive to CCFA across the age groups. 
Antibody titeration shows that 66% of the subjects positive to CCFA had antibody titre 
higher than 1:16. Age group 16-21 had the highest number of subjects with anti body titre 
higher than 1:16 Culture of samples into chicken’s embryonated eggs shows that 499 of the 
total samples positive to CCFA were positive to Chlamydia trachomatis specific inclusion 
bodies with age groups 16-21 and 22-27 having the highest positive results. Also the result 
from the embryonated eggs culture was 31 less than those CCFA with antibody titre of 1:16 
and above. Regression analysis showed that there was no significant (t=0.111, p=0.915, -
18.797-20.587; CI=99%) difference between the result obtained by culture into chicken’s 
embryonated eggs and CCFA as well as test using the monoclonal antibodies kits (CCFA 
t=1.176, p=0.284, -2.756-7.854; Culture t=2.410, p=0.053, -0.122-16.282; Monoclonal antibody 
t=-1.921, p=0.103, -21.415-2.576; CI=99%) however, the monoclonal antibody kits varied 
differently while culture into chicken’s embryonated eggs and CCFA varied in the same 
direction (table 5). ANOVA reveal a significant difference within groups of all the positive 





1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1024 Total 
10-15 - 2 2 2 1 - - - 7 
16-21 20 20 13 11 9 10 6 - 69 
22-27 31 19 42 - - - 5 - 66 
28-33 11 29 17 5 5 5 - 5 66 
34-39 21 18 13 3 10 5 5 - 54 
40-45 5 5 10 11 13 1 - 2 42 
46-51 3 8 8 5 5 4 4 1 35 
52-57 21 9 10 10 - - - - 30 
58-63 5 32 3 - 1 1 - - 37 
64-69 3 3 3 1 6 6 6 - 25 
Total 120 145 121 48 50 32 26 9 431 
Table 3. Antibody titeration of sera positive to CCFA. 
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Age Groups Test Performed CFT Culture Monoclonal 
10-15 7 6 7 
16-21 89 80 82 
22-27 97 89 91 
28-33 77 66 69 
34-39 75 67 71 
40-45 47 47 47 
46-51 38 38 38 
52-57 41 38 39 
58-63 42 40 40 
64-69 28 28 28 
Total  499 501 
Table 4. Distribution of Chlamydia in different test performed (CFT, Culture and Monoclonal 
antibodies). 
4. Discussion  
Infection of the genital with Chlamydia trachomatis cannot be overemphasized. Reports have 
it that the organism has been involved in both female and male urinogenital infection with 
the females worse hit in both mild and chronic infections [Okoror et al 2008). Chlamydia 
trachomatis have also been reported to cause about 40% non-gonoccocal urethritis and occur 
concurrently with about 25% cases with Niesseria gonorrheae with sparse report of Chlamydia 
trachomatis in non-specific urethritis especially in developing countries where Chlamydia 
trachomatis is not currently been screened for in the day to day clinical diagnosis (Okoror, 
2010). Reports also has it that relative frequency of Chlamydia trachomatis infections in 
developing countries is sparse and that infections could be higher than have been reported 
which is largely due to lack of diagnosis for Chlamydia trachomatis in developing countries 
which justifies this study. The lack of information on relative frequencies of Chlamydia 
trachomatis infection have let to lack of diagnosis in routine clinical diagnosis and therefore 
difficulty in treatment of Chlamydia trachomatis diseases like urethritis. This study is 
particularly concerned with the involvement of Chlamydia trachomatis in non-specific 
urethritis.  
The lack of treatment of Chlamydia trachomatis infections may be the reason why there was a 
high positive result for Chlamydia trachomatis in this study (59.9%) which is similar to earlier 
reports but the percentage positivity was far higher than an earlier report by Chernesky et 
al. (1994) This could be because Chernesky et al. (1994) carried out their study in Canada a 
developed country with routine clinical diagnosis for Chlamydia as opposed to this study in 
Nigeria where there is no routine clinical diagnosis for Chlamydia and hence no opportunity 
for treatment of the infection except the infection has come up with serious sequelae. Other 
bacteria involved in UTI were identified in order to establish the fact that infection were 
actually caused by multiple organism. De Jongh et al. (2009) screened 253 males with 
urethritis using PCR for Chlamydia trachomatis, Neisseria gonorrheae and Trichomonas vaginalis 
where they reported 15% positive samples for Chlamydia trachomatis and 7.5% co-infection 
with Neisseria gonorrheae in South African males a result similar with the one observed in 
this study though with a higher positive result which is also a reflection of lack of screening 
for Chlamydia trachomatis and most probably because they screened only males. Complement 
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fixation test though cumbersome and not very specific for Chlamydia trachomatis because of 
the group reactive antigen of Chlamydia spp still remains one of the most reliable serological 
tests (Okoror, 2010). However, the use of culture into embryonated eggs for examination of 
species-specific Chlamydia inclusion bodies helped to distinguish Chlamydia trachomatis form 
other Chlamydia spp that may have a cross-reaction with Chlamydia trachomatis. To further 
act as quality control, Chlamydia trachomatis monoclonal antibody spot test 
immunochromatographic kits were used to further enhance or validated the results 
confirmed with the culture into chicken’s embryonated eggs especially to take care of 
human error while observing for Chlamydia trachomatis inclusion bodies. Reports also have it 
that a titre of ≤1:16 are diagnostic. Though convalescence sera might affect the result of CFT 
which is why a combination of other tests was involved in this study with the CFT being the 
primary test. The difference in the results from culture in chicken’s embryonated eggs and 
that of complement fixation test as well as the spot test kit may be as a result of the fact that 
since CFT measures antibodies, infected individuals are detected even while still 
convalescing. Since both CFT and the spot test kit measure antibodies, there could be 
possibilities of an individual shedding the organism at convalescent stage without having 
the disease. The fact that CFT captures antibodies in convalescent stage of infection may be 
the reason while the culture result is lower than that of the CCFA, although the difference is 
insignificant (t=0.111, p=0.915, -18.797-20.587; CI=99%) (Table 6) statistically. The result from 
the monoclonal antibody test kit varies in the opposite direction as compared with that of 
the culture and CCFA is suggestive of the more sensitivity of the monoclonal antibody test 
kit and then justifies its use as confirmatory test. The significant difference within the age 
groups shows that though Chlamydia trachomatis UTI is more in the sexual active age of the 
adolescents and though the older ages may have the infection significantly, may have 
contacted the infection in their adolescent age since the organism is found of latent infection. 
Adults involved in indiscriminate sexual activities may also have contacted UTI which 
involved Chlamydia trachomatis which also accounts to why a high percentage of adults were 
positive to Chlamydia trachomatis UTI and also other organisms involved in non-specific 
urethritis.  
 
Model Mono CFT Culture 
1 
Correlations 
Mono 1.000 -.823 -.907 
CFT -.823 1.000 .508 
Culture -.907 .508 1.000 
Covariances 
Mono 24.033 -8.743 -14.912 
CFT -8.743 4.700 3.695 
Culture -14.912 3.695 11.235 
aDependent Variable: Total positive 
Key: Mono=Monoclonal antibody test 
Table 5. Coefficient correlationsa. 
Age is a factor to UTI especially as it involves the early age groups with lesser number as 
well as lower percentage of individuals with UTI and also non-specific urethritis involving 
Chlamydia trachomatis as most individuals in this age group are not yet sexually active. The 
 
Chlamydia Trachomatis in Non-Specific Urethritis 
 
79 
high percentage of females which is significantly different from those of their male 
counterparts both in the UTI generally, as well as multiple infection with Chlamydia 
trachomatis is not unconnected with the short urethral of the female genital organ which 
makes them more prone to UTI both in unhygienic environment as well as sexually as 
earlier reported. This study, however establish the fact that Chlamydia trachomatis is highly 
involved in UTI at the same time with other organisms. This makes treatment of UTI 
difficult especially in developing countries where Chlamydia trachomatis is not screened for in 
cases of UTI and hence the infection remains to lead to more serious sequelae.      
 




95.0% Confidence Interval for B 
 B Std. Error P Lower Bound Upper Bound 
(Constant) .895 8.048  .111 .915 -18.797 20.587 
CFT 2.549 2.168 2.245 1.176 .284 -2.756 7.854 
Culture 8.080 3.352 6.228 2.410 .053 -.122 16.282 
Mono -9.420 4.902 -7.518 -1.921 .103 -21.415 2.576 
Key: Mono=Monoclonal antibody test 
Table 6. Statistical coefficients. 
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fixation test though cumbersome and not very specific for Chlamydia trachomatis because of 
the group reactive antigen of Chlamydia spp still remains one of the most reliable serological 
tests (Okoror, 2010). However, the use of culture into embryonated eggs for examination of 
species-specific Chlamydia inclusion bodies helped to distinguish Chlamydia trachomatis form 
other Chlamydia spp that may have a cross-reaction with Chlamydia trachomatis. To further 
act as quality control, Chlamydia trachomatis monoclonal antibody spot test 
immunochromatographic kits were used to further enhance or validated the results 
confirmed with the culture into chicken’s embryonated eggs especially to take care of 
human error while observing for Chlamydia trachomatis inclusion bodies. Reports also have it 
that a titre of ≤1:16 are diagnostic. Though convalescence sera might affect the result of CFT 
which is why a combination of other tests was involved in this study with the CFT being the 
primary test. The difference in the results from culture in chicken’s embryonated eggs and 
that of complement fixation test as well as the spot test kit may be as a result of the fact that 
since CFT measures antibodies, infected individuals are detected even while still 
convalescing. Since both CFT and the spot test kit measure antibodies, there could be 
possibilities of an individual shedding the organism at convalescent stage without having 
the disease. The fact that CFT captures antibodies in convalescent stage of infection may be 
the reason while the culture result is lower than that of the CCFA, although the difference is 
insignificant (t=0.111, p=0.915, -18.797-20.587; CI=99%) (Table 6) statistically. The result from 
the monoclonal antibody test kit varies in the opposite direction as compared with that of 
the culture and CCFA is suggestive of the more sensitivity of the monoclonal antibody test 
kit and then justifies its use as confirmatory test. The significant difference within the age 
groups shows that though Chlamydia trachomatis UTI is more in the sexual active age of the 
adolescents and though the older ages may have the infection significantly, may have 
contacted the infection in their adolescent age since the organism is found of latent infection. 
Adults involved in indiscriminate sexual activities may also have contacted UTI which 
involved Chlamydia trachomatis which also accounts to why a high percentage of adults were 
positive to Chlamydia trachomatis UTI and also other organisms involved in non-specific 
urethritis.  
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high percentage of females which is significantly different from those of their male 
counterparts both in the UTI generally, as well as multiple infection with Chlamydia 
trachomatis is not unconnected with the short urethral of the female genital organ which 
makes them more prone to UTI both in unhygienic environment as well as sexually as 
earlier reported. This study, however establish the fact that Chlamydia trachomatis is highly 
involved in UTI at the same time with other organisms. This makes treatment of UTI 
difficult especially in developing countries where Chlamydia trachomatis is not screened for in 
cases of UTI and hence the infection remains to lead to more serious sequelae.      
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1. Introduction 
Catheters are used for effective drainage of the bladder, either temporally or permanently, 
in the presence of physiological and anatomical defects or obstruction of the lower urinary 
tract. Catheters are used for a variety of reasons, as follows, to maintain bladder drainage 
during and following surgery or epidurals anesthesia for minimizing and prevention of the 
risk of distension injuries;  investigations, for accurate urine output measurement, and 
measurement of post-micturition residuals; treatments, to relieve urinary retention or for 
chemotherapy instillation; intractable incontinence, as the final option for containment. 
2. Urethral catheterization 
Urethral catheterization is a routine medical procedure that allows direct drainage of the 
urinary bladder into an attached bag or container. It consists in the insertion of a catheter 
into a patient's bladder.  
Urinary catheterization is employed in hospital and nursing home settings to maintain urine 
output in patients who are undergoing surgery, or who are confined to the bed and 
physically unable to use a bedpan. Critically ill patients who require strict monitoring of the 
urinary output are also frequently catheterized. Urethral catheterization may be performed 
as either a therapeutic or a diagnostic procedure. Therapeutically, catheters may be placed 
to decompress the bladder in patients with acute or chronic urinary retention. In addition, 
catheters may be placed to facilitate bladder irrigation in patients with gross hematuria. 
Diagnostically, urinary catheters may be placed to obtain an uncontaminated urine sample 
for microbiologic testing, to measure urinary output in critically ill patients or during 
surgical procedures, or to measure post-void residuals. The only absolute contraindication 
to urethral catheterization is known or suspected urethral injury, usually in the setting of a 
pelvic fracture. 
Surely these interventions were performed already long time before recorded history. 
Although in the most ancient medical writings, such the code of Hammurabi -1700 B.C.- (1), 
there is no clear mention of catheterism, the condition of urinary retention is well described 
in an ancient Chinese medical text, the Huang Ti Nei Chingh Su Wen (mentioned in the 
Annals of the Former Han Dinasty- 206 B.C. to 25 A.C., but referred to a much earlier 
origin). It is a sort of dialogue where the emperor (Huang Ti) poses questions to a minister, 
whose answers convey a clear sense of organ-based pathology: “(…) When the bladder does 
not function efficiently, it causes retention of urine; when it functions without restraint, it 
causes copious urination” (2). If urinary retention was so specifically identified and 
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described, it is likely that it was treated with catheterization: the technology was available. 
For instance, hollow leaves of Allium Fistolosum, an onion plant, coated with laquer, were 
used as catheters in China around 100 B.C (3). The Sushruta Samhita, an early Indian 
surgical text dated approximately around 1000 B.C: describes tubes of gold, silver, iron and 
wood smeared with ghee (liquid butter) for evacuation of urine, management of strictures, 
instillation of medication and for assistance in lithotomy. Sushruta suggest also that “wine 
should be used before operation to produce insensibility to pain” (4).  
Urethral catheterization is then always well described among the medical writings of the 
first millennium and the Renaissance, even if it was not even mentioned by one of the most 
famous scientists ever, Leonardo da Vinci. During this period the main factor driving the 
need for diagnostic and therapeutic catheterization was the bladder stone. Even Benjamin 
Franklin, in a letter written on December 8th, 1752, described a flexible silver catheter he 
designed for his older brother John, who suffered from bladder stone. This device was made 
from a flat silver wire, wound spirally and then covered with waxed threadbound 
parchment (5). In 1756 Heuermann provided a good description of catheter therapy for 
benign prostatic hypertrophy, and during the next 150 years, according to Laurisden, this 
method was “absolutely Paramount” (6). 
Industrialization brought about the manufacturing ability to make better surgical 
instruments as well as the scientific means to fit the tool to the task: the configuration of the 
catheter was investigated by anatomical studies, and the designs of past millennia were for 
the most part found appropriate. The Goodyear patent for moldable hard rubber in 1851 
permitted faster and cheaper production of catheters: Auguste Nelaton, physician to 
Napoleon III, introduced a flexible rubber catheter in 1860 (7). Mercier the coudé catheter in 
1836 and the bicoudé in approximately 1841, with one or two bends near the tip 
respectively. By the late 19th century a wide armamentarium of catheters was available to 
the practitioner. George Tiemann’s catalogue of surgical instruments listed nearly 80 
different types of catheters. Special types were used for various purposes in cases of urethral 
strictures, stones or foreign bodies, and for evacuation of urinary retention, irrigating and 
distending the bladder (8). The development of the balloon catheter has been documented 
by Zorgniotti, who traced it back to Reybard’s device in 1853. Foley (1891 to 1966), an 
ingenious American urologist, devised a balloon catheter for haemostatis in prostatic 
surgery (9). He demonstrated the first production model at the annual meeting of the AUA 
in 1935. Although a different company (the Davol Rubber Company) retained the rights to 
the balloon catheter after applying a key patent five months later, the “Foley” name has 
become universally synonymous of self-retaining balloon catheter. 
By these times, lacking the scientific justification of the germ theory, medical practitioners, 
except for a few ones, had little interest in cleanliness around wounds. Joseph Lister 
experimented with urine putrefaction, and found out that was normally sterile and had an 
uncanny sense of host resistance (10). After his studies and the similar ones performed by 
Roberts, clean techniques and antiseptic principles became standard practice, and urethral 
catheterization thereby achieved another degree of safety (11).  
3. Diagnostic uses 
Bladder catheterization facilitates obtaining a specimen for urinalysis or culture (e.g. in 
children), measuring post-void residual volume, and undertaking more extensive 
urodynamic studies to diagnose causes of urinary incontinence. Radiographic contrast may 
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be instilled through a catheter to visualize bladder or urethral pathology, and document 
vesicoureteric reflux. The bladder may be distended with a saline solution to form a 
sonoluscent structure, prior to a pelvic ultrasound. 
4. Short-term (0-2 weeks) or intermediate term (2-6 weeks) therapeutic uses 
Indwelling catheters are used during labor following epidural anesthesia, and in the fluid 
management and tocolysis of patients with pre-eclampsia and eclampsia. An empty bladder 
facilitates pelvic dissection in patients undergoing hip and abdominopelvic surgical 
procedures. Moreover urethral catheterization enables measurement of intra- and post-
operative urine output and eases post-procedure patient care. Intermittent or short-term 
catheterization may be helpful in treating bladder neoplasms (Cytotoxic drugs and BCG 
may be administered intravesically), and mycotic infections (Amphotericin in fungal 
cystitis). 
Surely the primary care of any patient with acute urinary retention (that may arise from a 
variety of causes) is urethral catheterization: temporary decompression of the bladder 
through an indwelling catheter may be necessary until resolution of the primary cause of the 
retention.  
Short term or intermittent catheterization may be required following urethropexy or a sling 
procedure for bladder neck obstruction, when swelling and pain may cause retention. Other 
organic causes of obstructed voiding in women (neoplastic, inflammatory) may also be 
managed with clean intermittent or indwelling catheter drainage until the underlying 
condition is treated. Incomplete pelvic floor relaxation with resulting dysfunctional voiding 
may also be treated with catheterization. 
Gluteal, sacral or trochanteric skin trauma or decubitus ulcers contaminated by urine in an 
incontinent patient will respond to temporary urinary diversion through catheterization to 
maintain a moist and infection-free environment.11 
5. Long-term therapeutic uses (> 6 weeks) 
In selected cases of urinary incontinence not responding to conservative treatments Clean 
Intermittent Catheterization (CIC) may be carried out. This will maintain mobility and renal 
function, and minimize residual urine, infectious complications and calculus disease. In this 
setting another application of CIC is represented by the presence of a poorly contractile 
bladder that is usually unresponsive to behavioral or pharmacologic therapy. Surgery is 
generally not indicated for men with this condition, and in most cases, patients are required 
to perform CIC. 
During the last ten years CIC has become the standard care in patients with spinal cord 
injuries. Continuous or intermittent catheterization should be established immediately in a 
hypotonic bladder to prevent over-distention, infection and detrusor muscle damage. 
Spastic bladder following spinal injury may require condom catheter or long-term 
suprapubic drainage. In these cases CIC or continuous bladder drainage may also be helpful 
for incontinent patients, immobile subjects due to aging or finally in cases of terminal illness. 
However, continuous drainage should be used rarely, and only as a last resort. 
6. Catheter characteristics 
Urethral catheterization is the most frequent retrograde manipulation performed on the 
urinary tract. Catheters are placed to drain the bladder during and after surgical procedures, 
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to assess urinary output in critically ill patients, to collect reliable urine specimen and to 
assess post voiding residual urine. Such catheters can be left indwelling with a self-retaining 
balloon or used for clean intermittent catheterization procedure.   
The choice of a specific type of catheter depends upon the reasoning of catheterization. 
Large-caliber catheters are used to evacuate potential blood clots or to assess urinary output. 
Other catheter variables include balloon size and construction materials. In this way large 
balloons can be inflated to help hemostasis after transurethral resection of the prostate or in 
case of open prostatectomy. Sometimes the standard latex catheter can result in severe 
reactions in patients with latex allergies and silicone varieties are good alternatives in such 
situations. In particular the silicone catheters are usually manufactured with several grooves 
placed on the surface of catheter itself to allow an interface between the catheters and the 
urethra and thus avoiding the possibility of infection in the short term (1). Therefore the 
catheters can be distinguished by the shape of the tip, the characteristics, the diameter, the 
number of ways and the materials. 
Straight rubber or latex catheters often referred to as Robinson catheters, are straight 
catheters used for short-term catheterization, as in measurement of residual urine and 
instillation of medication chemotherapeutic agents or in case of radiological evaluation of 
the bladder. The tip of the Robinson catheter is rounded, with one or two drainage ports 
along the side. Self-retaining catheters like the Pezzer and Malecot catheters, are shaped in 
such a way that after placement at open surgery the catheter configuration maintains the 
catheter within a hollow viscus (Fig.1a). The advantage of these catheters include the 
excellent urinary drainage and the tip design, which make them ideal for use as cystostomy 
or nefrostomy tubes. Foley-types catheters are most often used for long-term urethral 
catheterization.  
The catheters are often named according to the characteristics of the proximal tip as follows: 
1. The Nelaton catheter is the standard catheter and has a rounded and straight proximal 
end. It has two lateral eyes for drainage (Fig.1b).  
2. The Mercier catheter has a rounded and angular (30-45°) tip. The angle helps the 
introduction of the catheter in the membranous or prostatic urethra (Fig.1c).  
3. The Tiemann catheter can have a cone shaped tip, which can be straight (olive-tip 
catheter) or angular (Fig.1d). 
4. Couvelaire catheter is used in case of bladder hemorrhage or after a urologic surgical 
intervention because it guarantees an efficient drainage. The structure can be rigid or 
semi-rigid and it has one drainage eye at the end and two lateral eyes (Fig.1e). 
5. Dufour catheter (semi-rigid, self-retaining) has three ways. The tip has a 30° curve, is 
open and with two staggered drainage eyes. It is used in case of gross haematuria 
(Fig.1f).   
External diameter is sized by Charrièr (1CH=1/3mm). The size of the catheter is selected 
according to specific clinical use. The length of catheter is usually 420mm for male, 260mm 
for female and a shorter for pediatric patients.  In clinical use the size of the catheter should 
guarantee a safe urine drainage without damaging the urethral mucosa and avoiding 
infections, stricture or scarring causing stenosis. The use of smaller than 14Ch is 
recommended in contrast with large catheter that increases the risk of blockage of 
paraurethral glands causing urethritis or other ascending infection. Silicon or silicon-coated 
catheters produce less tissue reaction and less encrustation than rubber catheters(2). They 
also have a larger lumen diameter than catheters made of rubber and thus are preferred by 
some for long-term indwelling catheterization.  
 




Fig. 1. Types of urinary catheters : a) Pezzer self-retaining catheter; b) Nelaton catheter; c) 
Mercier catheter; d) Tiemann catheter; e) Couvelaire catheter; f) Dufour catheter. 
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Fig. 1. Types of urinary catheters : a) Pezzer self-retaining catheter; b) Nelaton catheter; c) 
Mercier catheter; d) Tiemann catheter; e) Couvelaire catheter; f) Dufour catheter. 
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Catheters can have one, two or three ways. In two ways catheters, one way provides urine 
drainage, the other way which is provided with a valve allows the inflation of a balloon that 
is inserted in the bladder to keep the catheter securely in place. Three-way catheters have a 
small lumen inflating the balloon mechanism, a lumen for instilling irrigant and a larger 
lumen for bladder drainage. Silicone, PVC and latex are the most used materials to produce 
catheters. Latex and PVC are mostly used for short-term catheters or in intermittent 
catheterization. Silicone is more used for long-term catheters because it is considered to be 
biocompatible and it is recommended for patients who are allergic to latex. Different 
catheter surfaces, such as latex, silicone, or Teflon, have not been shown to alter the 
frequency of urinary infection. Silicone catheters may be less likely to become blocked by 
encrustations due to prolonged use (3,4). In this way it seems to be evident that the use of 
silicone catheters are less prone to infections. Thus, silicone catheters, which tend to be more 
expensive, should be reserved for residents shown to have a consistent problem with 
repeated catheter obstruction. In this context P aeruginosa had a higher rate of adherence to 
Teflon or silicon catheters than other gram-negative species. (5) Conflicting results 
describing the effectiveness of antimicrobial-coated catheters, including silver-coated 
catheters, in preventing infection for short-term catheters have been reported. These 
materials are likely to be less effective for long-term catheters, because duration of catheter 
use is such an overwhelming determinant for infection. Catheters available today have a 
roughly engineered surface that is extremely vulnerable to blockage by crystalline biofilms 
and therefore we hope that in the future new biomaterials, which limit biofilm formation, 
will be developed. 
7. Urethral catheter and related infections 
7.1 Epidemiology 
The catheterization is widely used to relieve anatomic or physiologic obstructions, to 
provide a dry environment for comatose or incontinent patients, and to permit the accurate 
measurement of urine output in severely ill patients. Unfortunately, when catheters are used 
inappropriately or when left in place too long they increase the risk of asymptomatic 
bacteriuria and urinary tract infection (UTI). The catheter-associated urinary infections 
(CAUTIs) have been reported to increase mortality and have a considerable economic 
impact. For these reasons catheter should be removed as soon as possible in order to prevent 
the risk of infection. Urinary tract infections account for 20 to 40% of hospital-associated 
infections, and an estimated 80% are associated with urinary catheter. The majority of 
studies say that 10 to 30% of people who are catheterized for a short period develop 
bacteriuria (often asymptomatic) and that after 30 days of catheterization bacteria can be 
found in the urine of all patients. The infections provoked by the use of a short-term catheter 
may prolong hospitalization by 2.4 to 4.5 days, and are likely to be associated to an increase 
in nosocomial mortality. Asymptomatic bacteriuria converts to symptomatic in 
approximately 24% of patients(7). Long-term urinary catheters are a leading cause of 
morbidity in acute care settings, accounting for up to 40% of hospital-associated infections 
(8,9). Within the hospital environment, the intensive care unit has the highest prevalence of 
nosocomial infections with estimated rates of 8–21% for nosocomial UTI of which 95% are 
catheter-associated(10). The daily incidence of bacteriuria in catheterized patients is 
approximately 3–10%. Among patients with bacteriuria, up to 25% will develop symptoms 
of local UTI, and about 3% will develop bacteremia (11). Catheter-associated UTI is the 
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second most common cause of nosocomial bloodstream infection. Patients who develop 
nosocomial UTI have their hospital stay extended by approximately 3 days and are nearly 
three times more likely to die during hospitalization than patients without such an infection. 
The case-fatality rate from UTI-associated bacteremia is approximately 13% within severely 
ill patients at highest risk (12,13).   
It Deserves a mention the CIC has emerged as the most practical to ménage urinary 
emptying dysfunction and reduces significant lower urinary tract infection. CIC has been 
effective in managing patients with spinal cord injury, diabetes, multiple sclerosis, outlet 
obstruction and continent urinary diversion. This management technique is not without 
complications, including urethral trauma, increased urinary infection, stone disease and 
even progression of the upper urinary tract deterioration that the management technique is 
attempting to prevent. A controversy has surrounded the concept of CIC vs. sterile 
technique from the beginning of its use. Regarding bacteriology and urinary tract infections 
and even for CIC most authors conclude that in the still existing light of many controversies 
in bacteriology and management of infections, CIC is an acceptable way of voiding a 
neuropathic bladder, enabling a voluntarily induced balanced micturition within a shorter 
period of bladder training, having less aggressive urinary tract infections by reducing the 
residual urine volume and last but not least assisting continence and avoiding unaesthetic 
leg-bags, aggressive indwelling catheters or irritating external urine collecting devices such 
as diapers. In his publication Kuhn observe that after CIC, in 13 out of 46 patients (28%) the 
type of bacteria in the urine did not change from that of the first bacteriological control. 
Antibiotic prophylaxis is probably ineffective in preventing symptomatic urinary tract 
infections. Recent Cochrane library reviews conclude that the current strength of evidence is 
weak and well-designed studies are strongly recommended. Based on the current evidence, 
it is not possible to state that any catheter type, technique or strategy of self-catheterization 
is better than another in prevention of infections. The sterile versus clean technique question 
is of relatively low importance because in community settings (where most IC takes place) a 
sterile technique is not practical. In hospital settings rising concerns about infection control 
indicate that a sterile technique would be needed for safety (14,15)  In any case intermittent 
catheterization is a commonly recommended procedure for people with incomplete bladder 
emptying not satisfactorily managed by other methods. 
7.2 Pathogenesis 
Indwelling urinary catheters are used for short-term (<14 days mainly in hospitals) and 
long-term (>30 days mainly in nursing homes and home care) urinary drainage (16). Short-
term catheterization usually results in bacteriuria that rapidly clears after removal of the 
catheter, especially with antibiotic therapy. Symptomatic urinary infection or febrile 
episodes are more commonly associated with long-term catheterization. An indwelling 
catheter impairs normal host defenses both by promoting increased access of 
microorganisms to the bladder and by compromising complete voiding. Generally, infection 
is introduced via two routes after catheterization: the intraluminal route via the inside 
lumen of the catheter, or the trans-urethral route between the catheter and the urethra. The 
infections that arise with catheterization are caused by bacteria from patient’s body or 
colonic flora and by bacteria found in the hospital setting. Bacteria can invade the lower 
urinary tract along the surface of the catheter or by its lumen. Bacteriuria that occurs during 
short-term catheterization is usually caused by a single organism. The most commonly 
isolated pathogen its Escherichia-coli and enterococci, pseudomonas, enterobacter, staphylococcus 
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aureus or epidermidis, klebsiella and serratia. In the long-term catheterization common 
urophatogens include Escherichia-coli, Pseudomonas aeruginosa and proteus mirabilis(17,18). 
Many of these pathogens develop a multiple antibiotic resistance and they could adhere to 
the catheter surface, in these case the catheter becomes a reservoir for the pathogens. The 
reason why bacteria migrate through the catheter into the bladder without being expelled 
by the urine is still not clear. Urine has a cleaning action that protects the bladder from 
backwards invasion of skin pathogens, which is why healthy subjects do not get an infection 
if bacteria is injected in the bladder. Most probably the reason why bacteria are not expelled 
in UTIs associated with catheterization is the adhesion of bacteria to the bladder urothelium. 
Epithelial cells in the bladder usually are coated with Lactobacillus that are not invasive nor 
virulent but can prevent virulent organisms from sticking to the bladder wall (19). When the 
coat of the cells is missing, colonization of bacteria and infections of the lower urinary tract 
begin. The mechanism is therefore strictly related to the adhesion of bacteria to the bladder 
during catheterization. Analysis with electron microscope of the surface of catheters show 
that indwelling catheters are rapidly colonized by a thick layer of microorganisms included 
in a protein matrix of the host, and by polysaccharides produced by bacteria that form a 
biofilm (20).  
The risk of urinary tract infection is related to the length of time that the catheter is in place. 
Most patients catheterized for a week or less should escape infection, but for the elderly and 
disabled patients who are catheterized for several months or years, bacteriuria is inevitable 
(21). Risk factors other than the duration of catheterization include contamination of the 
drainage-bag, diabetes mellitus, female patient, antibiotic usage and a compromised status 
of renal function. The risk of CAUTIs is increased in patients who are in urinary retention, in 
patients catheterized peripartum, in debilitated patients (22). In this case organisms that 
colonize the periurethral skin can migrate into the bladder through the mucoid film that 
forms between the epithelial surface of the urethra and the catheter. In addition, 
contamination of the urine in the drainage bag can allow organisms to access the bladder 
through the drainage tube and the catheter lumen (23). The initial bacteria that cause the 
urinary tract infections are usually Staphylococcus epidermidis, Escherichia coli or Enterococcus 
faecalis. As time goes by, other species appear in the residual bladder urine, including 
Pseudomonas aeruginosa, Proteus mirabilis, Providencia stuartii, Morganella morganii and 
Klebsiella pneumoniae.(8,23).  Biofilms containing 5 × 109 viable cells per centimeter can be 
found on long-term indwelling catheters removed from patients.(20) The biofilm 
populations, therefore are often outnumber than those in the urine. The most common 
species present in the mixed-population biofilms are E. faecalis, P. aeruginosa, E. coli, and P. 
mirabilis. The biofilms formed are generally sparse, and because the catheter is removed 
within a few days, they cause few problems. By contrast, long-term catheters become 
colonized by extensive biofilms, which can have profound effects on the health of the 
patient. By far the most troublesome biofilms are those that become crystalline in nature 
(24,25). These biofilms may be present on the outer surface of the catheter around the 
balloon and catheter tip, and can cause trauma to the bladder and urethral epithelia. The 
crystalline deposits on catheters have a similar composition to infection-induced kidney and 
bladder stones. Struvite (magnesium ammonium phosphate) and a poorly crystalline form 
of apatite (a hydroxylated calcium phosphate, in which a variable proportion of the 
phosphate groups are replaced by carbonate) are the principle crystalline components 
(23,26). Urease is the driving force of crystallization: it hydrolyzes urea, leading to the 
formation of ammonium and carbonate ions and an increase in urinary pH. As the urine 
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becomes alkaline, magnesium and calcium phosphate crystals are precipitated. Aggregates 
of this crystalline material accumulate in the urine and in the biofilm that develops on the 
catheter surfaces. The continued accumulation of crystalline bacterial biofilm blocks the flow 
of urine through the catheter (2) causing bladder over-distension and damaging the 
urothelium aiding the attachment of bacteria to epithelial surface. P. mirabilis is not usually a 
pioneer colonizer of the catheterized urinary tract, and is not commonly found in patients 
undergoing short-term catheterization(26). P. mirabilis is considered to be an ingenious 
organism capable of initiating crystalline biofilms. Microorganisms that grow in biofilm are 
less likely to respond to antibiotic treatments. The majority of catheters removed within the 
seventh day of catheterization are already colonized by a bacterial biofilm. The presence of a 
urinary catheter impairs the normal protective mechanisms of the bladder. The duration of 
catheterization is the important factor of bacteriuria (27) but important risk factors are also 
the microbial colonization of the periurethral area and perineum providing a route for 
bacterial entry along both the internal and the external surfaces. In addition, urine often 
pools in the bladder or in the catheter itself and urinary stasis encourages bacterial 
multiplication.  
8. Fungal urinary tract infections 
Fungal urinary tract infections (funguria) are rare in community medicine, but common in 
hospitals where 10 to 30% of urine cultures isolate Candida species Funguria, or candiduria, 
may develop as early as the first 2 weeks of hospitalization. An indwelling urinary catheter 
is a known risk factor for funguria. Candida albicans is the most commonly isolated fungal 
species (40–65%) from the urine, but other species such as Candida glabrata and Candida 
tropicalis, also may occur. Candida as well as staphylococci can reach the hub site via the 
hands of health personal (26) . Non-pharmacologic measures, such as removing unnecessary 
antibiotics, and removing the urinary catheter, are typically beneficial but generally 
inadequate without additional pharmacologic therapy. The most serious complication of 
untreated asymptomatic funguria is candidemia, which occurs in less than 10% of cases. 
(28).  
8.1 Diagnosis 
Patients with CAUTIs are usually asymptomatic. The presence of bacteria in the urine does 
trigger an inflammatory response in terms of pyuria and urinary interleukins. The most 
common presentation of symptomatic infection is fever often associated with haematuria. 
Symptomatic bacteriuria is characterized by the presence of dysuria, urgency, frequency and 
hematuria (28). Symptomatic UTI occurs when bacteriuria leads to either local symptoms of 
infection, or systemic symptoms. Urinary catheter-related bacteremia is diagnosed when the 
same organism is isolated from both the urine and the blood cultures in the absence of other 
likely sources of infection. The risk of asymptomatic bacteriuria to bacteremia conversion is 
approximately 3–4%, and the estimated attributable mortality of urinary tract-related 
bacteremia is approximately 13%. Catheter associated UTI is diagnosed at a lower level of 
bacteriuria (>102 or >103 CFU/ml) for asymptomatic infections, plus associated symptoms 
for the symptomatic infections (29,30).  The wide spectrum of potential infecting organism 
and increased likelihood of resistance means microbiological confirmation of the infecting 
organism and susceptibility testing are essential for determining optimal therapy. A positive 
urine culture supports a diagnosis of UTI but it is not sufficient to distinguish symptomatic 
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from asymptomatic infection. Thus, urine culture result must always be interpreted in the 
clinical context. In patients with short term indwelling catheter the specimen should be 
obtained by sampling through the catheter port. In patients with chronic indwelling catheter 
the preferred specimen is obtained from a new catheter placed immediately prior to 
initiating antimicrobial therapy (26). The urine specimen obtained through the new placed 
catheter reflects the bacteriology of the urine, rather than the biofilm.   
9. Prevention and treatment of catheter-associated urinary infections 
Prevention of UTI is therefore one of the most important tools in the treatment of 
catheterized subjects. The procedure of catheterization has to be done in order to avoid 
contamination of the intra or extra lumen drainage system. In accordance with the 2009 
guidelines of the English Department of Health to prevent urinary tract infections in 
catheterized subjects, it is well know that closed drainage is infection free for the first 15 
days and that after this period bacteria begin to spread in the bladder. In this context it 
seems that there are no differences in the infection rate between short-term sterile and short-
term clean catheterization techniques based on recent literature reviews(31,32). The first 
review compared sterile catheterization with clean catheterization. No difference was shown 
between the two groups of patients, even if the sample was too limited to show any possible 
differences. The second review based on 436 women in labor compared genital cleaning 
before catheterization using chlorhexidine with the one using tap water alone showing also 
in this case no significant differences. The conclusion was that antiseptics do not reduce the 
bacteriuria rate. On the contrary open catheter drainage systems lead to bacteriuria in 
virtually all patients in few days, and this system is not recommended. (Grade of 
recommendation: A)(33).  
Since as biofilm is the central factor in the pathogenesis of CAUTI, strategies designed to 
prevent biofilm formation with novel catheter material or coating are currently being 
investigated as shown in randomized trials reporting antimicrobial-impregnated catheters 
containing either nitrofurazone (34) or the combination of the broad-spectrum antibiotics 
minocycline and rifampin (35). This report demonstrated significant reductions in bacterial 
CAUTIs even if these results need further confirmations. In this way the advantage from the 
use of coated urinary catheters is not clear. In fact clinical trials have shown conflicting 
results as to the efficacy of silver oxide-coated catheters compared with uncoated catheters. 
In a prospective clinical trial involving hospitalized patients, silver oxide-coated catheters 
reduced the incidence of UTI only among women without antimicrobial agents 
administration compared with a control silicone catheter (36). A randomized study of 1,309 
patients catheterized longer than 24h failed to demonstrate the effectiveness of a silicone 
catheter coated externally with silver oxide compared to a standard silicone coated latex 
catheter. However, these silver oxide catheters showed a significantly increased incidence of 
bacteriuria (37). With regard to this, literature on silver alloy latex catheters has failed to 
resolve the controversy over their efficacy and at present there is insufficient evidence to 
recommend the use of silver alloy catheters (Grade of recommendation: B)(33). Therefore it 
is evident that the use of indwelling urinary catheters, due to their complications, should be 
strictly related to specific and inalienable clinical conditions. Current data do not support 
the treatment of asymptomatic bacteriuria, either during short-term catheterization or 
during long-term catheterization, because it will promote the emergence of resistant strains 
(33). In short-term catheterization, antibiotics may delay the onset of bacteriuria, but do not 
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reduce complications (33). A symptomatic complicated UTI associated with an indwelling 
catheter is treated with an agent with as narrow a spectrum as possible, based on culture 
and sensitivity results. The optimal duration is not well established. Treatment durations 
that are both too short as well as too long may cause the emergence of resistant strains. A 7-
day course may be a reasonable compromise (33).  
Finally in case of treatment of fungal urinary tract infection we know that it is recommended 
only when funguria is symptomatic or in cases of fungal colonization when host factors 
increase the risk of fungemia. The antifungal agents used for funguria are mainly 
fluconazole and amphotericin B deoxycholate, because other drugs have extremely low 
concentrations in urine. Intravesical amphotericin B and oral fluconazole therapy are each 
effective in treatment of funguria (28).  
10. Antibiotic prophylaxis and invasive urodynamics in female 
Invasive urodynamics involving catheterization of the lower urinary tract is an essential 
part in the evaluation of detrusor filling and voiding phase in patients needing assessment 
of bladder function(1).  
Urinary tract infections (UTI) are a recognized complication of urodynamic study. The 
natural history of bacteriuria after urodynamics is not completely known. The overall 
incidence of bacteriuria after urodynamic studies is not yet clear. In fact bacteriuria occurs in 
1-5% of hospitalized patients after single short-term catheterization and in ambulatory ones 
lower than 1%. After cystometry, the reported incidence of bacteriuria varies from 1.5% to 
30%, showing that the incidence of UTI in patients who underwent invasive urodynamics is 
present in most cases (2,3). In this context, the opinions on the safety of urodynamic studies 
differ among the authors. At present, published data on prophylaxis in urodynamics have 
showed contradictory results with a limited predictive value. Some investigators concluded 
that antibiotic prophylaxis seems to reduce the incidence of urinary tract infections and to 
protect patients from the risk of bacterial contamination from urethral catheterization, 
especially for those with high risk of infection(4). In this setting it was reported an overall 
infection rate of 15%, so concluding that antibiotic prophylaxis should be considered(5). 
Subsequently other authors reported that after invasive urodynamics the patients had UTI 
in 4% of cases, recommending the use of antibiotic before the procedure(4). In this way 
others reported an incidence of significant bacteriuria in less than of 1% of patients with 
antibiotic prophylaxis, so this approach is considered useful (6,). Similarly it was described 
that invasive urodynamics in postmenopausal female subjects are safe procedures without 
the necessity to perform it(1).  
Antimicrobial prophylaxis entails treatment with an antimicrobial agent before and for a 
limited time after a procedure to prevent local or systemic postprocedural infections. For 
most procedures, prophylaxis should be initiated between 30 minutes and 120 minutes 
before the procedure. Efficacious levels should be maintained for the duration of the 
procedure and, in special circumstances, a limited time (24 hours, at most) after the 
procedure(7).  
In this scenario several conditions are associated with a major risk of UTI with particular 
regard to women. In this setting many studies have revealed that for women presenting 
urogynecologic units to undergo an invasive urodynamic examination, there is a relatevely 
low incidence of bacteriuria (8%) after few days(8,9). Other series of a comparable number of 
women have shown incidences ranging from 1.6% to 17%(3). These discrepancies may be due 
 
Clinical Management of Complicated Urinary Tract Infection 
 
92
from asymptomatic infection. Thus, urine culture result must always be interpreted in the 
clinical context. In patients with short term indwelling catheter the specimen should be 
obtained by sampling through the catheter port. In patients with chronic indwelling catheter 
the preferred specimen is obtained from a new catheter placed immediately prior to 
initiating antimicrobial therapy (26). The urine specimen obtained through the new placed 
catheter reflects the bacteriology of the urine, rather than the biofilm.   
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recommendation: A)(33).  
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patients catheterized longer than 24h failed to demonstrate the effectiveness of a silicone 
catheter coated externally with silver oxide compared to a standard silicone coated latex 
catheter. However, these silver oxide catheters showed a significantly increased incidence of 
bacteriuria (37). With regard to this, literature on silver alloy latex catheters has failed to 
resolve the controversy over their efficacy and at present there is insufficient evidence to 
recommend the use of silver alloy catheters (Grade of recommendation: B)(33). Therefore it 
is evident that the use of indwelling urinary catheters, due to their complications, should be 
strictly related to specific and inalienable clinical conditions. Current data do not support 
the treatment of asymptomatic bacteriuria, either during short-term catheterization or 
during long-term catheterization, because it will promote the emergence of resistant strains 
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and sensitivity results. The optimal duration is not well established. Treatment durations 
that are both too short as well as too long may cause the emergence of resistant strains. A 7-
day course may be a reasonable compromise (33).  
Finally in case of treatment of fungal urinary tract infection we know that it is recommended 
only when funguria is symptomatic or in cases of fungal colonization when host factors 
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fluconazole and amphotericin B deoxycholate, because other drugs have extremely low 
concentrations in urine. Intravesical amphotericin B and oral fluconazole therapy are each 
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part in the evaluation of detrusor filling and voiding phase in patients needing assessment 
of bladder function(1).  
Urinary tract infections (UTI) are a recognized complication of urodynamic study. The 
natural history of bacteriuria after urodynamics is not completely known. The overall 
incidence of bacteriuria after urodynamic studies is not yet clear. In fact bacteriuria occurs in 
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low incidence of bacteriuria (8%) after few days(8,9). Other series of a comparable number of 
women have shown incidences ranging from 1.6% to 17%(3). These discrepancies may be due 
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to variability in age of patients, kwowing well that advancing age is associated with a higher 
rate of UTI, or with different catheterization techniques (the trauma caused by 
catheterization itself may leave the lower urinary tract more susceptible to a later 
infection)(10). Recently it showed that the low vascularization of soft tissues in bladder and 
urethra in postmenopausal female is associated with a higher risk of UTI perhaps because 
this condition could delay or prevent the effect of an antibiotic prophylactic drug, which 
probably cannot reach these tissues in an adequate manner and concentration(11). 
Recently some authors revealed that in postmenopausal women there is a slightly higher 
incidence rate of UTI after invasive urodynamics compared to the studies previously 
published in literature and this trend is not affected by the administration of an antibiotic 
prophylaxis. Urodynamic testing however remains a safe investigative procedure with low 
morbidity and infection rate in postmenopausal women when performed by sterile 
catheterization, even without any antibiotic prophylaxis(5).  
In conclusion, we could stop administering antibiotic prophylaxis to postmenopausal 
patients undergoing invasive urodynamics 
11. Conclusions 
Urinary tract infections represent the second most often observed infectious diseases in 
community, following the respiratory tract infections. In nosocomial setting, UTIs represent 
the most frequent diseases, whose incidence equates 40% of nosocomial infections overall 
considered; about 80% of UTIs is related to urinary catheterization. Therefore it is strongly 
suggested the opportunity to increase any prevention strategy able to reduce the incidence 
of infections related to urinary catheterization and its consequences, as a more rational 
length and modality of catheterization, in addition to the use of innovative catheters: 
recently the use of newborn materials, such as antibiotic-impregnated catheters or silver-
coated ones has started. By now, though, there was not enough evidence to suggest whether 
or not any standard catheter was better than another in terms of reducing the risk of urinary 
tract infection in hospitalised adults catheterised short-term. Siliconised catheters may be 
less likely to cause urethral side effects however, these results should be interpreted with 
some caution as the trials were small and the outcomes are still under investigation. 
12. Appendix: standard catheterization procedure 
1. Gather equipment. 
2. Explain procedure to the patient. 
3. Assist patient into supine position with legs spread and feet together. 
4. Open catheterization kit and catheter. 
5. Prepare sterile field, apply sterile gloves. 
6. Check balloon for patency. 
7. Generously coat the distal portion (2-5 cm) of the catheter with lubricant. 
8. Apply sterile drape. 
9. If female, separate labia using non-dominant hand. If male, hold the penis with the non-
dominant hand. Maintain hand position until preparing to inflate balloon. 
10. Using dominant hand to handle forceps, cleanse peri-urethral mucosa with cleansing 
solution. Cleanse anterior to posterior, inner to outer, one swipe per swab, discard swab 
away from sterile field. 
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11. Pick up catheter with gloved (and still sterile) dominant hand. Hold end of catheter 
loosely coiled in palm of dominant hand. 
12. In the male, lift the penis to a position perpendicular to patient's body and apply light 
upward traction (with non-dominant hand). 
13. Identify the urinary meatus and gently insert until 1 to 2 inches beyond where urine is 
noted. 
14. Inflate balloon, using correct amount of sterile liquid (usually 10 cc but check actual 
balloon size). 
15. Gently pull catheter until inflation balloon is snug against bladder neck. 
16. Connect catheter to drainage system. 
17. Secure catheter to abdomen or thigh, without tension on tubing. 
18. Place drainage bag below level of bladder. 
19. Evaluate catheter function and amount, color, odor, and quality of urine. 
20. Remove gloves, dispose of equipment appropriately, wash hands. 
21. Document size of catheter inserted, amount of water in balloon, patient's response  to 
procedure, and assessment of urine 
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11. Pick up catheter with gloved (and still sterile) dominant hand. Hold end of catheter 
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1. Introduction  
Urinary tract infections (UTIs) are among the most common conditions requiring medical 
treatment with 6-10% of all young females demonstrating bacteriuria (Raz 2001). The 
incidence of UTIs increases with age and 25-50% of females aged 80 or more have 
bacteriuria (Abrutyn et al. 1988). UTIs occur as a result of interactions between the 
uropathogen and host and their pathogenesis involves several processes. Initially the 
uropathogen attaches to the epithelial surface; it subsequently colonises and disseminates 
throughout the mucosa causing tissue damage. After the initial colonisation period, 
pathogens can ascend into the urinary bladder resulting in symptomatic or asymptomatic 
bacteriuria. Further progression may lead to pyelonephritis and renal impairment. Specific 
virulence factors residing on the uropathogen’s membrane are responsible for bacterial 
resistance to the normally effective defence mechanisms of the host. Recently, bacterial 
adhesins and their associated epithelial binding sites have been identified and natural anti-
adherence mechanisms are currently under investigation. 
An understanding of pathogenic and anti-adherence mechanisms may allow physicians to 
develop appropriate strategies for UTI prevention and adequate management protocols. In 
the present chapter we discuss current concepts on the pathogenesis of UTIs with particular 
emphasis on pathogenic bacteria, virulence factors, predisposing factors, natural defences 
within genitourinary tract and consequences when these defence mechanisms are altered. 
2. Routes of infection 
In healthy patients most uropathogens originate from rectal flora and enter the urinary tract 
via the urethra into the bladder (Handley et al. 2002). This is known as the ascending route 
and uropathogens initially adhere to and colonise urothelium of the distal urethra (Fig.1). 
Enhancement of this route is exacerbated in patients with soiling around the perineum, in 
patients with urinary catheters and in females that use spermicidal agents (Foxman 2002). In 
patients with established cystitis up to 50% of infections may ascend into the upper urinary 
tracts and most episodes of pyelonephritis are caused by ascension of bacteria from the 
bladder through the ureter and into the renal pelvis (Busch and Huland 1984). Bacterial 
ascent is aided by conditions such as pregnancy and ureteral obstruction as these conditions 
inhibit ureteral peristalsis. Bacteria that reach the renal pelvis can penetrate the renal 
parenchyma through the collecting ducts and disrupt the renal tubules. 
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In healthy individuals infection of the kidney through the haematogenous route is 
uncommon. Occasionally, the renal parenchyma may be breeched in patients with 
Staphylococcus aureus bacteraemia or Candida fungaemia that originate from oral sources 
in immunosuppressed patients (Smellie et al. 1975). On rare occasions bacteria from adjacent 
organs may penetrate the urinary tract via the lymphatics. Conditions associated with the 
lymphatic route are retroperitoneal abscesses and severe bowel infections. 
 
 
Fig. 1. Urinary tract infections may arise from ascending, haematogenous or lymphatic 
routes. Ascending routes of infection are most common among patients with an established 
UTI. 
3. Urinary pathogens 
3.1 Pathogenic bacteria  
E. coli accounts for 85% of community acquired and 50% of hospital acquired urinary tract 
infections. Within the E.coli species a number of subgroups (O1, O2, O4, O6, O7, O8, O18, 
O25, O68 and O75) are frequently isolated from patients with UTI (Brooks et al. 1981, 
Gruneberg 1969, Roberts and Phillips 1979, Vosti et al. 1964). Gram negative bacteria such as 
Klebsiella and Proteus; and Gram positive Enterococcus faecalis and Staphylococcus 
saprophiticus are causative agents for the remainder of community acquired infections 
(Kennedy et al. 1965). The remainder of hospital acquired infections usually occur after 
colonisation with Klebsiella, Enterobacter, Citrobacter, Serratia, Pseudomonas aeruginosa, 
Providencia, E. faecalis, or S. epidermidis (Kennedy et al. 1965). Notably, the patient’s age 
may influence they type of infective organism present with Staphylococcus saprophiticus 
now accounting for 10% of UTIs in young females compared to less than 1% in elderly 
female patients. 
3.2 Uncomplicated UTIs  
UTIs can be classified as either complicated or uncomplicated depending on underlying 
host factors and on underlying uropathogens as illustrated in table 1. The aetiology of 
uncomplicated UTIs has remained constant over the last 2 to 3 decades with E. coli 
accounting for the vast majority of cases. Previously, female patients with uncomplicated 
UTIs generally remained sensitive to a trimethoprim-sulfamethoxazole combination and the 
traditional approach to therapy had been an empirical short-course treatment with this 
antibiotic regimen (Hooton and Stamm 1997, Stamm and Hooton 1993). Unfortunately, a 
number of more recent studies have demonstrated increasing antimicrobial resistance 
among uropathogens causing uncomplicated cystitis and traditional antibiotic regimens 
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have been questioned (Gupta et al. 1999). One study investigated antimicrobial resistance 
among 4000 female petients with UTI isolates over a 5 year experimental time period. 
Results from this study demonstrated an increase in antimicrobial (E. coli) resistance from 
9% to 18% in patients treated with trimethoprim-sulfamethoxazole (Gupta et al. 1999). In 
addition, resistance to cephalothin (a first generation cephalosporin) increased from 20% to 
28% and resistance to ampicillin increased from 26% to 34%. Notably, resistance to 
nitrofrantoin and ciprofloxacin remained <1% after the 5 year period. This increase in 
bacterial resistance has been attributed to recent administration of trimethoprim-
sulfamethoxazole, diabetes mellitus, recent hospitalisation and recent administration of any 
other antibiotic (Wright et al. 1999). 
Clinical implications for increasing resistance trends include a potential alteration to 
antibiotic regimens commonly administered for treating uncomplicated UTIs. One study 
demonstrated a greater cure rate after a 7-day course of ciprofloxacin compared to a 14-day 
course of trimethprim-sulfamethoxazole in premenopausal females with uncomplicated 
pyelonephritis (Talan et al. 2000). In this study it is also notable that E. coli resistance to 
trimethoprim-sulfamethoxazole was significantly greater (18%) compared to ciprofloxacin 
(0%). Lower cure rates for uncomplicated UTIs in females treated with trimethoprim-
sulfamethoxazole have also been demonstrated in another study where failure rates 
increased from 3% to 13% in sensitive E.coli strains and from 27% to 40% in resistant strains 
(McCarty et al. 1999). Based on these studies antimicrobial treatment with either a 
fluoroquinolone, nitrofurantoin or fosfomycin are currently recommended for 
uncomplicated UTIs. Importantly, clincians should also be aware of the antimicrobial 
spectrum for these agents prior to administration as nitrofurantoin is not effective for 
treating uncomplicated pyelonephritis but highly effective for treating acute cystitis. 
Recurrent uncomplicated UTIs occur after 3 to 6 months in 25% to 35% of patients after their 
initial UTI. The second strain is caused by an identical strain to the first UTI in up to 60% of 
patients with recurrent UTI (Ronald 2003).  
3.3 Complicated UTIs  
Underlying host factors such as age, catheterisation, diabetes mellitus and spinal cord injury 
predispose to complicated UTIs (Fig. 2). In complicated UTIs less virulent uropathogens 
(that rarely cause disease in a normal urinary tract) can cause significant damage to an 
abnormal urinary tract. Studies have demonstrated associations between Group B 
streptococcal bacteraemia, Candida and Enterococci with complicated UTIs in the elderly 
population (Khan and Ahmed 2001, Munoz et al. 1997).  
 
 
Fig. 2. Predisposing factors for complicated UTIs. 
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Children with comorbidities are more likely to develop complicated UTIs and 
Staphylococcus aureus is the most frequently isolated micro-organism in paediatric patients 
with indwelling catheters (Schlager 2001). Candida and coagulase-negative staphylococci 
are associated with complicated UTIs after instrumentation of the paediatric urinary tract. 
Of note, enterobacteriaceae are the most frequently isolated uropathogen in children with 
uncomplicated UTIs (Schlager 2001).  
UTIs are among the top 10 complicating illnesses in patients with diabetes mellitus with E. 
coli, Klebsiella, Group B Streptococci and Enterococcus among the common uropathogens 
(Ronald and Ludwig 2001). In fact, Group B Streptococcus and Klebsiella are 2-3 times more 
common in patients with diabetes mellitus than in patients without the condition (Ronald 
and Ludwig 2001). However, E. coli remains the most causative uropathogen for UTIs in 
patients with diabetes as demonstrated in one prospective study where E. coli was isolated 
in 56.1% of diabetic patients with a UTI (Bonadio et al. 1999). There is a higher rate of 
bladder catheterisation in patients with diabetes and this factor may partially account for the 
higher incidence in this patient cohort (Ronald 2003). 
Common uropathogens causing complicated UTIs among patients with spinal cord injuries 
and indwelling catheters include E. coli, Pseudomonas and Proteus mirabilis (Mobley et al. 
1994). The latter is particularly associated with complicated UTIs as it possesses unique 
virulence factors that enhance its invasive potential (Coker et al. 2000). One study 
demonstrated a significant increase in nosocomial UTIs from 2.63 of 1000 patient days to 
4.35 of 1000 patient days over a 9 year period (p<0.003). Notably, 88% of nosocomial UTIs in 
this study were catheter related (Bronsema et al. 1993). 
 
Pathogens in uncomplicated UTIs Pathogens in complicated UTIs 
Escherichia coli Escherichia coli 
Staphylococcus saprophyticus Kelbsiella 
Kelbsiella Enetrobacter cloacae 
Enterococcus faecalis Serratia marcescens 
 Proteus mirabilis 
 Pseudomonas aeruginosa 
 Enterococcus faecalis 
 Group B streptococci 
Table 1. Underlying uropathogens commonly isoloated in complicated and uncomplicated 
urinary tract infection (UTI) (Ronald 2003). 
4. Bacterial adherence mechanisms 
4.1 Virulence factors   
Bacterial virulence factors play a significant role in determining whether an organism will 
invade the urinary tract and the level of infection acquired. Uropathogenic E. coli (UPEC) is 
present within bowel flora and pathogenic strains of this microorganism can infect the 
urinary tract by expressing specific virulence factors that permit adherence and colonisation 
of the lower urinary tract (Schlager et al. 2002, Yamamoto et al. 1997). Adherence of the 
micro-organism is dependent on 3 important environmental characteristics; firstly the 
bacteria’s own adhesive characteristics, secondly the receptive features of the urothelium 
and finally the fluid that is present between both surfaces (Schaeffer et al. 1981). Bacteria 
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will migrate proximally and precipitate a host derived inflammatory response after 
adhering to the mucosal surface. 
Adhesins found on the surface of the bacterial membrane are responsible for initial 
attachment onto urinary tract tissues (Mulvey 2002) (Fig. 3).  
 
 
Fig. 3. Adhesins on the uropathogen are responsible for attachment of the bacteria to the 
uroepithelial cell membrane of the host.  
Adhesins are classified as fimbrial or afimbrial, depending on whether the adhesin is 
displayed as part of a rigid fimbria or pilus. Fimbriae and pili are surface glycoproteins that 
function as ligands for glycolipid and glycoprotein receptors on uroepithelial cells. Bacteria 
may produce 100-400 pili on the same cell and other cells can produce the same pilus type. 
Each pilus is 5-10 μm in diameter and up to 2 μm in length (Klemm 1985). A pilus is 
composed of subunits referred to as pilin and they are classified as either mannose sensitive 
or mannose resistant, based on their ability to mediate haemagglutination of erythrocytes. 
The most common types of pili are types 1, P and S. Assemblance of pili within the urinary 
tract is mediated by the ‘chaperone/ usher pathway’ where periplasmic chaperones such as 
P pilus chaperone ‘PapD’ and type 1 pilus chaperone ‘FimC’ possess two immunoglobulin 
(Ig)-like domains that are oriented to form a boomerang like shape (Kau et al. 2005, Kuehn 
et al. 1993, Lau et al. 2005). These chaperones are important for binding with pilus subunits 
to form stable complexes. The FimC chaperone accelerates the folding of type 1 pilus 
subunits to strengthen its binding process after its initial attachment process (Vetsch et al. 
2004). 
4.2 Type 1 pili  
Type 1 pili are also referred to as mannose sensitive pili and they are commonly expressed 
in pathogenic and non pathogenic strains of E. coli. They are termed mannose sensitive as 
haemagglutination of erythrocytes is inhibited in the presence of mannose (Reid and Sobel 
1987). Type 1 pili are composed of a helical rod with repeating Fim A subunits that are 
bound to a distal tip structure containing the Fim H adhesin (Jones et al. 1995). During the 
colonisation process Fim H adhesins bind to mannosylated receptors that are found on the 
host’s uroepithelium. An inflammatory process occurs shortly after this binding process has 
been initiated. A number of studies have demonstrated that interactions between the Fim H 
adhesin and epithelial cells on the bladder’s surface are essential for colonisation and 
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infection of bladder epithelium with strains of uropathogenic E. coli (Sun 1996, Wu et al. 
1996). This specific ‘adhesin-epithelial cell’ binding process occurs when type 1 pili bind to 
uroplakin 1a (UP1a) and uroplakin 1b (UP1b) (Malaviya and Abraham 1998). (Fig. 4) 
Uroplakins are membrane proteins that are found on umbrella cells which line the luminal 
surface of the urinary bladder. Initially adhesin binding mechanisms were investigated in a 
mouse cystitis model where numerous bacteria attached to the urothelial surface of the 
mouse urinary tract shortly after an inoculation period. Scanning electron microscopy of the 
urothelial layers demonstrated that Fim H containing pili bound to the central cavity of 
uroplakin hexameric rings and this binding process is responsible for the initial steps 
leading to active UTI (Mulvey et al. 1998). 
 
 
Fig. 4. During the colonisation period FimH adhesins bind to umbrella cells via uroplakin 1a 
and uroplakin 1b membrane receptors. 
After binding to the epithelial surface the activated Fim H adhesins migrate towards deeper 
urothelial layers and penetrate the cell membrane (Mulvey et al. 2000). Once the 
uropathogen is intracellular the invasive process continues as bacteria proliferate within the 
cytosol to form clusters (Anderson et al. 2004b). Eight hours after inoculation the phenotypic 
appearance of the bacteria changes to an engulfing ‘biofilm’ like structure that protects 
against the host’s immune response and shields the uropathogen from its surrounding 
environment (Justice et al. 2004) (Fig. 5). A decrease in the rate of bacterial proliferation will 
allow for effective production of a ‘biofilm matrix’. This matrix can prevent the host’s 
neutrophils from penetrating its surface. The ‘biofilm’ concept stems from the idea that 
bacteria co-operate with one another to remain viable and proliferate after attaching to a 
suitable substrate. Previously, it has been demonstrated that biofilms play an important role 
in a number of disease processes (Kau et al. 2005, Parsek and Singh 2003). Bacterial biofilms 
can form within infected urinary tract calculi, during Pseudomonas infections in patients 
with cystic fibrosis and in infective endocarditis. During the disease process biofilms form 
irreversible associations with their host by forming extracellular polysaccharides that have 
specialised functions (Justice et al. 2004).   
Biofilms can form on many different types of bacteria however the sequence of events 
during the ‘formation process’ remains similar in all bacteria. Firstly, bacteria express 
extracellular polymeric substances that are initially reversible and subsequently become 
irreversible. Bacteria that have irreversibly attached to a surface will serve as a nidus for 
continued replication and recruitment of other bacteria. Irreversible attachment is usually 
established after 24 hours where the bacteria will develop into a complicated ‘tower’ like 
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structure and become filamentous (up to 70 µm in length). Morphological changes allow the 
uropathogen to evade the host’s immune response (Justice et al. 2004). Bacteria that have 
clustered will eventually detach from their group, become motile and flee the host cell. 
Bacterial adherence and replication will recur after the uropathogen escapes its intracellular 
environment and this effective replication process will allow bacterial invasion to persist 
(Anderson et al. 2004a) (Fig. 5). 
 
 
Fig. 5. After attaching to the epithelial surface the uropathogen will enter the cytosol (A). 
Intracellular bacteria rapidly proliferate within the first 24 hours (B). Subsequently, 
proliferation rate decreases and a protective biofilm matrix forms (C). Morphological 
changes allow the uropathogen to evade the host’s immune response. Uropathogens that 
have clustered become motile and detach from the biofilm to disperse (D). 
4.3 P Fimbriated pili  
P fimbriated pili or mannose resistant strains of E. coli are associated with uncomplicated 
pyelonephritis as the receptor for P fimbriae is the major glycolipid component present on 
renal cell membranes (Mulvey 2002). They are termed mannose resistant as they are not 
affected by mannose during the haemagglutination process for human erythrocytes 
(Vaisanen et al. 1981). PapG is an adhesin found at the tip of the pilus and it recognizes the 
α-d-galctopyranosyl-(1-4)-β-d-galctopyranoside receptor which is found on P-blood group 
antigens on the host’s uroepithelium (Kallenius et al. 1981) (Fig. 6). Mannose resistant 
adhesins that do not demonstrate digalactoside-binding affinity are referred to as ‘X’ 
adhesins. A correlation between severe UTIs and bacterial adherence was first identified in 
1976 (Eden et al. 1976). Strains of uropathogenic E. coli in girls with established 
pyelonephritis had an adhesive ability of 70-80% compared to 10% in strains that caused 
asymptomatic bacteriuria. P pili were present in 91% of strains that caused pyelonephritis 
compared to a prevalence of 7% in bowel isolates from healthy children (Eden et al. 1976). 
Although mannose resistant haemagglutinins (MRHA) are associated with pyelonephritis it 
is important to note that no link exists between MRHA and renal scarring.  
4.4 Phase variation  
Interestingly, in vivo studies have shown that environmental factors are responsible for 
rapid changes in pili in E. coli isolates.  This transformation process is known as known as 
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Fig. 6. P fimbiae bind to the α-d-galctopyranosyl-(1-4)-β-d-galctopyranoside receptor on the 
host’s renal epithelial cell via the PapG adhesin. 
phase variation and it involves alternating periods of piliated and nonpiliated adhesins 
during in vivo E. coli infection (Hultgren et al. 1986, Schaeffer et al. 1987). One study showed 
phase variation of pili using indirect immunofluorescense assays of voided urine in human 
patients. Analysis of the urine samples showed type 1 pili in 31 of 41 samples and P pili in 6 
of 18 samples with piliation status varying from predominantly piliated to nonpiliated cells 
(Kisielius et al. 1989). These results demonstrated that type 1 and P pili are expressed and 
subject to phase variation in vivo during acute UTIs. The process of phase variation among 
adhesins has notable clinical implications. Importantly, the presence of type 1 pili may 
facilitate adherence and colonisation of the host’s mucosa in the lower urinary tract. 
However, P pili may predominate as the infective process progresses and ascends. This 
transformation process occurs because primary mediators for the attachment of P pili to 
their glycolipid receptors are found within the kidney (Mulvey et al. 1998). 
4.5 Cell receptivity  
Epithelial cell receptivity also plays an important pathogenic role in female patients that are 
susceptible to recurrent UTI. The receptivity concept was established after vaginal epithelial 
cells were collected from patients susceptible to recurrent UTI with E. coli and compared 
with control samples that were resistant to UTI (Fowler and Stamey 1977). Results from this 
study demonstrated that strains of E. coli associated with cystitis ardently adhered to 
vaginal epithelial cells of susceptible females. Notably, buccal cell receptivity is also 
increased for different strains of E. coli in females with increased vaginal cell receptivity. 
These findings indicate a genotypic trait as the increase in receptor sites for strains of E. coli 
is not confined to the vagina in females with recurrent UTIs. Further analysis of this genetic 
concept by assessing human leukocyte antigens (HLAs) in females with recurrent UTIs has 
demonstrated that HLA-A3 may be a contributing factor. It has also been shown that a 
greater number of uropathogens attach to epithelial cell surface in females that are greater 
than 65 years of age compared to premenopausal females (i.e. age 18-40) (Schaeffer et al. 
1983). 
5. Predisposing factors for pathogenic adherence 
5.1 Alterations to the host’s natural defence mechanisms  
Normal flora around the vaginal introitus, periurethral region and urethra include 
microorganisms such as lactobacilli, coagulase negative staphylococci and streptococci that 
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form a barrier against pathogenic colonisation. Alterations in the vaginal mucosa and 
decreases in its pH are thought to play an important role for with coliforms (Hooton et al. 
1996a). Acute disruptions to this mucosal barrier are frequently attributed to spermicidal 
and antimicrobial agents that alter normal flora and induce increased receptivity for 
uropathogens (Hooton et al. 1996a). Host factors that contribute to the disruption of this 
mucosal barrier are illustrated in table 2. 
Comorbidities such as diabetes mellitus, sickle cell disease, hyperphosphataemia, gout and 
analgesics are also associated with altering the host’s natural defence mechanisms 
(Freedman 1975). The incidence of pyelonephritis is up to fivefold higher in diabetics 
compared to non diabetic patients (Nicolle et al. 1996). Furthermore, female patients with 
diabetes mellitus are 3 times more likely to develop pyelonephritis compared to male 
patients with the condition (Nicolle et al. 1996). Diabetes also predisposes patients to more 
complicated UTIs with an inflammatory urothelial response occurring in the upper tracts of 
up to 80% of diabetic patients with UTIs (Forland et al. 1977, Stapleton 2002). In addition, 
UTIs in this patient cohort are often caused by atypical organisms and complications may 
progress to include papillary necrosis, perinephric abscesses or multisystemic infections 
(Stapleton 2002). 
Urinary tract obstruction and stasis of urine flow can significantly alter the host’s defence 
mechanisms and both factors strongly predispose to complicated UTIs (Hooton 2000). 
During the obstructive process local mucosal defence mechanisms are disturbed as the 
epithelial lining over-distends and pooled urine functions as a mean for bacterial growth 
and proliferation (Hooton et al. 2000). Urinary catheters, particularly in patients with high 
residual volumes, are also ideal media for uropathogens to colonise the urinary tract. 
Finally, fistulae can facilitate direct access into the genoitourinary tract via the 
gastrointestinal system. 
 
Genetic Biological Behavioural Others 
Blood group antigen Congenital abnormalities Sexual intercourse 
Decreased 
mental status 
Non-secretor status Urinary obstruction Use of diaphragm  
Increased density of 
adhesion receptors Calculi Use of spermicides  
 Diabetes mellitus Antimicrobial use  
 Anatomical   
 Residual urine   
 Atrophic vaginitis   
 Urinary incontinence   
 Prior history of UTI   
 Maternal history of UTI   
 Urinary catheters   
 Stents   
 Immunological deficiency (HIV)   
 Renal transplant   
Table 2. Host factors that contribute to the pathogenesis of UTIs in female patients. 
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5.2 Anatomical and physiological factors  
It is widely acknowledged that a number of factors contribute to a greater prevalence in 
UTIs in females compared to males. In particular, female pelvic anatomy plays an important 
predisposing role for recurrent UTIs in female patients. One study investigated differences 
in perineal anatomical measurements and voiding characteristics in 100 females with a 
history of recurrent UTIs and in 113 females with no prior history of UTIs. Analysis of the 
results demonstrated that the urethra and anus were significantly closer together in cases of 
UTI (4.8 ± 0.6cm) compared to controls (5.0 ± 0.7cm, p= 0.03) (Hooton 2000). Other 
important physiological and anatomical factors that predispose to bacterial adherence in 
females (compared to males) include a drier urethral meatus, a shorter urethra and the 
absence of antibacterial properties provided by prostatic fluid (Lipsky 1989).  
5.3 Spermicidal compounds  
Nonoxynol-9 is a non-ionic surfactant that is the most active ingredient found in spermicidal 
compounds in the USA. Results from in vitro studies have shown that it is less active against 
uropathogenic bacteria compared to Lactobacillus (Hooton et al. 1991a, McGroarty et al. 
1990) with hydrogen peroxide-producing strains being particularly susceptible (Hooton et 
al. 1991a). Therefore, it appears that vaginal colonisation with hydrogen peroxide vaginal 
strains of lactobacilli may play an important role in bacterial resistance (Eschenbach et al. 
1989). This hypothesis has been tested in other studies where hydrogen peroxide-producing 
lactobacilli had a protective effect against bacterial vaginosis, symptomatic candidosis and 
vaginal colonisation with genital pathogens (Hawes et al. 1996, Hillier et al. 1992). In 
support of this hypothesis one case-control study has also demonstrated that vaginal 
colonisation with E. coli occurs more frequently in females without hydrogen peroxide-
producing lactobacilli compared to females with these strains (odds ratio 4.0; p=0.01) (Gupta 
et al. 1998). In this study, spermicidal use among females correlated with an increased risk 
of vaginal colonisation with E. coli (odds ratio 12.5; p<0.001) and with the absence of 
hydrogen peroxide-producing lactobacilli. Another study also showed decreased vaginal 
lactobacilli and an increase in vaginal coliforms after nonoxynol-9 instillation in the absence 
of sexual activity and diaphragm use (Rosenstein et al. 1998). 
Based on these studies, it seems likely that the antimicrobial activity of spermicides alters 
the vaginal ecosystem and provides a suitable environment for growth and proliferation of 
uropathogens. It is interesting to note that small amounts of nonoxynol-9 on condoms can 
increase the risk of UTI in females in the absence of sexual intercourse (Fihn et al. 1998, Fihn 
et al. 1996). 
5.4 Premenopausal females  
In premenopausal healthy females sexual intercourse and spermicide use are the most 
important factors predisposing to UTIs. One study demonstrated a 2.6 fold increased risk of 
UTI in females (age 24) that have sexual intercourse 3 times a week compared to females 
that do not have intercourse (Hooton et al. 1996a). It is hypothesised that an increased risk of 
UTI from sexual intercourse occurs from trauma at the introitus (Foxman et al. 1997, Hooton 
et al. 1991b) or through mechanical introduction of the uropathogen into the bladder 
(Hooton et al. 1991b). Other predisposing factors to UTI in premenopausal patients are a 
new sexual partner during the last year, having a first UTI less than 15 years of age and 
having a mother with a history of UTIs (Hooton et al. 1996a). Interestingly, the latter two are 
 
The Pathogenesis of Urinary Tract Infections 
 
111 
associated with a two- to four- fold increase in risk compared to normal females, perhaps 
suggesting a genetic predisposition. Finally, a previous history of UTI is a strong predictor 
of having a subsequent UTI. This may be attributable to a host’s biological or behavioural 
features or from persistent colonisation of a particular bacterial strain. 
5.5 Oestrogen  
The role of oestrogen in the pathogenesis of UTIs is controversial. In vitro studies have 
demonstrated that oestrogen permits adherence of uropthogens to vaginal epithelial cells 
(Hooton et al. 1996b). However, other studies also suggest that oestrogen deficiency in 
postmenopausal females may increase the risk of UTI (Haspels et al. 1981, Thomas et al. 
1980). In fact, one study showed that half of females aged 61 or older had genitourinary 
symptoms and 29% of this cohort also complained of urinary incontinence (Iosif and 
Bekassy 1984). Furthermore, the risk of UTI in postmenopausal females is decreased by 
topical application of oestrogen creams as demonstrated in one double-blinded-placebo 
controlled study (Raz and Stamm 1993). In this study results showed that vaginal 
colonization with E. coli was halved and lactobacillus colonization was re-established after 
topical application of oestrogen in postmenopausal females (Fig. 7). As a result vaginal pH 
was decreased along with colonisation with Enterobacteriaceae.  
 
 
Fig. 7. Proposed pathophysiology of UTIs in patients with oestrogen deficiency (Raz 2001). 
5.6 Genetic susceptibility  
Interleukin-8 is an inflammatory cytokine that promotes neutrophil migration across 
infected urothelial cells (Godaly et al. 1998, Godaly et al. 1997). Absence of its receptor 
CXCR1 has recently been shown to promote bacteraemia within the urinary tract as 
demonstrated in one study in knockout mice that lacked CXCR1 (Frendeus et al. 2001). A 
genetic predisposition to UTIs has been suggested in paediatric patients where children 
with recurrent pyelonephritis demonstrated a defect in the CXCR1 receptor (Frendeus et al. 
2000). 
5.7 Antimicrobial agents  
Animal and human studies suggest that antimicrobial agents predispose females to UTIs by 
altering their host’s vaginal ecology (Herthelius-Elman et al. 1992, Winberg et al. 1993). 
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5.2 Anatomical and physiological factors  
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Colonisation with E. coli is increased after administering  β-lactam antimicrobial agents in 
monkeys (Herthelius-Elman et al. 1992). Notably, trimethoprim and nirofuarantoin do not 
enhance vaginal colonisation with E.coli in similar trials on monkeys and these findings 
suggest that β-lactam antibiotics may be responsible for altering the genital flora of female 
patients. Less vaginal colonisation with uropathogens occurs after a course of co-
trimoxazole or fluoroquinolones when compared to β-lactam antimicrobials. Finally, the 
timing of antimicrobial agents also appears to play a role for increasing the risk of UTI. One 
prospective study on premenopausal females demonstrated an increased risk for UTI in 
females that had been prescribed antimicrobial therapy during the preceding 15-28 days 
compared to the previous 3-14 days (Smith et al. 1997).   
5.8 Urological factors  
Several urological factors are associated with a predisposition to UTIs in female patients. 
Cystocele, high post-void residual volume and urinary incontinence are strongly associated 
with recurrent UTIs as demonstrated in one case control study (Raz et al. 2000). In addition, 
surgery of the genitourinary tract often precedes the onset of a UTI and urological surgery 
itself is also an independent risk factor for recurrent UTI (Raz et al. 2000). 
6. Host response to pathogenic adherence 
A series of defence pathways are activated by the host after the uropathogen adheres to the 
mucosal surface. Epithelial cells exfoliate within hours of the initial infection and infected 
urothelial cells are shed during this process (Mysorekar et al. 2002). Secretion and excretion 
of the infected urothelial cells is mediated by type 1 piliated bacteriae that induce cell 
apoptosis (Mulvey et al. 1998). In healthy patients the epithelium lining the surface of the 
bladder is quiescent as the umbrella cell layer is renewed every few months. However these 
normally repressed proliferation and differentiation cascades are rapidly activated after the 
infective process in the murine cystitis model. These proliferation cascades have the 
potential to induce effective regeneration of an umbrella cell layer within 24 hours of the 
exfoliation process (Fig. 8)  Another study in mice has demonstrated that exfoliation of 
urothelial cells prevents uropathogenic E. coli from forming clusters (Anderson et al. 2004b). 
Notably, mice that elicited a mild exfoliation process in response to the uropathogen were 
more likely to form biofilms that migrated into deeper layers.  
The host’s innate immune response is primarily responsible for providing resistance to the 
invading uropathogen. Numerous cell types such as neutrophils, macrophages, eosinophils 
and natural killer cells are activated as the uropathogen invades. In addition, 
polymorphonuclear leukocytes synthesise nitric oxide by increasing the transcription of 
nitric oxide synthase and this process has a toxic effect on the invading pathogen (Poljakovic 
and Persson 2003, Poljakovic et al. 2001). During the initial inflammatory response period it 
is important to note that neutrophils play a key role as they migrate towards the infected 
site. The migratory process is mediated by pathogen-associated molecular pattern receptors 
(PAMPs) and Toll-like receptors (TLRs) (Anderson et al. 2004b). After lipopolysaccharides 
(LPS), peptidoglycans (PG) and other bacterial products are recognised TLRs activate 
signalling pathways that initiate immune and inflammatory responses to kill pathogens 
(Anderson et al. 2004a). TLR4 and its co-receptors (CD14 and MD2) recognise Gram-
negative bacterial LPS and activate the innate immune response (Haraoka et al. 1999). In 
addition, TLR11 is released from the kidney and activated to prevent the infection from 
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ascending towards the renal parenchyma (Zhang et al. 2004). Notably, more recent studies 
have demonstrated that uropathogens can suppress NFĸB and consequentially decrease the 
host’s inflammatory response. This tactic allows the uropathogen to invade into deeper 
tissues (Klumpp et al. 2001). After 7-10 days the adaptive immune response is activated 




Fig. 8. In healthy patients the umbrella cell layer lining the lumen of the urinary bladder is 
renewed every few months (A). However, epithelial cells exfoliate within 6 hours after 
infection with an invasive uropathogen (B). This excretory process allows for effective 
excretion of infected urothelial cells. Within 24 hours of exfoliation proliferation cascades 
induce effective regeneration of a new umbrella cell layer. 
Apart from triggering the initial inflammatory response, recruited neutrophils are also 
important for providing resistance to UTIs as demonstrated in one study on mice (Haraoka 
et al. 1999). Results from this study showed that UTIs are persistent in mice with specific 
genetic backgrounds and that UTIs will resolve spontaneously in mice with normal 
backgrounds. These findings suggest that specific host genes may be important for effective 
resolution of the UTI as demonstrated in another study on mice where TLR11 recognised 
uropathogenic E. coli and prevented its ascension into the kidneys (Hopkins et al. 1998). 
Interestingly, TLR11 is truncated in humans and susceptibility for pyelonephritis is 
increased. Furthermore, a study by Mysorekar et al demonstrated that females with 
recurrent UTIs had reduced levels of CD16 which led to decreased bacterial phagocytosis 
(Mysorekar et al. 2002). 
The urinary tract is a component of the secretory immune system as it is the first defence 
system encountered by invading uropathogens. Infections of the kidneys are associated with 
serum and kidney immunoglobulin synthesis and type specific antibodies have been 
detected in the host’s urine. Serum antibodies targeting type 1 and P pili have been detected 
after episodes of pyelonephritis with IgG and SIgA antibodies also detected in the urine 
(Rene et al. 1982). Synthesis of these specific antibodies occurs locally to enhance the 
opsonisation process in infected patients and to reduce adherence of E. coli (de Ree and van 
den Bosch 1987). The potential for modifying these immunological factors to decrease the 
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incidence of UTIs in susceptible patients has been explored through immunisation 
techniques in animal models. Vaccination with P fimbria has been shown to decrease 
adherence of P-fimbriated E. coli to uroepithelial cells and prevent pyelonephritis in 
monkeys (Roberts and Phillips 1979). In addition, vaccination with FimH adhesin has been 
shown to prevent cystitis in mice (Langermann et al. 1997). It is therefore plausible that 
vaccination techniques may reduce colonisation and ascending infections in susceptible 
female patients (Uehling et al. 1994a, Uehling et al. 1994b).   
7. Conclusions  
A renewed interest in the pathogenesis of UTIs has developed over recent years. Pathogenic 
mechanisms are complicated and influenced by the biological and behavioural features of 
the host as well as adhesins from the invading uropathogen. Advances at a molecular level 
have led to a greater understanding in adherence mechanisms between bacterial virulence 
factors and the host’s uroepithelial receptors. An improved understanding of these 
pathogenic mechanisms and associated host risk factors is important for developing novel 
strategies for the treatment and prevention of UTIs.  
8. References 
Abrutyn, E., Boscia, J. A. and Kaye, D. (1988) 'The treatment of asymptomatic bacteriuria in 
the elderly', J Am Geriatr Soc, 36(5), 473-5. 
Anderson, G. G., Dodson, K. W., Hooton, T. M. and Hultgren, S. J. (2004a) 'Intracellular 
bacterial communities of uropathogenic Escherichia coli in urinary tract 
pathogenesis', Trends Microbiol, 12(9), 424-30. 
Anderson, G. G., Martin, S. M. and Hultgren, S. J. (2004b) 'Host subversion by formation of 
intracellular bacterial communities in the urinary tract', Microbes Infect, 6(12), 1094-
101. 
Bonadio, M., Meini, M., Gigli, C., Longo, B. and Vigna, A. (1999) 'Urinary tract infection in 
diabetic patients', Urol Int, 63(4), 215-9. 
Bronsema, D. A., Adams, J. R., Pallares, R. and Wenzel, R. P. (1993) 'Secular trends in rates 
and etiology of nosocomial urinary tract infections at a university hospital', J Urol, 
150(2 Pt 1), 414-6. 
Brooks, H. J., Benseman, B. A., Peck, J. and Bettelheim, K. A. (1981) 'Correlation between 
uropathogenic properties of Escherichia coli from urinary tract infections and the 
antibody-coated bacteria test and comparison with faecal strains', J Hyg (Lond), 
87(1), 53-61. 
Busch, R. and Huland, H. (1984) 'Correlation of symptoms and results of direct bacterial 
localization in patients with urinary tract infections', J Urol, 132(2), 282-5. 
Coker, C., Poore, C. A., Li, X. and Mobley, H. L. (2000) 'Pathogenesis of Proteus mirabilis 
urinary tract infection', Microbes Infect, 2(12), 1497-505. 
de Ree, J. M. and van den Bosch, J. F. (1987) 'Serological response to the P fimbriae of 
uropathogenic Escherichia coli in pyelonephritis', Infect Immun, 55(9), 2204-7. 
Eden, C. S., Hanson, L. A., Jodal, U., Lindberg, U. and Akerlund, A. S. (1976) 'Variable 
adherence to normal human urinary-tract epithelial cells of Escherichia coli strains 
associated with various forms of urinary-tract infection', Lancet, 1(7984), 490-2. 
 
The Pathogenesis of Urinary Tract Infections 
 
115 
Eschenbach, D. A., Davick, P. R., Williams, B. L., Klebanoff, S. J., Young-Smith, K., 
Critchlow, C. M. and Holmes, K. K. (1989) 'Prevalence of hydrogen peroxide-
producing Lactobacillus species in normal women and women with bacterial 
vaginosis', J Clin Microbiol, 27(2), 251-6. 
Fihn, S. D., Boyko, E. J., Chen, C. L., Normand, E. H., Yarbro, P. and Scholes, D. (1998) 'Use 
of spermicide-coated condoms and other risk factors for urinary tract infection 
caused by Staphylococcus saprophyticus', Arch Intern Med, 158(3), 281-7. 
Fihn, S. D., Boyko, E. J., Normand, E. H., Chen, C. L., Grafton, J. R., Hunt, M., Yarbro, P., 
Scholes, D. and Stergachis, A. (1996) 'Association between use of spermicide-coated 
condoms and Escherichia coli urinary tract infection in young women', Am J 
Epidemiol, 144(5), 512-20. 
Forland, M., Thomas, V. and Shelokov, A. (1977) 'Urinary tract infections in patients with 
diabetes mellitus. Studies on antibody coating of bacteria', JAMA, 238(18), 1924-6. 
Fowler, J. E., Jr. and Stamey, T. A. (1977) 'Studies of introital colonization in women with 
recurrent urinary infections. VII. The role of bacterial adherence', J Urol, 117(4),  
472-6. 
Foxman, B. (2002) 'Epidemiology of urinary tract infections: incidence, morbidity, and 
economic costs', Am J Med, 113 Suppl 1A, 5S-13S. 
Foxman, B., Marsh, J., Gillespie, B., Rubin, N., Koopman, J. S. and Spear, S. (1997) 'Condom 
use and first-time urinary tract infection', Epidemiology, 8(6), 637-41. 
Freedman, L. R. (1975) 'Natural history of urinary infection in adults', Kidney Int Suppl, 4, 
S96-100. 
Frendeus, B., Godaly, G., Hang, L., Karpman, D., Lundstedt, A. C. and Svanborg, C. (2000) 
'Interleukin 8 receptor deficiency confers susceptibility to acute experimental 
pyelonephritis and may have a human counterpart', J Exp Med, 192(6), 881-90. 
Frendeus, B., Godaly, G., Hang, L., Karpman, D. and Svanborg, C. (2001) 'Interleukin-8 
receptor deficiency confers susceptibility to acute pyelonephritis', J Infect Dis, 183 
Suppl 1, S56-60. 
Godaly, G., Frendeus, B., Proudfoot, A., Svensson, M., Klemm, P. and Svanborg, C. (1998) 
'Role of fimbriae-mediated adherence for neutrophil migration across Escherichia 
coli-infected epithelial cell layers', Mol Microbiol, 30(4), 725-35. 
Godaly, G., Proudfoot, A. E., Offord, R. E., Svanborg, C. and Agace, W. W. (1997) 'Role of 
epithelial interleukin-8 (IL-8) and neutrophil IL-8 receptor A in Escherichia coli-
induced transuroepithelial neutrophil migration', Infect Immun, 65(8), 3451-6. 
Gruneberg, R. N. (1969) 'Relationship of infecting urinary organism to the faecal flora in 
patients with symptomatic urinary infection', Lancet, 2(7624), 766-8. 
Gupta, K., Scholes, D. and Stamm, W. E. (1999) 'Increasing prevalence of antimicrobial 
resistance among uropathogens causing acute uncomplicated cystitis in women', 
JAMA, 281(8), 736-8. 
Gupta, K., Stapleton, A. E., Hooton, T. M., Roberts, P. L., Fennell, C. L. and Stamm, W. E. 
(1998) 'Inverse association of H2O2-producing lactobacilli and vaginal Escherichia 
coli colonization in women with recurrent urinary tract infections', J Infect Dis, 
178(2), 446-50. 
Handley, M. A., Reingold, A. L., Shiboski, S. and Padian, N. S. (2002) 'Incidence of acute 
urinary tract infection in young women and use of male condoms with and without 
nonoxynol-9 spermicides', Epidemiology, 13(4), 431-6. 
 
Clinical Management of Complicated Urinary Tract Infection 
 
114 
incidence of UTIs in susceptible patients has been explored through immunisation 
techniques in animal models. Vaccination with P fimbria has been shown to decrease 
adherence of P-fimbriated E. coli to uroepithelial cells and prevent pyelonephritis in 
monkeys (Roberts and Phillips 1979). In addition, vaccination with FimH adhesin has been 
shown to prevent cystitis in mice (Langermann et al. 1997). It is therefore plausible that 
vaccination techniques may reduce colonisation and ascending infections in susceptible 
female patients (Uehling et al. 1994a, Uehling et al. 1994b).   
7. Conclusions  
A renewed interest in the pathogenesis of UTIs has developed over recent years. Pathogenic 
mechanisms are complicated and influenced by the biological and behavioural features of 
the host as well as adhesins from the invading uropathogen. Advances at a molecular level 
have led to a greater understanding in adherence mechanisms between bacterial virulence 
factors and the host’s uroepithelial receptors. An improved understanding of these 
pathogenic mechanisms and associated host risk factors is important for developing novel 
strategies for the treatment and prevention of UTIs.  
8. References 
Abrutyn, E., Boscia, J. A. and Kaye, D. (1988) 'The treatment of asymptomatic bacteriuria in 
the elderly', J Am Geriatr Soc, 36(5), 473-5. 
Anderson, G. G., Dodson, K. W., Hooton, T. M. and Hultgren, S. J. (2004a) 'Intracellular 
bacterial communities of uropathogenic Escherichia coli in urinary tract 
pathogenesis', Trends Microbiol, 12(9), 424-30. 
Anderson, G. G., Martin, S. M. and Hultgren, S. J. (2004b) 'Host subversion by formation of 
intracellular bacterial communities in the urinary tract', Microbes Infect, 6(12), 1094-
101. 
Bonadio, M., Meini, M., Gigli, C., Longo, B. and Vigna, A. (1999) 'Urinary tract infection in 
diabetic patients', Urol Int, 63(4), 215-9. 
Bronsema, D. A., Adams, J. R., Pallares, R. and Wenzel, R. P. (1993) 'Secular trends in rates 
and etiology of nosocomial urinary tract infections at a university hospital', J Urol, 
150(2 Pt 1), 414-6. 
Brooks, H. J., Benseman, B. A., Peck, J. and Bettelheim, K. A. (1981) 'Correlation between 
uropathogenic properties of Escherichia coli from urinary tract infections and the 
antibody-coated bacteria test and comparison with faecal strains', J Hyg (Lond), 
87(1), 53-61. 
Busch, R. and Huland, H. (1984) 'Correlation of symptoms and results of direct bacterial 
localization in patients with urinary tract infections', J Urol, 132(2), 282-5. 
Coker, C., Poore, C. A., Li, X. and Mobley, H. L. (2000) 'Pathogenesis of Proteus mirabilis 
urinary tract infection', Microbes Infect, 2(12), 1497-505. 
de Ree, J. M. and van den Bosch, J. F. (1987) 'Serological response to the P fimbriae of 
uropathogenic Escherichia coli in pyelonephritis', Infect Immun, 55(9), 2204-7. 
Eden, C. S., Hanson, L. A., Jodal, U., Lindberg, U. and Akerlund, A. S. (1976) 'Variable 
adherence to normal human urinary-tract epithelial cells of Escherichia coli strains 
associated with various forms of urinary-tract infection', Lancet, 1(7984), 490-2. 
 
The Pathogenesis of Urinary Tract Infections 
 
115 
Eschenbach, D. A., Davick, P. R., Williams, B. L., Klebanoff, S. J., Young-Smith, K., 
Critchlow, C. M. and Holmes, K. K. (1989) 'Prevalence of hydrogen peroxide-
producing Lactobacillus species in normal women and women with bacterial 
vaginosis', J Clin Microbiol, 27(2), 251-6. 
Fihn, S. D., Boyko, E. J., Chen, C. L., Normand, E. H., Yarbro, P. and Scholes, D. (1998) 'Use 
of spermicide-coated condoms and other risk factors for urinary tract infection 
caused by Staphylococcus saprophyticus', Arch Intern Med, 158(3), 281-7. 
Fihn, S. D., Boyko, E. J., Normand, E. H., Chen, C. L., Grafton, J. R., Hunt, M., Yarbro, P., 
Scholes, D. and Stergachis, A. (1996) 'Association between use of spermicide-coated 
condoms and Escherichia coli urinary tract infection in young women', Am J 
Epidemiol, 144(5), 512-20. 
Forland, M., Thomas, V. and Shelokov, A. (1977) 'Urinary tract infections in patients with 
diabetes mellitus. Studies on antibody coating of bacteria', JAMA, 238(18), 1924-6. 
Fowler, J. E., Jr. and Stamey, T. A. (1977) 'Studies of introital colonization in women with 
recurrent urinary infections. VII. The role of bacterial adherence', J Urol, 117(4),  
472-6. 
Foxman, B. (2002) 'Epidemiology of urinary tract infections: incidence, morbidity, and 
economic costs', Am J Med, 113 Suppl 1A, 5S-13S. 
Foxman, B., Marsh, J., Gillespie, B., Rubin, N., Koopman, J. S. and Spear, S. (1997) 'Condom 
use and first-time urinary tract infection', Epidemiology, 8(6), 637-41. 
Freedman, L. R. (1975) 'Natural history of urinary infection in adults', Kidney Int Suppl, 4, 
S96-100. 
Frendeus, B., Godaly, G., Hang, L., Karpman, D., Lundstedt, A. C. and Svanborg, C. (2000) 
'Interleukin 8 receptor deficiency confers susceptibility to acute experimental 
pyelonephritis and may have a human counterpart', J Exp Med, 192(6), 881-90. 
Frendeus, B., Godaly, G., Hang, L., Karpman, D. and Svanborg, C. (2001) 'Interleukin-8 
receptor deficiency confers susceptibility to acute pyelonephritis', J Infect Dis, 183 
Suppl 1, S56-60. 
Godaly, G., Frendeus, B., Proudfoot, A., Svensson, M., Klemm, P. and Svanborg, C. (1998) 
'Role of fimbriae-mediated adherence for neutrophil migration across Escherichia 
coli-infected epithelial cell layers', Mol Microbiol, 30(4), 725-35. 
Godaly, G., Proudfoot, A. E., Offord, R. E., Svanborg, C. and Agace, W. W. (1997) 'Role of 
epithelial interleukin-8 (IL-8) and neutrophil IL-8 receptor A in Escherichia coli-
induced transuroepithelial neutrophil migration', Infect Immun, 65(8), 3451-6. 
Gruneberg, R. N. (1969) 'Relationship of infecting urinary organism to the faecal flora in 
patients with symptomatic urinary infection', Lancet, 2(7624), 766-8. 
Gupta, K., Scholes, D. and Stamm, W. E. (1999) 'Increasing prevalence of antimicrobial 
resistance among uropathogens causing acute uncomplicated cystitis in women', 
JAMA, 281(8), 736-8. 
Gupta, K., Stapleton, A. E., Hooton, T. M., Roberts, P. L., Fennell, C. L. and Stamm, W. E. 
(1998) 'Inverse association of H2O2-producing lactobacilli and vaginal Escherichia 
coli colonization in women with recurrent urinary tract infections', J Infect Dis, 
178(2), 446-50. 
Handley, M. A., Reingold, A. L., Shiboski, S. and Padian, N. S. (2002) 'Incidence of acute 
urinary tract infection in young women and use of male condoms with and without 
nonoxynol-9 spermicides', Epidemiology, 13(4), 431-6. 
 
Clinical Management of Complicated Urinary Tract Infection 
 
116 
Haraoka, M., Hang, L., Frendeus, B., Godaly, G., Burdick, M., Strieter, R. and Svanborg, C. 
(1999) 'Neutrophil recruitment and resistance to urinary tract infection', J Infect Dis, 
180(4), 1220-9. 
Haspels, A. A., Luisi, M. and Kicovic, P. M. (1981) 'Endocrinological and clinical 
investigations in post-menopausal women following administration of vaginal 
cream containing oestriol', Maturitas, 3(3-4), 321-7. 
Hawes, S. E., Hillier, S. L., Benedetti, J., Stevens, C. E., Koutsky, L. A., Wolner-Hanssen, P. 
and Holmes, K. K. (1996) 'Hydrogen peroxide-producing lactobacilli and 
acquisition of vaginal infections', J Infect Dis, 174(5), 1058-63. 
Herthelius-Elman, M., Mollby, R., Nord, C. E. and Winberg, J. (1992) 'The effect of 
amoxycillin on vaginal colonization resistance and normal vaginal flora in 
monkeys', J Antimicrob Chemother, 29(3), 329-40. 
Hillier, S. L., Krohn, M. A., Klebanoff, S. J. and Eschenbach, D. A. (1992) 'The relationship of 
hydrogen peroxide-producing lactobacilli to bacterial vaginosis and genital 
microflora in pregnant women', Obstet Gynecol, 79(3), 369-73. 
Hooton, T. M. (2000) 'Pathogenesis of urinary tract infections: an update', J Antimicrob 
Chemother, 46 Suppl A, 1-7. 
Hooton, T. M., Fennell, C. L., Clark, A. M. and Stamm, W. E. (1991a) 'Nonoxynol-9: 
differential antibacterial activity and enhancement of bacterial adherence to vaginal 
epithelial cells', J Infect Dis, 164(6), 1216-9. 
Hooton, T. M., Hillier, S., Johnson, C., Roberts, P. L. and Stamm, W. E. (1991b) 'Escherichia 
coli bacteriuria and contraceptive method', JAMA, 265(1), 64-9. 
Hooton, T. M., Scholes, D., Hughes, J. P., Winter, C., Roberts, P. L., Stapleton, A. E., 
Stergachis, A. and Stamm, W. E. (1996a) 'A prospective study of risk factors for 
symptomatic urinary tract infection in young women', N Engl J Med, 335(7), 468-74. 
Hooton, T. M., Scholes, D., Stapleton, A. E., Roberts, P. L., Winter, C., Gupta, K., Samadpour, 
M. and Stamm, W. E. (2000) 'A prospective study of asymptomatic bacteriuria in 
sexually active young women', N Engl J Med, 343(14), 992-7. 
Hooton, T. M. and Stamm, W. E. (1997) 'Diagnosis and treatment of uncomplicated urinary 
tract infection', Infect Dis Clin North Am, 11(3), 551-81. 
Hooton, T. M., Winter, C., Tiu, F. and Stamm, W. E. (1996b) 'Association of acute cystitis 
with the stage of the menstrual cycle in young women', Clin Infect Dis, 23(3), 635-6. 
Hopkins, W. J., Gendron-Fitzpatrick, A., Balish, E. and Uehling, D. T. (1998) 'Time course 
and host responses to Escherichia coli urinary tract infection in genetically distinct 
mouse strains', Infect Immun, 66(6), 2798-802. 
Hultgren, S. J., Schwan, W. R., Schaeffer, A. J. and Duncan, J. L. (1986) 'Regulation of 
production of type 1 pili among urinary tract isolates of Escherichia coli', Infect 
Immun, 54(3), 613-20. 
Iosif, C. S. and Bekassy, Z. (1984) 'Prevalence of genito-urinary symptoms in the late 
menopause', Acta Obstet Gynecol Scand, 63(3), 257-60. 
Jones, C. H., Pinkner, J. S., Roth, R., Heuser, J., Nicholes, A. V., Abraham, S. N. and 
Hultgren, S. J. (1995) 'FimH adhesin of type 1 pili is assembled into a fibrillar tip 
structure in the Enterobacteriaceae', Proc Natl Acad Sci U S A, 92(6), 2081-5. 
Justice, S. S., Hung, C., Theriot, J. A., Fletcher, D. A., Anderson, G. G., Footer, M. J. and 
Hultgren, S. J. (2004) 'Differentiation and developmental pathways of 
 
The Pathogenesis of Urinary Tract Infections 
 
117 
uropathogenic Escherichia coli in urinary tract pathogenesis', Proc Natl Acad Sci U S 
A, 101(5), 1333-8. 
Kallenius, G., Mollby, R., Svenson, S. B. and Winberg, J. (1981) 'Microbial adhesion and the 
urinary tract', Lancet, 2(8251), 866. 
Kau, A. L., Hunstad, D. A. and Hultgren, S. J. (2005) 'Interaction of uropathogenic 
Escherichia coli with host uroepithelium', Curr Opin Microbiol, 8(1), 54-9. 
Kennedy, R. P., Plorde, J. J. and Petersdorf, R. G. (1965) 'Studies on the Epidemiology of 
Escherichia Coli Infections. Iv. Evidence for a Nosocomial Flora', J Clin Invest, 44, 
193-201. 
Khan, S. W. and Ahmed, A. (2001) 'Uropathogens and their susceptibility pattern: a 
retrospective analysis', J Pak Med Assoc, 51(2), 98-100. 
Kisielius, P. V., Schwan, W. R., Amundsen, S. K., Duncan, J. L. and Schaeffer, A. J. (1989) 'In 
vivo expression and variation of Escherichia coli type 1 and P pili in the urine of 
adults with acute urinary tract infections', Infect Immun, 57(6), 1656-62. 
Klemm, P. (1985) 'Fimbrial adhesions of Escherichia coli', Rev Infect Dis, 7(3), 321-40. 
Klumpp, D. J., Weiser, A. C., Sengupta, S., Forrestal, S. G., Batler, R. A. and Schaeffer, A. J. 
(2001) 'Uropathogenic Escherichia coli potentiates type 1 pilus-induced apoptosis 
by suppressing NF-kappaB', Infect Immun, 69(11), 6689-95. 
Kuehn, M. J., Ogg, D. J., Kihlberg, J., Slonim, L. N., Flemmer, K., Bergfors, T. and Hultgren, 
S. J. (1993) 'Structural basis of pilus subunit recognition by the PapD chaperone', 
Science, 262(5137), 1234-41. 
Langermann, S., Palaszynski, S., Barnhart, M., Auguste, G., Pinkner, J. S., Burlein, J., Barren, 
P., Koenig, S., Leath, S., Jones, C. H. and Hultgren, S. J. (1997) 'Prevention of 
mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination', 
Science, 276(5312), 607-11. 
Lau, Y. E., Rozek, A., Scott, M. G., Goosney, D. L., Davidson, D. J. and Hancock, R. E. (2005) 
'Interaction and cellular localization of the human host defense peptide LL-37 with 
lung epithelial cells', Infect Immun, 73(1), 583-91. 
Lipsky, B. A. (1989) 'Urinary tract infections in men. Epidemiology, pathophysiology, 
diagnosis, and treatment', Ann Intern Med, 110(2), 138-50. 
Malaviya, R. and Abraham, S. N. (1998) 'Clinical implications of mast cell-bacteria 
interaction', J Mol Med, 76(9), 617-23. 
McCarty, J. M., Richard, G., Huck, W., Tucker, R. M., Tosiello, R. L., Shan, M., Heyd, A. and 
Echols, R. M. (1999) 'A randomized trial of short-course ciprofloxacin, ofloxacin, or 
trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in 
women. Ciprofloxacin Urinary Tract Infection Group', Am J Med, 106(3), 292-9. 
McGroarty, J. A., Soboh, F., Bruce, A. W. and Reid, G. (1990) 'The spermicidal compound 
nonoxynol-9 increases adhesion of Candida species to human epithelial cells in 
vitro', Infect Immun, 58(6), 2005-7. 
Mobley, H. L., Island, M. D. and Massad, G. (1994) 'Virulence determinants of 
uropathogenic Escherichia coli and Proteus mirabilis', Kidney Int Suppl, 47, S129-36. 
Mulvey, M. A. (2002) 'Adhesion and entry of uropathogenic Escherichia coli', Cell Microbiol, 
4(5), 257-71. 
Mulvey, M. A., Lopez-Boado, Y. S., Wilson, C. L., Roth, R., Parks, W. C., Heuser, J. and 
Hultgren, S. J. (1998) 'Induction and evasion of host defenses by type 1-piliated 
uropathogenic Escherichia coli', Science, 282(5393), 1494-7. 
 
Clinical Management of Complicated Urinary Tract Infection 
 
116 
Haraoka, M., Hang, L., Frendeus, B., Godaly, G., Burdick, M., Strieter, R. and Svanborg, C. 
(1999) 'Neutrophil recruitment and resistance to urinary tract infection', J Infect Dis, 
180(4), 1220-9. 
Haspels, A. A., Luisi, M. and Kicovic, P. M. (1981) 'Endocrinological and clinical 
investigations in post-menopausal women following administration of vaginal 
cream containing oestriol', Maturitas, 3(3-4), 321-7. 
Hawes, S. E., Hillier, S. L., Benedetti, J., Stevens, C. E., Koutsky, L. A., Wolner-Hanssen, P. 
and Holmes, K. K. (1996) 'Hydrogen peroxide-producing lactobacilli and 
acquisition of vaginal infections', J Infect Dis, 174(5), 1058-63. 
Herthelius-Elman, M., Mollby, R., Nord, C. E. and Winberg, J. (1992) 'The effect of 
amoxycillin on vaginal colonization resistance and normal vaginal flora in 
monkeys', J Antimicrob Chemother, 29(3), 329-40. 
Hillier, S. L., Krohn, M. A., Klebanoff, S. J. and Eschenbach, D. A. (1992) 'The relationship of 
hydrogen peroxide-producing lactobacilli to bacterial vaginosis and genital 
microflora in pregnant women', Obstet Gynecol, 79(3), 369-73. 
Hooton, T. M. (2000) 'Pathogenesis of urinary tract infections: an update', J Antimicrob 
Chemother, 46 Suppl A, 1-7. 
Hooton, T. M., Fennell, C. L., Clark, A. M. and Stamm, W. E. (1991a) 'Nonoxynol-9: 
differential antibacterial activity and enhancement of bacterial adherence to vaginal 
epithelial cells', J Infect Dis, 164(6), 1216-9. 
Hooton, T. M., Hillier, S., Johnson, C., Roberts, P. L. and Stamm, W. E. (1991b) 'Escherichia 
coli bacteriuria and contraceptive method', JAMA, 265(1), 64-9. 
Hooton, T. M., Scholes, D., Hughes, J. P., Winter, C., Roberts, P. L., Stapleton, A. E., 
Stergachis, A. and Stamm, W. E. (1996a) 'A prospective study of risk factors for 
symptomatic urinary tract infection in young women', N Engl J Med, 335(7), 468-74. 
Hooton, T. M., Scholes, D., Stapleton, A. E., Roberts, P. L., Winter, C., Gupta, K., Samadpour, 
M. and Stamm, W. E. (2000) 'A prospective study of asymptomatic bacteriuria in 
sexually active young women', N Engl J Med, 343(14), 992-7. 
Hooton, T. M. and Stamm, W. E. (1997) 'Diagnosis and treatment of uncomplicated urinary 
tract infection', Infect Dis Clin North Am, 11(3), 551-81. 
Hooton, T. M., Winter, C., Tiu, F. and Stamm, W. E. (1996b) 'Association of acute cystitis 
with the stage of the menstrual cycle in young women', Clin Infect Dis, 23(3), 635-6. 
Hopkins, W. J., Gendron-Fitzpatrick, A., Balish, E. and Uehling, D. T. (1998) 'Time course 
and host responses to Escherichia coli urinary tract infection in genetically distinct 
mouse strains', Infect Immun, 66(6), 2798-802. 
Hultgren, S. J., Schwan, W. R., Schaeffer, A. J. and Duncan, J. L. (1986) 'Regulation of 
production of type 1 pili among urinary tract isolates of Escherichia coli', Infect 
Immun, 54(3), 613-20. 
Iosif, C. S. and Bekassy, Z. (1984) 'Prevalence of genito-urinary symptoms in the late 
menopause', Acta Obstet Gynecol Scand, 63(3), 257-60. 
Jones, C. H., Pinkner, J. S., Roth, R., Heuser, J., Nicholes, A. V., Abraham, S. N. and 
Hultgren, S. J. (1995) 'FimH adhesin of type 1 pili is assembled into a fibrillar tip 
structure in the Enterobacteriaceae', Proc Natl Acad Sci U S A, 92(6), 2081-5. 
Justice, S. S., Hung, C., Theriot, J. A., Fletcher, D. A., Anderson, G. G., Footer, M. J. and 
Hultgren, S. J. (2004) 'Differentiation and developmental pathways of 
 
The Pathogenesis of Urinary Tract Infections 
 
117 
uropathogenic Escherichia coli in urinary tract pathogenesis', Proc Natl Acad Sci U S 
A, 101(5), 1333-8. 
Kallenius, G., Mollby, R., Svenson, S. B. and Winberg, J. (1981) 'Microbial adhesion and the 
urinary tract', Lancet, 2(8251), 866. 
Kau, A. L., Hunstad, D. A. and Hultgren, S. J. (2005) 'Interaction of uropathogenic 
Escherichia coli with host uroepithelium', Curr Opin Microbiol, 8(1), 54-9. 
Kennedy, R. P., Plorde, J. J. and Petersdorf, R. G. (1965) 'Studies on the Epidemiology of 
Escherichia Coli Infections. Iv. Evidence for a Nosocomial Flora', J Clin Invest, 44, 
193-201. 
Khan, S. W. and Ahmed, A. (2001) 'Uropathogens and their susceptibility pattern: a 
retrospective analysis', J Pak Med Assoc, 51(2), 98-100. 
Kisielius, P. V., Schwan, W. R., Amundsen, S. K., Duncan, J. L. and Schaeffer, A. J. (1989) 'In 
vivo expression and variation of Escherichia coli type 1 and P pili in the urine of 
adults with acute urinary tract infections', Infect Immun, 57(6), 1656-62. 
Klemm, P. (1985) 'Fimbrial adhesions of Escherichia coli', Rev Infect Dis, 7(3), 321-40. 
Klumpp, D. J., Weiser, A. C., Sengupta, S., Forrestal, S. G., Batler, R. A. and Schaeffer, A. J. 
(2001) 'Uropathogenic Escherichia coli potentiates type 1 pilus-induced apoptosis 
by suppressing NF-kappaB', Infect Immun, 69(11), 6689-95. 
Kuehn, M. J., Ogg, D. J., Kihlberg, J., Slonim, L. N., Flemmer, K., Bergfors, T. and Hultgren, 
S. J. (1993) 'Structural basis of pilus subunit recognition by the PapD chaperone', 
Science, 262(5137), 1234-41. 
Langermann, S., Palaszynski, S., Barnhart, M., Auguste, G., Pinkner, J. S., Burlein, J., Barren, 
P., Koenig, S., Leath, S., Jones, C. H. and Hultgren, S. J. (1997) 'Prevention of 
mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination', 
Science, 276(5312), 607-11. 
Lau, Y. E., Rozek, A., Scott, M. G., Goosney, D. L., Davidson, D. J. and Hancock, R. E. (2005) 
'Interaction and cellular localization of the human host defense peptide LL-37 with 
lung epithelial cells', Infect Immun, 73(1), 583-91. 
Lipsky, B. A. (1989) 'Urinary tract infections in men. Epidemiology, pathophysiology, 
diagnosis, and treatment', Ann Intern Med, 110(2), 138-50. 
Malaviya, R. and Abraham, S. N. (1998) 'Clinical implications of mast cell-bacteria 
interaction', J Mol Med, 76(9), 617-23. 
McCarty, J. M., Richard, G., Huck, W., Tucker, R. M., Tosiello, R. L., Shan, M., Heyd, A. and 
Echols, R. M. (1999) 'A randomized trial of short-course ciprofloxacin, ofloxacin, or 
trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in 
women. Ciprofloxacin Urinary Tract Infection Group', Am J Med, 106(3), 292-9. 
McGroarty, J. A., Soboh, F., Bruce, A. W. and Reid, G. (1990) 'The spermicidal compound 
nonoxynol-9 increases adhesion of Candida species to human epithelial cells in 
vitro', Infect Immun, 58(6), 2005-7. 
Mobley, H. L., Island, M. D. and Massad, G. (1994) 'Virulence determinants of 
uropathogenic Escherichia coli and Proteus mirabilis', Kidney Int Suppl, 47, S129-36. 
Mulvey, M. A. (2002) 'Adhesion and entry of uropathogenic Escherichia coli', Cell Microbiol, 
4(5), 257-71. 
Mulvey, M. A., Lopez-Boado, Y. S., Wilson, C. L., Roth, R., Parks, W. C., Heuser, J. and 
Hultgren, S. J. (1998) 'Induction and evasion of host defenses by type 1-piliated 
uropathogenic Escherichia coli', Science, 282(5393), 1494-7. 
 
Clinical Management of Complicated Urinary Tract Infection 
 
118 
Mulvey, M. A., Schilling, J. D., Martinez, J. J. and Hultgren, S. J. (2000) 'Bad bugs and 
beleaguered bladders: interplay between uropathogenic Escherichia coli and innate 
host defenses', Proc Natl Acad Sci U S A, 97(16), 8829-35. 
Munoz, P., Llancaqueo, A., Rodriguez-Creixems, M., Pelaez, T., Martin, L. and Bouza, E. 
(1997) 'Group B streptococcus bacteremia in nonpregnant adults', Arch Intern Med, 
157(2), 213-6. 
Mysorekar, I. U., Mulvey, M. A., Hultgren, S. J. and Gordon, J. I. (2002) 'Molecular 
regulation of urothelial renewal and host defenses during infection with 
uropathogenic Escherichia coli', J Biol Chem, 277(9), 7412-9. 
Nicolle, L. E., Friesen, D., Harding, G. K. and Roos, L. L. (1996) 'Hospitalization for acute 
pyelonephritis in Manitoba, Canada, during the period from 1989 to 1992; impact of 
diabetes, pregnancy, and aboriginal origin', Clin Infect Dis, 22(6), 1051-6. 
Parsek, M. R. and Singh, P. K. (2003) 'Bacterial biofilms: an emerging link to disease 
pathogenesis', Annu Rev Microbiol, 57, 677-701. 
Poljakovic, M. and Persson, K. (2003) 'Urinary tract infection in iNOS-deficient mice with 
focus on bacterial sensitivity to nitric oxide', Am J Physiol Renal Physiol, 284(1), F22-
31. 
Poljakovic, M., Svensson, M. L., Svanborg, C., Johansson, K., Larsson, B. and Persson, K. 
(2001) 'Escherichia coli-induced inducible nitric oxide synthase and cyclooxygenase 
expression in the mouse bladder and kidney', Kidney Int, 59(3), 893-904. 
Raz, R. (2001) 'Postmenopausal women with recurrent UTI', Int J Antimicrob Agents, 17(4), 
269-71. 
Raz, R., Gennesin, Y., Wasser, J., Stoler, Z., Rosenfeld, S., Rottensterich, E. and Stamm, W. E. 
(2000) 'Recurrent urinary tract infections in postmenopausal women', Clin Infect 
Dis, 30(1), 152-6. 
Raz, R. and Stamm, W. E. (1993) 'A controlled trial of intravaginal estriol in postmenopausal 
women with recurrent urinary tract infections', N Engl J Med, 329(11), 753-6. 
Reid, G. and Sobel, J. D. (1987) 'Bacterial adherence in the pathogenesis of urinary tract 
infection: a review', Rev Infect Dis, 9(3), 470-87. 
Rene, P., Dinolfo, M. and Silverblatt, F. J. (1982) 'Serum and urogenital antibody responses 
to Escherichia coli pili in cystitis', Infect Immun, 38(2), 542-7. 
Roberts, A. P. and Phillips, R. (1979) 'Bacteria causing symptomatic urinary tract infection or 
asymptomatic bacteriuria', J Clin Pathol, 32(5), 492-6. 
Ronald, A. (2003) 'The etiology of urinary tract infection: traditional and emerging 
pathogens', Dis Mon, 49(2), 71-82. 
Ronald, A. and Ludwig, E. (2001) 'Urinary tract infections in adults with diabetes', Int J 
Antimicrob Agents, 17(4), 287-92. 
Rosenstein, I. J., Stafford, M. K., Kitchen, V. S., Ward, H., Weber, J. N. and Taylor-Robinson, 
D. (1998) 'Effect on normal vaginal flora of three intravaginal microbicidal agents 
potentially active against human immunodeficiency virus type 1', J Infect Dis, 
177(5), 1386-90. 
Schaeffer, A. J., Jones, J. M. and Dunn, J. K. (1981) 'Association of vitro Escherichia coli 
adherence to vaginal and buccal epithelial cells with susceptibility of women to 
recurrent urinary-tract infections', N Engl J Med, 304(18), 1062-6. 
Schaeffer, A. J., Radvany, R. M. and Chmiel, J. S. (1983) 'Human leukocyte antigens in 
women with recurrent urinary tract infections', J Infect Dis, 148(3), 604. 
 
The Pathogenesis of Urinary Tract Infections 
 
119 
Schaeffer, A. J., Schwan, W. R., Hultgren, S. J. and Duncan, J. L. (1987) 'Relationship of type 1 
pilus expression in Escherichia coli to ascending urinary tract infections in mice', 
Infect Immun, 55(2), 373-80. 
Schlager, T. A. (2001) 'Urinary tract infections in children younger than 5 years of age: 
epidemiology, diagnosis, treatment, outcomes and prevention', Paediatr Drugs, 3(3), 
219-27. 
Schlager, T. A., Hendley, J. O., Bell, A. L. and Whittam, T. S. (2002) 'Clonal diversity of 
Escherichia coli colonizing stools and urinary tracts of young girls', Infect Immun, 
70(3), 1225-9. 
Smellie, J., Edwards, D., Hunter, N., Normand, I. C. and Prescod, N. (1975) 'Vesico-ureteric 
reflux and renal scarring', Kidney Int Suppl, 4, S65-72. 
Smith, H. S., Hughes, J. P., Hooton, T. M., Roberts, P., Scholes, D., Stergachis, A., Stapleton, 
A. and Stamm, W. E. (1997) 'Antecedent antimicrobial use increases the risk of 
uncomplicated cystitis in young women', Clin Infect Dis, 25(1), 63-8. 
Stamm, W. E. and Hooton, T. M. (1993) 'Management of urinary tract infections in adults', N 
Engl J Med, 329(18), 1328-34. 
Stapleton, A. (2002) 'Urinary tract infections in patients with diabetes', Am J Med, 113 Suppl 
1A, 80S-84S. 
Sun, T. T. (1996) 'Epithelial growth and differentiation: an overview', Mol Biol Rep, 23(1), 1-2. 
Talan, D. A., Stamm, W. E., Hooton, T. M., Moran, G. J., Burke, T., Iravani, A., Reuning-
Scherer, J. and Church, D. A. (2000) 'Comparison of ciprofloxacin (7 days) and 
trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis 
pyelonephritis in women: a randomized trial', JAMA, 283(12), 1583-90. 
Thomas, T. M., Plymat, K. R., Blannin, J. and Meade, T. W. (1980) 'Prevalence of urinary 
incontinence', Br Med J, 281(6250), 1243-5. 
Uehling, D. T., Hopkins, W. J., Dahmer, L. A. and Balish, E. (1994a) 'Phase I clinical trial of 
vaginal mucosal immunization for recurrent urinary tract infection', J Urol, 152(6 Pt 
2), 2308-11. 
Uehling, D. T., Hopkins, W. J., James, L. J. and Balish, E. (1994b) 'Vaginal immunization of 
monkeys against urinary tract infection with a multi-strain vaccine', J Urol, 151(1), 
214-6. 
Vaisanen, V., Elo, J., Tallgren, L. G., Siitonen, A., Makela, P. H., Svanborg-Eden, C., 
Kallenius, G., Svenson, S. B., Hultberg, H. and Korhonen, T. (1981) 'Mannose-
resistant haemagglutination and P antigen recognition are characteristic of 
Escherichia coli causing primary pyelonephritis', Lancet, 2(8260-61), 1366-9. 
Vetsch, M., Puorger, C., Spirig, T., Grauschopf, U., Weber-Ban, E. U. and Glockshuber, R. 
(2004) 'Pilus chaperones represent a new type of protein-folding catalyst', Nature, 
431(7006), 329-33. 
Vosti, K. L., Goldberg, L. M., Monto, A. S. and Rantz, L. A. (1964) 'Host-Parasite Interaction 
in Patients with Infections Due to Escherichia Coli. I. The Serogrouping of E. Coli 
from Intestinal and Extraintestinal Sources', J Clin Invest, 43, 2377-85. 
Winberg, J., Gezelius, L., Guldevall, L. and Mollby, R. (1993) 'Cephadroxil promotes vaginal 
colonization with Escherichia coli', Infection, 21(4), 201-5. 
Wright, S. W., Wrenn, K. D. and Haynes, M. L. (1999) 'Trimethoprim-sulfamethoxazole 
resistance among urinary coliform isolates', J Gen Intern Med, 14(10), 606-9. 
 
Clinical Management of Complicated Urinary Tract Infection 
 
118 
Mulvey, M. A., Schilling, J. D., Martinez, J. J. and Hultgren, S. J. (2000) 'Bad bugs and 
beleaguered bladders: interplay between uropathogenic Escherichia coli and innate 
host defenses', Proc Natl Acad Sci U S A, 97(16), 8829-35. 
Munoz, P., Llancaqueo, A., Rodriguez-Creixems, M., Pelaez, T., Martin, L. and Bouza, E. 
(1997) 'Group B streptococcus bacteremia in nonpregnant adults', Arch Intern Med, 
157(2), 213-6. 
Mysorekar, I. U., Mulvey, M. A., Hultgren, S. J. and Gordon, J. I. (2002) 'Molecular 
regulation of urothelial renewal and host defenses during infection with 
uropathogenic Escherichia coli', J Biol Chem, 277(9), 7412-9. 
Nicolle, L. E., Friesen, D., Harding, G. K. and Roos, L. L. (1996) 'Hospitalization for acute 
pyelonephritis in Manitoba, Canada, during the period from 1989 to 1992; impact of 
diabetes, pregnancy, and aboriginal origin', Clin Infect Dis, 22(6), 1051-6. 
Parsek, M. R. and Singh, P. K. (2003) 'Bacterial biofilms: an emerging link to disease 
pathogenesis', Annu Rev Microbiol, 57, 677-701. 
Poljakovic, M. and Persson, K. (2003) 'Urinary tract infection in iNOS-deficient mice with 
focus on bacterial sensitivity to nitric oxide', Am J Physiol Renal Physiol, 284(1), F22-
31. 
Poljakovic, M., Svensson, M. L., Svanborg, C., Johansson, K., Larsson, B. and Persson, K. 
(2001) 'Escherichia coli-induced inducible nitric oxide synthase and cyclooxygenase 
expression in the mouse bladder and kidney', Kidney Int, 59(3), 893-904. 
Raz, R. (2001) 'Postmenopausal women with recurrent UTI', Int J Antimicrob Agents, 17(4), 
269-71. 
Raz, R., Gennesin, Y., Wasser, J., Stoler, Z., Rosenfeld, S., Rottensterich, E. and Stamm, W. E. 
(2000) 'Recurrent urinary tract infections in postmenopausal women', Clin Infect 
Dis, 30(1), 152-6. 
Raz, R. and Stamm, W. E. (1993) 'A controlled trial of intravaginal estriol in postmenopausal 
women with recurrent urinary tract infections', N Engl J Med, 329(11), 753-6. 
Reid, G. and Sobel, J. D. (1987) 'Bacterial adherence in the pathogenesis of urinary tract 
infection: a review', Rev Infect Dis, 9(3), 470-87. 
Rene, P., Dinolfo, M. and Silverblatt, F. J. (1982) 'Serum and urogenital antibody responses 
to Escherichia coli pili in cystitis', Infect Immun, 38(2), 542-7. 
Roberts, A. P. and Phillips, R. (1979) 'Bacteria causing symptomatic urinary tract infection or 
asymptomatic bacteriuria', J Clin Pathol, 32(5), 492-6. 
Ronald, A. (2003) 'The etiology of urinary tract infection: traditional and emerging 
pathogens', Dis Mon, 49(2), 71-82. 
Ronald, A. and Ludwig, E. (2001) 'Urinary tract infections in adults with diabetes', Int J 
Antimicrob Agents, 17(4), 287-92. 
Rosenstein, I. J., Stafford, M. K., Kitchen, V. S., Ward, H., Weber, J. N. and Taylor-Robinson, 
D. (1998) 'Effect on normal vaginal flora of three intravaginal microbicidal agents 
potentially active against human immunodeficiency virus type 1', J Infect Dis, 
177(5), 1386-90. 
Schaeffer, A. J., Jones, J. M. and Dunn, J. K. (1981) 'Association of vitro Escherichia coli 
adherence to vaginal and buccal epithelial cells with susceptibility of women to 
recurrent urinary-tract infections', N Engl J Med, 304(18), 1062-6. 
Schaeffer, A. J., Radvany, R. M. and Chmiel, J. S. (1983) 'Human leukocyte antigens in 
women with recurrent urinary tract infections', J Infect Dis, 148(3), 604. 
 
The Pathogenesis of Urinary Tract Infections 
 
119 
Schaeffer, A. J., Schwan, W. R., Hultgren, S. J. and Duncan, J. L. (1987) 'Relationship of type 1 
pilus expression in Escherichia coli to ascending urinary tract infections in mice', 
Infect Immun, 55(2), 373-80. 
Schlager, T. A. (2001) 'Urinary tract infections in children younger than 5 years of age: 
epidemiology, diagnosis, treatment, outcomes and prevention', Paediatr Drugs, 3(3), 
219-27. 
Schlager, T. A., Hendley, J. O., Bell, A. L. and Whittam, T. S. (2002) 'Clonal diversity of 
Escherichia coli colonizing stools and urinary tracts of young girls', Infect Immun, 
70(3), 1225-9. 
Smellie, J., Edwards, D., Hunter, N., Normand, I. C. and Prescod, N. (1975) 'Vesico-ureteric 
reflux and renal scarring', Kidney Int Suppl, 4, S65-72. 
Smith, H. S., Hughes, J. P., Hooton, T. M., Roberts, P., Scholes, D., Stergachis, A., Stapleton, 
A. and Stamm, W. E. (1997) 'Antecedent antimicrobial use increases the risk of 
uncomplicated cystitis in young women', Clin Infect Dis, 25(1), 63-8. 
Stamm, W. E. and Hooton, T. M. (1993) 'Management of urinary tract infections in adults', N 
Engl J Med, 329(18), 1328-34. 
Stapleton, A. (2002) 'Urinary tract infections in patients with diabetes', Am J Med, 113 Suppl 
1A, 80S-84S. 
Sun, T. T. (1996) 'Epithelial growth and differentiation: an overview', Mol Biol Rep, 23(1), 1-2. 
Talan, D. A., Stamm, W. E., Hooton, T. M., Moran, G. J., Burke, T., Iravani, A., Reuning-
Scherer, J. and Church, D. A. (2000) 'Comparison of ciprofloxacin (7 days) and 
trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis 
pyelonephritis in women: a randomized trial', JAMA, 283(12), 1583-90. 
Thomas, T. M., Plymat, K. R., Blannin, J. and Meade, T. W. (1980) 'Prevalence of urinary 
incontinence', Br Med J, 281(6250), 1243-5. 
Uehling, D. T., Hopkins, W. J., Dahmer, L. A. and Balish, E. (1994a) 'Phase I clinical trial of 
vaginal mucosal immunization for recurrent urinary tract infection', J Urol, 152(6 Pt 
2), 2308-11. 
Uehling, D. T., Hopkins, W. J., James, L. J. and Balish, E. (1994b) 'Vaginal immunization of 
monkeys against urinary tract infection with a multi-strain vaccine', J Urol, 151(1), 
214-6. 
Vaisanen, V., Elo, J., Tallgren, L. G., Siitonen, A., Makela, P. H., Svanborg-Eden, C., 
Kallenius, G., Svenson, S. B., Hultberg, H. and Korhonen, T. (1981) 'Mannose-
resistant haemagglutination and P antigen recognition are characteristic of 
Escherichia coli causing primary pyelonephritis', Lancet, 2(8260-61), 1366-9. 
Vetsch, M., Puorger, C., Spirig, T., Grauschopf, U., Weber-Ban, E. U. and Glockshuber, R. 
(2004) 'Pilus chaperones represent a new type of protein-folding catalyst', Nature, 
431(7006), 329-33. 
Vosti, K. L., Goldberg, L. M., Monto, A. S. and Rantz, L. A. (1964) 'Host-Parasite Interaction 
in Patients with Infections Due to Escherichia Coli. I. The Serogrouping of E. Coli 
from Intestinal and Extraintestinal Sources', J Clin Invest, 43, 2377-85. 
Winberg, J., Gezelius, L., Guldevall, L. and Mollby, R. (1993) 'Cephadroxil promotes vaginal 
colonization with Escherichia coli', Infection, 21(4), 201-5. 
Wright, S. W., Wrenn, K. D. and Haynes, M. L. (1999) 'Trimethoprim-sulfamethoxazole 
resistance among urinary coliform isolates', J Gen Intern Med, 14(10), 606-9. 
 
Clinical Management of Complicated Urinary Tract Infection 
 
120 
Wu, X. R., Sun, T. T. and Medina, J. J. (1996) 'In vitro binding of type 1-fimbriated 
Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections', Proc 
Natl Acad Sci U S A, 93(18), 9630-5. 
Yamamoto, S., Tsukamoto, T., Terai, A., Kurazono, H., Takeda, Y. and Yoshida, O. (1997) 
'Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis 
caused by Escherichia coli', J Urol, 157(3), 1127-9. 
Zhang, D., Zhang, G., Hayden, M. S., Greenblatt, M. B., Bussey, C., Flavell, R. A. and Ghosh, 
S. (2004) 'A toll-like receptor that prevents infection by uropathogenic bacteria', 
Science, 303(5663), 1522-6. 
8 
Urinary Tract Immunology 
Kelesidis Theodoros 
Department of Medicine, Division of Infectious Diseases,  
David Geffen School of Medicine at UCLA,  
Los Angeles, California,  
USA 
1. Introduction 
Urinary tract infection (UTI) is one of the most common infections in humans. It is estimated 
that 40% of women and 12% of men will experience a symptomatic UTI, with incidences 
peaking in their early 20s or after age 85, respectively (1). Approximately 25% of these women 
will experience recurrence within 6 to 12 months (1).  Uropathogenic Escherichia coli (UPEC) is 
the most common etiological agent responsible for uncomplicated UTI. In the United States 
alone, the estimated annual societal cost of UTI is more than 3 billion dollars (1). 
Despite significant advances in the understanding of UPEC biology, mechanistic details 
regarding the host response to UTI and full comprehension of genetic loci that influence 
susceptibility require additional work. As new and intriguing details of how uropathogens 
initiate infections and persist within the urinary tract have emerged, so has important 
information regarding how the immune system functions within the urinary tract. The 
complex cross-linking for innate and adaptive immune response as well as humoral and 
cellular effectors is the key to the urinary tract immune system and to its defense against 
pathogenic microorganisms. As antibiotic therapy becomes increasingly ineffective, 
modulating the innate and adaptive immune system in the urinary tract using TLR4 ligands 
and other immunomodulators may become viable options to combat UTIs. 
2. Innate responses to urinary tract infections  
2.1 Host factors that prevent colonization of urinary tract with UPEC 
Uroepithelial adherence is critical for establishment of UTI. The urinary tract, comprised of 
the urethra, bladder, ureters and the kidneys, represents a formidable mechanical barrier to 
infection. In addition to the relative impregnability of the epithelium lining the tract, 
potential pathogens have to contend with the powerful flushing action of urine and the 
aggregating actions of urinary mucins (2;3). UPEC strains possess an impressive repertoire 
of adhesins that enable them to aggregate and adhere to cellular surfaces (4).  Consequently, 
the first line of host defense against UTI is concentrated on preventing UPEC adherence to 
the bladder mucosa. The luminal surface of the bladder is lined with highly sulfated and 
anionic glycosaminoglycans (GAGs) that contribute to bladder wall impermeability and 
afford an antimicrobial anti-adherence property. Intuitively, urine flow seems to be a 
convenient defense mechanism; however, FimH binds to mannose moieties using “catch-
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bonds,” interactions that are actually strengthened by the sheer stress induced during urine 
flow (5). Thus, more active mechanisms, like umbrella cell exfoliation (6) that occurs by an 
apoptosis-like mechanism and is promoted by FimH (7) remove adherent UPEC.  Tamm-
Horsfall protein (THP) is a high-molecular-weight protein present in human urine (8) that 
binds E. coli fimbriae (9) by virtue of its mannose moieties, inhibiting fimbrial interaction 
with uroplakin receptors (10). This phenotype translated in vivo as thp−/− mice were 
unable to control lower-UTI (11). THP also appears to act as an innate-adaptive 
immunoregulatory molecule that can activate dendritic cells (12). 
2.2 Host signaling in response to UPEC recognition  
Of the various immune surveillance molecules the Toll-like receptor (TLR) family is the best 
characterized (13-16). Unlike the receptor for the FimH adhesin of UPEC, which promotes 
bacterial invasion and subsequent invasion of BECs (17), the TLRs function by detecting 
different PAMPs and then mobilizing appropriate immune defences. The common TLRs 
encountered in the urinary tract include TLR2 (recognizes bacterial lipoteichoic acid or 
lipoprotein), TLR3 (recognizes double stranded RNA), TLR4 [recognizes 
lipopolysaccharides (LPS)], TLR5 (recognizes flagellin), TLR9 (recognizes unmethylated 
CpG DNA of bacteria and viruses), and TLR11 (recognizes profiling of parasites). TLR5 and 
TLR11 are other TLRs shown in in vivo studies to contribute to immune defence in the 
urinary tract (13;16). TLR5 is predominantly expressed on bladder cells whereas TLR11 is 
primarily on kidney cells  (13;16). Perhaps the best studied of these TLRs is TLR4, which is 
well expressed on epithelial cells of the kidney and bladder (14). 
Toll-like receptor 4 (TLR4) is important for signalling of innate immunity in response to 
UTI 
Upon successful adherence to the uroepithelium, Toll-like receptor (TLR) recognition of 
pathogen-associated molecular patterns generates signaling cascades to control infection 
and direct adaptive responses (18). Particular close attention has been given to the role of 
TLR4 in UTIs.  LR4 mutation (TLR4-/-) mice failed to initiate an immune response against 
UTI, and they developed an asymptomatic carrier state resembling human asymptomatic 
bacteriuria (ABU) (19) . Interestingly, recent studies have shown that TLR4 has antimicrobial 
roles that appear to be specific to the urinary tract (20) (21). These include promotion of IL-6 
and IL-8 secretion by activation of the MyD88- or cAMP-dependent signaling pathway, 
inhibition of bladder epithelial cell (BEC) invasion by bacteria, and expulsion of UPEC 
harboring in BECs (21-24). Clinical research found that children with UTI have lower TLR4 
expression than age-matched controls without UTI. In relation to UTI history, children with 
low TLR4 expression on their neutrophils display an asymptomatic bacteriuria (ABU) 
carrier state lacking both inflammation and bacterial clearance (25).   Meanwhile, adult 
patients with chronic UTI were found to have lower TLR4 expression than healthy controls 
without UTI (26). All these imply that enhanced TLR4 expression possibly contributes to 
increased mucosal immune response. 
It has been known that C3H/HeJ mice, harboring a mutation in the Toll/interleukin-1 
receptor (TIR) domain of TLR4, cannot resolve UTI as efficiently as LPS-responsive 
C3H/HeN counterparts (27). In accordance, tlr4−/− mice had significantly higher bacterial 
burdens in their bladders than similarly infected wild-type mice (28).  This clearance defect 
is the result of insufficient downstream cytokine and chemokine production and neutrophil 
recruitment (29).  Data from mouse chimeras disclosed that TLR4 on both stromal and 
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hematopoietic cells is critical for normal inflammatory responses and clearance of UPEC in 
the bladder and kidney (30). Correspondingly, children with low TLR4 expression on their 
neutrophils display an asymptomatic bacteriuria (ABU) carrier state lacking both 
inflammation and bacterial clearance (25). A similar response is exhibited by C3N/HeJ mice 
following UPEC inoculation (31). 
TLR4-mediated signaling is mainly LPS independent 
TLR4-mediated signaling in the urinary tract does not appear to be the result of the 
archetypal interaction with LPS. Both the role of LPS in and the molecular trigger of TLR4 
signaling by UPEC are topics of debate (32). Studies using the A498 human kidney cell line 
indicate that TLR4 signaling in response to UPEC requires P fimbriae and can be mediated 
independently of LPS (33). Mechanistic details regarding this phenomenon include P 
fimbriae binding to surface glycosphingolipids (GSLs) and subsequent release of the GSL 
membrane-anchoring domain, ceramide (34). Ceramide appears to act as a TLR4 agonist and 
the putative intermediate for TLR4 signaling initiated by P fimbriae (34). Lastly, the FimH 
tip adhesin of type 1 fimbriae was recently shown to directly interact with TLR4, an 
additional means for LPS-independent stimulation by UPEC fimbriae (35) 
TLR4-mediated signaling is also LPS dependent 
In contrast to LPS-independent signaling by P fimbriae, there appears to be a cooperative 
stimulation of TLR4 by LPS and type 1 fimbriae (36). This cooperative stimulation directly 
correlates with the level of cluster of differentiation 14 (CD14) expression on bladder cells 
(24). CD14 is an accessory molecule required for optimal TLR4 signaling in response to LPS 
(24). Immunohistochemical (IHC) analysis of human bladder biopsies revealed that CD14 
expression is localized to the submucosa (37), suggesting that uroepithelial cells exposed to 
the lumen have little to no CD14 expression and therefore may not respond efficiently to 
LPS alone. These results support a role for both independent and cooperative TLR4 
stimulation by UPEC fimbriae.  
Downstream signalling pathways important for signalling of innate immunity in 
response to UTI 
Infection of knockout mice has revealed critical roles for myeloid differentiation primary 
response protein 88 (MyD88), TIR domain-containing adaptor inducing beta interferon (TRIF), 
and TRIF-related adaptor molecule (TRAM) in signaling for UPEC clearance (38). It is also 
apparent that different fimbrial types influence the corresponding downstream signaling 
pathways (38). Regardless of the fimbria involved in stimulation, all pathways involving these 
adaptor molecules result in activation of NF-κB and proinflammatory gene expression. Song 
and colleagues identified an accompanying proinflammatory bladder cell signaling pathway 
that is also dependent on TLR4 but results in a spike in intracellular calcium levels (39). This 
calcium spike leads to adenylyl cyclase 3 (AC3)-mediated increase in cAMP, protein kinase A 
(PKA) activation, phosphorylation of the cAMP response element-binding protein 
transcription factor (CREB), and proinflammatory gene expression such as transcription of IL-
6 and IL-8 (39). Using selective blockade of these signaling cascades, Song et al. determined 
that activation of epithelial IL-6 secretion by E. coli might even be faster via the CREB pathway 
than the canonical pathway and can also be activated by TLR2 and TLR3 ligands (39). 
Other TLR pathways important for signalling of innate immunity in response to UTI 
Other TLR pathways have been implicated in host defense during UTI. In a recent case-
control study of adult women with a history of UTI in which TLR genes were examined, 
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recruitment (29).  Data from mouse chimeras disclosed that TLR4 on both stromal and 
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hematopoietic cells is critical for normal inflammatory responses and clearance of UPEC in 
the bladder and kidney (30). Correspondingly, children with low TLR4 expression on their 
neutrophils display an asymptomatic bacteriuria (ABU) carrier state lacking both 
inflammation and bacterial clearance (25). A similar response is exhibited by C3N/HeJ mice 
following UPEC inoculation (31). 
TLR4-mediated signaling is mainly LPS independent 
TLR4-mediated signaling in the urinary tract does not appear to be the result of the 
archetypal interaction with LPS. Both the role of LPS in and the molecular trigger of TLR4 
signaling by UPEC are topics of debate (32). Studies using the A498 human kidney cell line 
indicate that TLR4 signaling in response to UPEC requires P fimbriae and can be mediated 
independently of LPS (33). Mechanistic details regarding this phenomenon include P 
fimbriae binding to surface glycosphingolipids (GSLs) and subsequent release of the GSL 
membrane-anchoring domain, ceramide (34). Ceramide appears to act as a TLR4 agonist and 
the putative intermediate for TLR4 signaling initiated by P fimbriae (34). Lastly, the FimH 
tip adhesin of type 1 fimbriae was recently shown to directly interact with TLR4, an 
additional means for LPS-independent stimulation by UPEC fimbriae (35) 
TLR4-mediated signaling is also LPS dependent 
In contrast to LPS-independent signaling by P fimbriae, there appears to be a cooperative 
stimulation of TLR4 by LPS and type 1 fimbriae (36). This cooperative stimulation directly 
correlates with the level of cluster of differentiation 14 (CD14) expression on bladder cells 
(24). CD14 is an accessory molecule required for optimal TLR4 signaling in response to LPS 
(24). Immunohistochemical (IHC) analysis of human bladder biopsies revealed that CD14 
expression is localized to the submucosa (37), suggesting that uroepithelial cells exposed to 
the lumen have little to no CD14 expression and therefore may not respond efficiently to 
LPS alone. These results support a role for both independent and cooperative TLR4 
stimulation by UPEC fimbriae.  
Downstream signalling pathways important for signalling of innate immunity in 
response to UTI 
Infection of knockout mice has revealed critical roles for myeloid differentiation primary 
response protein 88 (MyD88), TIR domain-containing adaptor inducing beta interferon (TRIF), 
and TRIF-related adaptor molecule (TRAM) in signaling for UPEC clearance (38). It is also 
apparent that different fimbrial types influence the corresponding downstream signaling 
pathways (38). Regardless of the fimbria involved in stimulation, all pathways involving these 
adaptor molecules result in activation of NF-κB and proinflammatory gene expression. Song 
and colleagues identified an accompanying proinflammatory bladder cell signaling pathway 
that is also dependent on TLR4 but results in a spike in intracellular calcium levels (39). This 
calcium spike leads to adenylyl cyclase 3 (AC3)-mediated increase in cAMP, protein kinase A 
(PKA) activation, phosphorylation of the cAMP response element-binding protein 
transcription factor (CREB), and proinflammatory gene expression such as transcription of IL-
6 and IL-8 (39). Using selective blockade of these signaling cascades, Song et al. determined 
that activation of epithelial IL-6 secretion by E. coli might even be faster via the CREB pathway 
than the canonical pathway and can also be activated by TLR2 and TLR3 ligands (39). 
Other TLR pathways important for signalling of innate immunity in response to UTI 
Other TLR pathways have been implicated in host defense during UTI. In a recent case-
control study of adult women with a history of UTI in which TLR genes were examined, 
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polymorphisms in TLR1, TLR4, and TLR5 were correlated with protection from, or 
susceptibility to, some UTI phenotypes (40). TLR2 is stimulated by peptidoglycan, as might 
be presented by gram-positive uropathogens, including Enterococcus and Staphylococcus 
species, as well as by lipoproteins and perhaps OmpA (41) of other extraintestinal 
pathogenic E. coli.  Tlr2−/− mice appear to respond normally to acute UTI (31). TLR5 
appears to play a UPEC recognition role in the bladder (13). TLR5 recognizes the structural 
subunit of flagella, which are essential for UPEC motility in the urinary tract induces 
inflammatory cytokines and chemokines (13). Mice lacking TLR5, which responds to 
bacterial flagellin, permit higher bacterial loads in the bladder and kidney following 
transurethral inoculation (13). In contrast to TLR5 which has a bladder-specific role during 
UTI, TLR11 has a kidney-specific role during UTI (16). The murine receptor TLR11, 
associated with a pseudogene in humans, also appears to respond to uropathogenic bacteria 
(16). Conversely, tlr11−/− mice are more susceptible than wild-type mice to UPEC kidney 
infection (16) a UPEC-encoded homolog has yet to be identified for TLR11 ligand. The fact 
that there is a stop codon in the open reading frame of human genomic and cell line tlr11 
sequences may help explain acute and recurrent UTI susceptibility in humans (16).  
Other Non-TLR pathways important for signalling of innate immunity in response to 
UTI 
Surface molecules other than TLRs are also involved in host-UPEC interactions. Upon UPEC 
exposure, the cytoplasmic tail of uroplakin IIIa undergoes phosphorylation, and 
intracellular calcium levels increase, presumably important events for uroepithelial cell 
apoptosis and exfoliation(42) Although uroplakin Ia is thought to be the main receptor for 
UPEC FimH in vivo (167, 256, 286), type 1 fimbriae may bind to a number of host molecules, 
including uroplakin complexes (42) extracellular matrix proteins (43) CD molecules (44), 
and integrins (45). The CD44 ligand, hyaluronic acid (HA), accumulates in the urinary tract 
during UTI; UPEC can bind HA, thereby facilitating interaction with CD44 and tissue 
invasion (46). In accordance with this, cd44−/− mice are more resistant to UPEC kidney 
colonization and successive dissemination (46). Also, there are still unidentified players in 
inflammation and clearance of UPEC. For example, LPS-responder C3H/OuJ mice were 
found to be equally susceptible to UTI as non-LPS-responder C3H/HeJ mice yet 
demonstrated elevated levels of inflammation (47), revealing a susceptibility locus to map. 
2.3 Metabolic host pathways against UPEC during UTI 
Host factors against iron metabolism of UPEC 
That E. coli strains causing UTI have several functionally redundant systems dedicated to 
iron uptake (48) suggests that the urinary tract, like other host niches, is an iron-limited 
environment (49). Siderophores are secreted iron-chelating molecules that allow bacteria to 
scavenge free and host protein-bound iron (50). Enterobactin, for instance, can bind free 
ferric ions with a higher affinity than transferrin (51)  a host iron transport protein 
responsible for regulating the free iron concentration in serum(52). A transferrin family 
member, lactoferrin, evokes antimicrobial activity by sequestering iron over a range of pH. 
Lactoferrin is secreted by kidney cells and is found in neutrophil granules and thus could be 
involved in combating UTI (53). Both transferrin and lactoferrin have been shown to evoke 
direct antimicrobial activity by disrupting Gram-negative membranes (54). 
In addition to iron sequestration, there are host factors that directly counter the action of 
siderophores. Early studies indicated that serum albumin, alone or in concert with other 
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serum proteins, can impede bacterial siderophore function (55). In addition, the mammalian 
protein lipocalin 2 (Lcn2) can bind and sequester enterobactin and similar catecholate 
siderophores (56). Lcn2 inhibits enterobactin-dependent propagation of E. coli in vitro, and 
lcn2−/− mice are unable to control systemic E. coli burdens as well as wild-type mice (56) 
Production of Lcn2 is induced by TLR4, implicating iron regulation as a part of the immune 
response to infection(56). Murine GeneChip and quantitative PCR (qPCR) analyses 
confirmed that Lcn2 mRNA is upregulated by the uroepithelium of infected mice (57). 
Interestingly, these results were obtained in C3H/HeJ mice, indicating that a TLR4-
independent signaling pathway can activate transcription of the lcn2 gene in response to 
UTI. Not surprisingly, UPEC has evolved a mechanism to counter Lcn2 siderophore 
sequestration. Encoded within the iroA gene cluster are glycosyltransferases that modify 
enterobactin in such a way that it cannot be bound by Lcn2 (58). Thus, both the host and 
UPEC have systems in place to manage their own iron stores and to inhibit iron acquisition 
by the other—a molecular arms race for an essential nutrient. 
2.4 Metabolic host factors against UPEC 
The role for bacterial central metabolism during infection has only been recently appreciated 
(59).  Genes important for glucose import were upregulated by the uroepithelium of 
C3H/HeJ mice experiencing UTI, possibly for either nutrient sequestration or energy to 
combat infection(57).  This fact, coupled with the knowledge that UPEC does not chemotax 
toward glucose in vitro (60) or utilize glucose as a primary carbon source in vivo (61) 
implies that UPEC may have evolved to use alternative carbon sources in the urinary tract. 
These results imply that nutrient acquisition is also a crucial aspect of bacterial pathogenesis 
and the host response that may influence the outcome of UTI. 
2.5 Epithelial host pathways against UPEC during UTI 
Life cycle of UPEC in urinary tract epithelium 
There has been a growing body of literature revealing that UPEC appears to have three 
distinct intracellular lifestyle components within the urinary tract (62). The first is uptake by 
apical endocytosis of Rab27b+/CD63+ fusiform vesicles, which are subsequently recycled 
back to the cell surface and exocytosed (20). The other two pathways both begin with uptake 
into a membrane-bound compartment which can lead to either a quiescent nonreplicative 
existence (63) or escape from compartmental life to undergo a highly replicative phase in the 
cell cytoplasm. While internalization via the fusiform vesicle pathway may be a side effect of 
normal bladder epithelium function, cellular uptake by the other two pathways is perhaps 
intended by UPEC to establish a reservoir to persist in the urinary tract (63). Indeed, UPEC 
has been shown to exist in the urinary tract for weeks, even after antibiotic treatment (64). 
Infection of 10 genetically distinct mouse strains also revealed that some strains were more 
susceptible to persistence than others, indicating that host hereditary components may also 
contribute to the ability of UPEC to persevere in the urinary tract (65). 
2.6 Epithelial host factors have important role against compartmental escape of UPEC 
Infected mouse bladder explants monitored by time lapse fluorescence videomicroscopy 
generated a model for the intracellular UPEC life cycle instigated after uptake in a 
membrane-bound compartment (nonfusiform vesicle route)(66). While the mechanism of 
compartmental escape remains undefined, once contained in cytoplasmic “intracellular 
bacterial communities” (IBCs), UPEC can undergo several changes in morphology, 
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polymorphisms in TLR1, TLR4, and TLR5 were correlated with protection from, or 
susceptibility to, some UTI phenotypes (40). TLR2 is stimulated by peptidoglycan, as might 
be presented by gram-positive uropathogens, including Enterococcus and Staphylococcus 
species, as well as by lipoproteins and perhaps OmpA (41) of other extraintestinal 
pathogenic E. coli.  Tlr2−/− mice appear to respond normally to acute UTI (31). TLR5 
appears to play a UPEC recognition role in the bladder (13). TLR5 recognizes the structural 
subunit of flagella, which are essential for UPEC motility in the urinary tract induces 
inflammatory cytokines and chemokines (13). Mice lacking TLR5, which responds to 
bacterial flagellin, permit higher bacterial loads in the bladder and kidney following 
transurethral inoculation (13). In contrast to TLR5 which has a bladder-specific role during 
UTI, TLR11 has a kidney-specific role during UTI (16). The murine receptor TLR11, 
associated with a pseudogene in humans, also appears to respond to uropathogenic bacteria 
(16). Conversely, tlr11−/− mice are more susceptible than wild-type mice to UPEC kidney 
infection (16) a UPEC-encoded homolog has yet to be identified for TLR11 ligand. The fact 
that there is a stop codon in the open reading frame of human genomic and cell line tlr11 
sequences may help explain acute and recurrent UTI susceptibility in humans (16).  
Other Non-TLR pathways important for signalling of innate immunity in response to 
UTI 
Surface molecules other than TLRs are also involved in host-UPEC interactions. Upon UPEC 
exposure, the cytoplasmic tail of uroplakin IIIa undergoes phosphorylation, and 
intracellular calcium levels increase, presumably important events for uroepithelial cell 
apoptosis and exfoliation(42) Although uroplakin Ia is thought to be the main receptor for 
UPEC FimH in vivo (167, 256, 286), type 1 fimbriae may bind to a number of host molecules, 
including uroplakin complexes (42) extracellular matrix proteins (43) CD molecules (44), 
and integrins (45). The CD44 ligand, hyaluronic acid (HA), accumulates in the urinary tract 
during UTI; UPEC can bind HA, thereby facilitating interaction with CD44 and tissue 
invasion (46). In accordance with this, cd44−/− mice are more resistant to UPEC kidney 
colonization and successive dissemination (46). Also, there are still unidentified players in 
inflammation and clearance of UPEC. For example, LPS-responder C3H/OuJ mice were 
found to be equally susceptible to UTI as non-LPS-responder C3H/HeJ mice yet 
demonstrated elevated levels of inflammation (47), revealing a susceptibility locus to map. 
2.3 Metabolic host pathways against UPEC during UTI 
Host factors against iron metabolism of UPEC 
That E. coli strains causing UTI have several functionally redundant systems dedicated to 
iron uptake (48) suggests that the urinary tract, like other host niches, is an iron-limited 
environment (49). Siderophores are secreted iron-chelating molecules that allow bacteria to 
scavenge free and host protein-bound iron (50). Enterobactin, for instance, can bind free 
ferric ions with a higher affinity than transferrin (51)  a host iron transport protein 
responsible for regulating the free iron concentration in serum(52). A transferrin family 
member, lactoferrin, evokes antimicrobial activity by sequestering iron over a range of pH. 
Lactoferrin is secreted by kidney cells and is found in neutrophil granules and thus could be 
involved in combating UTI (53). Both transferrin and lactoferrin have been shown to evoke 
direct antimicrobial activity by disrupting Gram-negative membranes (54). 
In addition to iron sequestration, there are host factors that directly counter the action of 
siderophores. Early studies indicated that serum albumin, alone or in concert with other 
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serum proteins, can impede bacterial siderophore function (55). In addition, the mammalian 
protein lipocalin 2 (Lcn2) can bind and sequester enterobactin and similar catecholate 
siderophores (56). Lcn2 inhibits enterobactin-dependent propagation of E. coli in vitro, and 
lcn2−/− mice are unable to control systemic E. coli burdens as well as wild-type mice (56) 
Production of Lcn2 is induced by TLR4, implicating iron regulation as a part of the immune 
response to infection(56). Murine GeneChip and quantitative PCR (qPCR) analyses 
confirmed that Lcn2 mRNA is upregulated by the uroepithelium of infected mice (57). 
Interestingly, these results were obtained in C3H/HeJ mice, indicating that a TLR4-
independent signaling pathway can activate transcription of the lcn2 gene in response to 
UTI. Not surprisingly, UPEC has evolved a mechanism to counter Lcn2 siderophore 
sequestration. Encoded within the iroA gene cluster are glycosyltransferases that modify 
enterobactin in such a way that it cannot be bound by Lcn2 (58). Thus, both the host and 
UPEC have systems in place to manage their own iron stores and to inhibit iron acquisition 
by the other—a molecular arms race for an essential nutrient. 
2.4 Metabolic host factors against UPEC 
The role for bacterial central metabolism during infection has only been recently appreciated 
(59).  Genes important for glucose import were upregulated by the uroepithelium of 
C3H/HeJ mice experiencing UTI, possibly for either nutrient sequestration or energy to 
combat infection(57).  This fact, coupled with the knowledge that UPEC does not chemotax 
toward glucose in vitro (60) or utilize glucose as a primary carbon source in vivo (61) 
implies that UPEC may have evolved to use alternative carbon sources in the urinary tract. 
These results imply that nutrient acquisition is also a crucial aspect of bacterial pathogenesis 
and the host response that may influence the outcome of UTI. 
2.5 Epithelial host pathways against UPEC during UTI 
Life cycle of UPEC in urinary tract epithelium 
There has been a growing body of literature revealing that UPEC appears to have three 
distinct intracellular lifestyle components within the urinary tract (62). The first is uptake by 
apical endocytosis of Rab27b+/CD63+ fusiform vesicles, which are subsequently recycled 
back to the cell surface and exocytosed (20). The other two pathways both begin with uptake 
into a membrane-bound compartment which can lead to either a quiescent nonreplicative 
existence (63) or escape from compartmental life to undergo a highly replicative phase in the 
cell cytoplasm. While internalization via the fusiform vesicle pathway may be a side effect of 
normal bladder epithelium function, cellular uptake by the other two pathways is perhaps 
intended by UPEC to establish a reservoir to persist in the urinary tract (63). Indeed, UPEC 
has been shown to exist in the urinary tract for weeks, even after antibiotic treatment (64). 
Infection of 10 genetically distinct mouse strains also revealed that some strains were more 
susceptible to persistence than others, indicating that host hereditary components may also 
contribute to the ability of UPEC to persevere in the urinary tract (65). 
2.6 Epithelial host factors have important role against compartmental escape of UPEC 
Infected mouse bladder explants monitored by time lapse fluorescence videomicroscopy 
generated a model for the intracellular UPEC life cycle instigated after uptake in a 
membrane-bound compartment (nonfusiform vesicle route)(66). While the mechanism of 
compartmental escape remains undefined, once contained in cytoplasmic “intracellular 
bacterial communities” (IBCs), UPEC can undergo several changes in morphology, 
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categorized as early, middle, and late IBC stages (66). Late IBCs that escape exfoliation with 
umbrella cells contain filamentous UPEC that are not present in C3H/HeJ mice, indicating 
that this morphological change may be a bacterial stress response to TLR4-mediated 
immune activation (66). This murine background also experienced increased incidence and 
severity of IBCs compared to immunocompetent mice (66). Urothelial cells proximal to IBCs 
in C3H/HeJ mice upregulate transferrin receptor, Lcn2, complement system components 
(C3, factor B, and CD55), and lysozyme (57). Involucrin and suprabasin transcripts were also 
increased, indicating that, in addition to gene products that function to eradicate bacteria, 
proteins important for epithelial integrity may be an imperative host response during UTI 
(57). 
Notably, TLR4 also plays a noninflammatory role in host defense against UPEC by 
modulating the activity of the observed secretory and vesicular internalization pathways. 
TLR4-mediated PKA activation suppresses the lipid raft endocytic pathway (21), a possible 
effort to prevent the establishment of persistence reservoirs. Also along these lines, UPEC 
exocytosis in fusiform vesicles was actually accelerated by TLR4-mediated recognition of 
LPS and dependent on the activities of cAMP, Rab27b, caveolin-1, and the scaffolding 
protein MyRIP (22). 
The role of urothelial regeneration in response to UPEC infection 
One of the consequences of UPEC infection is exfoliation of the superficial facet cell layer 
that lines the surface of the bladder lumen (67).  Microarray analyses probing regenerative 
signals revealed that, in addition to genes involved in cell biological processes, 
inflammatory cytokines, chemokines, signaling molecules, and transcription factors are also 
upregulated in response to inoculation (68). While regeneration itself appears to be a 
function of basal stem/progenitor cells in the transitional epithelium (68) studies of the gut 
epithelium unveiled macrophages as “cellular transceivers” that relay MyD88-dependent 
inputs from the epithelium to colonic epithelial progenitors via direct contact (69). Whether 
or not macrophages play a similar role in the urinary tract remains unknown. 
2.7 Antimicrobial peptides, cytokines and chemokines against UPEC during UTI 
Antimicrobial peptides (AMPs) are short positively charged peptides secreted by both 
epithelial and hematopoietic cells that disrupt bacterial membranes and can be chemotactic 
for certain immune cells (70). Human β-defensin-1 mRNA and protein were found in kidney 
tissue, implicating this AMP in host defense against UPEC (71). More convincingly, mice 
deficient in defb1, a murine homolog of human β-defensin, have a significantly higher 
incidence of bacteriuria (72). Murine β-defensin is also a dendritic cell (DC) ligand that 
instigates upregulation of costimulatory molecules and maturation (73). The human 
cathelicidin, LL-37, and its murine homolog, cathelin-related antimicrobial peptide 
(CRAMP), are secreted in response to UPEC exposure (44). Studies using CRAMP-deficient 
mice revealed that epithelial-derived CRAMP is important during the early stages of UTI 
while leukocyte-derived CRAMP likely functions later when bacteria penetrate the kidney 
epithelium (46). 
2.8 Cytokines and chemokines against UPEC during UTI 
The role of IL-8-mediated neutrophil recruitment in phenotypic susceptibility to UTIs  
Human C-X-C ligand 8 (hCXCL8; interleukin-8 [IL-8]) is the main chemoattractant for 
neutrophils in humans, and murine CXCL1 (mCXCL1) and mCXCL2 (also known as KC 
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and MIP-2, respectively) are the functional mouse homologs of IL-8 (26).  Bladder and 
kidney cell lines secrete IL-8 in response to UPEC (26). Human and murine studies both 
demonstrate that neutrophil migration to the UPEC-infected urinary tract is dependent on 
IL-8 (26). Additionally, mCXCL2 secretion is dependent on TLR4, as secretion was deficient 
in infected C3H/HeJ mice (100). hCXCR1 and hCXCR2 are receptors for a number of 
chemokines, including IL-8 (26). Both are expressed in bladder and kidney biopsies, and 
transmigration studies indicated that hCXCR1 plays a dominant role in IL-8-dependent 
neutrophil migration (74). Consistent with this, children prone to pyelonephritis tend to 
have low hCXCR1 expression and heterozygous hCXCR1 polymorphisms (74). Using a large 
cohort of families that included children with a history of recurrent UTIs, Svanborg and 
colleagues found that low CXCR1 (IL-8 receptor) expression levels correlated with the 
incidence of acute pyelonephritis (75). Subsequently, CXCR1 mutations and polymorphisms 
were identified in several patients with recurrent pyelonephritis (76). Although CXCR1 
mutations were not correlated with pyelonephritis in a separate cohort of Italian children, 
IL-8 gene polymorphisms were found in this latter group (77). hCXCR1 deficiency results in 
impaired bacterial clearance but, unlike TLR4 deficiency, with intact inflammatory signaling 
that ultimately results in tissue damage(31).  
Similarly, mice lacking mCXCR2 (the functional homolog for hCXCL1) experience 
subepithelial accumulation of neutrophils, increased bacterial titers, and renal scarring after 
UPEC inoculation (78) and increased susceptibility to experimental UTI and urinary tract–
derived bacteremia (79;80). These data indicate that normal function of neutrophils, their 
chemotactic ligands, and their chemokine receptors are required for bacterial clearance 
without postinflammatory sequelae. 
The role of other cytokines in phenotypic susceptibility to UTIs  
Despite ample information on IL-8 in vitro and in vivo, a complete picture of the cytokine 
and chemokine dynamics during UTI was lacking. In response, a longitudinal assessment 
using a Bio-Plex format was conducted(81). Chemokine (C-C motif) ligand 2 (CCL2 or MCP-
1), CCL4 (or MIP-1b), CCL5 (or RANTES), CXCL1, IL-1β, IL-6, IL-12p40, IL-17, tumor 
necrosis factor alpha (TNF-α), and granulocyte-colony stimulating factor (G-CSF) were all 
upregulated in bladder homogenates from UPEC-infected C57BL/6 mice (81). These results 
agreed with patient and cell line data regarding upregulation of IL-6 in response to UPEC 
(82). In mice, TNF-α expression was elevated at 1 h post-inoculation for rapid mobilization 
of acute responses (81); this waned at later time points, likely to prevent the deleterious 
effects of uncontrolled TNF-α signaling (16). Expression of most cytokines and chemokines 
peaked around 24 h post-inoculation, returning to near baseline at 2 weeks (81). These 
dynamics correlate well with the peak and resolution of bacterial burdens in C57BL/6 
mice(81). One notable exception was IL-17, which was highly upregulated from 6 h to 1 
week post-inoculation, remaining above baseline through the 2-week experimental 
duration(81).  Importantly, IL-17A (the Th17 signature cytokine) contributes to innate 
clearance of UPEC through a mechanism involving cytokine and chemokine secretion and 
macrophage and neutrophil influx (26). Similar to TLR adaptor molecule usage (38) the type 
of fimbriae expressed also seems to influence the repertoire of chemokines secreted. 
Specifically, kidney cells exposed to type 1-fimbriated UPEC secrete neutrophil-associated 
chemokines, while P fimbriae-stimulated cells secrete chemokines targeting antigen-
presenting cell (APC)- and Th1-specific cytokines, exemplified by CCL2 and CCL5 
expression (83). In addition, IFN-γ and IL-4 (signature cytokines of the Th1 and Th2 
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categorized as early, middle, and late IBC stages (66). Late IBCs that escape exfoliation with 
umbrella cells contain filamentous UPEC that are not present in C3H/HeJ mice, indicating 
that this morphological change may be a bacterial stress response to TLR4-mediated 
immune activation (66). This murine background also experienced increased incidence and 
severity of IBCs compared to immunocompetent mice (66). Urothelial cells proximal to IBCs 
in C3H/HeJ mice upregulate transferrin receptor, Lcn2, complement system components 
(C3, factor B, and CD55), and lysozyme (57). Involucrin and suprabasin transcripts were also 
increased, indicating that, in addition to gene products that function to eradicate bacteria, 
proteins important for epithelial integrity may be an imperative host response during UTI 
(57). 
Notably, TLR4 also plays a noninflammatory role in host defense against UPEC by 
modulating the activity of the observed secretory and vesicular internalization pathways. 
TLR4-mediated PKA activation suppresses the lipid raft endocytic pathway (21), a possible 
effort to prevent the establishment of persistence reservoirs. Also along these lines, UPEC 
exocytosis in fusiform vesicles was actually accelerated by TLR4-mediated recognition of 
LPS and dependent on the activities of cAMP, Rab27b, caveolin-1, and the scaffolding 
protein MyRIP (22). 
The role of urothelial regeneration in response to UPEC infection 
One of the consequences of UPEC infection is exfoliation of the superficial facet cell layer 
that lines the surface of the bladder lumen (67).  Microarray analyses probing regenerative 
signals revealed that, in addition to genes involved in cell biological processes, 
inflammatory cytokines, chemokines, signaling molecules, and transcription factors are also 
upregulated in response to inoculation (68). While regeneration itself appears to be a 
function of basal stem/progenitor cells in the transitional epithelium (68) studies of the gut 
epithelium unveiled macrophages as “cellular transceivers” that relay MyD88-dependent 
inputs from the epithelium to colonic epithelial progenitors via direct contact (69). Whether 
or not macrophages play a similar role in the urinary tract remains unknown. 
2.7 Antimicrobial peptides, cytokines and chemokines against UPEC during UTI 
Antimicrobial peptides (AMPs) are short positively charged peptides secreted by both 
epithelial and hematopoietic cells that disrupt bacterial membranes and can be chemotactic 
for certain immune cells (70). Human β-defensin-1 mRNA and protein were found in kidney 
tissue, implicating this AMP in host defense against UPEC (71). More convincingly, mice 
deficient in defb1, a murine homolog of human β-defensin, have a significantly higher 
incidence of bacteriuria (72). Murine β-defensin is also a dendritic cell (DC) ligand that 
instigates upregulation of costimulatory molecules and maturation (73). The human 
cathelicidin, LL-37, and its murine homolog, cathelin-related antimicrobial peptide 
(CRAMP), are secreted in response to UPEC exposure (44). Studies using CRAMP-deficient 
mice revealed that epithelial-derived CRAMP is important during the early stages of UTI 
while leukocyte-derived CRAMP likely functions later when bacteria penetrate the kidney 
epithelium (46). 
2.8 Cytokines and chemokines against UPEC during UTI 
The role of IL-8-mediated neutrophil recruitment in phenotypic susceptibility to UTIs  
Human C-X-C ligand 8 (hCXCL8; interleukin-8 [IL-8]) is the main chemoattractant for 
neutrophils in humans, and murine CXCL1 (mCXCL1) and mCXCL2 (also known as KC 
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and MIP-2, respectively) are the functional mouse homologs of IL-8 (26).  Bladder and 
kidney cell lines secrete IL-8 in response to UPEC (26). Human and murine studies both 
demonstrate that neutrophil migration to the UPEC-infected urinary tract is dependent on 
IL-8 (26). Additionally, mCXCL2 secretion is dependent on TLR4, as secretion was deficient 
in infected C3H/HeJ mice (100). hCXCR1 and hCXCR2 are receptors for a number of 
chemokines, including IL-8 (26). Both are expressed in bladder and kidney biopsies, and 
transmigration studies indicated that hCXCR1 plays a dominant role in IL-8-dependent 
neutrophil migration (74). Consistent with this, children prone to pyelonephritis tend to 
have low hCXCR1 expression and heterozygous hCXCR1 polymorphisms (74). Using a large 
cohort of families that included children with a history of recurrent UTIs, Svanborg and 
colleagues found that low CXCR1 (IL-8 receptor) expression levels correlated with the 
incidence of acute pyelonephritis (75). Subsequently, CXCR1 mutations and polymorphisms 
were identified in several patients with recurrent pyelonephritis (76). Although CXCR1 
mutations were not correlated with pyelonephritis in a separate cohort of Italian children, 
IL-8 gene polymorphisms were found in this latter group (77). hCXCR1 deficiency results in 
impaired bacterial clearance but, unlike TLR4 deficiency, with intact inflammatory signaling 
that ultimately results in tissue damage(31).  
Similarly, mice lacking mCXCR2 (the functional homolog for hCXCL1) experience 
subepithelial accumulation of neutrophils, increased bacterial titers, and renal scarring after 
UPEC inoculation (78) and increased susceptibility to experimental UTI and urinary tract–
derived bacteremia (79;80). These data indicate that normal function of neutrophils, their 
chemotactic ligands, and their chemokine receptors are required for bacterial clearance 
without postinflammatory sequelae. 
The role of other cytokines in phenotypic susceptibility to UTIs  
Despite ample information on IL-8 in vitro and in vivo, a complete picture of the cytokine 
and chemokine dynamics during UTI was lacking. In response, a longitudinal assessment 
using a Bio-Plex format was conducted(81). Chemokine (C-C motif) ligand 2 (CCL2 or MCP-
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lineages, respectively) and IL-10 (a T-regulatory [Treg] effector cytokine) knockout mice 
were tested for susceptibility to both acute cystitis and pyelonephritis (84). While il4−/− and 
il10−/− mice appear to experience infection dynamics similar to the wild type, ifnγ−/− mice 
had increased incidence and severity of UTI (84) implying a role for IFN-γ and Th1-
mediated inflammatory responses during UTI. 
2.9 The role of neutrophils in immune responses to UPEC-mediated UTI 
Infected mouse bladders examined histologically display thickening of epithelium 
accompanied by robust infiltration of inflammatory cells and edema in the lamina propria 
(85). Neutrophils are the most rapid and abundant responders to the infected urinary tract 
(85). Efficient migration of neutrophils requires intracellular adhesion molecule 1 (ICAM-1) 
expression by epithelial cells and β2 integrin (CD11b/CD18) expression by neutrophils (30). 
G-CSF is also required for the neutrophil response, and unexpectedly, mice with neutralized 
G-CSF are more resistant to UTI(81). Although monocyte/macrophage numbers were 
similar in anti-G-CSF-treated mice, cytokines important for macrophage activation were 
upregulated, potentially leading to accelerated clearance by enhanced phagocytic killing 
(81). Despite counterintuitive phenotypes with respect to cytokine knock-down, antibody-
mediated knockdown of the neutrophil population confirmed their crucial role in bacterial 
clearance, especially within the kidney (86). Lastly, the electrostatic properties of the UPEC 
P fimbrial tip adhesin may interfere with neutrophil binding, a potential host response 
evasion tactic specific to the kidney (86). 
2.10 The role of APCs in immune responses to UPEC-mediated UTI 
Compared to the neutrophil response, relatively little is known about APCs in the context of 
UTI. In mice, resident CD11c+ cells that express low to intermediate levels of F4/80 and 
CD11b macrophage markers were found in the kidney (87) while CD11c+ cells expressing 
the major histocompatibility class II activation marker were found in the bladder (30). In 
spite of macrophage marker expression, CD11c+ kidney cells had physical and functional 
characteristics of DCs (87). At 24 h post inoculation, CD11c+ cells that migrate to the bladder 
did not express CD8α, Gr-1, or B220 and thus were not plasmacytoid or lymphoid but 
appeared to be TNF-α- and inducible NOS (iNOS)-producing (Tip)-DCs (88) that express 
intermediate levels of CD11b. Infection studies in mice lacking Tip-DCs suggested that they 
are not necessary for the host response to acute UTI (88). Since Tip-DCs are necessary for the 
generation of mucosal IgA (89), their role may lie in mediating the humoral response to 
UPEC. Similar to what was observed for DCs, there appears to be a resident population of 
macrophages in bladder tissue that increases by several orders of magnitude in response to 
UTI (81). Monocytes expressing high levels of Gr-1, which can give rise to macrophages or 
DCs, are also recruited to the bladder in response to UPEC infection. Release of these cells 
from the bone marrow was dependent on CCR2 (90), and, correspondingly, CCL2 is 
upregulated in the bladder response to UTI(81). 
2.11 The role of the antimicrobial compound nitric oxide (NO) in immune responses to 
UPEC-mediated UTI 
Some of the factors utilized by neutrophils, macrophages, and DCs for pathogen uptake and 
destruction have been described during UTI. iNOS generates the antimicrobial compound 
nitric oxide (NO) from l-arginine and was originally reported to be secreted by macrophages 
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(91). Although iNOS is rapidly upregulated in the inoculated bladder(92) two independent 
groups reported that inos−/− mice are equally as susceptible to UTI as wild-type mice, 
suggesting that neuronal NOS, endothelial NOS, or myeloperoxidase may act as 
compensatory factors (93) Alternatively or in addition, inos−/− animals may lack a 
colonization phenotype because there are several factors (Hfq and Nsr-regulated genes, 
polyamines, and flavohemoglobin) expressed by UPEC that enhance tolerance to reactive 
nitrogen species in vitro (94) suggesting that NO production may be an ineffective host 
defense against UPEC.  
2.12 The role of the complement in immune responses to UPEC-mediated UTI 
With respect to the complement system, it appears that UPEC is able to bind C3 to enter host 
uroepithelial cells via the surface receptors Crry or CD46 (95). Correspondingly, c3−/− mice 
are more resistant to renal damage and infection (95). As C3 levels are significantly higher in 
the urine of UTI patients (96) UPEC may stimulate C3 production for pathogenic means or 
has evolved to exploit this host defense factor. 
2.13 The role of innate-like lymphocytes (ILLs) in acute UTI host defense  
Infection studies using severe combined immunodeficient (SCID) mice that lack functional B 
and T cells and nude mice that lack thymically derived T cells provide preliminary evidence 
of a role for innate-like lymphocytes (ILLs) in acute UTI host defense (97).  Epithelial γδ T 
cells, B-1 cells, and natural killer T (NKT) cells are ILLs: cellular subsets that have relatively 
invariant receptors and reside in specific locations of the body (26). After a 2-day primary 
infection, SCID mice had significantly higher bacterial counts in their bladder and kidneys, 
while nude mice were colonized similarly to wild-type animals (97). The lack of a 
colonization phenotype in nude mice suggests that either antibody responses independent 
of thymus-derived T-cell help or extrathymically produced T cells may play a role in innate 
clearance of UPEC. The latter suggestion has some experimental support.  
The role of γδ T cells 
γδ T cells can be produced extrathymically and rapidly secrete cytokines in response to 
stimulation (98). Resident γδ T cells found in the bladder increase in response to UTI (26), 
and TCR δ−/− mice are more susceptible to UTI than isogenic controls (84). As γδ TCR+ 
cells express IL-17A during UPEC-mediated UTI  (26) this rapid-response cell population 
may function in concert with other innate factors to mediate neutrophil influx for clearance 
of UPEC.  
The role of B-1 cells 
B-1 cells spontaneously secrete large quantities of polyspecific IgM against bacterial and 
self-antigens, and in contrast to conventional (B-2) B cells, do not require T-cell help (99). 
While IgM secreted by B-1 cells might play a role in innate clearance of UPEC, current 
evidence suggests otherwise. JHD mice, lacking both B-1 and B-2 cells (100) infected and 
monitored over a 14-day time period exhibited no significant increase in incidence or 
severity of cystitis (84).  
The role of NK T cells 
On a final note regarding ILLs, administration of α-galactosylceramide (α-GalCer), a ligand 
for CD1d-restricted NKT cells, alleviates renal UPEC infection (101).  Consistent with this, a 
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resident population of NK1.1+ cells (potentially NK or NKT cells) in the bladder of C57BL/6 
mice that increases in response to UTI has been reported (26). Studies using a systemic E. 
coli infection model suggested that, similar to γδ T cells, NKT cells may act as early 
amplifiers of the innate immune response to UTI by rapid cytokine secretion (102). 
3. Genetic factors that contribute to innate immunity 
Although susceptibility to UTI thus far appears to be related primarily to function of the 
innate immune system, additional determinants are likely important in this polygenic 
phenotype. For example, the increased susceptibility of C3H/HeJ mice was recently 
suggested to be due to at least two other loci in addition to Tlr4 (103) Accelerating progress 
in genomic sequencing methodology might facilitate the elucidation of other contributing 
genes, but these efforts may be hampered somewhat by the continuous, rather than discrete, 
nature of UTI susceptibility phenotypes in human populations. 
The individual's response to UTI is variable and the susceptibility to the infection is 
inheritable. Lundstedt et al. found in a family study, 15% of the relatives of pyelonephritis-
prone children had UTI history, whereas the value was 3% in the controls(75). A evaluation 
of a familal predisposition about women with recurrent UTI described that 65.5% of 
mothers, 60.7% of daughters, and 48.6% of sisters of the women had a similar history (104). 
Many studies discovered that genitic variations of TLR4 and CXCR1 are association with 
susceptibility to different type of UTIs. And TLR4(896)AG genotype and TLR4(896)G alleles 
could increase the risk for UTI in childhood (76;105), CXCR1 G (2608) C gene polymorphism 
and expression are strong linked to acute pyelonephritis in children (77). Reduced 
expression levels of CXCR1 and TLR4 in neutrophils are associated with pyelonephritis, 
recurrent cystitis, and asymptomatic bacteriuria in children and premenopausal women  
(25)(78;106). Although these studies suggest the association of gene polymorphisms and 
expression of TLR4 and CXCR1 to UTIs, whether the variants are associated with UTI in 
adults is still unknown. 
3.1 Other host factors that contribute to innate immunity 
Other mediators also shape the extent of the polymorphonuclear leukocyte (PMN) response 
to infection. Perpetuation of the PMN response might be controlled by cytokines such as IL-
17, which has an emerging role in bridging innate to adaptive immunity(107) and is present 
at high levels in the bladder at later time points. Plasminogen activator inhibitor type 1 
(PAI-1) influences cell migration through its effects on integrin binding; upon UPEC 
infection of mice lacking PAI-1, kidneys bore significantly higher bacterial burdens and 
fewer PMN infiltrates than wild-type counterparts did (108). UPEC infection was recently 
demonstrated to induce the secretion of granulocyte colony-stimulating factor (gCSF) in the 
bladder, and antibody-mediated depletion of this cytokine reduced PMN influx following 
UPEC infection (81).  
Finally, the secretion of a number of soluble antibacterial compounds into the urinary tract 
is induced by UPEC infection. UPEC infection also elicits the production of nitric oxide in 
association with upregulation of the iNOS gene (92). However, UPEC may employ 
strategies to resist the antibacterial effect of nitric oxide, as mice deficient in iNOS generally 
have shown no increased susceptibility to UTI (93;109). Among short antibacterial peptides, 
the human cathelicidin LL-37 is detectable in the urine during human cystitis, and mice 
deficient in its ortholog (CRAMP) demonstrate increased susceptibility to UTI (110).  
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4. Cellular and humoral adaptive immune responses to UPEC-mediated UTI 
Existing data regarding adaptive immune responses to UPEC are relatively limited. In a 
seminal study, Thumbikat and colleagues engineered a strain of UPEC to express 
ovalbumin to examine mechanisms behind antigen-specific adaptive immune responses in 
experimental UTI (111). In response to reinfection, CD4+ and CD8+ cells infiltrated the 
bladder and expressed the CD69 activation marker in the spleen (111), extending the 
findings of early IHC studies probing T- and B-cell populations in infected bladders (109). 
Furthermore, splenocytes, enriched splenic T cells, or serum antibodies from previously 
infected donor mice each protected wild-type naïve recipient mice against UPEC challenge 
(111). This result suggests that protection derived from natural infection is antibody 
mediated, as UPEC-specific antibody-secreting plasma cells could be present in both 
splenocyte and enriched T-cell preparations. As expected, transfers from naïve donor mice 
did not facilitate enhanced protection to recipients (111). This result is in contrast to a 
previous murine adoptive transfer study where SCID recipients receiving splenocytes from 
either naïve or vaccinated wild-type donors exhibited equal levels of enhanced clearance, 
despite the presence of antigen-specific plasma cells in the vaccinated donor cells (97). This 
result suggests that simply reconstituting immunosuppressed mice with lymphoid cells 
provides the means (likely stimulatory cytokines for phagocytic cells) for enhanced 
clearance. Conversely, wild-type recipient mice used in the former study only exhibited 
enhanced clearance when given cells or serum from antigen-educated, vaccinated donors 
(111), indicating that enhanced protection in individuals with intact immune systems will be 
provided only by stimulation of an effective adaptive immune response. 
4.1 The role of T cells in adaptive immune responses to UPEC-mediated UTI 
T-cell subsets are characterized by transcription factors and cytokines involved in their 
differentiation and the particular effector cytokines they secrete. To date, studies have not 
implicated a skew toward Th1- or Th2-mediated UTI immunity (111). DC phagocytosis of 
infected apoptotic cells is the key event required for DCs to secrete the cytokine milieu 
necessary for Th17 development (112), and both DCs and infected apoptotic cells are present 
in the bladder during UTI. Despite this connection, IL-17A is dispensable for the generation 
of a protective response in a murine reinfection model, suggesting that Th17 cells may not 
play a role in adaptive responses to UPEC infection (26). Similar to APCs and other 
lymphocytes, there are resident CD8+ cells in the bladder that increase in response to 
infection (26;111). It has been suggested that the observed CD8+ cells are either classical 
cytotoxic T cells or intraepithelial lymphocytes that exert cytotoxic effects on UPEC- or 
virus-infected cells or rapidly secrete cytokines to mobilize innate immune responses (26). 
Lastly, the role of Treg subsets in UTI host defense has not been formally examined. 
4.2 The role of antibody-mediated clearance in adaptive immune responses to UPEC-
mediated UTI 
Despite the lack of detail regarding T-cell responses to UTI, there is ample evidence for 
antibody-mediated clearance of UPEC. The genitourinary tract has been recognized as part 
of the secretory immune system (113). UPEC-specific antibodies are detected in the urine of 
infected patients and in the urine or serum of animals exposed to UPEC antigens (111). 
Urinary IgG and IgA from UTI patients are capable of inhibiting UPEC adherence (114).  
Patient studies have also suggested that antibody responses to pyelonephritis are, in 
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general, stronger and last longer than humoral responses to cystitis (115). Analysis of 
murine urine and serum samples collected before and after vaccination with OMP iron 
receptors allowed identification of immunological correlates of vaccine-induced protection 
against UTI (116). Specifically, levels of either urinary IgA or serum IgG (relative to serum 
IgM; denoted the class switch index) inversely correlated with bladder colonization in 
vaccinated mice (116).  Presumably, urinary IgA plays a direct role in UPEC clearance from 
the bladder mucosa, while IgG may be a marker for class switching by B cells or also play a 
direct role in mucosal bacterial clearance. As mentioned earlier, infected JHD mice had wild-
type levels of colonization in response to primary infection, suggesting that B cells have no 
role in innate clearance of UPEC (84). However, this result is not unexpected since both 
antigen presentation and antibody-mediated protection provided by B cells would likely 
play a role in adaptive responses, indicating a need for reevaluation of these mice in UPEC 
reinfection and vaccination challenge models. 
5. Immunomodulation as therapeutic option for UTI 
There are several practiced and proposed therapeutics for UTI management. Prophylactic 
treatments include estrogen in postmenopausal women  (117) or cranberry juice  (118) 
although the efficacy of the former remains controversial. Immunomodation strategies are 
emerging therapies for UTIs especially in the setting of increasing antimicrobial resistance. 
5.1 Non-vaccine strategies 
Since the lining of the urinary tract is highly enriched in TLR4 molecules, administering 
TLR4 specific ligands directly to the urinary tract could trigger TLR4 mediated innate 
immune responses thereby enhancing local reactivity and resistance to infection. Treatment 
of UPEC-infected mice with forskolin, a drug that increases intracellular cyclic AMP (cAMP) 
levels, expels UPEC from intracellular vesicles into the extracellular milieu, rendering the 
bacteria susceptible to immune responses and antibiotics (20). Similarly, exposing the 
bladder to protamine sulfate, a highly cationic protein, removes bound and intracellular 
UPEC by causing umbrella cells to exfoliate (63)), unfortunately with a significant level of 
discomfort, as reported by study volunteers (119). In addition to a number of nonspecific 
chemical treatments (120)), both small-molecule inhibitors (121) and specific antibody 
directed against FimH (122) demonstrated some utility in preventing bacterial adherence. 
While antibiotic therapy remains the standard treatment for UTI, overuse leads to 
deleterious alterations of the normal host microbiota (123) and selection for resistant strains 
(124), prompting the need for vaccine-mediated prevention of UTI. 
Astragalus is a Chinese herbal medicine, and Astragalus polysaccharide (APS) is its main 
components. Previous studies have demonstrated that APS could induce enhancement of 
expression of TLR4 on bladder epithelial cells (125) and astragalus also increases the TLR4 
expression on monocytes in UTI patients. These suggest that similar to LPS, APS can 
activate pre-inflammatory factor secretion during the early stages of infection similar to LPS, 
promote TLR4 expression, and involve mucosal innate immunity of the urinary tract. 
However it remains to be seen whether this herbal medicine can be a therapeutic option for 
UTI. 
These observations suggest that activators of the TLR4 signalling pathway in the urinary 
tract can be effective therapeutic agents against infections. Furthermore, it is not necessary 
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to use TLR4 ligands for activation of the pathway. Inducers of downstream substrates of the 
pathway are also effective activators of the innate immune response. Even if TLR4 ligands 
are employed for therapeutic use, it is unlikely that LPS will be the ligand of choice since 
LPS has intrinsic toxicity. A TLR4 ligand with greatly improved safety profiles, such as 
monophosphoryl lipid (MPL), could be used in its place (126). 
5.2 Vaccines 
The involvement of TLRs in the immune response to UTI and current knowledge of their 
ability to incite innate and direct adaptive responses make them attractive adjuvant 
candidates for UTI vaccines (127). These and other mucosal adjuvants and variations in 
vaccination routes and schedules must be tested in an effort to generate UPEC-specific local 
and systemic antibodies(128) and optimize production of immunological memory, not 
tolerance . A more detailed knowledge of adaptive immune responses to UPEC is a 
prerequisite for the development of next-generation candidate vaccines for the prevention of 
UTI. More recently, a variety of experimental approaches have been applied to search for 
immunodominant epitopes, revealing an array of new candidate targets, and thus a number 
of vaccine antigens have been explored (26). 
Lipopolysaccharide (LPS) and side chain (O) antigen as vaccine targets 
Early vaccine studies focused on the lipopolysaccharide (LPS) side chain (O) antigen (129). 
There are trends regarding the frequencies of particular O antigens among UTI isolates(130) 
and O-antigen-specific antibodies demonstrate an anti-adhesive effect (130).  Nonetheless, 
significant structural heterogeneity may represent an insurmountable obstacle for 
development of an O-antigen-based vaccine. Furthermore, a study evaluating antibody 
responses in mice intranasally vaccinated with a killed E. coli lacking capsule and O antigen 
demonstrated that these surface features actually obstruct optimal humoral responses (131) 
P fimbriae as vaccine targets 
Later studies involved vaccines directed against particular virulence factors. The pore-
forming toxin alpha-hemolysin (HlyA) and P fimbriae are proposed minimal factors 
required for colonization of and dissemination from the kidney (132). P fimbriae are 
adherence organelles that play a role in kidney colonization in mice and humans (133). 
There are convincing data using both murine (132) and primate models (134) that 
vaccination against P fimbriae or HlyA prevents renal colonization and damage. 
Additionally, to overcome P fimbrial allelic variability, linear peptide sequences that 
generated cross-reactive antibodies were evaluated as protective antigens (135). Despite 
these successes, vaccines targeting P fimbriae may not be effective because of their limited 
role during bladder colonization. Type 1 fimbria is a bona fide virulence factor of UPEC and, 
in contrast to P fimbria, is critical for bladder colonization (136). Animals vaccinated with 
various components of type 1 fimbriae had increased levels of antigen-specific antibodies 
and decreased levels of colonization upon challenge (137). Unfortunately, expression of type 
1 fimbria is subject to phase variation, allowing UPEC to evade humoral responses targeting 
this organelle(138). Additionally, since nonpathogenic isolates also express type 1 fimbriae 
(139), targeting this population may result in detrimental disruption of the host microbiota. 
Also of note, both P and type 1 fimbriae were not necessary for colonization of the human 
neurogenic bladder, indicating the need for alternative targets in certain high-risk patient 
groups (140). Although vaccines based on P or type 1 pilus components have generated 
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general, stronger and last longer than humoral responses to cystitis (115). Analysis of 
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(124), prompting the need for vaccine-mediated prevention of UTI. 
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components. Previous studies have demonstrated that APS could induce enhancement of 
expression of TLR4 on bladder epithelial cells (125) and astragalus also increases the TLR4 
expression on monocytes in UTI patients. These suggest that similar to LPS, APS can 
activate pre-inflammatory factor secretion during the early stages of infection similar to LPS, 
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However it remains to be seen whether this herbal medicine can be a therapeutic option for 
UTI. 
These observations suggest that activators of the TLR4 signalling pathway in the urinary 
tract can be effective therapeutic agents against infections. Furthermore, it is not necessary 
 
Urinary Tract Immunology 
 
133 
to use TLR4 ligands for activation of the pathway. Inducers of downstream substrates of the 
pathway are also effective activators of the innate immune response. Even if TLR4 ligands 
are employed for therapeutic use, it is unlikely that LPS will be the ligand of choice since 
LPS has intrinsic toxicity. A TLR4 ligand with greatly improved safety profiles, such as 
monophosphoryl lipid (MPL), could be used in its place (126). 
5.2 Vaccines 
The involvement of TLRs in the immune response to UTI and current knowledge of their 
ability to incite innate and direct adaptive responses make them attractive adjuvant 
candidates for UTI vaccines (127). These and other mucosal adjuvants and variations in 
vaccination routes and schedules must be tested in an effort to generate UPEC-specific local 
and systemic antibodies(128) and optimize production of immunological memory, not 
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immunodominant epitopes, revealing an array of new candidate targets, and thus a number 
of vaccine antigens have been explored (26). 
Lipopolysaccharide (LPS) and side chain (O) antigen as vaccine targets 
Early vaccine studies focused on the lipopolysaccharide (LPS) side chain (O) antigen (129). 
There are trends regarding the frequencies of particular O antigens among UTI isolates(130) 
and O-antigen-specific antibodies demonstrate an anti-adhesive effect (130).  Nonetheless, 
significant structural heterogeneity may represent an insurmountable obstacle for 
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There are convincing data using both murine (132) and primate models (134) that 
vaccination against P fimbriae or HlyA prevents renal colonization and damage. 
Additionally, to overcome P fimbrial allelic variability, linear peptide sequences that 
generated cross-reactive antibodies were evaluated as protective antigens (135). Despite 
these successes, vaccines targeting P fimbriae may not be effective because of their limited 
role during bladder colonization. Type 1 fimbria is a bona fide virulence factor of UPEC and, 
in contrast to P fimbria, is critical for bladder colonization (136). Animals vaccinated with 
various components of type 1 fimbriae had increased levels of antigen-specific antibodies 
and decreased levels of colonization upon challenge (137). Unfortunately, expression of type 
1 fimbria is subject to phase variation, allowing UPEC to evade humoral responses targeting 
this organelle(138). Additionally, since nonpathogenic isolates also express type 1 fimbriae 
(139), targeting this population may result in detrimental disruption of the host microbiota. 
Also of note, both P and type 1 fimbriae were not necessary for colonization of the human 
neurogenic bladder, indicating the need for alternative targets in certain high-risk patient 
groups (140). Although vaccines based on P or type 1 pilus components have generated 
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substantial mucosal antibody responses, protection from subsequent infections has been 
incomplete, perhaps because of phase variation in the expression of these antigens during 
infection. 
Iron pathway as target for vaccine 
Iron is essential for nearly all organisms (141) and UPEC strains encode a battery of genes 
involved in iron acquisition. Vaccination with UPEC outer membrane protein (OMP) 
fractions enriched for iron receptors protects against experimental sepsis (142). Additionally, 
mice vaccinated subcutaneously with denatured IroN, an OMP siderophore receptor and 
urovirulence factor (143), had both increased levels of antigen-specific serum IgG and 
reduced kidney colonization upon challenge (144). Undetectable levels of IgA in the bladder 
mucosa after this vaccination may explain why these animals were not protected from 
cystitis (144). Recently, a broad functional vaccinology initiative was conducted using an 
“omics” approach to identify vaccine candidates: UPEC proteins that are pathogen-specific, 
antigenic, surface-exposed, and in vivo expressed (26). Strikingly, the top targets identified 
by this approach were all OMPs functioning in iron uptake. Intranasal vaccination with 
three of six candidates afforded protection from cystitis and pyelonephritis, suggesting that 
combining antigenic motifs found in these proteins may be an effective multivalent vaccine 
for UTI (26). 
Other vaccine targets 
Vaccines consisting of bacterial components or whole cells have also been assessed. 
Transurethral immunization of mice with a live-attenuated UPEC strain lacking the ability 
to persist in the urinary tract engendered heterologous protection (145) a potential platform 
for further development. SolcoUrovac, a vaginal suppository containing 10 heat-killed 
uropathogenic strains, has been tested in mice , in nonhuman primates , and in clinical trials 
(26). While safe, SolcoUrovac vaccination did not result in appreciable increases in local 
specific antibody, nor did it afford protection without periodic readministration (146). 
Vaccine strategies to combat UTIs 
Since B and T cells, which mediate adaptive immunity are critically dependent on signals 
derived from the innate immune system, modulators that boost innate immune responses 
may be of value in boosting adaptive immune responses (147-150). Thus, 
immunomodulators used to boost innate immune responses in the urinary tract may be also 
employed to boost adaptive immune responses. One of the reasons for administering 
vaccine antigens against UTIs in the genitourinary tract, as in the case of the vaginal 
mucosal vaccine mentioned above, is to evoke secretory IgA (sIgA) antibodies in the 
mucosal surfaces of the urinary tract. Whereas subcutaneous, intramuscular, or intravenous 
immunization evokes strong systemic IgG responses to the vaccine antigens, they fail to 
evoke IgA antibodies in the mucosal surfaces of the urinary tract where infections are 
initiated and where antibodies are most needed (111).  
However, administering vaccines directly to the urinary tract is neither easy nor practical. A 
much more accessible mucosal site for the delivery of vaccines is the nasal passages. 
Delivery of proteus antigens into the nasal passages of mice have been shown to evoke high 
levels of sIgA in the urine and this was accompanied by impressive protection against 
Proteus mirabilis induced UTI (151). Immunization at nasal sites has been shown to be highly 
effective in evoking antigen specific serum IgG as well as sIgA responses in various mucosal 
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sites presumably due to activation of the nasal associated lymphoid tissue (NALT) found in 
the nasal passage. Since the NALT is a potent immunologically inductive and sampling site, 
it can respond vigorously to vaccine antigens and if TLR ligands or other adjuvants are 
present, this response may be even more magnified (152). Taken together, an alternate or 
complementary approach for the management of UTIs in the future could be targeted 
administration of modulators of the TLR signalling pathway to boost both innate and 
adaptive responses in the urinary tract. 
Cumulatively, all the indications suggest that the urinary tract is able to mount an 
appreciable and protective adaptive immune response and that this property can be 
harnessed for vaccination purposes. An important and as yet unanswered question is the 
duration of protection in the urinary tract following infection or vaccination. Since up to 
25% of women with UTIs that have no underlying immune competency issues have 
recurrences (153) it is conceivable that the immunity generated in the urinary tract could be 
relatively short lived and therefore frequent vaccinations may be required. 
6. Conclusion 
The over use of broad spectrum antibiotics has led to the emergence of antibiotic resistant 
bacteria many of which have been implicated in UTIs. As a consequence, management of 
these infections constitutes a serious and growing medical challenge. Modulating or co-
opting the powerful innate and adaptive immune systems of the urinary tract could 
potentially have important therapeutic and prophylactic implications for the treatment of 
UTIs, particularly where conventional approaches are ineffective.  
There is considerable work to be done to better understand the mechanisms of protective 
immunity against UPEC in the bladder. Specifically, available knockout mouse strains could 
be used to systematically evaluate the role of various receptors, signaling molecules, 
cytokines and chemokines, and cell types in controlling UPEC-mediated UTI and eliciting 
potent adaptive and memory immune responses. Ideally, the field can acquire insights on 
UTI immunity at a level suitable to rationally develop a much-needed vaccine that elicits 
sterilizing immunity against UPEC in the human urinary tract. 
Unlike antibiotic treatment, immunomodulation will not be broadly applicable. Instead, it 
will have to be tailored to each patient and must take into consideration, among other 
factors, the virulence and antibiotic resistance profile of the infecting bacteria as well as the 
age, immune competence and genetic make-up of the patient. For example, employing TLR4 
ligands to boost immunity in patients with defective TLR4 genes will not be productive but 
the use of activators of downstream components of the pathway could be useful. Thus, for 
these proposed emerging strategies to be completely effective, comprehensive information 
regarding relevant traits of the pathogen and the host will become necessary. 
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antigenic, surface-exposed, and in vivo expressed (26). Strikingly, the top targets identified 
by this approach were all OMPs functioning in iron uptake. Intranasal vaccination with 
three of six candidates afforded protection from cystitis and pyelonephritis, suggesting that 
combining antigenic motifs found in these proteins may be an effective multivalent vaccine 
for UTI (26). 
Other vaccine targets 
Vaccines consisting of bacterial components or whole cells have also been assessed. 
Transurethral immunization of mice with a live-attenuated UPEC strain lacking the ability 
to persist in the urinary tract engendered heterologous protection (145) a potential platform 
for further development. SolcoUrovac, a vaginal suppository containing 10 heat-killed 
uropathogenic strains, has been tested in mice , in nonhuman primates , and in clinical trials 
(26). While safe, SolcoUrovac vaccination did not result in appreciable increases in local 
specific antibody, nor did it afford protection without periodic readministration (146). 
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Since B and T cells, which mediate adaptive immunity are critically dependent on signals 
derived from the innate immune system, modulators that boost innate immune responses 
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vaccine antigens against UTIs in the genitourinary tract, as in the case of the vaginal 
mucosal vaccine mentioned above, is to evoke secretory IgA (sIgA) antibodies in the 
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immunization evokes strong systemic IgG responses to the vaccine antigens, they fail to 
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sites presumably due to activation of the nasal associated lymphoid tissue (NALT) found in 
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Many biofilms are quite harmful but others can have a positive impact, namely lining 
healthy intestine and female genito-urinary tract. Biofilms have significant implications for 
clinical pharmacology, particularly related to antibiotic resistance, drug adsorption onto and 
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therapy. 
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After insertion of the device into the body the material surface enters into contact with body 
fluids around the implant. In case of the urinary tract Tamm-Horsfall glycoprotein, various 
ions, polysaccharides and other components diffuse toward the implant surface from the 
urine within minutes [6]. Macromolecular components (serum albumin, fibrinogen, 
collagen, fibronectin) from these body fluids adsorb extremely fast onto the material 
surfaces to form a conditioning film, prior to the arrival of the first organisms [7]. The 
creation of a conditioning film alters the surface characteristics of implants.  The role of the 
conditioning film is vital as many pathogens do not have mechanisms allowing them to 
adhere directly or strongly onto bare implant surfaces [8]. 
The next step in the development of a biofilm is the approach and attachment of 
microorganisms. The ability of microorganisms to adhere to surfaces is influenced by 
electrostatic and hydrophobic interactions, ionic strength, osmolality and urinary pH [9,10].  
In order for bacteria to react to a surface or an interface like an air-water interface, these cells 
must be able to ’sense’ their proximity to these surfaces. The planktonic ’free-floating’ 
bacterial cells release both protons and signaling molecules as they move through the bulk 
fluid. These protons and signaling molecules must diffuse radially away from the floating 
cell, if not adjacent to any surface or interface. But a significantly higher concentration of 
either protons or signaling molecules can develop on the side of the bacterial cell close to 
any surface. This allows the cell to sense that it is near a surface because diffusion is limited 
on this side [4]. After the planktonic bacterial cell has sensed the surface, it may commit to 
the active process of adhesion and biofilm formation.  
There is no single process or theory, which can completely describe microbial adhesion. The 
initial adhesion is reversible and involves hydrophobic and electrostatic forces. It is followed 
by irreversible attachment provided by bacterial polysaccharides which anchor the 
organisms to the surface. Subsequently, colonization takes by species factors, such as slow 
migration and spreading, rolling, packing and adhesion of the progress. A developed 
biofilm consists of groups of microorganisms, sometimes in mushroom-like forms, 
separated by interstitial spaces that are filled with the surrounding fluid [11]. The growth 
rates of organisms on a surface as well as the strategies used by microorganisms to spread 
over a surface are important for colonization. These strategies are species specific which can 
influence the distribution of a biofilm on a surface [12].  
The final stage of microbial colonization of a surface is the formation of a biofilm structure. 
At this point, the microorganisms have created a microenvironment protective against many 
antimicrobial agents and host immune defense mechanisms. Biofilm has been described as 
having a heterogeneous structure with a rough surface [13]. The microcolony is actually the 
basic structural unit of the biofilm, similar to the tissue which is the basic unit of growth of 
more complex organisms. Depending on the species involved, the microcolony may be 
composed of 10-25% cells and 75-90% exopolysaccharide (EPS) matrix. The biofilm contains 
‘water channels’ which allow transporting of essential nutrients and oxygen for the growth 
of the cells [14]. Microorganisms within the biofilm also secrete chemical signals that 
mediate population density-dependent gene expression, which has an important role in 
biofilm development [15]. In summary, the biofilm is usually built up of three layers [16]: 
1. the linking film which attaches to the surface of tissue or biomaterials 
2. the base film of compact microorganisms  
3. the surface film as an outer layer, where planktonic organisms can be released free-
floating and spreading over the surface. 
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3. Antimicrobial susceptibility of bacteria in biofilm 
Infections caused as a result of biofilm formation are characterized by particularly strong 
antibiotic and immune resistance patterns. Bacteria within the biofilms differ in behaviour 
and in phenotypic form from the planktonic bacteria. Antimicrobial agents are effective 
against planktonic bacteria and appear to clear mucosal surfaces of adherent bacterial 
microcolonies but frequently fail to eradicate bacterial biofilms on urological devices. The 
use of antibiotics is currently one of the possibilities of the prevention of biofilm formation. 
However, even in the presence of antibiotics bacteria can adhere, colonize and survive on 
implanted medical devices as has been shown for urinary catheters and ureteral stent 
surfaces in vitro and in vivo [17,18,19]. The problem in conventional clinical microbiology is 
how to treat patients in the best way when choosing antibiotics is based on bacterial cultures 
derived from planktonic bacterial cells which differ very much from bacteria in the biofilm 
mode. This can stand behind the clinical failure rate of treating chronic bacterial infection.  
The failure of antimicrobial agents to treat biofilms has been associated with a variety of 
mechanisms (4) [18,19,20,21,22,23,24]. One mechanism of biofilm resistance to antimicrobial 
agents is the failure of an agent to penetrate the full depth of the biofilm (extrinsic 
resistance). The extracellular matrix for instance may block the penetration at the very 
beginning.  
- One mechanism is the failure of an agent to penetrate the full depth of the biofilm 
(extrinsic resistance). The extracellular matrix may block the penetration at the very 
beginning. 
- The organisms growing at a slower rate within the biofilm are more resistant to the 
effects of antimicrobial agents, which require active growth. 
-  Bacteria within biofilm are phenotypically so different from their planktonic 
counterparts that antimicrobial agents developed against the latter often fail to 
eradicate organisms in the biofilm. Bacteria within a biofilm activate many genes which 
alter the cell envelope, the molecular targets and the susceptibility to antimicrobial 
agents (intrinsic resistance). Current opinion is that phenotypic changes caused by a 
genetic switch, when approximately 65-80 proteins change, play a more important role 
in the protection from antimicrobial agents than the external resistance provided by the 
exopolysaccharide matrix. 
- Bacteria within a biofilm can sense the external environment, communicate with each 
other and transfer genetic information and plasmids within biofilm.  
- Bacteria in a biofilm can usually survive the presence of antimicrobial agents at a 
concentration 1000-1500 times higher than the concentration that kills planktonic cells of 
the same species. 
According to in vitro and in vivo studies aminoglycosides and beta-lactam antibiotics can 
prevent the formation of ‘young’ biofilms, while fluoroquinolones are effective in case of 
both ‘young’ and ‘older’ biofilms because of their good penetrative qualities. They are 
present in biofilms even one or two weeks after the end of the antibiotic treatment [25-28].  
Most researchers believe that antibiotics can only slow down the progress of biofilm 
formation by eliminating unprotected planktonic bacteria and reducing the metabolic 
activity of bacteria on the biofilm surface [23, 29-30]. However, during an acute febrile phase 
of a biofilm infection. 
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4. Indwelling urethral catheters 
Due to the urinary catheter the development of bacteriuria and biofilm formation is 
inevitable. Urinary catheters are readily targets of biofilm development on their inner and 
outer surfaces once they are inserted. The long-term use of them leads to infection in most of 
the cases. The surface of a catheter (depending on its material) provides sufficient 
circumstances for bacteria to adhere and spread along in two ways. One route is when 
organisms ascend the catheter extraluminally by direct inoculation at the time of the 
catheter insertion or migrate in the mucous sheath that surrounds the external aspect of the 
catheter. Extraluminal organisms are primarily endogenous, originating from the 
gastrointestinal tract. These organisms colonize the patient’s perineum and ascend the 
urethra after catheter insertion [13,31,32,33,34] Approximately 70% of bacteriuria in 
catheterized women is believed to occur through the extraluminal entry.  
Bacteria can ascend the catheter also by an intraluminal route, which occurs when organisms 
gain access to the internal lumen of the catheter. These organisms are usually introduced 
from exogenous sources, for instance with cross transmission from the hands of health care 
personnel [13,32,33,35]. Adhesion of microorganisms to catheter materials depends on the 
hydrophobicity of the organism and catheter surface.  
5. The biofilms and the encrustation and blockage of catheters 
An additional problem in use of medical biomaterials in the urinary tract environment is the 
development of encrustation and consecutive obstruction. When the drained urinary tract 
becomes infected by urease producing bacteria such as Proteus mirabilis, the bacterial urease 
generates ammonia from urea and elevates the pH of the urine. Under these alkaline 
conditions, crystals of calcium phosphate (hydroxyapatite) and magnesium ammonium 
phosphate (struvite) are formed and trapped in the organic matrix surrounding the cells [20, 
21, 36,37]. Progression of these encrustations eventually blocks the catheter lumen. 
6. Ureteral stents 
In vitro and in vivo studies confirmed the difficulty in detecting biofilm formation by using 
conventional laboratory procedures [38, 39]. Reid at al found that 90% of indwelling silicone 
double J stents were colonized by adherent bacteria, however the incidence of urinary 
infection detected clinically was only 27% [38]. The difficulty in detecting biofilm formation 
by using conventional laboratory procedures was confirmed in a large study where 237 
ureteral stents were tested. It was shown that 68% of stents were actually colonized but only 
30% of patients were found to have bacteriuria [39]. Therefore, a negative urine culture does 
not rule out the possibility of stent colonization.  The study testified correlation between the 
length of the indwelling time and the development of infection.  
7. Penile prostheses 
The prosthesis-associated chronic pain due to subclinical infection is more common than 
clinically apparent infection (3). Staphylococcus species, especially Staphylococcus 
epidermidis are the most common pathogens found in penile prostheses infection (35-56%) 
[40], while Gram-negative enteric bacteria are liable for 20 % of infections [41,42]. S. 
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epidermidis was cultured in 40% of penile prosthesis removed for malfunction with no 
clinical evidence of infection [43]. Staphylococcal species were also found to enhance biofilm 
formation. These cases can be ‘silent’ for many years before becoming clinically evident [44] 
in contrast to Gram-negative  bacterial infection (Pseudomonas aeruginosa, E.coli, Serratia 
marcescens, and Proteus mirabilis) being responsible for 20% of  infections, which usually 
become manifest in a month after implantation [43].  
To reduce the risk of device associated infections many modifications have been developed 
such as antibiotic and hydrophilic coated devices.Hydrophilic penile prosthesis coating was 
has been shown to decrease bacterial adherence in vitro and in animal models [45]. 
Antibiotic prophylaxis is desirable for the above-mentioned facts. Since the most common 
pathogen is the Staphylococcus epidermidis, first-generation cephalosporins, broad-
spectrum penicillin should be used [46]. In cases of chronic pain, long-term administration 
of quinolones eased 60% of symptoms. Lack of success involves the necessity of implant 
removal. 
8. Artificial urinary sphincters (AUS) 
Around 3% of the AUS become infected and symptoms are mainly associated with the 
control pump device. Avoiding the risk factors as infected urine, prolonged urinary 
retention and large bladder residual can reduce this high occurrence [43,46]. Since the parts 
of the sphincter device form one continuous surface, the AUS is suggested to be removed 
entirely as the first step to eliminate the infection. The reimplantation must be preceded by 
the complete treatment of the infected area. This is not always achievable as many of these 
patients are paraplegic or have a neurogenic bladder with recurrent UTIs [43,46].  
9. Infected urinary calculi 
In case of urease-producing bacteriuria the infection can be conjoined with the formation of 
struvite and calcium phosphate calculi as described above. The infected calculi grow rapidly 
and provide safe environment for the bacteria adhered to the biofilm [47]. The complete 
removal of all stone fragments during stone operation (PCNL, URS, combined with 
ESWL), prolonged administration of antibiotics (8-10 weeks for destroying urease-
producing bacteria) and metaphylaxis are the features of the most effective treatment 
strategy. 
10. Chronic bacterial prostatitis 
Although the diagnosis and classification of chronic prostatitis have been standardized, the 
differentiation of chronic non-bacterial from bacterial inflammation is still challenging. 
Being out of the sweeping effect of streaming urine the prostatic ducts and acini provides 
safe circumstances to planktonic bacteria to multiply rapidly and induce a host response 
with infiltration of acute inflammatory cells into the ducts. The ducts become engorged with 
infiltrate composed of dead and living bacteria as well as living and dying acute 
inflammatory cells, desquamated epithelial cells and cellular debris. At this point it is 
relatively easy to eradicate all the offending organisms which are in a ‘planktonic state’ with 
appropriate antibiotic therapy. If the bacteria persist from either clinically acute or more 
likely, subacute inflammation, they can form sporadic bacterial microcolonies or biofilms 
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epidermidis was cultured in 40% of penile prosthesis removed for malfunction with no 
clinical evidence of infection [43]. Staphylococcal species were also found to enhance biofilm 
formation. These cases can be ‘silent’ for many years before becoming clinically evident [44] 
in contrast to Gram-negative  bacterial infection (Pseudomonas aeruginosa, E.coli, Serratia 
marcescens, and Proteus mirabilis) being responsible for 20% of  infections, which usually 
become manifest in a month after implantation [43].  
To reduce the risk of device associated infections many modifications have been developed 
such as antibiotic and hydrophilic coated devices.Hydrophilic penile prosthesis coating was 
has been shown to decrease bacterial adherence in vitro and in animal models [45]. 
Antibiotic prophylaxis is desirable for the above-mentioned facts. Since the most common 
pathogen is the Staphylococcus epidermidis, first-generation cephalosporins, broad-
spectrum penicillin should be used [46]. In cases of chronic pain, long-term administration 
of quinolones eased 60% of symptoms. Lack of success involves the necessity of implant 
removal. 
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control pump device. Avoiding the risk factors as infected urine, prolonged urinary 
retention and large bladder residual can reduce this high occurrence [43,46]. Since the parts 
of the sphincter device form one continuous surface, the AUS is suggested to be removed 
entirely as the first step to eliminate the infection. The reimplantation must be preceded by 
the complete treatment of the infected area. This is not always achievable as many of these 
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10. Chronic bacterial prostatitis 
Although the diagnosis and classification of chronic prostatitis have been standardized, the 
differentiation of chronic non-bacterial from bacterial inflammation is still challenging. 
Being out of the sweeping effect of streaming urine the prostatic ducts and acini provides 
safe circumstances to planktonic bacteria to multiply rapidly and induce a host response 
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appropriate antibiotic therapy. If the bacteria persist from either clinically acute or more 
likely, subacute inflammation, they can form sporadic bacterial microcolonies or biofilms 
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adherent to the epithelium of the ductal system (2b) [48,49]. These bacteria also produce an 
exopolysaccharide slime or glycocalyx that envelops these adherent microcolonies. The 
bacteria persisting in the prostate gland within these focal biofilms can provoke persistent 
immunological stimulation and subsequent chronic inflammation [48]. The diagnosis of 
chronic bacterial prostatitis can be difficult as colonized bacteria will not get into the 
prostatic secretion or urine sample. Antimicrobial therapy eradicates the planktonic bacteria 
but not the adherent bacterial biofilms deep within the prostate gland. Another cause of 
unsuccessful treatment may be the fact that the bacteria within biofilms differ significantly 
from their planktonic counterparts in metabolic rate, molecular targets and expression of 
antimicrobial binding proteins [3,19]. There is a need in development of diagnostic tools 
which would be able to recognize small adherent bacterial biofilms which exist deep within 
the prostate gland in chronic bacterial prostatitis.  New treatment regimens should be 
carried out in order to be able to deliver much higher antibiotic concentrations to the biofilm 
within the prostatic duct.  
11. Intracellular bacterial biofilm-like pods in the recurrent cystitis 
Entry of E. coli into the urinary tract is not well understood, although sexual intercourse is 
the most clearly defined predisposing factor. Presumably, a small number of E. coli from the 
vaginal or enteric flora are introduced into the bladder during an average incident, and it 
seems plausible that in most cases the innate defenses in the bladder would be able to 
prevent infection. However, sometimes Uropathogenic E.Coli (UPEC) clearly possess 
mechanisms to overcome these defenses and establish a foothold in the bladder. UPEC 
pathogenesis initiates with bacterial binding of superficial bladder epithelial cells. Initial 
colonization events activate inflammatory and apoptotic cascades in the epithelium, which 
is normally inert and only turns over every 6 to 12 months. Bladder epithelial cells respond 
to invading bacteria in part by recognizing bacterial lipopolysaccharide (LPS) via the Toll-
like receptor pathway, which results in strong neutrophil influx into the bladder. In 
addition, interactions mediated by adhesin FimH at the tips of type 1 pili with the bladder 
epithelium stimulate exfoliation of superficial epithelial cells, causing many of the 
pathogens to be shed into the urine.  Genetic programs are activated that lead to 
differentiation and proliferation of the underlying transitional cells in an effort to renew the 
exfoliated superficial epithelium. Despite the robust inflammatory response and epithelial 
exfoliation, UPEC are able to maintain high titers in the bladder for several days.  
A bacterial mechanism of FimH-mediated invasion into the superficial cells apparently 
allows evasion of these innate defenses. Initially, bacteria replicate rapidly inside superficial 
cells as disorganized clusters. Subsequently, bacteria in the clusters divide without much 
growth in cell size, resulting in coccoid-shaped bacteria, presumably due to changes in 
genetic programs. Furthermore, the bacterial clusters became highly compact and organized 
into biofilm-like structures, termed intracellular bacterial communities (IBCs), inside 
bladder superficial cells [50]. The IBCs push the bladder superficial cell membranes outward 
to give a “pod” like appearance by scanning electron microscopy. Bacteria in the IBCs are 
held together by exopolymeric matrices, reminiscent of biofilm structures [51]. At some 
point during this IBC developmental process, bacteria on the edges of IBCs become 
elongated again, become motile and start to move away from IBCs. Bacteria can exit out of 
infected bladder cells, probably due to compromised membrane integrity. UPEC undergo 
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such IBC cascade to increase in numbers, resulting in high bacterial titers in the bladder. In 
addition, bacteria in these intracellular niches can create a chronic quiescent reservoir in the 
bladder, which can persist undetected for several months without bacteria shedding in the 
urine [52,53,54]. Bacteria in IBCs are completely resistant to 3- and 10-day courses of 
antibiotics [55].   
12. Biofilm and pyelonephritis 
Once bacteria reach the kidney either by ascending infection or vesicoureteral reflux they 
are able to adhere to the urothelium and papillae. Nickel et al showed that bacteria could 
adhere in thin biofilms to the urothelium before invading the renal tissue with resultant 
pyelonephritis [47]. These bacterial biofilms are more easily eradicated by antimicrobial 
agents, in contrast to the biofilms on catheter surfaces [51], which may be ascribed to the 
effective synergistic actions of antimicrobial agents and host defenses against the biofilms on 
urothelium [56].  
13. Biofilm in bacterial vaginosis 
Bacterial vaginosis (BV) is the most common vaginal disorder in adult women  [57].  
Although it is a non-fatal disease, BV presents an increased risk for other more severe 
clinical outcomes, such as preterm birth and HIV infections [58,59]. As defined by Amsel 
clinical criteria, BV exhibits at least 3 of the following 4 clinical symptoms: 1) elevation of 
vaginal fluid pH to above 4.5; 2) detectable “fishy odor” of vaginal fluid upon addition of 
10% potassium hydroxide; 3) presence of clue cells, vaginal epithelial cells covered with 
bacteria, in vaginal fluid; and 4) milky vaginal discharge. The vaginal flora of healthy 
women consists predominantly of Gram-positive lactobacilli, especially Lactobacillus cripatus 
and Lactobacillus jensenii [60-62]. Productions of antimicrobial proteins as well as the 
maintenance of acidic pH and hydrogen peroxide (H2O2) in the vaginal fluid by these 
bacteria contribute critically to the establishment of a healthy ecosystem in the vagina [61-
63]. On the other hand, the vaginal microbiota of women with BV showed a loss of 
Lactobacillus species and an increase in microbial diversity dominated by Gardnerella vaginalis 
and to a lesser extend, many other bacterial organisms, including Porphyromonas, 
Mobiluncus, and Prevotella species [64-66]. 
The attempts to demonstrate G. vaginalis as the causative pathogen of BV have failed [67], 
many studies have demonstrated unequivocally that G. vaginalis is present in the majority of 
BV vaginal cultures in high numbers [64, 68, 69]. One additional complication with BV is the 
high recurrent rate of infection, despite of efficient resolution of infection by antibiotic 
treatments [70]. The recurrence nature of this disease prompted the speculation that 
bacterial biofilms are involved in BV. G. vaginalis poses the intrinsic ability to form biofilm in 
vitro [71-73]. Similar to other bacterial biofilm phenotypes, G. vaginalis biofilm is more 
resistant to antibiotic treatments compared to it planktonic counterparts [73]. 
Swidsinski and co-workers demonstrated the presence of bacterial biofilms on the vaginal 
epithelium of biopsies from women with BV [68]. These biofilm showed characteristics of 
dense surface bacterial biofilm and were comprised predominantly of G. vaginalis. Although 
G. vaginalis was also detected in biopsies from healthy women, they were present in very 
small numbers and infrequent. The sensitivity and specificity of FISH technique also 
allowed the researchers to identify the presence of Gram-positive (Streptococcus spp., 
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allows evasion of these innate defenses. Initially, bacteria replicate rapidly inside superficial 
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growth in cell size, resulting in coccoid-shaped bacteria, presumably due to changes in 
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bladder superficial cells [50]. The IBCs push the bladder superficial cell membranes outward 
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such IBC cascade to increase in numbers, resulting in high bacterial titers in the bladder. In 
addition, bacteria in these intracellular niches can create a chronic quiescent reservoir in the 
bladder, which can persist undetected for several months without bacteria shedding in the 
urine [52,53,54]. Bacteria in IBCs are completely resistant to 3- and 10-day courses of 
antibiotics [55].   
12. Biofilm and pyelonephritis 
Once bacteria reach the kidney either by ascending infection or vesicoureteral reflux they 
are able to adhere to the urothelium and papillae. Nickel et al showed that bacteria could 
adhere in thin biofilms to the urothelium before invading the renal tissue with resultant 
pyelonephritis [47]. These bacterial biofilms are more easily eradicated by antimicrobial 
agents, in contrast to the biofilms on catheter surfaces [51], which may be ascribed to the 
effective synergistic actions of antimicrobial agents and host defenses against the biofilms on 
urothelium [56].  
13. Biofilm in bacterial vaginosis 
Bacterial vaginosis (BV) is the most common vaginal disorder in adult women  [57].  
Although it is a non-fatal disease, BV presents an increased risk for other more severe 
clinical outcomes, such as preterm birth and HIV infections [58,59]. As defined by Amsel 
clinical criteria, BV exhibits at least 3 of the following 4 clinical symptoms: 1) elevation of 
vaginal fluid pH to above 4.5; 2) detectable “fishy odor” of vaginal fluid upon addition of 
10% potassium hydroxide; 3) presence of clue cells, vaginal epithelial cells covered with 
bacteria, in vaginal fluid; and 4) milky vaginal discharge. The vaginal flora of healthy 
women consists predominantly of Gram-positive lactobacilli, especially Lactobacillus cripatus 
and Lactobacillus jensenii [60-62]. Productions of antimicrobial proteins as well as the 
maintenance of acidic pH and hydrogen peroxide (H2O2) in the vaginal fluid by these 
bacteria contribute critically to the establishment of a healthy ecosystem in the vagina [61-
63]. On the other hand, the vaginal microbiota of women with BV showed a loss of 
Lactobacillus species and an increase in microbial diversity dominated by Gardnerella vaginalis 
and to a lesser extend, many other bacterial organisms, including Porphyromonas, 
Mobiluncus, and Prevotella species [64-66]. 
The attempts to demonstrate G. vaginalis as the causative pathogen of BV have failed [67], 
many studies have demonstrated unequivocally that G. vaginalis is present in the majority of 
BV vaginal cultures in high numbers [64, 68, 69]. One additional complication with BV is the 
high recurrent rate of infection, despite of efficient resolution of infection by antibiotic 
treatments [70]. The recurrence nature of this disease prompted the speculation that 
bacterial biofilms are involved in BV. G. vaginalis poses the intrinsic ability to form biofilm in 
vitro [71-73]. Similar to other bacterial biofilm phenotypes, G. vaginalis biofilm is more 
resistant to antibiotic treatments compared to it planktonic counterparts [73]. 
Swidsinski and co-workers demonstrated the presence of bacterial biofilms on the vaginal 
epithelium of biopsies from women with BV [68]. These biofilm showed characteristics of 
dense surface bacterial biofilm and were comprised predominantly of G. vaginalis. Although 
G. vaginalis was also detected in biopsies from healthy women, they were present in very 
small numbers and infrequent. The sensitivity and specificity of FISH technique also 
allowed the researchers to identify the presence of Gram-positive (Streptococcus spp., 
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Enterococcus spp. and Staphylococcus spp.) and Gram-negative (Escherichia coli and Proteus 
spp.) bacteria embedded within the G. vaginalis biofilms. Furthermore, in a subsequent 
publication, Swidsinski and colleagues reported the resurgence of dense bacterial biofilms at 
1-week post-cessation of metronidazole treatment [74]. These biofilms were comprised 
principally of G. vaginalis and Atopobium vaginae. These clinical data strongly support the 
presence and involvement of bacterial biofilm in BV. It is interesting to note, however, that 
Saunders et al. [72] demonstrated that incubation of preformed G. vaginalis biofilm with 
certain strains of L. reuteri or L. iners resulted in the disruption of biofilm and decreased 
viability of G. vaginalis.  
14. Prevention of biofilm formation in the urinary tract 
The harsh and potentially fatal consequences of microbial biofilm infections generated 
efforts to prevent their formation, particularly on indwelling medical devices using chemical 
and mechanical approaches. Catheters coated with hydrogel, silver salts, and antimicrobials 
have been evaluated; however, they provide minimal reduction in infection incidence (75). 
Antibiotic (minocycline, rifampicin, nitrofurantoin)  impregnated catheters lowered the rate 
of asymptomatic bacteriuria compared to catheters without impregnation at less than one 
week but difference was not statistically significant at greater than one week, and the 
authors concluded that the data were too few to draw conclusions about long-term 
catheterization. [76] 
Silver alloy  catheters significantly reduced the incidence of asymptomatic bacteriuria at less 
than one week of catheterization [76]. Beyond one week the estimated effect was smaller but 
the risk of asymptomatic bacteriuria was still less in the silver alloy group. There are no 
available clinical trials with appropriate setting about the effect of silver alloy coated 
catheters on bacteriuria or biofilm formation in case of long-term catheterisation. 
De Ridder et al found that fewer patients using hydrophilic-coated catheter (64%) for CIC 
experienced UTIs compared to the uncoated catheter group (82%)[77]. However, in a 
randomised controlled study the authors did not find significant difference between 
hydrophilic-coated  and uncoated indwelling urethral catheters in place for 6 weeks with 
respect to symptomatic urinary tract infection and microbiological analysis of urine culture 
[78]. 
Heparin coated ureteral stents did not show any organic (biofilms) or anorganic (crystals) 
deposits after being in situ for up to 6 weeks whereas significant biofilms were 
demonstrated in 33% of uncoated stents [79]. 
15. Use of low-energy surface acoustic waves (SAW) 
Biofilm formation can be prevented- or delayed- by applying low intensity nanowaves 
along the surfaces of an indwelling catheter. This approach opens new options for 
pharmacological prevention of urinary tract infections (80,81).The concept of using low-
energy SAW is based on the hypothesis that these acoustic waves are able to disrupt the 
formation of biofilms if transmitted directly to indwelling medical devices by inhibiting the 
adhesion of planktonic bacteria to their surface.  Hazan et al. demonstrated the the 
effectiveness of Low-Energy Surface Acoustic Waves  in the prevention of biofilm formation 
in an animal model in vivo. They found that SAW treatment reduced biofilm formation in 
vitro, leaving catheters virtually clean of adherent microorganisms, irrespective of the types 
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of bacteria that were examined. In the animal model SAW treated catheters showed strong 
inhibition of bacterial biofilm compared to controls [82]. 
In a double blind sham controlled randomized study related to short term catheterization, 
applying SAW releasing device to catheters prevented biofilm formation in all of the 
catheters whereas biofilm was present in 63% of the control group [83].  
A workgroup of the authors of the present article performed a prospective parallel group 
comparative study on the efficacy of the SAW treatment in case of long-term catheterisation 
(8 weeks). SAW treatment lowered the rate of significant bacteriuria (33% vs. 81%) and the 
rate of biofilm formation was also significantly lower in the SAW group compared to the 
controls[84].  
16. Conclusion 
The number of biomaterial devices used in urology has been increasing permanently. 
Biofilm infections have a major impact on implants or devices placed in the human body. 
The mechanism and the different bacterial and host factors taking part in the formation of 
biofilms have been extensively researched in the last decades, such ideal method has not 
been developed yet. Antimicrobial agents are effective against planktonic bacteria and 
appear to clear mucosal surfaces of adherent bacterial microcolonies but frequently fail to 
eradicate bacterial biofilms on urological devices. Several different approaches to disease 
prevention are being investigated and some promising results have been obtained.  
17. References 
[1] Mardis HK, Kroeger RM (1988) Ureteral stents. Urol Clin North Am 15:471-479 
[2] Biering-Sorensen F (2002) Urinary tract infection in individuals with spinal cord lesion. 
Current Opinion in Urology 12: 45-49 
[3] Choong S, Whitfield H (2000) Biofilms and their role in infections in urology Brit J 
Urology 86: 935-941 
[4] Costerton JW (1999) Introduction to biofilm. Int J Antimicrob Agents 11: 217-221 
[5] Habash M, Reid G (1999) Microbial Biofilms: Their development and significance for 
medical device-related infections. J Clin Pharmacology 39: 887-898 
[6] Fletcher M (ed.) (1996) Bacterial Adhesion: Molecular and Ecological Diversity. New 
York: Wiley-Liss 
[7] Busscher HJ, Stokoos I, Schakenraad JM (1991) Two-dimensional spatial arrangement of 
fibronectin adsorbed to biomaterials with different wettabilities. Cells Mater 1:  
49-57 
[8] Busscher HJ, Weerkamp AH (1987) Specific and non-specific interactions in bacterial 
adhesion to solid substrata. FEMS Microbiol Rev 46:165-173 
[9] Van Loosdrecht MCM, Lyklema J, Norde W, Schraa G, Zehnder AJB (1987) The role of 
bacterial cell hydrophobicity in adhesion. Appl Environ Microbiol 53:1893-1897 
[10] Van Loosdrecht MCM, Lyklema J, Norde W, Schraa G, Zehnder AJB (1987) 
Electrophoretic mobility and hydrophobicity as a measure to predict the initial 
steps of bacterial adhesion. Appl Environ Microbiol 53:1989-1901 
[11] Denstedt J.D., Wollin T.A., Reid G (1998) Biomaterials used in urology: Current issues 
of biocompatibility, infection and encrustation. J of Endourology 12:493-500 
 
Clinical Management of Complicated Urinary Tract Infection 
 
152 
Enterococcus spp. and Staphylococcus spp.) and Gram-negative (Escherichia coli and Proteus 
spp.) bacteria embedded within the G. vaginalis biofilms. Furthermore, in a subsequent 
publication, Swidsinski and colleagues reported the resurgence of dense bacterial biofilms at 
1-week post-cessation of metronidazole treatment [74]. These biofilms were comprised 
principally of G. vaginalis and Atopobium vaginae. These clinical data strongly support the 
presence and involvement of bacterial biofilm in BV. It is interesting to note, however, that 
Saunders et al. [72] demonstrated that incubation of preformed G. vaginalis biofilm with 
certain strains of L. reuteri or L. iners resulted in the disruption of biofilm and decreased 
viability of G. vaginalis.  
14. Prevention of biofilm formation in the urinary tract 
The harsh and potentially fatal consequences of microbial biofilm infections generated 
efforts to prevent their formation, particularly on indwelling medical devices using chemical 
and mechanical approaches. Catheters coated with hydrogel, silver salts, and antimicrobials 
have been evaluated; however, they provide minimal reduction in infection incidence (75). 
Antibiotic (minocycline, rifampicin, nitrofurantoin)  impregnated catheters lowered the rate 
of asymptomatic bacteriuria compared to catheters without impregnation at less than one 
week but difference was not statistically significant at greater than one week, and the 
authors concluded that the data were too few to draw conclusions about long-term 
catheterization. [76] 
Silver alloy  catheters significantly reduced the incidence of asymptomatic bacteriuria at less 
than one week of catheterization [76]. Beyond one week the estimated effect was smaller but 
the risk of asymptomatic bacteriuria was still less in the silver alloy group. There are no 
available clinical trials with appropriate setting about the effect of silver alloy coated 
catheters on bacteriuria or biofilm formation in case of long-term catheterisation. 
De Ridder et al found that fewer patients using hydrophilic-coated catheter (64%) for CIC 
experienced UTIs compared to the uncoated catheter group (82%)[77]. However, in a 
randomised controlled study the authors did not find significant difference between 
hydrophilic-coated  and uncoated indwelling urethral catheters in place for 6 weeks with 
respect to symptomatic urinary tract infection and microbiological analysis of urine culture 
[78]. 
Heparin coated ureteral stents did not show any organic (biofilms) or anorganic (crystals) 
deposits after being in situ for up to 6 weeks whereas significant biofilms were 
demonstrated in 33% of uncoated stents [79]. 
15. Use of low-energy surface acoustic waves (SAW) 
Biofilm formation can be prevented- or delayed- by applying low intensity nanowaves 
along the surfaces of an indwelling catheter. This approach opens new options for 
pharmacological prevention of urinary tract infections (80,81).The concept of using low-
energy SAW is based on the hypothesis that these acoustic waves are able to disrupt the 
formation of biofilms if transmitted directly to indwelling medical devices by inhibiting the 
adhesion of planktonic bacteria to their surface.  Hazan et al. demonstrated the the 
effectiveness of Low-Energy Surface Acoustic Waves  in the prevention of biofilm formation 
in an animal model in vivo. They found that SAW treatment reduced biofilm formation in 
vitro, leaving catheters virtually clean of adherent microorganisms, irrespective of the types 
 
Biofilm and Urogenital Infections 
 
153 
of bacteria that were examined. In the animal model SAW treated catheters showed strong 
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1. Introduction 
1.1 Escherichia coli virulence and urinary tract infections 
Urinary tract infections are a major public health concern in developed countries and also 
represent one of the most common hospital-acquired infections. Most uncomplicated UTIs 
are caused by E. coli, accounting for up to 90% of community-acquired and approximately 
50% of nosocomial UTIs (Vila et al., 2002). The origin of these strains is frequently the 
patient’s own intestinal flora. In comparison to commensal strains, UPEC present several 
virulence factors that allow them to colonize host mucosal uro-epithelium, injure and invade 
host tissues, overcome host defence mechanisms, incite a host inflammatory response and 
eventually proceed from the lower urinary tract to the renal cavities and tissues. The 
virulence factors involved in UTIs include surface virulence factors such as type 1 fimbriae, 
P, S and F1C fimbriae; exported virulence factors such as -haemolysin, cytotoxic 
necrotising factor 1 (CNF1), secreted autotransporter toxin (SAT), cytolethal distending 
toxin (CDT) and cytolysin A (Caprioli et al., 1987; Lai et al., 2000; Smith et al., 1963; Tóth et 
al., 2000).  
A common problem in UTI is recurrence, even in patients without anatomic abnormalities 
or indwelling bladder catheters. It is estimated that 40 to 50% of adult healthy women have 
experienced at least one UTI in their lifetime, and there is a tendency for these infections to 
become chronic due to a high rate of recurrence (Ulett et al., 2007). The persistence of the 
same E. coli strain in the urinary tract may be the cause of recurrent prostatitis. In fact, it has 
been shown that after an episode of acute prostatitis, cultures of expressed prostatic 
secretions are still positive three months after the end of a six-week course of therapy in one 
third of men (Kravchick et al., 2004). This may be related to the capacity of bacteria to form 
biofilm structures. Biofilm can promote persistence in the urinary tract and on biomaterial 
surfaces by protecting bacteria from the clearing out effect of hydrodynamic forces and the 
killing activity of host defence mechanisms and antibiotics (Hanna et al., 2003).  
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1.2 Biofilm and factors involved in its formation 
Biofilm is defined as a structured community of bacterial cells enclosed in a self-produced 
polymeric matrix and adherent to an inert or living surface (Costerton et al., 1999). Biofilm 
formation is carried out in four steps: adhesion or attachment, early development of biofilm 
structure, maturation and dispersion of cells from the biofilm into the surrounding 
environment and return to the planktonic state.    
Several surface determinants are involved in biofilm formation such as:  
1.2.1 Flagella and motility 
Motile E. coli generally present multiple peritrichous flagella. Motility is involved in 
colonization of host organisms or target organs and promotes initial cell-to-surface contact. 
1.2.2 Fimbriae 
Fimbriae are one of the virulent factors associated with host tissue adhesion of pathogenic E. 
coli strains (Finlay et al., 1997). Among these, type 1 fimbriae are the most common among 
E. coli and have an important role in the initial attachment to abiotic surface in biofilm 
formation (Pratt et al., 1998).  
1.2.3 Autotransporter proteins 
These secretory proteins present all the requirements for secretion across the cytoplasmic 
and the outer membrane to the bacterial cell surface (Desvaux et al., 2004). Among these 
proteins Ag43, AIDA (adhesin involved in diffuse adherence) and TibA are involved in 
adhesion. Antigen 43 promotes aggregation of cells through Ag43-Ag43 interactions by an 
intercellular handshake mechanism (Hasman et al., 1999). Ag43 and type 1 fimbriae are 
expressed co-ordinately in the cells which normally produce only one type of adherence 
structure at a time (Schembri et al., 2001). AIDA and TibA are autotransporters with 
homology to Ag43. 
1.2.4 Curli 
Curli fimbriae aggregate at the cell surface to form 6- to 12-nm-diameter structures whose 
length varies between 0.5 and 1 μm. Curli adhesive fibres also promote biofilm formation to 
abiotic surfaces both by facilitating initial cell–surface interactions and subsequent cell–cell 
interactions (Cookson et al., 2002; Uhlich et al., 2006; Vidal et al., 1998).  
1.2.5 F conjugative pilus 
The F-pilus promotes both initial adhesion and biofilm maturation through nonspecific 
attachment to abiotic surfaces and subsequent cell-to-cell contacts which stabilize the 
structure of the biofilm (Ghigo et al., 2001; Molin & Tolker-Nielsen, 2003; Reisner et al., 
2003). 
1.2.6 Exopolysaccharide production 
The biofilm matrix is composed by exopolysaccharide. This matrix forms a hydrated viscous 
layer which protects embedded bacteria from desiccation and from host defences because 
bacteria forming this structure may not be recognised by the immune system. The matrix 
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may also be involved in the protection of the bacteria against toxic molecules such as 
antimicrobials, hydroxyl radicals, and superoxide anions). The biofilm matrix could also 
inhibit wash-out of enzymes, nutrients, or even signalling molecules that could then 
accumulate locally and create more favourable microenvironments within the biofilm 
(Redfield et al., 2002; Starkey et al., 2004; Welch et al., 2002). All these aspects of the matrix 
could contribute to development of phenotypic resistance of pathogenic E. coli biofilms and 
lead to persistent infections (Anderson et al. 2003; Justice et al. 2004). In addition, the 
exopolysaccharide interactions with other components of the matrix favour the three-
dimensional growth of the biofilm (White et al., 2003). The exopolysaccharides most 
frequently found in the matrix are poly-β-1,6-N-acetyl-glucosamine, cellulose, colanic acid, 
lipopolysaccharides and capsules. 
In this chapter, the role of biofilm in urinary tract infections and its relation with virulence 
factors and antimicrobial resistance is explained. 
2. Evolution of antimicrobial resistance in uropathogenic Escherichia coli 
(UPEC) 
Several studies have demonstrated an increase in antibiotic resistance levels in E. coli 
causing community-acquired urinary tract infection (UTI) (Barret et al., 1999; Daza et al., 
2001; Goettsch et al., 2000; Goldstein, 2000; Gupta et al., 2001a). Some authors have 
suggested that most of these studies are likely to reflect a selection bias because few UTIs are 
being cultured routinely and culture results are available from patients with complications, 
recent treatment, and recurrence of infection or suspected resistance (Gupta et al., 2001b). 
However, taking into account the worldwide increase in antibiotic resistance, this factor can 
be a major problem in complicated and uncomplicated community-acquired UTIs. Hence, as 
suggested by the Infectious Diseases Society of America (IDSA), knowledge of local 
resistance rates and surveillance studies to monitor changes in the susceptibility of E. coli is 
highly recommended. (Warren et al., 1999) 
Cotrimoxazole has been the drug of choice for empiric therapy of uncomplicated UTI in 
women during several years. However, resistance to this compound is higher than 20% in 
many countries. In Spain, a multicentre study performed in 2006 found a resistance level of 
32%, (Andreu et al., 2008) quite similar to the result  of 33.9 %found in a previous study 
completed four years beforehand (Andreu et al., 2005), making the differences found 
between regions noteworthy (range 23% to 37.3%). Results from a single centre also in Spain 
found a resistance rate of 25%, with isolates from complicated UTIs (28%) being more 
resistant than those than from uncomplicated UTIs (22%) (Alós et al., 2005). In the USA, 
resistance to cotrimoxazole has risen from 15% in 1998 to 21.3% in 2003-2004 (Gupta et al., 
2001b)). Again, geographic variations were observed in another study among states (15% to 
40%) in the USA and in Canada (10.2 to 48.5%) (Zhanel et al., 2006). 
Betalactam antibiotics are widely used in the treatment of UTIs. Among them, ampicillin or 
amoxicillin are not recommended as first line drugs due to high levels of resistance. In the 
multicentre study from Spain (Andreu et al., 2008) the rate of resistance was 60.7% with 
clear differences between regions, the lowest value being 36.8%. Despite ampicillin not 
having been used to treat uncomplicated cystitis for a long time, resistance to this 
compound has increased along the years. Amoxicillin plus clavulanic acid shows a high 
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level of activity compared to ampicillin. Resistance to this drug was only found in 8.1% of 
isolates with a variation according to geographic zones of 3% to 18.3% (Andreu et al., 2008). 
Other oral betalactams like cefuroxime (8.9% of resistance) or cefixime (6.9% of resistance) 
show good activity against E. coli urinary isolates, but resistance to both drugs was higher in 
elderly patients (>60 years)(Andreu et al., 2008). An E. coli producer of extended spectrum 
betalactamases should always be considered as an aetiological agent of UTIs. In the Spanish 
multicentre study (Andreu et al., 2008) this agent represented 5.2% of E. coli isolates with 
most (79.1%) being recovered from patients over the age of 60 years. These isolates are also 
frequently resistant to fluorquinolones and cotrimoxazole.  
Fluorquinolones can be an option to treat UTIs, but their utility is hampered by resistance 
rates. In Europe, resistance to ciprofloxacin in UPEC was low in the period from 1999-2000, 
with the highest values found in Portugal (5.8%) and Spain (14.7%) (Kahlmeter, 2003). The 
multicentre study published by Zhanel et al. (2006) reported a rate resistance in UPEC of 
only 1.1% in Canada and 6.8% in the USA, with great differences between regions (2.9% to 
20.3%). In the Spanish multicentre study (Andreu et al., 2008) resistance to ciprofloxacin was 
found in 23.9% of all UPEC isolates and, again, significant geographical differences were 
found (12.5% to 37.3%). Interestingly, the study by Alós et al., (2005) showed that resistance 
to ciprofloxacin was higher in UPEC recovered in complicated UTIs (19.5%) than in UPEC 
isolated in uncomplicated UTIs (8.5%). Both studies found that elderly patients showed 
higher levels of resistance to fluorquinolones. 
Nitrofurantoin shows a good activity against UPEC isolates with only 3.8% resistant isolates 
(Andreu et al., 2008). However, dosage and potential pulmonary toxicity limits their 
usefulness. Fosfomycin remains as the most active oral antibiotic against UPEC isolates. 
Resistance to this drug was of 1.7% in the multicentre study published by Andreu et al., 
(2008) and the compound usually maintains its activity against ESBL producers. 
3. Relationship between virulence factors and antimicrobial resistance in 
UPEC 
The level of quinolone-resistance in E. coli clinical isolates has steadily increased in most 
European countries. When the analysis is stratified according to the different UTIs it is 
found that the percentage of quinolone-resistant E. coli isolates causing pyelonephritis is 
lower that those causing cystitis (Velasco et al., 2001). This data suggested that the 
quinolone-resistant E. coli lost the ability to colonize the kidney epithelia. In order, to prove 
this hypothesis a study investigating some urovirulence factors in nalidixic acid resistant E. 
coli clinical isolates compared with a group of quinolone-susceptible clinical isolates was 
carried out. Haemolysin, cytotoxic necrotizing factor-1 (CNF-1) and the autotransporter 
toxin (sat) were less prevalent in nalidixic acid-resistant than in nalidixic acid susceptible 
strains. These results suggested that resistance to quinolones may be associated with a 
decrease in the presence of some virulence factors in uropathogenic E. coli (Vila et al., 2002). 
A study related quinolone resistance and low virulence with phylogenetic origin, mainly in 
phylogenetic group A, which show a high level of resistance to quinolones and has a low 
number of urovirulence factors (Johnson JR, et al., 2003). Among the four phylogenetic 
groups (A, B1, B2 and D), B2 is considered the most virulent. Therefore in a subsequent 
study, 31 virulence factors were analyzed among nalidixic acid-susceptible and –resistant E. 
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coli clinical isolates from phylogenetic group B2 and again haemolysin and CNF-1 were less 
prevalent among nalidixic acid-resistant E. coli strains (Horcajada JP, et al. 2005). All three 
genes (hly, encoding haemolysin; cnf, encoding the cytotoxic necrotizing factor and sat, 
encoding the autotransporter toxin) have their localization in pathogenicity islands in 
common. Therefore, we thought that the link between the acquisition of resistance to 
quinolone and lower prevalence of some virulence factors could be explained by the fact 
that quinolones have been shown to induce the SOS system (Phillips I. et al., 1987) and this 
induction can favour the release of a genome phage integrated in the bacterial chromosome. 
Since the structure of the genome phage and the pathogenicity islands is genetically similar 
it can be hypothesized that the induction of the SOS system by quinolones would favour the 
release and loss of the pathogenicity island. Indeed, this hypothesis was proven incubating 
haemolysin-positive, quinolone-susceptible E. coli strains with subinhibitory concentrations 
of ciprofloxacin and searching for haemolysin-negative E. coli mutants. It was shown that 
these mutants can suffer a partial or total loss of the pathogenicity island, carrying the hly 
and cnf genes through a dependent and independent SOS pathway, respectively (Soto et al., 
2006). All the abovementioned results suggest that the acquisition of quinolone resistance 
may generate E. coli strains with lower virulence. 
4. Relationship between biofilm formation, urovirulence factors and 
antimicrobial resistance 
Biofilm formation may be considered as another pathogenic determinant which allows the 
strains to persist a long time in the genito-urinary tract and interfere with bacterial 
eradication. Biofilm endows bacteria with several advantages, such as the acquisition of 
antibiotic tolerance, expression of several virulence factors and an increased resistance 
against phagocytosis and other host defence mechanisms. Actually, biofilms are probably 
the usual living condition of bacteria in natural environments and they are, indeed, 
regularly involved in infections associated with biomaterials such as catheters or prostheses. 
In these clinical processes, biofilm formation is the main culprit of the characteristic 
persistence of the infection, despite appropriate antibiotic therapy and hydrodynamic forces 
(Hanna et al., 2003). More than 50% of all bacteria infections reported involve biofilm 
formation (Costerton et al., 1999). 
Acute UTI caused by UPEC can lead to recurrent infection, which is denominated “relapse” 
when it is caused by the same strain as that involved in the original UTI or as “re-infection” 
when it involves different strains. Approximately 25% of women with an episode of acute 
cystitis later develop recurrent UTI being an important burden to the health system. A study 
of women with recurrent UTI showed that 74% of strains causing relapse were biofilm 
formers (Soto et al., 2007). It had been demonstrated that uropathogens can persist within 
the bladder tissue in underlying epithelial cells or creating pod-like bulges on the bladder 
surface being a source of recurrent UTI (Mulvey et al., 2000; Anderson et al., 2003). Two 
virulence factors related to iron-uptake system, yersiniabactin and aerobactin, have also 
been associated with relapse (Johnson et al., 2001; Soto et al., 2006) due to the need of the 
bacteria to capture iron for growth in a stressful environment such as the vagina. However, 
biofilm production may be the key determinant for the persistence of UPEC in the vaginal 
reservoir, the bladder epithelial cells or both.  
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against phagocytosis and other host defence mechanisms. Actually, biofilms are probably 
the usual living condition of bacteria in natural environments and they are, indeed, 
regularly involved in infections associated with biomaterials such as catheters or prostheses. 
In these clinical processes, biofilm formation is the main culprit of the characteristic 
persistence of the infection, despite appropriate antibiotic therapy and hydrodynamic forces 
(Hanna et al., 2003). More than 50% of all bacteria infections reported involve biofilm 
formation (Costerton et al., 1999). 
Acute UTI caused by UPEC can lead to recurrent infection, which is denominated “relapse” 
when it is caused by the same strain as that involved in the original UTI or as “re-infection” 
when it involves different strains. Approximately 25% of women with an episode of acute 
cystitis later develop recurrent UTI being an important burden to the health system. A study 
of women with recurrent UTI showed that 74% of strains causing relapse were biofilm 
formers (Soto et al., 2007). It had been demonstrated that uropathogens can persist within 
the bladder tissue in underlying epithelial cells or creating pod-like bulges on the bladder 
surface being a source of recurrent UTI (Mulvey et al., 2000; Anderson et al., 2003). Two 
virulence factors related to iron-uptake system, yersiniabactin and aerobactin, have also 
been associated with relapse (Johnson et al., 2001; Soto et al., 2006) due to the need of the 
bacteria to capture iron for growth in a stressful environment such as the vagina. However, 
biofilm production may be the key determinant for the persistence of UPEC in the vaginal 
reservoir, the bladder epithelial cells or both.  
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The study of the factors contributing to biofilm formation may be important to conceive new 
therapeutic solutions for the treatment of these infections. On comparing UPEC collected 
from patients with cystitis, pyelonephritis or prostatitis it had been observed that strains 
causing prostatitis presented a higher capacity to form “in vitro” biofilm than those causing 
cystitis and pyelonephritis (Soto et al., 2007). The increased capacity to form biofilm of these 
strains could be a possible explanation for the persistence of such strains in the prostatic 
secretory system. 
Wu and colleagues (Wu et al., 1996) suggested that the inhibition of bacterial attachment to 
an uroepithelial surface, a crucial initial event involving precise interactions between groups 
of bacterial adhesive molecules called adhesins and their cognate urinary tract receptors, 
could be interesting to avoid biofilm formation. One of the virulence factors involved in the 
initial steps of biofilm is type 1 fimbriae which play an important role in the adhesion to the 
host epithelial cells (Prüss et al., 2006) and confer binding to -D-mannosylated proteins, 
such as uroplakins, which are abundant in the bladder (Wu et al., 1996). It had been found 
that biofilm-producing E. coli strains showed a significantly greater type 1 fimbriae 
expression than non-biofilm producing strains (Soto et al., 2007).  
Another mechanism by which UPEC promotes the formation of biofilms is via expression of 
proteins that mediate cell-cell aggregation (Ulett et al., 2007). Of these, Ag43 is also 
associated with the early stages of biofilm development (Schembri et al., 2003), although it 
has been demonstrated that the Ag43 can be dispensable for biofilm formation being 
replaced by alternative factors, such as conjugative pili (Guigo et al., 2001; Reisner et al., 
2003). Ag43 is expressed on the surface of UPEC cells located within intracellular biofilm-
like bacterial pods in the bladder epithelium, indicating that it may contribute to survival 
and persistence during prolonged infection (Anderson et al., 2003). 
On the other hand, among of the virulence factors studied, only haemolysin seems to 
present an association with biofilm production. In fact, haemolysin-positive UPEC strains 
were strongly linked to prostatitis also shown to have a higher frequency of “in vitro” 
biofilm formation (Andreu et al., 1997; Johnson et al., 2005; Mitsumori et al., 1999; Ruiz et al., 
2002; Soto et al., 2007; Terai et al., 1997). These data confirm that the tropism and 
invasiveness of E. coli strains for the prostate rely mainly on haemolysin but also provide a 
possible explanation for the persistence of such strains in the prostatic secretory system by 
means of their increased ability to form biofilm. 
It has been previously reported that most E. coli isolates collected from faeces belong to 
phylogenetic groups A and B1, with phylogenetic groups B2 and D being the most 
frequently isolated in urine and considered as virulent. The differences in the phylogenetic 
background of these two groups of isolates from urine and faeces indicate that the prostate 
was not, in most of the cases, colonized by commensal bacteria from the intestinal tract. 
Strains belonging to phylogenetic group B2 presented a higher capacity to form biofilm than 
those belonging to phylogenetic groups A, B1 and D (Soto et al., 2007). 
A relationship between nalidixic acid susceptibility and “in vitro” biofilm formation seems 
to exist. Studies comparing biofilm positive UPEC strains versus biofilm negative UPEC 
strains showed that the percentage of nalidixic acid resistant strains was higher among those 
non-biofilm formers than among biofilm-formers (Soto et al., 2007). In fact, acquisition of 
quinolone resistance causes a decrease in the “in vitro” production of biofilm by a decrease 
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in the expression of type 1 fimbriae, avoiding the first step of biofilm formation, the 
adhesion to the surfaces (unpublished data).  
5. Conclusion 
Biofilm formation is an important feature related to relapsed UTI, and likely plays an 
important role in prostatitis caused by E. coli. In addition, a link between acquisition of 
quinolone resistance acquisition and decrease in biofilm formation and loss of some 
virulence factors has been suggested.   
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Urinary tract infections (UTI) are considered as one of the most common groups of 
infections in humans and affecting either the upper (kidneys--pyelonephritis) or the lower 
(bladder--cystitis) part of the urinary tract (Thomson and Armitage, 2010).  
The gastrointestinal tract is a reservoir from which uropathogens emerge. Reflecting this, 
Enterobacteriaceae are the most important cause of UTI in all population groups, accounting 
for more than 95% of all UTIs. Among these microbes, E. coli is by far the most common 
invader, causing some 90% of UTIs in outpatients and approximately 50% in hospitalized 
patients. Whilst, the frequency of P. mirabilis causing outpatient and inpatients UTIs were 
3.2% and 12.7% respectively, these value were reversed to 26.6% and 9.3% when all strains 
of Proteus species were examined (Talkoff-Robin et al, 2008). In a most recent multicentre 
study involving nine Spanish hospitals, 784 women with uncomplicated cystitis were 
evaluated for the frequencies of isolated uropathogens and their susceptibility to antibiotics. 
Among the 650 pathogens isolated, the first group of the most frequent bacterial agents was 
Escherichia coli (79.2%) followed by Staphylococcus saprophyticus (4.4%), Proteus mirabilis 
(4.3%), Enterococcus faecalis (3.3%), and Klebsiella pneumoniae (2.3%) (Palou et al, 2011). 
In contrast to E. coli strains, it appears that all strains of P. mirabilis, regardless of isolate 
origin, are capable of infecting the urinary tract (Sosa et al, 2006). Proteus is particularly 
significant as a renal pathogen especially in causing upper UTI because of its propensity to 
promote struvite renal calculi (Ronald and Nicolle, 2007). 
2. Asymptomatic bacteriuria and subclinical urinary infections 
Bacteriuria might be either symptomatic or asymptomatic. An estimated 40% of women and 
12% of men will experience at least one attack of symptomatic or overt UTI during their 
lifetime, and approximately a quarter of affected women will suffer recurrent UTIs within 6-
12 months (Nielubowicz and Mobley, 2010).  
Asymptomatic bacteriuria (ABU) is considered as one of the most common findings in 
women all over the world. It is defined as the presence of ≥105 cfu/ml of the same bacterial 
species in two consecutive midstream urine samples (Schmiemann et al, 2010). Although in 
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the majority of patients with ABU the site of infection is in the lower urinary tract, some 
individuals with ABU, however, do have upper tract involvement (Ronald and Nicolle, 
2007). In a cross-sectional longitudinal study, Kunin and associates have found that among 
16,000 schoolgirls with ages ranging between 6 to 18 years the prevalence of UTI was 1.2%, 
and two-third of 5% girls who had one or more episodes of bacteriuria were asymptomatic 
(Kunin, 1970). It also appears that the prevalence of asymptomatic bacteriuria increases with 
age and this has been reported by Gaymans et al (1976), where in a study of 1,758 Dutch 
women, the prevalence of bacteriuria was found to be increased from 2.7% of women aged 
15 to 24 years to 9.3% of women aged 65 years or older. 
Although it is usually true to say that bacteriuria is a valid indicator of either bacterial 
localization or infection of the urinary tract, studies in animals (Mulvey et al, 1998) and 
humans (Elliott et al, 1985) have indicated that bacteria may reside in the urothelium in the 
absence of bacteriuria. The majority of patients with kidney or upper tract infection show 
the clinical signs and symptoms of pyelonephritis, but in others this might not be the case. 
In a study by Stamey et al (1965), using ureteral catheterization it was shown that 50 percent 
of women with asymptomatic bacteriuria had infection in their upper tracts, and that a 
small but significant proportion of women with preliminary associated cystitis also had 
upper UTI. It is possible that bacteria within the kidney or upper urinary tract may remain 
latent in a nidus of infection for any length of time (Cattell, 2005). For example Proteus spp. 
can form urinary calculi and remain dormant inside these infected stones undetected and 
resistant to the effects of antibiotics used. It should also be stressed that P. mirabilis is 
probably the second most common microbe among the family of Enterobacteriaceae after E. 
coli in causing UTI, especially of the upper tract in middle-aged and elderly women (Senior, 
1979). 
3. Rheumatoid arthritis and urinary tract infections 
Rheumatoid arthritis (RA) is a potentially disabling chronic systemic polyarthropathy with a 
world-wide distribution and an increased likelihood to have a considerable amount of 
negative impacts on the economical status of the patient and society (Zhang and Anis 2011). 
The cause of this disease is generally agreed to be due to a combined action of genetic and 
environmental (mainly microbial) factors (Firestein, 2009). 
Among the urologists and rheumatologists, the evidence of the link between UTIs and RA is 
not apparently recognized because of the consistent lack of data supporting this association 
and more probably because of the possibility for an existing hidden infection expressed in 
the form of asymptomatic bacteriuria in patients with RA.  
In a preliminary study carried out by a group from Tel Aviv, it has been found that 35 
percent of patients with RA and secondary Sjogren’s syndrome had recurrent attacks of 
UTIs (Tishler et al, 1992). Furthermore, another group from Edinburgh, using a necroscopic 
examination of kidneys from dead patients with RA, found that approximately 17.6 percent 
of males and 22.7 percent of female patients showed signs of chronic pyelonephritis 
(Lawson and Maclean, 1966). A similar result was found in a previous study carried out by a 
group from Copenhagen, where a considerably high degree of associated non-obstructive 
pyelonephritis and renal papillary necrosis was detected among the renal autopsy materials 
from patients with RA (Clausen and Pedersen, 1961). However, this kind of association 
between RA and UTIs was not always observed (Vandenbroucke et al, 1987). This 
discrepancy in the results with an apparent lack of the epidemiological link between urinary 
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infections and RA could be due to the occurrence of sub-clinical or occult infections, which 
are merely characterized by bacteriuria. 
4. Proteus in the urine of patients with RA 
RA is most probably caused or initiated by an upper urinary tract infection with Proteus 
bacteria. Regarding this particular subject, more than 100 articles have been published by 
our and various other collaborative as well as independent groups throughout the world 
(Ebringer et al, 2010). 
The first evidence of a link between Proteus microbe and RA was reported nearly three 
decades ago where in a study by Chandler and co-workers, it was shown that among a 
panel of 30 microbial agents tested, the mean geometric titres of antibodies were raised only 
against Proteus OXK and herpes virus hominis microbes in 22 newly diagnosed RA patients 
when compared to 22 control subjects (Chandler et al, 1971). Meanwhile, this disease-
microbe association was established fourteen years later in a study by our group, where a 
significant elevation of Proteus antibodies (p<0.001) was shown in 30 patients with RA 
compared to 41 healthy controls (Ebringer et al, 1985). To search for the source of this 
microbe in urinary tract of RA patients various studies were carried out by our and other 
independent groups: 
1. In a controlled study of 89 patients with RA from London, P. mirabilis was isolated from 
the urine of 63% of female and 50% of male patients and these results were found to be 
significant in comparison to female (32%) (p<0.001) or male (11%) (p<0.001) healthy 
subjects. However, the frequency of the isolation of Proteus from urine of men and 
women patients without RA (osteoarthritis, fibromyalgia, psoriasis, gout, and systemic 
lupus erythematosus) was 7% and 35% respectively, which were similar to those 
obtained from healthy men (11%) and women (32%) individuals (Figure 1). 
Furthermore, a positive correlation was found between high anti-Proteus antibody 
levels in sera of RA patients and the number of colony-forming units obtained from 
urine specimens of these patients (Wilson et al, 1997). 
2. In another study carried out by a group of scientists from Dundee in the UK, a 
significantly increased isolation rate of Proteus microbes from the urine of 76 patients 
(33%) were detected when compared to those of 48 gender-matched healthy individuals 
(4%) (Senior et al 1999) and this isolation rate was found to be occurring twice more 
frequently as E. coli. In the same study significant elevations (p<0.001) of antibodies 
against P. mirabilis were detected in the urine and serum samples of patients with RA 
when compared to the corresponding healthy subjects.  
Another group, however, was unable to find a significant increase in the isolation of Proteus 
microbes from the urine or faeces of RA patients (McDonagh et al, 1994).  
5. Proteus virulence factors and cross-reactive antigens 
The main virulence factors which have been involved in the uropathogenetic mechanisms 
and utilized by the major group of uropathogens, namely E. coli and P. mirabilis include 
motility, adherence, biofilm formations, β-lactamase productions, toxin productions, 
hydrolytic enzyme productions, metal acquisitions and evasion of the host immune 
defenses (Dobrindt, 2010).  
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the majority of patients with ABU the site of infection is in the lower urinary tract, some 
individuals with ABU, however, do have upper tract involvement (Ronald and Nicolle, 
2007). In a cross-sectional longitudinal study, Kunin and associates have found that among 
16,000 schoolgirls with ages ranging between 6 to 18 years the prevalence of UTI was 1.2%, 
and two-third of 5% girls who had one or more episodes of bacteriuria were asymptomatic 
(Kunin, 1970). It also appears that the prevalence of asymptomatic bacteriuria increases with 
age and this has been reported by Gaymans et al (1976), where in a study of 1,758 Dutch 
women, the prevalence of bacteriuria was found to be increased from 2.7% of women aged 
15 to 24 years to 9.3% of women aged 65 years or older. 
Although it is usually true to say that bacteriuria is a valid indicator of either bacterial 
localization or infection of the urinary tract, studies in animals (Mulvey et al, 1998) and 
humans (Elliott et al, 1985) have indicated that bacteria may reside in the urothelium in the 
absence of bacteriuria. The majority of patients with kidney or upper tract infection show 
the clinical signs and symptoms of pyelonephritis, but in others this might not be the case. 
In a study by Stamey et al (1965), using ureteral catheterization it was shown that 50 percent 
of women with asymptomatic bacteriuria had infection in their upper tracts, and that a 
small but significant proportion of women with preliminary associated cystitis also had 
upper UTI. It is possible that bacteria within the kidney or upper urinary tract may remain 
latent in a nidus of infection for any length of time (Cattell, 2005). For example Proteus spp. 
can form urinary calculi and remain dormant inside these infected stones undetected and 
resistant to the effects of antibiotics used. It should also be stressed that P. mirabilis is 
probably the second most common microbe among the family of Enterobacteriaceae after E. 
coli in causing UTI, especially of the upper tract in middle-aged and elderly women (Senior, 
1979). 
3. Rheumatoid arthritis and urinary tract infections 
Rheumatoid arthritis (RA) is a potentially disabling chronic systemic polyarthropathy with a 
world-wide distribution and an increased likelihood to have a considerable amount of 
negative impacts on the economical status of the patient and society (Zhang and Anis 2011). 
The cause of this disease is generally agreed to be due to a combined action of genetic and 
environmental (mainly microbial) factors (Firestein, 2009). 
Among the urologists and rheumatologists, the evidence of the link between UTIs and RA is 
not apparently recognized because of the consistent lack of data supporting this association 
and more probably because of the possibility for an existing hidden infection expressed in 
the form of asymptomatic bacteriuria in patients with RA.  
In a preliminary study carried out by a group from Tel Aviv, it has been found that 35 
percent of patients with RA and secondary Sjogren’s syndrome had recurrent attacks of 
UTIs (Tishler et al, 1992). Furthermore, another group from Edinburgh, using a necroscopic 
examination of kidneys from dead patients with RA, found that approximately 17.6 percent 
of males and 22.7 percent of female patients showed signs of chronic pyelonephritis 
(Lawson and Maclean, 1966). A similar result was found in a previous study carried out by a 
group from Copenhagen, where a considerably high degree of associated non-obstructive 
pyelonephritis and renal papillary necrosis was detected among the renal autopsy materials 
from patients with RA (Clausen and Pedersen, 1961). However, this kind of association 
between RA and UTIs was not always observed (Vandenbroucke et al, 1987). This 
discrepancy in the results with an apparent lack of the epidemiological link between urinary 
 
Rheumatoid Arthritis is Caused by Asymptomatic Proteus Urinary Tract Infections 
 
173 
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Fig. 1. Percentage isolation of Proteus bacteria from the urine of rheumatoid arthritis (RA) 
and non-RA patients and healthy controls. (Urine cultures were measured down to the level 
of 1 cfu/ml of urine, to determine presence or absence of  bacterial signal). 
In contrast to E. coli, P. mirabilis is the main producer of the urease enzyme (Rozaliski et al, 
1997), which hydrolyzes urea into ammonia and carbonate. One of the hallmarks of UTI 
caused by P. mirabilis is the production of urinary stones through action of urease. These 
stones which are a composite of magnesium ammonium phosphate crystals (struvite), might 
act as infective reservoirs of Proteus microbes, and basically protected from host defenses 
and antibiotic treatment (Li et al, 2002).  
Proteus microbes possess various different antigens. Two of these were found to resemble 
self tissue antigens. The Proteus haemolysin protein possesses six amino acid molecules 
“ESRRAL” which resembles a similar amino acid motif “EQRRAA” present in the HLA-
DR1/4 genetic molecules (Wilson et al, 1995) frequently found in association with RA 
(Stastny, 1976). Whilst another group of antigens comprising five amino acid molecules 
“IRRET” which is present in Proteus urease resembles the “LRREI” motif present in type XI 
collagens (Wilson et al, 1995), which is found in hyaline cartilage of the joint tissues. 
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6. Proteus antibodies and their role in the pathogenetic mechanism of RA 
Elevated levels of antibodies to P. mirabilis have been detected in patients with RA among 
many populations from 14 different countries including UK, USA, France, and Netherlands 
(Ebringer et al, 2010). These results have been detected by using various immunological 
methods carried out by collaborative (Table 1) and other independent (Tables 2) groups. The 
specificity of Proteus antibodies in patients with RA was shown in many studies. Deighton et 
al, found that antibodies to P. mirabilis but not to four different viruses (Deighton1 et al, 
1992) were elevated significantly in RA patients. Moreover, in a review analysis it was 
shown that in patients with RA there were significant elevations of antibodies to Proteus but 
not against more than 20 other enterobacterial or uropathogenic microbes, including E. coli 
(Rashid et al, 2007). 
As the result of molecular mimicry or similarity between Proteus and self antigens, patients 
infected with Proteus microbes will produce not only antibodies against this microbe but 
also against the self tissue molecules carrying the cross-reactive antigens. These antibodies 
will bind to and be cytopathic to the joint tissues which carry Proteus cross-reactive antigens 
(Wilson et al, 2003) and this immune reaction will lead to the release of more self tissue 
antigens with a consequent production of further autoantibodies, propagation of the 
pathological process and the development of classical RA, in the same way that Streptococcus 
causes rheumatic fever and valvular lesions in the heart (Guilherme et al, 2011). 
7. A proposal for a new treatment in RA—eradication of Proteus microbes 
Currently the pharmacologic treatment of RA mainly involves the use of disease modifying 
anti-rheumatic drugs and biological agents (Haraoui and Pope, 2011). In concurrent use 
with these medical treatments other therapeutic measures can be employed in order to 
eradicate Proteus bacteria from the urinary tract which could help to prevent further tissue 
and joint damages in patients with RA. These measures could involve the use of cranberry 
juice products, antibiotics or even vaccination.  
Cranberry products have been used widely for several decades for the prevention and 
treatment of UTIs. A meta-analysis has established that recurrence rates of UTIs over 1 year 
are reduced approximately by 35% in young to middle-aged women (Guay, 2009). Other 
studies, however, either supported (Ferrara et al, 2009) or disputed (Barbosa-Cesnik et al, 
2011) the effect of cranberry preparations in the prevention of UTIs. 
Although the use of anti-microbial agents has not been recognized in the management of 
RA, some antibiotics have already been tried with encouraging results. Among these are 
sulphasalazine, metronidazole, rifampicin and minocycline (Ebringer et al, 2003). Some 
problems, however, exist in regard to the use of antibiotics against Proteus microbes. Firstly, 
Proteus infection affects mainly the kidneys and upper urinary tract (Fairley, et al, 1971) 
where the use of ordinary sterilizing substances and antibiotics can be less effective. 
Secondly, P. mirabilis possesses various virulence factors which enhance its urinary 
epithelial invasiveness rendering this microbe resistant to antibiotics (Mathoera et al, 2002). 
Thirdly, when an infected struvite stone is present in the kidney, none of the antibiotic 
agents seems to be effective unless the stone is removed by surgery or shock-wave therapy. 
In order to test the effects of antibiotics in patients with RA through prospective 
longitudinal studies, the search for an effective anti-Proteus chemotherapeutic agent is 
mandatory. In a most recent study from Japan it was shown that all of the P. mirabilis strains 
including extended system β-lactamase (ESBL)-producing strains were susceptible to 
penicillin derivatives combined with β-lactamase inhibitors (Ishikawa et al, 2011). In another 
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study, it was shown that among the three carbapenems tested, meropenem was the most 
potent antibiotic being effective against the majority of the Proteus species isolates (Lee et al, 
2011). If patients with RA respond to anti-microbial measures, prophylaxis of susceptible 
individuals could be instigated by the mean of immunization with attenuated antigens from 
causative microbe or other cross-reactive microbes among the Enterobacteriaceae group 
(Scavone et al, 2011).  
It is logical to start treating patients with RA from early stages of the disease in order to 
prevent further irreversible joint damages from occurring. If such early therapy is 
undertaken the possibility arises that RA may be eradicated in the same way that rheumatic 
fever has been eliminated in the Western World by the means of early treatment of 
Streptoccocal tonsillitis with penicillin and other related antibiotics. 
8. General discussion 
It generally appears that there is an apparent relationship between Proteus asymptomatic 
UTIs and RA. The main hallmark of this association is based on showing the linkage 
between RA and Proteus but not other microbes in the majority of studies carried out by 
various groups throughout the world. The combination of isolation of Proteus microbes in 
the urine and elevation of antibodies in sera of RA patients as well as the evidence for the 
cytopathic effects of these antibodies against the joint tissue cross-reactive antigens, forms 
the major evidence for the role of this microbe in the development of RA. Elimination of 
Proteus microbes by using cranberry juice, antibiotics could have a remarkable effect in the 
management of RA patients alongside currently used anti-rheumatic drugs. It would appear 
that the management of RA may be relevant to urologists as well as to rheumatologists. 
 
YEAR RA HC METHOD P VALUE REFERENCE 
1985 30 41 AM P<0.001 Ebringer et al 
1988 32 18 ELISA P<0.05 Khalafpour et al 
1995 50 49 ELISA P<0.001 Fielder et al 
1995 40 30 ELISA P<0.001 Wilson et al 
1995 34 33 ELISA+IIF P<0.001 Subair et al 
1996 66 60 ELISA P<0.001 Tiwana et al 
1997 50 50 ELISA P<0.001 Tani et al 
1997 89 234 ELISA P<0.001 Wilson et al 
1997 60 60 ELISA P<0.001 Tiwana et al 
1998 25 34 IIF P<0.001 Blankenberg-Sprenkels 
et al 
1999 114 69 IIF P<0.001 Rashid et al 
2003 51 38 ELISA P<0.001 Wilson et al 
2004 159 53 IIF P<0.001 Rashid et al 
2006 50 38 ELISA P<0.0001 Rashid et al 
2007 70 20 ELISA P<0.001 Rashid et al 
RA = rheumatoid arthritis; HC = healthy controls; AM = agglutination method ; ELISA = enzyme-
linked immunosorbent assay; IIF = indirect immunofluorescence. 
Table 1. Studies carried out by various collaborative groups showing increased anti-Proteus 
antibodies in patients with RA compared to HC individuals (number of subjects indicated in 
each study). 
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YEAR RA CONTROLS* METHOD P VALUE REFERENCE 
1988 29 30 ELISA P<0.01 Rogers et al 
1991 9 10+10 (AS+HC) ELISA p<0.01; NS Murphy et al 
1992 142 121 IIF P<0.0001 Deighton2 et al 
1994 87 29 (non-RA) IIF P<0.003 McDonagh et al 
1995  27 27 (non-RA) ELISA; IB P<0.0001 Senior et al 
1996 40 40 ELISA P<0.001 Dybwad et al 
1997 70 82 AM P<0.001 Wanchu et al 
1999 39 51 ELISA p<0.001 Chou et al 
2003 50 25 AM P<0.001 Gautam et al 
2005 59 63 IB P<0.01 Weisbart et al 




Newkirk et al 
*Controls are always healthy individuals unless otherwise stated; RA = rheumatoid arthritis; AS = 
ankylosing spondylitis; HC = healthy control; SpA = spondyloarthropathy; UA = undifferentiated 
arthritis; ELISA = enzyme-linked immunosorbent assay; IIF = indirect immunofluorescence; AM = 
agglutination method; IB = immunoblot; NS = not significant. 
Table 2. Studies carried out by independent groups showing increased anti-Proteus 
antibodies in patients with RA compared to controls. 
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1. Introduction 
Urinary tract infections (UTIs) and their complications represent one of the most common 
causes of medical consultation with high cost to medical services and high morbidity and 
mortality. Urinary stones are another medical challenge that represents an acute or chronic 
clinical setting for patients requiring most of the time active treatment, either as an invasive 
or as a non-invasive management, thus increasing costs and risks. The combination of both 
clinical scenarios —urinary tract infection and urinary stone— is common and can trigger a 
systemic inflammatory response syndrome (SIRS) before, during or after medical treatment 
(i.e. antibiotics) and/or surgical manipulation of infected urinary stones. It is believed that 
SIRS is due to the release of endotoxins from infected urinary stones, developing 
endotoxemia, bacteremia and urosepsis. If not controlled, multiple organ failure syndrome 
(MOF) and death of the patient may occur. Urologists are familiar with these scenarios 
where not only prevention and diagnosis but also an early and appropriated treatment is 
crucial. Unfortunately, the use of prophylactic antibiotics does not guarantee prevention of 
these fatalities. The aim of this chapter is to review the evidence of possible endotoxin 
release during invasive and non-invasive treatment of infected urinary stones as a trigger of 
SIRS and sepsis. 
2. Urinary tract infections 
Urinary tract infections are the second most frequent infections in developed countries and 
uropathogenic Escherichia coli (E. coli) a non-urea-splitting bacterium represents 80 % of 
uncomplicated UTIs (Oelschlaeger et al., 2002). There is a geographic variation about E. coli 
and several other Gram-negative, as well as Gram-positive bacteria and fungi causing 
complicated and uncomplicated UTIs among specific populations. Virulence of bacteria 
causing UTIs is determinant for progression of the disease. Some virulence factors in 
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uropathogenic E. Coli, as adhesins (Type 1 pili, Dr-family pili, P fimbriae, F1C fimbriae, S 
fimbriae) and toxins (CNF1, Hemolysin and Sat)  (Oelschlaeger et al., 2002), could explain 
the systemic forms of invasion of the bloodstream by some Enterobacteriaceae in possible 
synergism with the release of endotoxins that may result in SIRS and urosepsis. These 
virulence factors are reviewed elsewhere in this book. 
2.1 Urinary bacterial epidemiology 
Urinary tract infections in Western countries are mainly caused by E. coli (90 %), Proteus spp, 
Klebsiella spp, and Pseudomonas spp (McRae & Shortliffe, 2000; Bochud & Calandra, 2003). 
Variation in proportions and specific populations have been reported and described 
(Foxman, 2003; Savas et al., 2006). Bacterial resistance is another important issue that 
increases morbidity and mortality. For further details and specific information about 
bacterial epidemiology in UTIs we invite the reader to consult other sections of this book. 
2.1.1 Endotoxins 
To invade hosts, bacteria use a variety of substances, some of them are essential for their 
survival. In Gram-negative bacteria, specific molecular patterns composed of lipid and 
sugar moieties represent some of the most toxic virulence factors of bacterial origin. 
Structurally classified as lipopolysaccharides (LPS), these substances have no chemical 
homologs among human cells, and are known as endotoxins, to denote their ability for 
causing fever, shock and organ injury when released in mammalian endothelial vessels 
(Beutler, 2000). The presence of endotoxins in the blood-stream is named endotoxemia and 
can trigger SIRS. LPS have specific structural motifs which are typical of different bacterial 
species. However, all of them are known to induce endotoxemia and sepsis (Bochud & 
Calandra, 2003). Endotoxins are known to be recognized by cell-surface proteins, the LPS 
receptors, which are widely distributed in animals as part of their immune systems (from 
insects to vertebrates). However, a strong inflammatory reaction after LPS recognition is 
restricted to a handful of species, including humans (Beutler, 2000). According to numerous 
studies in cellular and animal models, recognition of LPS by their receptors initiate a 
cascade of intracellular signals guiding the secretion of pro-inflammatory mediators 
(Beutler, 2000; Triantafilou & Triantafilou, 2005). An emerging concern is the toxicity of LPS 
after microbial death, especially in the context of hospital-acquired infections. In fact, 
released LPS keep their full toxic potential, unless inactivation processes take place in the 
host to degrade endotoxins (Munford et al., 2009). 
3. Urinary stones 
Urinary stones have been reported in human history since antiquity. Traditionally, stones 
have been classified according to their main mineral content. The etiology of urinary stones 
is wide, including chronic dehydration, urinary tract malformations, obstructed uropathy, 
metabolic diseases (i.e. hyperparathyroidism, gout, and obesity), foreign body inside 
urinary tract, infections, etc. The risk for stone disease in patients of developed countries is 
close to 10 % life-long. An increase in the incidence of stone disease related with changes in 
the life style, modifications on the diet, morbid obesity surgery syndrome and new drugs 
has been reported in Western countries in recent years. For example, in the United States, an 
increase of 37 % in stone disease was observed over the last 20 years (Straub & Hautmann, 
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2005). A variation in the frequency and in the composition of the minerals forming the 
urinary stones was also observed. 
There is a large variety of urinary stone compositions. If the main component is more than 
80 % of the total mass, the stone is named “pure”. If the main component is at least 50 % of 
the stone, it is named mixed. In Western countries, struvite stones used to represent 15-30 % 
of cases. Nowadays only 2 % of stones are struvite (McALeer et al., 2003; Kramer et al., 
2000). The explanation of that decrease is unknown. In developing countries and Eastern 
countries there is a large variation among incidence, prevalence and stone composition. For 
example, in India a report including 1050 urinary calculi from surgically treated patients 
(900 renal and 150 ureteral) revealed 93.04 % oxalate calcium stones (80 % calcium oxalate 
monohydrate [COM] and 20 % calcium oxalate dihydrate [COD]), 1.92 % struvite stones, 
1.48 % apatite stones, 0.95 % uric acid stones and 2.96 % mixed stones. Surprisingly, 89.98 % 
of the staghorn stones consisted of oxalates and only 4.2 % were struvite (Ansari et al., 2005). 
A study in Japan showed that the most common stone composition was struvite (32.1 %) 
and mixed calcium oxalate phosphate (22.2 %) (Akagashi et al., 2004). These differences 
could be explained by variations in ethnics, epigenetics, geographical area, diet, life-style, 
and different metabolism.  
3.1 Infected stones 
It has been suggested that urinary stones can be infected mainly in two ways. Stones 
develop due to several mechanisms which may or may not be associated to obstructive 
uropathy (i.e. hyperparathyroidism). The first way in which a stone can be infected is by 
ascending bacteria. Once the stone is formed, ascending bacteria may reach its surface, 
invade the interstice and become part of it (Takeuchi et al., 1984; Abrahams & Stoller, 2003). 
Adherence of new minerals could cover and paste bacteria layers. In this case, the stone acts 
as a reservoir for bacteria. Due to the poor penetration of drugs into the stone matrix the 
action of antibiotics is limited (Prabakharan et al., 1999). This phenomenon can be the reason 
of bacterial resistance, repeated, chronic or complicated UTIs in several patients, therefore 
increasing the risk of urosepsis. The most possible scenario according to the most frequent 
stone component and urinary bacteria in our Western world is a calcium stone infected with 
E. coli. In this case, the urinary stone forms first and gets infected by bacteria afterwards.   
The second scenario is that bacteria living inside the urinary tract and causing chronic UTIs 
produce the stones. These bacteria are named urea-splitting bacteria. Members of this group 
are Proteus, Klebsiella, Pseudomonas, Providencia, Serratia spp, Staphylococcus aureus and 
Ureaplasma urealyticum, among others. P. mirabilis accounts for more than half of all urease-
positive urinary infections (Kramer et al., 2000). Urea-splitting bacteria change the urine pH 
(> 7.2) and allow easier precipitation of phosphate with several compounds, mainly 
ammonium and magnesium (Abrahams & Stoller, 2003). The result is a compound 
phosphate named struvite (magnesium-ammonium-phosphate [MAP] stones and/or triple 
phosphate stones). Another type of phosphate stones are apatite stones (calcium phosphate). 
The terms “infectious stones” or “infection stones” are used as synonymous of struvite 
stones and represent up to 15 % of all stones sent for analysis in the Western world (Kramer 
et al., 2000).  Infected stones that contain struvite may originate de novo, but often pre-
existing stones are infected with urea-splitting bacteria (Kramer et al., 2000). There is 
evidence that urinary tract infections caused by urease-producing microorganisms are not 
exclusively related to the formation of struvite stones. Considering this scenario, Proteus 
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mirabilis and struvite stones are the most likely combination. In this case, the risk for 
urosepsis is also patent.  
It has been suggested that some agents named nanobacteria could have a role in the 
development of calcium-based urinary stones (Kajander & Çiftçioglu, 1998); however, this  
is not yet well established (Kramer et al., 2000).  A prevalence of nanobacteria in 0.5 % of 
1000 stones was reported; but nanobacteria are still difficult to identify (Abrahams & Stoller, 
2003). 
3.1.1 Bacterial epidemiology of infected urinary stones 
Urinary stone cultures from fragments retrieved during stone surgery were not a common 
practice until recently. Negative urine culture before urinary surgery was considered safe. In 
general urology it has been a routine to have a negative midstream urine culture before 
doing any endoscopic procedure. Recent studies suggest that voiding urine culture is not 
representative of upper urinary tract pelvis infection or pelvis infected stone bacteria 
(Mariappan & Loong, 2004; Mariappan et al., 2005a). A group of 73 patients with unilateral 
stone-obstructed ureter were treated with ureterorenoscopy and lithotripsy. Midstream 
urine (MSU) sample culture and sensitivity were performed the morning of the endoscopic 
surgery. During the procedure a pelvis urine sample and stone fragments were collected for 
culture and sensitivity with an aseptic technique in a retrograde approach. The authors 
reported that 25 (34.3 %) patients had positive stone culture, 43 (58.9 %) had positive pelvic 
urine and 21 (28.8 %) had positive MSU culture. The most common isolated bacterium was 
E coli. The MSU culture and sensitivity test had 30.2 % sensitivity and 73 % specificity to 
detect pelvic urine culture and sensitivity. The same test had a low positive predictive value 
and negative predictive value in relation to infected pelvic urine (positive predictive value = 
0.62, negative predictive value = 0.42) (Mariappan & Loong, 2004). According to these 
authors, in case of a ureteral obstructive uropathy secondary to a stone, MSU culture and 
sensitivity do not represent infected urine proximal to the obstruction or infected stone. 
Stone components were not analyzed. In conclusion, pelvic urine and stone cultures were 
considered as a more appropriate indicator of upper urinary tract infection. Collection of the 
obstructed urine for culture and sensitivity are recommended.          
Mariappan and colleagues (2005a) studied a group of 54 patients with renal stones who 
were candidates for percutaneous nephrolithotomy (PCNL). Various specimens were 
collected for culture and sensitivity, i.e., MSU sample, bladder urine sample, renal pelvic 
urine sample and crushed stone sample. The objective of the study was to identify the most 
predictive analysis of urosepsis. MSU culture was positive in 11.1 % of cases, stone culture 
was positive in 35.2 % and pelvic urine was positive in 20.4 % of cases.  A wide variety of 
bacteria were isolated. In 37 % of the patients SIRS was developed and 5.5 % experienced 
septic shock. Pelvic urine culture predicted infected stones better than bladder urine culture. 
Patients with infected stones or pelvic urine were found to be at a relative risk for urosepsis 
that was at least four times greater (P = 0.0009). The authors concluded that positive stone 
and pelvic urine are better predictors of potential urosepsis than bladder urine and 
recommend routine collections of these specimens. Stone components were not analyzed. 
The bacterial epidemiology of infected urinary stones also depend on differences in 
geographic area, strains, bacterial resistance, bacterial virulence, exposure to some kind of 
antibiotics and environment.   
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4. Sepsis and urosepsis 
Sepsis is an extreme health condition that threatens life of patients with a high cost for the 
healthcare systems. Reports from US and European surveys have estimated that severe 
sepsis accounts for 2–11 % of all admissions to hospitals or intensive care units. The most 
common microbes isolated from patients with severe sepsis and septic shock are Gram 
negative bacilli (mainly E. coli, Klebsiella species and Pseudomonas aeruginosa) and Gram 
positive cocci (mainly Staphylococci and Streptpcocci spp). Most cases of Gram negative sepsis 
are caused by E coli and Klebsiella species followed by P. aeruginosa. Infections usually occur 
in the lung, abdomen, bloodstream, or urinary tract (Bochud & Calandra, 2003).  In a trial 
performed in an intensive care unit with 142 septic patients having a urinary catheter, 
urosepsis occurred in 15.8 % of them (Rosser et al., 1999). Urosepsis in adults comprises 
approximately 25 % of all sepsis cases and in most cases is due to complicated urinary tract 
infections (Wagenlehner et al., 2007). An incidence of sepsis associated with obstructed 
uropathy and urinary stones treated surgically has also been reported in 1.28 % of cases 
(O'Keeffe et al., 1993).  Rao et al. (1991) found an incidence of septic shock after endoscopic 
manipulation for urinary stone in about 1% of treated patients. Sepsis is an advanced stage 
of uncontrolled systemic inflammatory response syndrome that may turn toward 
irreversible multiple organ failure and death. 
5. Endotoxins and sepsis 
Activation of local and systemic metabolic response to trauma and SIRS is mainly caused by 
activation of IL-1 and tumor necrosis factor-α (TNF-α). It is well established that after 
recognition by cognate receptors, LPS trigger the synthesis and release of pro-inflammatory 
cytokines (Triantafilou & Triantafilou, 2005). Once IL-1 and TNF are secreted, they activate 
several other reactions like complement factors, exacerbating the host inflammatory 
response. As a consequence, MOF or death may result. In vitro human blood monocytes 
produce IL-1 and TNF-α when they are exposed to 25 to 50 pg/mL of endotoxin 
concentration. These endotoxin levels have been reported in the bloodstream of patients 
during septic shock (Dinarello & Cannon, 1993). In a clinical report of 97 consecutive 
patients, 56 % developed sepsis syndrome with about 26 pg/mL  of TNF-α.; 37 % had 20 
pg/mL of IL-1 and in 80 %, 415 pg/mL of IL-6 was detected, including a LPS mean 
concentration of 2.6 endotoxin units (EU)/mL (1 EU/mL = 0.6 ng/mL) (Casey et al., 1993). 
The level of procalcitonin has also been used as a sepsis marker. Another assay with healthy 
volunteers demonstrated elevation of procalcitonin (peak up to about 4 ng/mL at 6 hours) 
after I.V. administration of 4 ng/kg of body weight of endotoxin derived from E coli 
0113:H10:k (Dandona et al., 1994). In a new human model of low grade inflammation, 10 
healthy male subjects were exposed to 3 ng/kg body weight of endotoxin (LPS) derived 
from E. coli in I.V. bolus injection versus I.V. infusion during 4 hours. Results revealed that 
TNF-α, IL-6 and neutrophil response were earlier and more pronounced in the bolus trial, 
suggesting that sudden release of endotoxins triggers faster and higher release of cytokines 
and inflammatory mediators similar to sepsis. Changes in cytokines measured in the 
infusion trial would be a more representative model of human systemic low-grade 
inflammation in chronic disease (Taudorf et al., 2007). 
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6. Infected urinary stones and urosepsis 
In a study on 700 patients, the prevalence of sepsis related with obstructed uropathy and 
urinary stones treated surgically was 1.28 %. These nine patients developed SIRS and sepsis 
during 6 hours postoperative. Although males and females were treated in roughly equal 
proportions, all of the patients who developed severe sepsis were females. There were six 
deaths accounting for 66 % mortality (O'Keeffe et al., 1993). Septic shock following urinary 
stone manipulation was reported with an incidence of 1 % and mortality up to 80 % (Rao et 
al., 1991). 
In an effort to predict septicemia following endourological manipulation for stones in the 
upper urinary tract, 117 patients were studied and classified according to the procedure 
performed (Rao et al., 1991): Percutaneous nephrolithotomy, push-back/push-bang 
procedure, double-J and extracorporeal shock wave lithotripsy (SWL), ureteroscopy, SWL 
alone and only cystoscopy. Blood samples for bacterial culture, endotoxin and tumor 
necrosis factor assay were collected before, at onset, at the end and one hour after 
completing the procedure. Preoperative bacteriuria was present in 35 % of the patients. The 
mean endotoxin level of the entire group —except the cystoscopy group— was 16.2 pg/mL 
(range 11 to 58.3 pg/mL). In the cystoscopy group the mean endotoxin level was 11.7 
pg/mL (range 11 to 12.2 pg/mL). All patients (16) with preoperative endotoxemia had 
increased levels of endotoxin detected in subsequent samples (mean increase 15 pg/mL, 
range 0.5 to 64 pg/mL). The tumor necrosis factor was greater than 15 pg/mL in four cases 
preoperatively. Postoperatively there was elevation of the tumor necrosis factor only in 12 
patients. The authors reported that in case of upper urinary tract manipulation, the risk of 
bacteremia was higher. The risk was greatest after performing the push-back method and 
least after cystoscopy. Combination of preoperative endotoxemia, bacteriuria and the type 
of procedure had 85 % of sensitivity, 84 % of specificity and a positive predictive value of 52 
% for the development of postoperative bacteremia. A total of 41 patients had pyrexia and 
17 patients had rigors and fever 2 to 3 hours after the end of the procedure. No patient 
suffered septic shock; however, this complication developed in a female patient one week 
after percutaneous nephrolithotomy. Serum endotoxin and tumor necrosis factor levels after 
admission of this patient to the intensive care unit were 67.7 pg/mL and 3,827.5 pg/mL, 
respectively (Rao et al., 1991). 
Measurements of LPS were done in 34 renal stones, stored for several months and classified 
as infection stones (16), i.e., struvite and calcium apatite, and non-infection stones (18) 
composed of 50 % calcium oxalate monohydrate (McALeer et al., 2003). All stones were 
weighed, aseptically crushed and aliquots were tested for endotoxins. Four stones of each 
group were aseptically washed and crushed separately. Washed materials and crushed 
stones were processed in MacConkey agar culture to recover bacteria colonizing the stones. 
Mean endotoxin concentration in the infection group was 12,223 ng per gram of stone and 
340.3 ng per gram of stone in the non-infection group. The difference was statistically 
significant (P = 0.001). These results reveal an almost 36 times higher concentration of 
endotoxins in the infection stones. No living bacteria were recovered on the MacConkey 
plates from crushed stones from neither group. The authors concluded that large amounts of 
endotoxins can be found in infected renal stones even months after they were removed from 
the body, and long after viable bacteria could be detected. Furthermore, endotoxin may 
remain after bacteria are no longer viable or have been killed with antibiotic therapy 
(Munford et al., 2009).  Non-infectious stones can also contain endotoxin but in a lower 
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amount (McALeer et al., 2003). McALeer et al. (2002) published a case report of an 8 year old 
boy with a left staghorn calculus treated with holmium laser percutaneous 
nephrolithotripsy (PCNL). Culture specific antibiotic were administered to the patient, both 
orally and intravenously, before, during and after surgery.  Intraoperative fluid and pleural 
fluid cultures (urologists lost percutaneous access from lower pole calyx with 
intraperitoneal extravasation and pleural effusions) were obtained. A urine culture was 
performed before and after stone manipulation. All samples grew a few colonies of Proteus 
mirabilis. Blood cultures were requested but could not be obtained; serum endotoxin results 
could not be obtained either. Two hours after procedure the patient developed disseminated 
intravascular coagulopathy. Twelve hours after stone manipulations the patient died despite 
aggressive support care. Stone composition was apatite (80%) and struvite (10%). Post-
mortem culture of the stone grew several colonies of Proteus mirabilis.  The assay of the stone 
fragments for endotoxin showed concentrations of 285,600 pg per gram, suggesting that 
endotoxemia can induce sepsis syndrome without concomitant bacteremia. The authors 
concluded that the outstanding endotoxin concentration of the renal stone was the source of 
the fatal outcome. 
There is not a general consensus on how to best prevent sepsis in patients undergoing 
surgical treatment of urinary stones. Pre-surgical, trans-surgical and post-surgical strategies 
have been proposed. The combination of multiple factors can prevent, trigger or worsen 
sepsis. For example, control of metabolic or cardiopulmonary diseases is important. 
Although antibiotic prophylaxis does not completely avoid the risk of developing sepsis, it 
is a recommendation for stone surgery according to the American Urological Association 
(AUA) and the European Association of Urology (EAU) guidelines on urinary tract infection 
(Grabe et al., 2011; Wolf et al., 2010). It is suggested to define an antibiotic prophylaxis 
according to local bacterial populations, resistance and antibiotic sensitivity patterns. In a 
prospective controlled trial, Mariappan et al. (2006) and Bag et al. (2011) reported the 
beneficial use of one week ciprofloxacin and nitrofurantoin regimen respectively, before 
percutaneous nephrolithotomy. Furthermore it has been found that renal stones larger than 
20 mm are more likely to be culture positive (Mariappan et al., 2005a; 2005b). Mariappan 
and colleagues (2005a) suggested to obtain pelvic urine and stone samples for culture and 
sensitivity as a routine during surgical stone procedures, with the aim of administering 
proper antibiotic regimen if later urosepsis develops. If an unusual urine sample (i.e. 
turbidity, foully) is obtained, culture and sensitivity is a must. In this case, a nephrostomy 
tube should be left in place and the initial procedure rescheduled until sterile urine is 
confirmed. 
An increase of pressure inside the urinary tract system generated by the irrigation fluid 
results in a potential bacterial and endotoxin translocation into the bloodstream. Auge et al. 
(2004) reported significant reduction in urinary tract pressures using ureteral access sheath 
if working both in distal ureter and inside the renal pelvis. Bacteria and likely endotoxins 
may emerge from several kinds of urinary stones and not exclusively from struvite stones 
(Hugosson et al., 1990; McALeer et al., 2003). In post-surgical stage, the most critical 
evidences of SIRS are during the first 6 hours post-procedure and seem to correlate with 
cytokines release into the bloodstream after endotoxin stimulus (Dandona et al., 1994; 
O'Keeffe et al., 1993; Rao et al., 1991; Taudorf et al., 2007). It has been suggested that if other 
causes of SIRS different than infection (i.e. cardiogenic or pulmonary events, atelectasis, 
hypovolemia and pain) have been ruled out and if SIRS persists, then sepsis could be the 
explanation (Monga, 2005). Close vital signs and symptoms monitoring and high suspicious 
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6. Infected urinary stones and urosepsis 
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group were aseptically washed and crushed separately. Washed materials and crushed 
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have been proposed. The combination of multiple factors can prevent, trigger or worsen 
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tube should be left in place and the initial procedure rescheduled until sterile urine is 
confirmed. 
An increase of pressure inside the urinary tract system generated by the irrigation fluid 
results in a potential bacterial and endotoxin translocation into the bloodstream. Auge et al. 
(2004) reported significant reduction in urinary tract pressures using ureteral access sheath 
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explanation (Monga, 2005). Close vital signs and symptoms monitoring and high suspicious 
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index for sepsis is crucial at this stage. Once urosepsis is diagnosed, an early tissue 
oxygenation, appropriate initial antibiotic therapy, inotropic and nutritional support with 
invasive monitoring at intensive therapy unit is required. Empirical broad-spectrum 
antibiotics regimen is prescribed according to local bacteria, sensitivity and resistance 
patterns. If cultures were performed from bladder urine, pelvis urine or stone sample, direct 
therapy must be installed as soon as results are obtained (Mariappan et al., 2005b). 
Wagenlehner and his group (2007) reported that the treatment of urosepsis comprises four 
major aspects: Early goal-directed therapy, optimal pharmacodynamics exposure to 
antimicrobials both in blood and in the urinary tract, control of complicating factors in the 
urinary tract and specific sepsis therapy.  They considered that interdisciplinary approach is 
necessary to achieve an optimal goal of treatment. At any of these stages, it is very 
important to act as soon as possible if any evidence of initial SIRS and urosepsis is 
addressed. It is necessary to instruct the patient and relatives once discharged from the 
hospital, that if SIRS develops, urgent evaluation in an emergency unit is crucial (Rao et al., 
1991). There is no doubt that further research is required and that several other issues have 
to be considered; however, these do not fall within the scope of this chapter. 
7. Research on bacterial suspensions and extracorporeal shock wave 
lithotripsy 
Several articles report the bactericidal effect of shock waves in vitro; however, results remain 
controversial. Elbers et al. (1988) observed no effect of shock waves on calculi inoculated 
with urease-positive calculogenic bacteria. Bacteria from different genera and species have 
different resistances to physical, chemical and environmental factors; such variations in 
bacteria may determine the degree of susceptibility to shock waves. For instance, we have 
previously found that shock wave-induced cavitation contributes to L. monocytogenes, S. 
typhimurium and E. coli O157:H7 inactivation; however, L. monocytogenes was more sensitive 
to shock waves than E. coli O157:H7 (Alvarez et al., 2004). Kerfoot and colleagues (1992) 
found no effect of shock wave application on S. aureus; however von Eiff et al. (2000) 
reported inactivation of a different strain of the same bacteria.  Similarly, whereas Ohshima 
et al. (1991) observed no effect of shock waves on the viability of E. coli strains DSM 1077 
and JM 109/pKPDH2, Loske et al. (1999) reported inactivation of E. coli strain ATCC 10536. 
Patel et al. (2005) reported no effect of shock waves on a five-stain cocktail of E. coli 
O157:H7, whereas Podolak et al. (2005)  reported shock wave inactivation of a slightly 
different cocktail of the same E. coli. Various shock wave generators were used by these 
authors, which may explain their different results. When performing in vitro exposure of 
bacteria in suspension by shock waves generated with electrohydraulic shock wave 
generators, the electromagnetic radiation produced at the spark gap contributes to 
microorganism inactivation. During SWL this radiation (visible and UV) does not penetrate 
into the calculus. Besides, electromagnetic radiation, compression, tensile stress, and 
cavitation may also damage bacteria. Cavitation is produced by the trailing tensile pulse of 
the shock wave. A cloud of bubbles forms at the focus of every lithotripter after the passage 
of each shock wave. During collapse, they create secondary shock waves, powerful jet blasts 
of fluid (microjets), high temperature gradients, and free radicals (Crum, 1988). If a second 
shock wave is sent during, or shortly after, the stable phase of the bubbles, their collapse can 
be intensified. This technique, referred to as “tandem SWL” has proven to reduce in vivo 
SWL treatment time by 50 % (Fernández et al., 2009). To test the efficiency of tandem shock 
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waves to inactivate bacteria, Alvarez and colleagues (2008) used an experimental 
piezoelectric tandem shock wave generator that generates two shock waves shifted in time. 
The effects of single and tandem shock waves on the viability of L. monocytogenes and E. coli 
O157:H7 suspensions were studied. Tandem shock waves were generated at delays of 450 
and 900 microseconds. No effect on bacteria viability was reported after exposure to 8,000 
single shock waves, but significant bacteria inactivation was reported after 3,400 tandem 
shock waves. The delay yielding the highest inactivation was 900 microseconds.  
8. Research with stone models 
Efforts to develop an ideal stone model have been done worldwide to perform in vitro and 
in vivo fragmentation tests exposing artificial stone models to different lithotripter energy 
settings. To study the inactivation of bacteria by shock waves and the bactericidal effect of 
different intracorporeal lithotripters, we developed an artificial calcium sulphate stone 
model infected homogenously with E. coli, a mixed struvite-calcium sulphate stone infected 
with P. mirabilis and a calcium sulphate stone infected with P. mirabilis. 
8.1 The bactericidal effect of intracorporeal lithotripters 
Only a few authors report results on the interaction of infected urinary stones with 
intracorporeal lithotripters. Artificial kidney stones, infected with E. coli, were manufactured 
by our research group to evaluate the bactericidal effect of shock waves, and the differences 
on intra-bacterial protein release produced by four different intracorporeal lithotripters. The 
stone models were exposed to a holmium laser, an electrohydraulic, a pneumatic and an 
ultrasonic intracorporeal lithotripter using two energy settings. Non-infected control stones 
were manufactured by casting a mixture of gypsum cement, Velmix-stone (Kerr Division of 
Syborn Corp., Romulus, MI, USA) and distilled water in cylindrical molds (diameter = 10 
mm, height = 10 mm). A saline solution containing E. coli was used instead of distilled water 
to manufacture the infected stones.  Cells were obtained in the stationary phase of growth. 
Stones were placed on a copper mesh with 1.8 mm by 1.8 mm openings at the bottom of a 
specially designed lucite test tube. The lucite tube was placed inside a standard laboratory 
test tube, containing 10 mL of saline solution. The tip of the lithotripter was introduced 
inside the lucite tube (see Figure 1). Five infected stones were fragmented with each 
lithotripter at each energy level (low and high) during a fixed time. After treatment all 
remaining stone fragments were crushed with a hand press. The suspension containing 
stone powder and bacteria was centrifuged, serially diluted and incubated on agar plates. 
Viable counts were made by plating on trypticase soy agar supplemented with 0.6 % (w/v) 
yeast extract (TSAY). Bactericidal action was defined as the logarithmic difference of colony 
forming units (CFU) per milliliter between untreated and treated stones. To study the effect 
of the lithotripters on bacteria living outside the stone, an E. coli suspension was exposed to 
the action of each lithotripter, using the same energy settings and exposure times as for 
infected stones. The process was repeated five times for each lithotripter at each energy 
setting. Stone fragmentation of infected stones was repeated as described before, in order to 
measure the release of protein (LPS) as a result of in vitro lithotripsy. After treatment, certain 
amount of the suspension was centrifuged and placed inside a spectrophotometer to 
measure absorbance at 280 nm. Results revealed that the variation in the amount of bacteria 
inside the stones was not significant. Complete inactivation resulted with the 
electrohydraulic lithotripter at both energy levels. No difference was observed between 
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index for sepsis is crucial at this stage. Once urosepsis is diagnosed, an early tissue 
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typhimurium and E. coli O157:H7 inactivation; however, L. monocytogenes was more sensitive 
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inactivation obtained with the other lithotripters at their low energy settings. Increasing the 
energy resulted in higher bacteria inactivation for the laser, pneumatic and ultrasonic 
lithotripter. The laser lithotripter produced the lowest bacteria inactivation. Inactivation 
increased as the energy setting of the laser, pneumatic and ultrasonic lithotripter was 
changed from low to high. No bacteria inactivation was observed using the pneumatic 
lithotripter in an E. coli suspension alone. No viable bacteria could be observed after using 
the laser, the electrohydraulic and the ultrasonic lithotripter in the infected suspension 
(without stone). Maximum protein release occurred at low energy with the electrohydraulic 
lithotripter and protein was denaturized by this lithotripter at the high energy setting. No 
difference was observed between the amount of protein released with the laser, the 
pneumatic, and the ultrasonic lithotripters at both energy levels. The four lithotripters 
inactivated more than 99 % of the initial amount of bacteria; however, this antibacterial 
effect does not necessarily indicate that lithotripters sterilize stone fragments. The presence 
of free endotoxins liberated from bacteria after lithotripsy may increase the risk of sepsis. 
These findings could explain local and systemic inflammation response by the immune 
system of some patients developing in SIRS and sepsis (Gutiérrez et al., 2008). 
 
 
Fig. 1. Photograph of the special lucite test tube with copper mesh bottom (not seen) placed 
inside a standard glass laboratory test tube during in vitro fragmentation of an artificial 
infected kidney stone with a laser lithotripter.  
Our group also studied the effect of the four above-mentioned intracorporeal lithotripters 
on the bacterial inactivation of artificial struvite stones inoculated with Proteus mirabilis. 
Again two energy settings were tested with each lithotripter, with exception of the 
pneumatic lithotripter, which was used only at one intensity. Calcium sulphate stones and 
struvite-gypsum stones were manufactured and homogeneously infected with P. mirabilis. 
Details on the methodology of producing infected stones can be found in the literature 
(Gutiérrez et al., 2008; Gómez-Núñez et al., 2009). Infected calcium sulphate and infected 
struvite-gypsum stones were exposed to each device at each intensity level until complete 
fragmentation. The treatment time was dependant on the lithotripter and the intensity level. 
After in vitro lithotripsy, the suspension containing stone debris and P. mirabilis was diluted 
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and incubated on agar plates. A sham group of non-treated infected stones was crushed 
with a hand press to determine the amount of bacteria surviving inside the artificial stones. 
The whole experiment was repeated three times. The initial viable count in the sham group 
was about 6.02 log10 CFU/mL. Results revealed that all lithotripters inactivated a high 
percentage of P. mirabilis. No statistically significant difference was observed between 
calcium sulphate and infected struvite-gypsum stones (Gómez-Núñez et al., 2009). 
Prabakharan and colleagues (1999) reported an in vitro assay using 46 “natural” struvite 
stone models (fragments), sterilized in an autoclave and reinfected with P. mirabilis, coming 
from patients treated for urinary stones. The stones were exposed to shock waves generated 
with an extracorporeal lithotripter, as well as to the action of an ultrasonic, an 
electrohydraulic, a pneumatic, and a Holium:YAG laser intracorporeal lithotripter. No 
bacterial inactivation was observed, except for the laser intracorporeal lithotripter. A 
possible lack of this trial could be the variability of stone shape, composition, and non-
homogeneous bacteria colonization of the stone. 
In conclusion, it seems that the stone material plays a minor role regarding bacterial 
inactivation due to intracorporeal lithotripsy. Furthermore, according to our results, 
intracorporeal lithotripters are very harmful to bacteria; however, whether bacterial 
destruction is desirable or not is still unknown.  
8.2 The bactericidal effect of extracorporeal lithotripters 
A reduction in bacteriuria and resolution of urinary tract infection after SWL has been 
reported by several authors (Beck & Riehle, 1991; Gerdesmeyer et al., 2005; Michaels et al., 
1988; Pode et al., 1988); however, it is not known if the stone protects bacteria or if other 
mechanisms, such as shear, contribute to the bactericidal effect of shock waves. To answer 
these questions, infected stones were exposed in vitro to shock waves from both an 
electrohydraulic and a piezoelectric lithotripter.  Energy comparable to that used in SWL 
was used, so that the stress on the bacteria was similar to that experienced by bacteria living 
inside calculi during shock wave treatment. Two types of artificial kidney stones (soft and 
hard) were manufactured by mixing different amounts of gypsum cement and Velmix-
stone, as explained in the previous section. In this case the length and diameter of the 
models were about 7 mm and 8 mm, respectively. Salmonella enterica serovar typhimurium in 
the stationary phase of growth was used to inoculate the stones. Stones to be treated were 
placed inside a translucent polypropylene bag, filled with deionized water, heat sealed, and 
centered at the lithotripter focus. All fragments from shock wave treated stones, as well as a 
set of intact control stones, were completely crushed using a hand press until stone powder 
was obtained. All bags were opened and dilutions of the suspension containing stone 
powder and bacteria were inoculated on TSAY plates and incubated at 35 C. About 29 % of 
all bacteria were inactivated with the piezoelectric lithotripter and 14 % with the 
electrohydraulic lithotripter. This study demonstrated that the bactericidal action of shock 
waves is weaker inside the stones than in the fluid outside them (Quintero et al., 2008). 
Whether it is desirable for a lithotripter to inactivate instead of destroying bacteria is still to 
be answered. 
9. Conclusions 
Sepsis is a serious health condition with high mortality and cost. Advances in the 
manufacture of standardized infected stone models and in vitro assays could help to better 
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understand the pathophysiology of sepsis associated to urinary tract infection alone and 
UTIs with infected stones. In vitro fragmentation of artificial stones could also help to 
understand and prevent the pathophysiology and phases of Gram negative sepsis. 
According to our initial results, living bacteria infecting urinary stones release endotoxins as 
part of their metabolic activity or as a consequence of bacteria lysis during intracorporeal 
and extracorporeal lithotripsy. Bacteria fragments could be a source of endotoxin even in the 
case of urine voiding and urine pelvis negative cultures. Further research related with 
release of LPS during lithotripsy and its relation with triggering sepsis is urgently needed. 
Absorption of LPS into the bloodstream by reflux due to open pyelolymphatic and 
pyelovenous channels during obstructive uropathy, bacterial translocation, interaction with 
lithotripters, increased irrigation pressure during endoscopic surgery, and rupture of the 
hemato-urinary barrier (microtrauma) should be studied. On the other hand, recent 
investigations (Soriano et al., 2005; Opal, 2003) have been revealing valuable information 
about sepsis mediators, such as cytokines, including tumor necrosis factor (TNF), 
interferons, complement factors or nitric oxide, anti-LPS host hydrolases, and bacterial 
factors. Translational studies focusing clinical strategies based on benchmark discoveries 
regarding LPS-triggered toxemia therefore represent a major task for the urologist. The main 




 During sepsis, a 25 - 50 pg/mL LPS concentration has 
been reported in the bloodstream.  
 LPS concentrations of up to 285,600 pg per gram stone 
have been reported in a fatal case of urosepsis. 
 Release of LPS has been observed after in vitro 
lithotripsy to infected artificial kidney stones. 
 In vitro application of conventional single-pulse shock 
waves revealed a limited bactericidal effect against 
bacteria in suspension and bacteria inoculated inside 
artificial stones. 
 In vitro application of tandem shock waves to bacterial 
suspensions inactivates bacteria efficiently. 
 In vitro intracorporeal lithotripsy revealed an 
outstanding effect against bacteria in artificial infected 
urinary stones. 
 The bactericidal effect of both extra- and 
intracorporeal lithotripsy should be studied carefully 
due the possible release of large amounts of LPS.     
 Under certain circumstances, this initial evidence 
could explain triggering of SIRS, urosepsis and MOF. 
 
Table 1. Infected Urinary Stones, Endotoxins and Urosepsis. LPS. Lipopolysaccharide; SWL. 
Extracorporeal shock wave lithotripsy; SIRS. Systemic inflammatory response syndrome; 
MOF. Multiple organ failure.  
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Chronic Prostatitis / Chronic Pelvic  
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1. Introduction 
Chronic prostatitis (CP) refers to "inflammation" of the prostate and is thought to be related 
to either an acute or chronic infection of the prostate gland. It is important to distinguish 
chronic prostatitis / chronic pelvic pain syndrome (CPPS) from other forms of infections of 
the prostate gland which include chronic bacterial prostatitis and acute bacterial prostatitis 
[1]. The aetiology, pathogenesis, and optimal treatment of CP/CPPS continue to be 
evaluated. In addition to an infective and inflammatory pathogenesis hypothesized for 
patients with CP/CPPS, it is important to highlight a variable degree of neuropathic pain. 
We present the current definition, pathogenesis and new treatment methodologies being 
developed to treat CP/CPPS, which continue to be a challenging clinical entity to treat 
worldwide by Urologist. 
2. Definition and classification 
The European Urology Association [EAU] 2010 guidelines use the term "Painful Prostate 
Syndrome (PPS)" instead of the initial terminology by the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK) of CP/CPPS. PPS or CP/CPSS is defined as PPS is 
persistent discomfort or pain in the pelvic region with sterile specimen cultures and either 
significant or insignificant white blood cell counts in prostate-specific specimens (i.e., 
semen, expressed prostatic secretions, and urine collected after prostate massage) [2]. As 
there are no clinically relevant diagnostic or therapeutic consequences arising from 
differentiating between inflammatory and noninflammatory subtypes, CP/CPPS can be 
regarded as one entity. 
The National Institute of Health (NIH) International Collaborative Prostatitis Network 
developed a prostatitis classification system in 1995, which termed CP/CPPS as ‘Category 
III prostatitis’ defined by its abacterial nature and occurrence with or without prostatic 
inflammation [3, 4]. A summary of this classification is presented in Table 1. 
As per the NIH classification in actual clinical practice, both Type I (Acute Bacterial 
Prostatitis) and Type II (Chronic Bacterial Prostatitis) only account for approximately 5-10% 
of patients [5]. Acute prostatitis is characterized by a sudden onset of fever and dysuria. 
Chronic prostatitis is clinically characterized by recurrent episodes associated with recurrent 
same organism. Patients tend to be asymptomatic in-between episodes of infections.    
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NIH Consensus Clinical descriptor Clinical details 
Type I  Acute bacterial prostatitis 
Severe symptoms of prostatitis, 
symptoms of systemic infection and 
acute bacterial urinary tract infection 
with bacteriuria and pyuria  
Type II Chronic bacterial prostatitis 
Chronic bacterial infection of the 
prostate gland with or without 
symptoms of prostatitis, usually with 
recurrent UTI's cause by the same 
bacteria 
Type III A Inflammatory subtype 
a 
(CP/CPPS) 
Characterized by chronic pelvic pain 
and possibly voiding symptoms with 
no bacterial infection; leucocytes 
present in expressed prostatic 
secretions or semen 
Type III B Non-Inflammatory subtype  
Characterized by chronic pelvic pain 
and possibly voiding symptoms with 
no bacterial infection; leukocytes 
present in expressed prostatic 
secretion or semen 
Type IV Asymptomatic Inflammatory prostatitis  
Evidence of inflammation without 
symptoms of prostatitis or UTI 
aWBC semen > 106/ml, WBC EPS > 5 p hpf, WBC VB3 > 10 p hpf 
Table 1. NIH classification of prostatitis syndromes. 
Type III is classified as CP/CPPS and PPS as per the latest EAU guidelines. Patients within 
this category constitute about 90% of cases and it is hence very important to understand the 
definition of Type IIIA and Type IIIB categories. Type IIIA refers to the presence of white 
blood cells (WBC) in semen, after a prostate massage urine specimen (VB3) or expressed 
prostatic secretion (EPS). Type IIIB refers to patients with pelvic pain with no evidence of 
inflammation on semen, VB3 or EPS. 
Type IV patients are asymptomatic  and are commonly diagnosed during work up for 
infertility and lower urinary tract symptoms  (LUTS) where they have an elevated PSA. In 
the MTOPS study, there is a strong link between prostatic inflammation to increased LUTS 
or the risk of acute urinary retention in a cohort of BPH subjects [6]. This may suggest that 
Type IV prostatitis may not be "asymptomatic" after all.  
3. Epidemiology 
Prostatitis is a significant health problem with prevalence rates of 11-16%.[7,8] More than 2 
million consultations for prostatitis are required every year in the United States[9]. 
Prostatitis has a significant impact on the quality of life (QoL) comparable to active Crohn's 
disease or a recent myocardial infarction.[10] with up to 50% of men affected by it at some 
stage of their lives.[11,12]. 
In a large recent review by Krieger et al [13], the prevalence of prostatitis symptoms in 
10,617 men was 8.2% (873). Amongst these patients the prevalence of prostatitis symptoms 
ranged from 2.2% to 9.7%, with a median rate of 8.7%.  
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Prostatitis-like symptoms result in a substantial number of physician visits. Sixty percent of 
participants with prostatitis-like symptoms seek medical help [13, 14]. The odds of a 
prostatitis diagnosis is 13-fold greater during visits to urologists than during visits to 
primary care physicians [15].  Additionally, patients with prostatitis tend to receive 
antimicrobials therapy in 45% of cases compared to 27% of the time for patients with no 
genitourinary symptoms [15]. Men with prostatitis symptoms appear to be at increased risk 
for persistent symptoms and for recurrent episodes.  Although the pathogenesis of prostates 
is still being evaluated, it is common in clinical practice to see patients recurrently with 
acute episodes of prostatitis with a background of chronic prostatitis. These patients hence 
have a substantially higher cumulative probability of subsequent episodes of prostatitis [16]. 
4. Pathogenesis 
The aetiology and pathophysiology of CP/CPPS remains a mystery, although central 
neurological mechanisms probably play a role. Patients with PPS show no evidence of 
infection; they do not have urethritis, urogenital cancer, urethral stricture, or neurologic 
disease involving the bladder, and they do not exhibit any overt renal tract disease [17]. 
Hence, the exact aetiology of CP/ CPPS is unknown. The main factor that continues to be 
evaluated in patients with CP / CPPS is whether infection and inflammation are responsible 
for the clinical symptomology of these patients. The difficulty in pinpointing etiologic 
mechanisms and obtaining efficacious therapies is probably due to the heterogeneity of 
factors that contribute to CP/CPPS. Despite this complexity, most experts agree that pain is 
the defining feature of the condition.  
The initial concept of infection and inflammation arose when True et al [18], analyzed the 
outcome of Prostate histopathology in 368 biopsies from 97 patients with the CP/CPPS. In 
these patients prostatic inflammation was detected in only 33% of patients, including 29% 
with mild (less than 10 leukocytes per 1 mm. field) and 4% with moderate (between 10 and 
200) or severe (more than 200) infiltrate. Of the 3 patients with moderate inflammation 1 had 
glandular, 1 periglandular and 3 multifocal or diffuse distribution of leukocytes in the 
interstitium. Although 33% of patients had inflammation on prostate biopsies, only 5% of 97 
patients had moderate to severe inflammation. This study questioned the assocaition and 
role of inflammation in the pathogenesis of CP/CPPS. Despite this CP/CPPS continues to be 
diagnosed on the basis of symptoms. It is diagnosed from a history of persistent 
genitourinary pain and an absence of other lower urinary tract pathologies. The severity of 
disease, its progression and treatment response can be assessed only by means of a 
validated symptom-scoring instrument [19, 20]. 
Patients with CP/CPPS are diagnosed traditionally using the gold-standard four-glass test 
for bacterial localisation [21]. However, as this test is cumbersome to perform and hence the 
diagnostic efficiency may be enhanced cost effectively by a simple screening procedure, that 
is, the two-glass test, or by pre- and post-massage test (PPMT) [22], with PPMT able to 
indicate the correct diagnosis in >96% of patients [23]. These tests use the concept of White 
blood cells (WBC) as a marker on inflammation. White blood cells can be found in seminal 
plasma and prostatic fluid of asymptomatic patients and in patients with pelvic pain [24]. 
Schaeffer et al [24], examined whether leukocytes and bacteria correlate with symptom 
severity in men with chronic prostatitis/chronic pelvic pain syndrome. In this landmark 
publication, 488 men were classified into the CP/CPPS criteria NIH criteria. Participants 
were classified as category IIIa based on WBC counts of 5 or more, or 10 or more (5+, 10+) in 
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the expressed prostatic secretion, or 1+ or 5+ either in the post-expressed prostatic secretion 
urine (voided urine 3) or semen. Uropathogens were classified as localizing if the designated 
bacterial species were absent in voided urine 1 and voided urine 2 but present in expressed 
prostatic secretion, voided urine 3 or semen, or present in expressed prostatic secretion, 
voided urine 3 or semen at 2 log concentrations higher than at voided urine 1 or 2. 
Associations between symptoms and inflammation and infection were investigated using 
generalized Mantel-Haenszel methods. Of all participants 50% had urethral leukocytes and 
of 397 with expressed prostatic secretion samples 194 (49%) and 122 (31%) had 5+ or 10+ 
WBCs in expressed prostatic secretion, respectively. The prevalence of category IIIa ranged 
from 90% to 54%, depending on the composite set of cut points. None of the index measures 
were statistically different (p >0.10) for selected leukocytosis subgroups. Based on prostate 
and semen cultures, 37 of 488 men (8%) had at least 1 localizing uropathogen. None of the 
index measures were statistically different (p >0.10) for selected bacterial culture subgroups. 
The authors thus concluded that men with chronic prostatitis routinely receive anti-
inflammatory and antimicrobial therapy despite leukocytes and bacterial counts which do 
not correlate with severity of symptoms. These findings suggest that factors other than 
leukocytes and bacteria also contribute to symptoms associated with chronic pelvic pain 
syndrome.  
Based on current studies the initiator of the inflammatory process in CP / CPPS within the 
prostate is thought to be a local infection, chemical irritation, dysfunctional voiding, 
intraductal reflux, neuromuscular disturbances or an immunological process. Regardless of 
the triggering factor, the resultant inflammatory process causes tissue oedema and increased 
intra-prostatic pressure leading to local hypoxia and varied mediator-induced tissue 
damage. This leads to altered neurotransmission in sensory nerve fibres thereby resulting in 
the pain and other symptoms associated with the condition [25]. We now present each 
aetiology associated with CP / CPPS. 
The common etiologies associated with CP / CPPS include 
- 4A. Infection  
- 4B. Inflammation and Autoimmunity 
- 4C. Neurological  
- 4E. Psychological  
- 4F. Additional Conditions 
4A. Infection 
An acute episode of prostatitis and recurrent episodes of chronic prostatitis can be caused 
by organisms that are commonly responsible for Urinary Tract Infections (UTI). The 
majority of organisms isolated within both patients groups include Escherichia coli in the 
community. Additionally bacteria responsible for both acute and chronic prostatitis include 
Pseudomonas and Streptococcus faecalis. The symptoms of CP / CPPS are identical to those of 
prostatic infection. Pontari et al [26], conducted a questionnaire to evaluate the 
demographic, behavioural, clinical and medical history characteristics of men with chronic 
prostatitis/chronic pelvic pain syndrome (CP/CPPS) and asymptomatic controls. In their 
study they analyzed the outcome of 463 men with CP/CPPS and 121 asymptomatic age-
matched controls. Interestingly, compared to controls, men with CP/CPPS reported a 
significantly greater lifetime prevalence of nonspecific urethritis (12% vs 4%, P = 0.008), 
cardiovascular disease (11% vs 2%, P = 0.004), neurological disease (41% vs 14%, P < 0.001), 
psychiatric conditions (29% vs 11%, P < 0.001), and haematopoietic, lymphatic or infectious 
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disease (41% vs 20%, P < 0.001). Hence, the outcome of this publication suggested that a 
range of self-reported medical conditions are associated with CP/CPPS with a higher 
proportion reporting a history of nonspecific uretheritis caused due to gonorrhoeal, 
trichomonal and henital herpetic infections. It was also suggested that rare episodes of 
recurrent cystitis in young males is caused due to secondary infections of the prostatic ducts. 
An important factor associated with recurrent infections in CP is ascending urethral 
infection and reflux of urine into ejaculatory and prostatic ducts [27]. Bacteria can be 
isolated preferentially from an expressed prostatic secretion (EPS) or a post-prostatic 
massage urine specimen rather than from the mid-stream urine (MSU) sample or can be 
demonstrated on the prostatic biopsy specimen [28,29]. The concept of intraprostatic reflux 
was demonstrated by Kirby et al [30]. In this publication the authors injected carbon 
particles into the bladders of men about to undergo a transurethral resection of prostate 
(TURP). On histological analysis of the resected TURP specimen, carbon particles could be 
demonstrated which suggested a intraprostatic reflux.   
Blacklock et al [31], noted that some patients with CP / CPPS had some pathogens identified 
in vaginal cultures of their sexual partners. Magri et al [32], evaluated 55 symptomatic 
patients with CP / CPPS they were subjected to segmented tests to localise Chlamydia 
trachomatis in first voided urine (VB1), prostatic secretions (EPS), post-massage voided 
(VB3) or semen specimens. Patients were divided in three treatment groups: the 'urethral 
involvement' group (VB1 positive, EPS/VB3/Semen negative) was treated with 500 mg 
day(-1) azithromycin for 3 days. The 'prostatitis' group (VB1 negative, EPS/VB3/semen 
positive) with 4-week levofloxacin-azithromycin combination. A third group, 'Urethral and 
Prostate group' (VB1, EPS/VB3/semen positive) received both treatments in sequence. In 
patients prosatitis, eradication of Chlamydia trachomatis was paralleled by marked, 
sustained symptom improvement and by significant decrease of serum prostate-specific 
antigen (PSA) levels. Compared with Urethral  patients, undergoing rapid regression of 
symptoms related to painful micturition after short-term azithromycin, U+P patients 
showed symptom and pathogen persistence in VB3/EPS/semen and required additional 
treatment with 4-week levofloxacin-azithromycin to achieve pathogen eradication, symptom 
regression, and decrease of PSA. The results from this publication support a causative role 
of Chlamydia trachomatis in CP / CPPS. 
Mardh et al [33], evaluated the role of Chlamydia trachomatis in non-acute prostatitis was 
investigated by cultural and serological techniques in a study of 53 adult males. C. 
trachomatis was isolated from the urethra of only one of the 53 patients and from none of 
the 28 specimens of prostatic fluid from the same patients. By means of a modified 
microimmunofluorescent test, serum chlamydial IgG antibodies at a titre of 1/64 or greater, 
or IgM antibodies at a titre of 1/8 or greater, or both were detected in six of the patients, 
suggesting a recent or current chlamydial infection, while IgG or IgA antibodies at a titre of 
1/8 or greater were detected in the specimens of prostatic fluid from two of the 28 men 
studied. In the seven patients with evidence of chlamydial infection, as well as in a further 
13 of the 53 patients studied, the presenting symptoms suggested non-gonococcal urethritis 
(NGU) rather than prostatitis. Thus in this study, C. trachomatis would appear to play a 
minor aetiological role, if any, in CP / CPPS. 
Based on current literature and evidence, there continues to be inconsistencies in the 
response to antibacterial treatment and the inability to consistently isolate any pathogenic 
organisms in the appropriate specimens in patients with CP / CPPS.  
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the expressed prostatic secretion, or 1+ or 5+ either in the post-expressed prostatic secretion 
urine (voided urine 3) or semen. Uropathogens were classified as localizing if the designated 
bacterial species were absent in voided urine 1 and voided urine 2 but present in expressed 
prostatic secretion, voided urine 3 or semen, or present in expressed prostatic secretion, 
voided urine 3 or semen at 2 log concentrations higher than at voided urine 1 or 2. 
Associations between symptoms and inflammation and infection were investigated using 
generalized Mantel-Haenszel methods. Of all participants 50% had urethral leukocytes and 
of 397 with expressed prostatic secretion samples 194 (49%) and 122 (31%) had 5+ or 10+ 
WBCs in expressed prostatic secretion, respectively. The prevalence of category IIIa ranged 
from 90% to 54%, depending on the composite set of cut points. None of the index measures 
were statistically different (p >0.10) for selected leukocytosis subgroups. Based on prostate 
and semen cultures, 37 of 488 men (8%) had at least 1 localizing uropathogen. None of the 
index measures were statistically different (p >0.10) for selected bacterial culture subgroups. 
The authors thus concluded that men with chronic prostatitis routinely receive anti-
inflammatory and antimicrobial therapy despite leukocytes and bacterial counts which do 
not correlate with severity of symptoms. These findings suggest that factors other than 
leukocytes and bacteria also contribute to symptoms associated with chronic pelvic pain 
syndrome.  
Based on current studies the initiator of the inflammatory process in CP / CPPS within the 
prostate is thought to be a local infection, chemical irritation, dysfunctional voiding, 
intraductal reflux, neuromuscular disturbances or an immunological process. Regardless of 
the triggering factor, the resultant inflammatory process causes tissue oedema and increased 
intra-prostatic pressure leading to local hypoxia and varied mediator-induced tissue 
damage. This leads to altered neurotransmission in sensory nerve fibres thereby resulting in 
the pain and other symptoms associated with the condition [25]. We now present each 
aetiology associated with CP / CPPS. 
The common etiologies associated with CP / CPPS include 
- 4A. Infection  
- 4B. Inflammation and Autoimmunity 
- 4C. Neurological  
- 4E. Psychological  
- 4F. Additional Conditions 
4A. Infection 
An acute episode of prostatitis and recurrent episodes of chronic prostatitis can be caused 
by organisms that are commonly responsible for Urinary Tract Infections (UTI). The 
majority of organisms isolated within both patients groups include Escherichia coli in the 
community. Additionally bacteria responsible for both acute and chronic prostatitis include 
Pseudomonas and Streptococcus faecalis. The symptoms of CP / CPPS are identical to those of 
prostatic infection. Pontari et al [26], conducted a questionnaire to evaluate the 
demographic, behavioural, clinical and medical history characteristics of men with chronic 
prostatitis/chronic pelvic pain syndrome (CP/CPPS) and asymptomatic controls. In their 
study they analyzed the outcome of 463 men with CP/CPPS and 121 asymptomatic age-
matched controls. Interestingly, compared to controls, men with CP/CPPS reported a 
significantly greater lifetime prevalence of nonspecific urethritis (12% vs 4%, P = 0.008), 
cardiovascular disease (11% vs 2%, P = 0.004), neurological disease (41% vs 14%, P < 0.001), 
psychiatric conditions (29% vs 11%, P < 0.001), and haematopoietic, lymphatic or infectious 
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disease (41% vs 20%, P < 0.001). Hence, the outcome of this publication suggested that a 
range of self-reported medical conditions are associated with CP/CPPS with a higher 
proportion reporting a history of nonspecific uretheritis caused due to gonorrhoeal, 
trichomonal and henital herpetic infections. It was also suggested that rare episodes of 
recurrent cystitis in young males is caused due to secondary infections of the prostatic ducts. 
An important factor associated with recurrent infections in CP is ascending urethral 
infection and reflux of urine into ejaculatory and prostatic ducts [27]. Bacteria can be 
isolated preferentially from an expressed prostatic secretion (EPS) or a post-prostatic 
massage urine specimen rather than from the mid-stream urine (MSU) sample or can be 
demonstrated on the prostatic biopsy specimen [28,29]. The concept of intraprostatic reflux 
was demonstrated by Kirby et al [30]. In this publication the authors injected carbon 
particles into the bladders of men about to undergo a transurethral resection of prostate 
(TURP). On histological analysis of the resected TURP specimen, carbon particles could be 
demonstrated which suggested a intraprostatic reflux.   
Blacklock et al [31], noted that some patients with CP / CPPS had some pathogens identified 
in vaginal cultures of their sexual partners. Magri et al [32], evaluated 55 symptomatic 
patients with CP / CPPS they were subjected to segmented tests to localise Chlamydia 
trachomatis in first voided urine (VB1), prostatic secretions (EPS), post-massage voided 
(VB3) or semen specimens. Patients were divided in three treatment groups: the 'urethral 
involvement' group (VB1 positive, EPS/VB3/Semen negative) was treated with 500 mg 
day(-1) azithromycin for 3 days. The 'prostatitis' group (VB1 negative, EPS/VB3/semen 
positive) with 4-week levofloxacin-azithromycin combination. A third group, 'Urethral and 
Prostate group' (VB1, EPS/VB3/semen positive) received both treatments in sequence. In 
patients prosatitis, eradication of Chlamydia trachomatis was paralleled by marked, 
sustained symptom improvement and by significant decrease of serum prostate-specific 
antigen (PSA) levels. Compared with Urethral  patients, undergoing rapid regression of 
symptoms related to painful micturition after short-term azithromycin, U+P patients 
showed symptom and pathogen persistence in VB3/EPS/semen and required additional 
treatment with 4-week levofloxacin-azithromycin to achieve pathogen eradication, symptom 
regression, and decrease of PSA. The results from this publication support a causative role 
of Chlamydia trachomatis in CP / CPPS. 
Mardh et al [33], evaluated the role of Chlamydia trachomatis in non-acute prostatitis was 
investigated by cultural and serological techniques in a study of 53 adult males. C. 
trachomatis was isolated from the urethra of only one of the 53 patients and from none of 
the 28 specimens of prostatic fluid from the same patients. By means of a modified 
microimmunofluorescent test, serum chlamydial IgG antibodies at a titre of 1/64 or greater, 
or IgM antibodies at a titre of 1/8 or greater, or both were detected in six of the patients, 
suggesting a recent or current chlamydial infection, while IgG or IgA antibodies at a titre of 
1/8 or greater were detected in the specimens of prostatic fluid from two of the 28 men 
studied. In the seven patients with evidence of chlamydial infection, as well as in a further 
13 of the 53 patients studied, the presenting symptoms suggested non-gonococcal urethritis 
(NGU) rather than prostatitis. Thus in this study, C. trachomatis would appear to play a 
minor aetiological role, if any, in CP / CPPS. 
Based on current literature and evidence, there continues to be inconsistencies in the 
response to antibacterial treatment and the inability to consistently isolate any pathogenic 
organisms in the appropriate specimens in patients with CP / CPPS.  
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4B. Inflammation and autoimmunity 
Both acute and chronic inflammation is now thought to be associated with CP / CPPS. The 
core of Inflammation lies with the presence of both pro and anti-inflammatory cytokines 
present with the prostate in comparison to normal asymptomatic patients. The main 
cytokines linked with CP / CPPS are Interleukin - 8 [34], Interleukin - 10 [35] and Tumour 
Necrosis Factor - alpha (TNF-α) [36].  
The concentration of citric acid is a significant parameter of prostate gland function [37]. 
Substantial amounts of citric acid are produced and stored in the gland. A decrease in its 
concentration is observed in cases of inflammation or cancer of the prostate gland [38]. In 
addition to citric acid there is now a new interest in the evaluation of polymorphonuclear 
(PMN) leukocytes and PMN elastase levels in patients with PC / CPPS. Zdrodowska-
Stefanow et al [39], evaluated PMN leukocytes , PMN elastase and citric acid concentrations 
in chronic prostatitis patients regardless of aetiology and in a parallel group with C 
trachomatis infection. In this paper the analysis of expressed prostatic secretions (EPC) of 46 
patients with chronic prostatitis was evaluated for leukocyte count, PMN elastase (ELISA) 
and citric acid concentrations. All patients have an additional analysis for C. trachomatis 
infection (ligase chain reaction). Analysis confirmed increased PMN cell counts (≥10 per 
high-power field) in 73.9% of patients and increased PMN elastase concentration (<250 
ng/ml) in 78.3%. In 44.4% of the patients the elastase concentration indicated moderate 
(250–1000 ng/ml) and in 55.6% acute infection (≥1000 ng/ml). Decreased citric acid 
concentration (<18.12 mg/ml) in the EPS was found in 65.2% of the men. C. trachomatis 
prostate infection was detected in 17.4% of the patients and all of these men had higher 
inflammation parameters and lower citric acid concentrations. The authors concluded that 
CP /CPSS associated with C. trachomatis infection were accompanied by an increase in 
inflammation markers and a decrease in citric acid concentration.  
Autoimmunity is characterized by recognition of self by the immune system with the 
resulting immune response destroying or damaging normal cells and tissues. T lymphocytes 
are principally responsible for the recognition of antigens by the immune system. CD4 T 
cells recognize processed peptide antigens in association with the MHC class II molecule 
and play a significant role in the effector function of CD8 T-cells and B-cell activation. In 
previous work we have shown that soluble components in normal semen can be recognized 
by CD4 T lymphocytes in men with CP/CPPS [40, 41]. The current concept of autoimmunity 
is best recognized in patients with non-specific granulomatous prostatitis (NSGP). Within 
this group of patients it is the HLA class II allele DRB1*1501 in Caucasian men is associated 
with CP/CPPS [42].  
In a landmark paper evaluating the link between autoimmunity and CP / CPPS, 
Kouiavskaia et al [40], aimed to assess whether T cells from a group of men with CP/CPPS 
would recognize peptides derived from the normal self prostatic proteins prostate specific 
antigen (PSA) and prostatic acid phosphatase (PAP).  The authors used purified CD4 T cells 
from the peripheral blood of 31 patients with CP/CPPS and from the buffy coat preparation 
of 27 normal male blood donors that were stimulated in vitro with a panel of immunogenic 
peptides from PSA and PAP and assayed for reactivity with the peptides by IFN-γ ELISPOT 
assay. The data from this study suggested that the peptides such as PAP133-152, PAP173-192, 
PSA171-190, PSA221-240 represent promiscuous epitopes able to be presented by different HLA-
DR alleles. High level of the peptides promiscuity was supported by the results of both 
analysis of MHC class II allele expression by the individuals responding to the peptides in 
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the IFN-γ ELISPOT assay and analysis of the direct binding of the peptides to MHC class II 
molecules. In vitro functional assays showed that autoreactive T cells specific for the 
peptides are present and can be activated in the patients with CP/CPPS and normal male 
blood donors, identified PAP as a possible target protein for autoimmune reactivity in the 
patients with CP/CPPS and demonstrated that autoimmune reactions to the 
immunodominant peptide PAP173-192 might be involved in the disease development. The 
data supported autoimmunity as a potential aetiology for CP/CPPS in some patients and 
suggest that immunosuppressive therapies might logically be tested in the treatment of this 
complex and frustrating disorder. The authors found that Peptide PAP173-192 was more 
frequently recognized by CD4 T cells from the patients with CP/CPPS compared to the 
healthy donors. Peptide reactivity was more commonly observed in cases compared to 
normal male blood donors for any PSA peptide or any tested peptides. This study 
demonstrated a strong link between autoimmunity and CP / CPPS in that CD4 T cells from 
patients with CP/CPPS had a higher frequency of recognition of the self prostatic proteins 
PAP and PSA compared to normal male blood donors.   
4C. Neurological  
CP/CPPS is associated with the patient developing pain and this suggests a possible 
neurological link with the diagnosis. The pain perceived by these patients can be a 
combination of either local pain within the pelvis or more central pain. Hence, one further 
hypothesis in the development of CP/CPPS includes dysfunction of the nervous system that 
attributes to the patients symptoms. Despite attributing a strong neurological link few of the 
agents that have been studied in clinical trials target pain pathways directly, particularly 
those in the central nervous system (CNS). Recent animal model studies on retrograde 
labelling of the prostate and pelvic floor indicates that there are double labelled cells in the 
dorsal root ganglion in the lumbar and sacral cord [42]. Patients with CPPS are thought to 
have an altered sensation of the perineum in comparison to control patients without 
CP/CPPS. The mechanism of this 'altered' innervations is poorly understood and is thought 
to be related to reflex sympathetic dystrophy of the perineum and pelvic floor [43-45]. 
4E. Psychological  
Psychological stress is also commonly associated with the exacerbation of  symptoms related 
to CP/CPPS. The initial evidence of a strong psychological link was after Wallner et al [46], 
collected data from 703 men enrolled in the Flint Men’s Health Study, a population-based 
health study of African American men. Participants were interviewed about their health 
history and lifestyle factors, such as physical activity. They also answered questions about 
stress and emotional health. In this study poor emotional health, high levels of stress (as 
perceived by study participants), and a lack of social support were associated with a history 
of CP. The findings were consistent with a previous study by Collins et al [47], which also 
reconfirmed that patients with severe stress at work or home were 1.2 and 1.5 times more 
likely to report CP, respectively, than those whose lives were relatively stress-free. 
Ullrich et al [48], associated stress to be an important factor responsible for the development 
of CP/CPPS. In this study , 200 men were interviewed about the level of stress and degree 
of pain intensity by telephone a month after the men were diagnosed with CP and then 
again three, six, and 12 months later. This publication concluded that the men with more 
perceived stress during the six months following diagnosis were in more pain after a year 
than those who experienced less stress. Despite the limitations of the study, such as the lack 
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4B. Inflammation and autoimmunity 
Both acute and chronic inflammation is now thought to be associated with CP / CPPS. The 
core of Inflammation lies with the presence of both pro and anti-inflammatory cytokines 
present with the prostate in comparison to normal asymptomatic patients. The main 
cytokines linked with CP / CPPS are Interleukin - 8 [34], Interleukin - 10 [35] and Tumour 
Necrosis Factor - alpha (TNF-α) [36].  
The concentration of citric acid is a significant parameter of prostate gland function [37]. 
Substantial amounts of citric acid are produced and stored in the gland. A decrease in its 
concentration is observed in cases of inflammation or cancer of the prostate gland [38]. In 
addition to citric acid there is now a new interest in the evaluation of polymorphonuclear 
(PMN) leukocytes and PMN elastase levels in patients with PC / CPPS. Zdrodowska-
Stefanow et al [39], evaluated PMN leukocytes , PMN elastase and citric acid concentrations 
in chronic prostatitis patients regardless of aetiology and in a parallel group with C 
trachomatis infection. In this paper the analysis of expressed prostatic secretions (EPC) of 46 
patients with chronic prostatitis was evaluated for leukocyte count, PMN elastase (ELISA) 
and citric acid concentrations. All patients have an additional analysis for C. trachomatis 
infection (ligase chain reaction). Analysis confirmed increased PMN cell counts (≥10 per 
high-power field) in 73.9% of patients and increased PMN elastase concentration (<250 
ng/ml) in 78.3%. In 44.4% of the patients the elastase concentration indicated moderate 
(250–1000 ng/ml) and in 55.6% acute infection (≥1000 ng/ml). Decreased citric acid 
concentration (<18.12 mg/ml) in the EPS was found in 65.2% of the men. C. trachomatis 
prostate infection was detected in 17.4% of the patients and all of these men had higher 
inflammation parameters and lower citric acid concentrations. The authors concluded that 
CP /CPSS associated with C. trachomatis infection were accompanied by an increase in 
inflammation markers and a decrease in citric acid concentration.  
Autoimmunity is characterized by recognition of self by the immune system with the 
resulting immune response destroying or damaging normal cells and tissues. T lymphocytes 
are principally responsible for the recognition of antigens by the immune system. CD4 T 
cells recognize processed peptide antigens in association with the MHC class II molecule 
and play a significant role in the effector function of CD8 T-cells and B-cell activation. In 
previous work we have shown that soluble components in normal semen can be recognized 
by CD4 T lymphocytes in men with CP/CPPS [40, 41]. The current concept of autoimmunity 
is best recognized in patients with non-specific granulomatous prostatitis (NSGP). Within 
this group of patients it is the HLA class II allele DRB1*1501 in Caucasian men is associated 
with CP/CPPS [42].  
In a landmark paper evaluating the link between autoimmunity and CP / CPPS, 
Kouiavskaia et al [40], aimed to assess whether T cells from a group of men with CP/CPPS 
would recognize peptides derived from the normal self prostatic proteins prostate specific 
antigen (PSA) and prostatic acid phosphatase (PAP).  The authors used purified CD4 T cells 
from the peripheral blood of 31 patients with CP/CPPS and from the buffy coat preparation 
of 27 normal male blood donors that were stimulated in vitro with a panel of immunogenic 
peptides from PSA and PAP and assayed for reactivity with the peptides by IFN-γ ELISPOT 
assay. The data from this study suggested that the peptides such as PAP133-152, PAP173-192, 
PSA171-190, PSA221-240 represent promiscuous epitopes able to be presented by different HLA-
DR alleles. High level of the peptides promiscuity was supported by the results of both 
analysis of MHC class II allele expression by the individuals responding to the peptides in 
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the IFN-γ ELISPOT assay and analysis of the direct binding of the peptides to MHC class II 
molecules. In vitro functional assays showed that autoreactive T cells specific for the 
peptides are present and can be activated in the patients with CP/CPPS and normal male 
blood donors, identified PAP as a possible target protein for autoimmune reactivity in the 
patients with CP/CPPS and demonstrated that autoimmune reactions to the 
immunodominant peptide PAP173-192 might be involved in the disease development. The 
data supported autoimmunity as a potential aetiology for CP/CPPS in some patients and 
suggest that immunosuppressive therapies might logically be tested in the treatment of this 
complex and frustrating disorder. The authors found that Peptide PAP173-192 was more 
frequently recognized by CD4 T cells from the patients with CP/CPPS compared to the 
healthy donors. Peptide reactivity was more commonly observed in cases compared to 
normal male blood donors for any PSA peptide or any tested peptides. This study 
demonstrated a strong link between autoimmunity and CP / CPPS in that CD4 T cells from 
patients with CP/CPPS had a higher frequency of recognition of the self prostatic proteins 
PAP and PSA compared to normal male blood donors.   
4C. Neurological  
CP/CPPS is associated with the patient developing pain and this suggests a possible 
neurological link with the diagnosis. The pain perceived by these patients can be a 
combination of either local pain within the pelvis or more central pain. Hence, one further 
hypothesis in the development of CP/CPPS includes dysfunction of the nervous system that 
attributes to the patients symptoms. Despite attributing a strong neurological link few of the 
agents that have been studied in clinical trials target pain pathways directly, particularly 
those in the central nervous system (CNS). Recent animal model studies on retrograde 
labelling of the prostate and pelvic floor indicates that there are double labelled cells in the 
dorsal root ganglion in the lumbar and sacral cord [42]. Patients with CPPS are thought to 
have an altered sensation of the perineum in comparison to control patients without 
CP/CPPS. The mechanism of this 'altered' innervations is poorly understood and is thought 
to be related to reflex sympathetic dystrophy of the perineum and pelvic floor [43-45]. 
4E. Psychological  
Psychological stress is also commonly associated with the exacerbation of  symptoms related 
to CP/CPPS. The initial evidence of a strong psychological link was after Wallner et al [46], 
collected data from 703 men enrolled in the Flint Men’s Health Study, a population-based 
health study of African American men. Participants were interviewed about their health 
history and lifestyle factors, such as physical activity. They also answered questions about 
stress and emotional health. In this study poor emotional health, high levels of stress (as 
perceived by study participants), and a lack of social support were associated with a history 
of CP. The findings were consistent with a previous study by Collins et al [47], which also 
reconfirmed that patients with severe stress at work or home were 1.2 and 1.5 times more 
likely to report CP, respectively, than those whose lives were relatively stress-free. 
Ullrich et al [48], associated stress to be an important factor responsible for the development 
of CP/CPPS. In this study , 200 men were interviewed about the level of stress and degree 
of pain intensity by telephone a month after the men were diagnosed with CP and then 
again three, six, and 12 months later. This publication concluded that the men with more 
perceived stress during the six months following diagnosis were in more pain after a year 
than those who experienced less stress. Despite the limitations of the study, such as the lack 
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of health data on participants prior to diagnosis, the paper concluded that treatment in 
patients with CP / CPPS should include stress management techniques.  
4F. Additional health conditions  
Additional health conditions associated with CP / CPPS include - Irritable bowel syndrome, 
Fibromyalgia and chronic fatigue syndrome .  
5. Diagnosis 
There is no gold standard for diagnostic testing for the CPPS [49]. The 4-glass or 2-glass test 
may provide information on prostatic inflammation (e.g., the number of white cells per 
high-power field), but this finding is not helpful in the diagnosis or management of the 
condition. Among men with presumed chronic pelvic pain syndrome and no history of 
urinary tract infection, up to 8% have been found to have positive prostatic localization 
cultures, but these findings have also been reported in a similar percentage of asymptomatic 
men [50].  
The current EAU 2008 guidelines highlight that CP/CPPS is more of a symptomatic 
diagnosis. To facilitate in the diagnosis the following an initial sterile pre-massage urine 
(voided bladder urine-2 [VB2]) is collected, patient with CP/CPPS shows less than 10,000 
colony-forming units of uropathogenic bacteria in expressed prostatic secretions (EPS) and 
insignificant numbers of leucocytes or bacterial growth in ejaculate. Diagnostic efficiency 
may be enhanced cost-effectively by a simple screening procedure, i.e. the two-glass test or 
pre-post-massage test (PPMT) [49]. In an extensive analysis of both tests, PPMT was able to 
indicate the correct diagnosis in more than 96% of patients [50]. 
Additional tests performed to facilitate diagnosis include a flowrate studies, urodynamic 
assessments and a transrectal ultrasound to exclude an obstructed seminal vesicle. A 
transrectal ultrasound is indicated in patients with CP/CPPS and painful ejaculation. In 
these patients a transrectal ultrasonography may reveal enlargement of the seminal vesicle 
caused by obstruction of the ejaculatory duct; such an obstruction may be associated with or 
exacerbate the chronic pelvic pain syndrome. Isolated case reports suggest that the 
correction of the obstruction may relieve pain, although this cannot be proved because of a 
lack of data [51]. A urodynamic assessment can be performed when patients have 
concomitant lower urinary tract symptoms that are refractory to treatment. 
To assess the accurate symptomology at the time of diagnosis it is essential for patients tom 
complete the The NIH Chronic Prostatitis Symptom Index. This 9 item, self-administered 
tool leads to the development of a score between is 0 to 43 points [52]. A summary of the 
current investigations from our department based on current European Association of 
Urology guidelines summarized in Figure 1. 
6. Treatment 
The treatment of CP/CPPS continues to be challenging. We divide the Urological treatment 
into Medical and Surgical categories. 
6A. Urological medical treatment 
Effective treatment for the CP/CPPS remains uncertain. Factors complicating the 
management of this condition include its probably multifactorial pathogenesis, lack of a 
gold standard for diagnostic testing, and the methodological limitations of many treatment  
 




Fig. 1. Our departments guidelines for the initial investigating patients with CP/CPPS. 
studies. Most current treatment strategies focus on symptomatic relief. Despite of numerous 
advocated strategies and new drugs being developed, the US Preventive Services Task Force 
system best summarizes current treatments for CP/CPSS as grade 1 which is defined as 
"drug therapy where current evidence is insufficient to assess the balance of benefits and 
harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of 
benefits and harms cannot be determined." 
The predominant medical treatment of drugs include:- 
1. Antibiotics 
2. Alpha blockers 
3. Anti-inflammatories 
4. 5 α reductase inhibitors 
5. Pentosulphan Polyphosphate 
6. Additional therapies [Physical therapy, Myofascial and trigger point therapy] 
The current mechanism of action and evidence to support the above mentioned treatment is 
summarized in Table 2.  
The Urological Surgery Treatment in patients with CP/CPPS include 
1. Prostatic Massage 
2. Transurethral Microwave therapy 
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of health data on participants prior to diagnosis, the paper concluded that treatment in 
patients with CP / CPPS should include stress management techniques.  
4F. Additional health conditions  
Additional health conditions associated with CP / CPPS include - Irritable bowel syndrome, 
Fibromyalgia and chronic fatigue syndrome .  
5. Diagnosis 
There is no gold standard for diagnostic testing for the CPPS [49]. The 4-glass or 2-glass test 
may provide information on prostatic inflammation (e.g., the number of white cells per 
high-power field), but this finding is not helpful in the diagnosis or management of the 
condition. Among men with presumed chronic pelvic pain syndrome and no history of 
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The treatment of CP/CPPS continues to be challenging. We divide the Urological treatment 
into Medical and Surgical categories. 
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management of this condition include its probably multifactorial pathogenesis, lack of a 
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Fig. 1. Our departments guidelines for the initial investigating patients with CP/CPPS. 
studies. Most current treatment strategies focus on symptomatic relief. Despite of numerous 
advocated strategies and new drugs being developed, the US Preventive Services Task Force 
system best summarizes current treatments for CP/CPSS as grade 1 which is defined as 
"drug therapy where current evidence is insufficient to assess the balance of benefits and 
harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of 
benefits and harms cannot be determined." 
The predominant medical treatment of drugs include:- 
1. Antibiotics 
2. Alpha blockers 
3. Anti-inflammatories 
4. 5 α reductase inhibitors 
5. Pentosulphan Polyphosphate 
6. Additional therapies [Physical therapy, Myofascial and trigger point therapy] 
The current mechanism of action and evidence to support the above mentioned treatment is 
summarized in Table 2.  
The Urological Surgery Treatment in patients with CP/CPPS include 
1. Prostatic Massage 
2. Transurethral Microwave therapy 
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1. Antibiotics Reduces and cures 
infections. This further 
reduces inflammation 
and hence improves 
symptoms of 
CP/CPPS. 
A. Levofloxacin in 80 patients 
for 6 weeks. Outcome - 6 
point decrease in NIH 
symptoms [53] 
B. Ciprofloxacin in 196 
patients for 4-6 weeks. 













B. RCTs have  
failed to show 
significant 
beneficial effects of 
antibiotics 
compared to 
placebo in patients 
who have already 
failed antibiotic 
treatment 
2. Alpha blockers Inhibit neurological 
activation induced by 
sympathetic 
overactivation 
A. Meta-analysis of treatment 
with Alpha blockers in men 
with CP/CPPS showed 
significant reduction in 
symptoms over a duration of 
3 months [55]. 









Reduce systemic or 
prostatic inflammation, 
autoimmunity, CNS 
transmission of pain 
signals, and central 
sensitization 
 
A. Main symptom of 
CP/CPPS is pain. Hence, it is 
very important to control this 
symptom. 
B. Tricyclic Antidepressants 
are widely used for pain and 
act by inhibiting central 
neuronal reuptake of 
Norepinephrine and 
Serotonin. Both substances 
linked to pain. 
C. Current medication 
recommenced includes - 
Gabapentin, Pregabalin and 
Amitriptyline 
D. COX 2 inhibitors are now 
being investigated as these 
drugs regulate prostaglandin 
production. In an RCT of the 
COX2 inhibitor rofecoxib, the 
NIH-CPSI total and pain 
scores showed improvement 
in the rofecoxib group, but the 
difference between rofecoxib 
and placebo was not 
statistically significant [56]. 
Adverse effects of 
Tricyclic include 
dry mouth, dry 
nose, and increased 
body temperature. 
Other side effects 
may include 
drowsiness, 




delirium and coma 
are also some of the 
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4. 5 α reductase 
inhibitors 
 
Reduction in prostatic 
volume 
A. One randomized, placebo-
controlled trial of Finasteride 
showed that scores on the 
Prostatitis Symptom Severity 
Index and the International 
Prostatitis Symptom Survey 
decreased significantly after 1 
year of treatment, but pain 
scores did not change 
significantly [57]. 
B. Response rates at 6 months 
(defined as an improvement 
of more than 25% in scores on 
the NIH Chronic Prostatitis 
Symptom Index) were not 
significantly better for 
Finasteride than for placebo 
(33% vs. 16%) [58]. 















layer of the bladder, 
stabilize prostatic 
stromal mast cells 
 
CP/CPPS is thought to be 
related conditions, and 
Pentosan Polysulfate has been 
tested in an RCT for CP/CPPS . 
The results showed some 
clinical benefit in the 
treatment arm, but the change 
in total NIH-CPSI score was 




minimal side effects 









Reduce pelvic floor 
muscle dysfunction 
A. Physical therapy, 
Myofascial therapy and 
trigger point therapy reduce 
symptoms related to 
CP/CPPS. 
B. A recent study has 
demonstrated a statistically 
significant improvement in 
symptoms in the patients 
receiving myofascial therapy 
for CP/CPPS in comparison 
to the pharmacological 
medication mention in 
category 1-3. 
None reported 
Table 2. Urological Medical Treatment of CP/CPPS. 
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6B. Urological Surgery Treatment 
The latter two treatments have side effects including reterograde ejaculation and erectile 
dysfunction. These must be highlighted to patients being offered Urological Surgery for 
medically refractory CP/CPPS which continues to be a clinically challenging category of 
patients to manage.  
1. Prostate Massage 
The rationale of this procedure is to try to expel dense prostatic secretion and/or to force an 
obstructed outlet duct. In order to avoid damage to the integrity of a prostatic acinus which 
could lead to worsening of the inflammation, it should be done with care, and in my 
opinion, not before the patient has had hot baths and drugs for a couple of days. It seems 
very helpful in those patients in whom TRUS has shown a sectorial oedema in the prostate. 
In my experience, patients with massive calcifications in the veru-region are rarely helped 
by this manoeuvre; this seems understandable, as those calcifications cannot be removed by 
massage, but, on the contrary, manipulation can traumatize this area and worsen the 
situation. I see my patients 2-3 times a week for a total of about 6-8 sessions.  
2. Transurethral Microwave therapy 
Transurethral microwave thermotherapy, which is widely available, can achieve 
temperatures of more than 45°C within prostatic tissue. One small randomized trial (20 
patients) suggested that transurethral microwave thermotherapy significantly improved the 
quality of life at 3 months, as compared with sham treatment [61]; four patients reported 
transient adverse effects, including hematuria, urinary tract infection, impotence, urinary 
retention, urinary incontinence, and premature ejaculation, but whether these patients 
received active or sham treatment was not stated. 
3. Transurethral Resection of Prostate 
Transurethral resection of the prostate (TURP) is advocated for CP/CPPS based on a few 
anecdotal experiences, but there are absolutely no reliable data or experiences to 
substantiate a treatment effect [62]. Patient with significant lower urinary tract symptoms 
with a background of CP/CPPS may benefit from this therapy. 
7. Conclusion 
Chronic Prostatitis / Chronic Pelvic pain syndrome continues to be a challenging clinical 
entity for urologists. A thorough clinical evaluation and organizing appropriate clinical 
investigations are essential to establish a potentially treatable cause, although this is not 
found in all patients. With new avenues of autoimmunity and inflammation being explored 
as a strong link in the pathogenesis of CP/CPPS, we envisage that this may well direct 
future treatment strategies. However, based on current clinical practice a combination of 
treatment trial including newer biomarkers, genomic, immunological, imaging studies, 
epidemiologic and symptom-based assessments, will maximize the ability to identify an 
effective treatment strategy in the future. 
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1. Introduction 
The treatment of recurrent lower urinary tract infections in young female patients remains 
controversial (Naber, 2000; Stamatiou, 2005; Wagenlehner, 2009). Recurrent lower UTI is 
often associated with sexual intercourse. The association of UTI with sexual intercourse 
poses both medical and psychological problems for these patients (Stamatiou, 2005). Usually 
these patients are young females. Repeated courses of antibiotic therapy and postcoital 
antibiotics prophylactic help some, but not all patients. Conventional antimicrobial therapy 
has limited success and often has to be repeated (Naber, 2000). A remarkable increase of 
antibiotic resistance is also noted in uncomplicated UTI (Wagenlehner, 2009). 
“Intravaginal urethral displacement” during sexual intercourse appears to play a role in 
both the development of these symptoms and the recurrence of UTI symptoms by 
contamination of microbial agents in the distal urethra (Stamatiou, 2005), which may often 
lead to cystitis. The repositioning of the distal part of the urethra may potentially minimize 
microbial contamination in this area. The operation makes it possible to withdraw the 
meatus from the area concerned. Careful mobilization of the distal part of the urethra with 
modern technology and fine absorbable suture materials provides minimal invasion and 
may be considered an option for patients with recurrent UTI associated with sexual 
intercourse. 
In this chapter we shall present detailed surgical techniques and long-term results of distal 




From 1995 to 2010 two hundred and seventy one female patients underwent surgical 
treatment in the Urology Department of MSMSU for recurrent UTI associated mainly with 
sexual intercourse. The patients’ age ranged from 16 to 48 years (mean 25.9 years) – Group I. 
All of them exhibited failure of standard drug therapy, including UTI prophylaxis (three-
day antimicrobial treatment is recommended for simple cystitis (Valiquette, 2001). All 
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patients had practiced additional prophylactic methods, such as perineal hygiene, post-
coital micturition, with sufficient fluid intake, but with little benefit. The patients themselves 
also believed that the conservative treatments being used were of little benefit. The mean 
duration of symptoms before urethral transposition was scheduled 2,7 years (13 months – 
4,5 years). After the failure of traditional medical and conservative therapies (hygiene, 
antibiotic therapy) all patients underwent surgery.  
Table 1 shows the age distribution of patients scheduled for surgery.  
All patients had long suffered from recurrent infections of the lower urinary tract, mainly 
from symptoms of acute cystitis. Usually these were cases of classic “honeymoon” cystitis. 
In all cases, the manifestation of the disease coincided with the beginning of regular sexual 
life. The UTI symptoms were related directly to sexual intercourse, with the duration of 
recurrences increasing with time and the efficiency of conservative treatment progressively 
decreasing. It should be noted that sexual sensation became dull in all women, with 
decreased sexual activity due to the fear of a recurrence of UTI and discomfort in the 
perineal area. 
57 patients (mean age 26, 9) with the same histories, anatomical findings, symptoms and 
signs of lower UTI, receiving conventional antibiotic treatment, served as controls – Group 
II.  Repeated short and long-term courses of antibiotics were used according to urinary 
culture. It should be noted that this group served as a control for the first year. These 
patients were advised to have surgery as they showed the same anatomical features, but 
they initially refused to undergo surgical treatment.  
The mean follow up time of the 271 patients from Group I was 52.5 months (48 – 57 months). 






Table 1. Age distribution of patients scheduled for surgery. 
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2.2 Preoperative evaluation 
Full medical histories were obtained. During vaginal examinations, special emphasis was 
given to the position of the distal urethra. A plastic penile imitator was introduced vaginally 
to evaluate urethral movements simulating intercourse. Detailed pelvic examination was 
described by Hrischhorn in 1966. We believe that a finger exam and stretching the fingers 
widely apart does not provide adequate understanding or a complete assessment of the 
meatal movements. For this reason we decided to use a plastic penile imitator. Urinalysis 
(including nitrite dipstick and leukocyte esterase test), urinary culture and urinary tract 
ultrasonography to exclude anatomical abnormalities were performed in all patients. 
Cystoscopy, carried out in all cases, was always normal apart from the occasional finding of 
urethrotrigonitis. All patients were counseled extensively regarding anatomy and the 
technique of this procedure. 
2.3 Surgical techniques 
This technically simple operation allows the elimination of peculiar «lateral tractions» that 
permanently displace the meatus into the vaginal lumen during intercourse and subsequent 
frictions by causing retrograde infection of the urinary tract by vaginal microflora. The 
operation makes it possible to withdraw the meatus from the area concerned and hence 
create conditions for further adequate anti-microbal therapy.  
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The patient is placed in the standard lithotomy position and a conventional cleansing 
preparation with a sterile covering is used. The procedure starts by analyzing existing 
urethral-hymenal fusions. In cases where these fusions are well-developed, and limit the 
mobilization of the distal part of the urethra, they should be dissected widely in the 
transverse fashion. 
In order to mobilize the distal part of the urethra and create a submucosal bed for 
subsequent urethral transposition, an inverse tennis racket incision is performed with a fine 
11 blade scalpel. The distal portion of the urethra should be exposed widely in order to be 
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(3) 
Fig. 1. Incision used for mobilization of the distal urethra. 
 
 
Fig. 2. Exposed distal urethral portion. 
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The edges of the distal urethra are fixed by interrupted sutures from synthetic absorbable 




Fig. 3. The initial step of fixing the urethra: the exposed part of the urethral tube is fixed to 
the apex of the incision. 
Sufficient mobilization of the distal part of the urethra should provide tension-free fixation 
in the apical part of the submucosal bed. (Fig.3). Tension-free fixation can be achieved by 
both careful and wide mobilization of the distal urethra and the suturing of previously 
transversely dissected hymenal fusions longitudinally. 
Care must be taken to provide secure fixation of the external meatus in a new area with the 
final step of the operation being vaginal mucosa closure. 
In cases of vaginal anatomical narrowness, encountered in nulliparas, or marked hymenal 
ring, the described operation is supplemented by a hymenectomy that enlarges the vaginal 
orifice and creates the optimal conditions for further sexual life, minimizing bacterial 
contamination.  
2.4 Follow up 
A 16 Fr. Foley catheter was placed for three days. All patients were treated postoperatively 
with standard antibiotic therapy course for a mean time of three weeks.  Patients were 
required to avoid sexual intercourse postoperatively for one month. The mean hospital stay 
was 2,6 days. 
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3. Results 
Patients from Group I were evaluated after three months, showing no postoperative 
complications. Those who wished to begin sexual activity were able to do so after one 
month. Coital activity was resumed with no further recurrence of pre op. dyspareunia. 
Examinations of  204 (75,3%) patients from Group I one year later showed no symptoms and 
signs of UTI. 67 (24,7%) patients required further antimicrobial prophylaxis after the 
procedure because of the longer preoperative duration of their symptoms. 19 patients (7,1%) 
showed poor results. 183 patients were available for additional examinations after three and 
five years, (mean 52,5 months) revealing stable results with no lower UTI for these patients. 
It should be noted that the flow rate remained unchanged postoperatively, with no signs of 
obstruction or dysfunctional voiding. Patients did not complain about sexual dysfunction 
postoperatively, although it should be noted that we did not conduct in-depth evaluations.  
Group II patients were followed up for one year. 46 (80,7%) of them were found to have 
recurrent symptoms with poor response to the therapy, and had to undergo repeated 
treatment.       
4. Discussion & conclusion 
Recurrent UTI and dysuria associated with sexual intercourse represent a common 
urological problem. The relationship of lower urinary tract symptoms with sexual activity is 
well recognized in terms of onset and recurrence. This condition automatically leads to 
dyspareunia (Valiquette, 2001).  
It seems that distal urethral vaginal ectopy with intravaginal movements of the external 
meatus during sexual intercourse plays an important role in the development of acute UTI 
with symptoms of acute cystitis (Reed, 1970). The antimicrobal defense mechanism of the 
urethra is altered by frequent recurrences, and conventional antimicrobal therapy may not 
help. Careful physical examination may provide a detailed evaluation of distal urethral 
position and assess urethral-hymenal fusions. Initial work done by Hirshhorn in early 1966 
concluded that bilateral hymenotomies may provide a stable effect with no further 
recurrence of urethritis or cystitis (Hirshhorn, 1966). This type of procedure has been used in 
our department for many years with limited success.  We feel that simple finger evaluation 
of the distal urethra movements will not provide adequate information in order to select 
candidates for surgery. We have developed a simple method of assessment of the urethral 
position by simulating sexual intercourse with a plastic penile imitator. We now believe that 
all younger sexually active females who develop dysuria after sexual intercourse should be 
evaluated by this method in order to exclude intravaginal movements of the distal urethra.  
In 1972 Alan R. Alexander et al. published a limited study on bilateral hymenectomy alone 
or with urethral transposition, achieving good results (Alexander et al, 1970). They 
considered urethral transposition a radical operation which should be reserved for only 
those cases in which the patients failed to respond to simple bilateral hymenectomy. We 
may understand that at that time there was not such a wide variety of antibiotics. Therefore 
some cases could have benefited from simple bilateral hymenectomy. We now try to 
prescribe longer courses of antibiotic treatment with stronger agents. We may therefore 
assume that our patients would not benefit from a simple bilateral hymenectomy.  
Careful mobilization of the distal part of the urethra with modern technology and fine 
absorbable suture materials provides minimal invasion and may be considered an option for 
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The edges of the distal urethra are fixed by interrupted sutures from synthetic absorbable 
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some cases could have benefited from simple bilateral hymenectomy. We now try to 
prescribe longer courses of antibiotic treatment with stronger agents. We may therefore 
assume that our patients would not benefit from a simple bilateral hymenectomy.  
Careful mobilization of the distal part of the urethra with modern technology and fine 
absorbable suture materials provides minimal invasion and may be considered an option for 
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patients with recurrent UTI associated with sexual intercourse. It should be emphasized that 
we do not advocate this procedure as a primary choice. This means that all patients showing 
this type of UTI should be initially treated conservatively, and scheduled for surgery only if 
this treatment is unsuccessful.  
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1. Introduction 
Healthcare-associated urinary infection is one of the most frequent infections and it is 
responsible for more than 40% of nosocomial or healthcare-associated infections (HAIs) and 
nursing homes for the elderly. The complexity and diversification of health services 
currently offered has motivated an enlargement in literature about infectious complications 
that may happen in each one of these scenarios; and according to the recommendations 
from literature since 2007 (1), in this chapter, urinary tract infection will be approached as a 
result of the care provided at hospitals or nosocomial care (NUTI). 
Due to the fact that most of NUTIs are associated to urinary tract instrumentation, i.e. 
secondary to either indwelling or intermittent vesical catheterization, cystoscopies or any 
invasive urologic procedures, or to nephrostomy tube placement, this chapter will 
emphasize in the most recurrent complication derived from the use of these medical 
devices: urinary catheter-associated bacteriuria (UCAB). 
2. Epidemiology 
The risk to acquire a NUTI depends on: location of Urinary Catheter (UC), catheterization’s 
period of time, catheter care measures and host’s susceptibility. 13.2 % of inpatients, 4.9% in 
nursing homes for the elderly and 3.9% of home care patients have urinary catheters (14). 
After just one catheterization of the urinary tract, infection rates vary from 1% to 5% to 100% 
in patients who have indwelling urinary catheter with open drainage system. Likewise, and 
regardless of the use of closed drainage system, more than 20% of patients with urinary 
catheters might become infected when mishandling of closed drainage system (3, 4).  
Among risk factors that increase acquiring a catheter-associated urinary tract infection 
(CAUTI) are: advanced age, debilitating disease and postpartum. 
In the National Nosocomial Infections Surveillance in United States, between 1992 and 1997, 
data from 112 medical intensive care units was includes with 181.993 patients and 715.930 
patient-days of follow up. They found 14.177 HAIs, where NUTI was the most frequent 
diagnosis, with 31% of the cases, followed by nosocomial pneumonia and primary 
bloodstream infection (5). 
Information about the epidemiology of nosocomial infections is provided in developing 
countries by the International Nosocomial Infection Control Consortium (INICC). This 
multicenter, international surveillance system proceeded data in 2008 about 98 intensive 
care units around the world. Those units belonged public and private hospitals in 18 
countries in Latin-America, Africa, Asia and Europe. Between 2002 and 2007 a total of 1212 
 
Clinical Management of Complicated Urinary Tract Infection 224 
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NUTI were reported in 202.311 patient-days, with a median rate of 6.49 per 1.000 catheter-
days. Those ICU that had medical and neurosurgical patients had the highest rates, with 
9.63 and 8.29 infection per 1.000 catheter-days, respectively (6).  Previous studies have 
shown that different kinds of patients had different rates of infections because of different 
risk factors that need to be addressed with different control strategies. 
Urinary Catheter-associated NUTIs are caused by a variety of pathogens: E. coli, Klebsiella, 
Proteus, Enterococcus, Pseudomonas, Enterobacter, Serratia and Candida. Many of these 
microorganisms constitute intestinal flora, but they can also be acquired through cross 
contamination from other patients or hospital personnel, or through exposure to 
contaminated solutions or non-sterile equipment. NUTIs produced by Serratia marcescens y 
Pseudomonas cepacia have great epidemiologic meaning since its isolation from catheterized 
patients clearly suggest that they are obtained from exogenous flora, as normally these 
organisms are not part of the intestinal flora. 
Secondary becteremia for NUTI can be present even in a 4% of the patients and it occupies 
the second place among bacteremias of secondary cause; it has even been related to 
mortality rates ranging from 13 to 30%, nonetheless, in a study performed in a ICU to 
determine the impact on UC use in death outcomes, it showed that once all confounding 
variables were controlled, mortality was not higher in patients with UC --mortality in ICU 
patients OR 0,846 (IC 95% 0,695-1,086) versus mortality in hospitals OR 0,949 (IC 95% 0,763-
1,181) -- (7).     
3. Urinary catheters (UC) 
Every year, millions of UCs are used in the different hospital services: Intensive Care Units 
(ICU), rehabilitation, neurology, neurosurgery and internal medicine, also in nursing homes 
for the elderly. Approximately, 25% patients in hospitals use UCs, considering the following 
criteria for its use: 
1. Surgery 
2. Urine output measure 
3. Urine voiding when urine retention; generally caused by processes of urinary tract 
obstruction. 
4. Urinary incontinence (8). 
The majority of urinary tract complications are second to bacteriuria production. Trauma 
and urethritis are other less frequent complications. 
A urinary catheter is a device which has been used since 1927, when Frederick E.B. Foley 
introduced it to control post-surgical bleeding in prostatectomy (9). From 1927 until 1950, 
UCs were used as open drainage system, i.e., urine made contact with air when drained, this 
led to 100% of the patients with open drainage system to develop bacteriuria at the fourth 
day of use (10). From 1950 to 1960, another system was implemented. This system used a 
drainage tube connected to a bag which collected urine, thus leading to the origin of closed 
drainage system. In this case, 100% of the patients developed bacteriuria at the thirtieth day 
of use. (9, 11) 
Urinary catheters are classified as per: 
1. Place of insertion. 
2. Period of catheterization. 
3. Material 
Regarding the first, they can be urethral, suprapubic or nephrostomy catheters. As for the 
period of catheterization, there are two kinds, one for long-term catheterization, usually 
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with indwelling Foley catheters, and for short-term catheterization, nelaton intermittent 
catheters are commonly used. And finally, catheters can be made in latex, silicone or Teflon, 
they can be latex or silicone-covered and some are coated with an antiseptic or antibiotic. 
They also have different diameters. 
The majority of nosocomial CAUTIs are produced by bacteria which come from patient’s 
own colon, which is known as endemic infection, whereas epidemic or secondary infection 
can be explained by different causes: incorrect aseptic techniques for equipment such as 
cystoscopes, contaminated irrigation solutions or contaminated disinfectants used for 
cleaning before catheter insertion, and the most recurrent: cross –transmission through 
hospital personnel hands. 
4. Pathogenesis 
NUTI production is often multifactorial, the main mechanisms to describe the process are: 
4.1 Defense process and urinary infection 
An average urinary tract has defense mechanisms to prevent or minimize interaction 
between epithelial cells and bacteria. Though a large amount of infectious agents that cause 
UTI previously colonize the periurethral area, the urethra represents the first obstacle for 
these agents to reach the bladder.  Had the microorganism gone through the urethra and 
entered the bladder, micturition will purify 99.9% of these bacteria with the help of 
uromodulin and oligosaccharide -which are present in urine-, by a neutralizing action. 
However, a biofilm may remain adhered to the vesical mucosa, in which case, 
glycosaminoglycan inhibits bacterial adherence to epithelial cells. Still, in the case that these 
cells become infected; an acute inflammatory response is produced as a result of cytokine 
liberation of the infected epithelial cells. The last protecting instance of epithelial cells is an 
exfoliation process through which microorganisms are removed from the host. Antibody 
production and host cellular response contribute to a slower reaction, thus helping in the 
last states of acute infection.  
4.2 Biofilms and urinary catheters 
UC use can interfere with some of these natural defense mechanisms. Catheters increase 
urethral colonization by uropathogens, especially in women. Both, inner and outer catheter 
surfaces are niches where bacteria adhere to creating a biofilm which covers and protects 
bacteria from urinary flow and polymorphonuclear action. 
A biofilm is a microorganism community that permanently adheres to biological or inert 
surfaces and it is embedded in a matrix of extracellular polymeric substances modifying 
growing and genetic transcription phenotypes. Bacteria constitute biofilms in especially 
high-stress environments, e.g. fast and turbulent flow milieus, which in return increases 
adhesion of floating cells on surfaces. Once a biofilm is formed and the exopolysaccharide 
matrix has been secreted by cells, the resultant structure is highly viscoelastic and resistant 
to mechanical breaking. Hence, the nature in structure and physiological attributes of 
biofilm’s constituent organisms provide an inherent resistance to antimicrobial agents. (12) 
4.3 Handling and care precautions of urinary catheters 
Another factor encouraging CAUTIs in health care institutions is a failure in the draining 
system, therefore, large amounts of bacteria remain in the bladder and catheter presence 
interrupts interaction between glycosaminoglycan and epithelial cells. (11) 
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4.4 Hematogenous or lymphatic dissemination 
It is important to remember that certain microorganism reach the kidney through 
bloodstream dissemination from a distant organ. The most common microorganisms in this 
particular scenario are: S. aureus, Candida,  Salmonella and some species of Pseudomonas, for 
this reason, isolation of any of these in urine always suggests two possible sources: urinary 
tract or a source different from the kidney compromising it through hematogenous 
dissemination. 
To summarize, CAUTIs at health care institutions can be present in four ways (13): 
1. Early extraluminal: By direct inoculation of microorganisms in the bladder at the 
moment of UC insertion. 
2. Late extraluminal: By microorganisms ascending from perineum to urethra and to 
catheter’s outer surface. 
3. Intraluminal: Due to closed-drainage system failure or when collected bag is 
contaminated.  
4. In rare opportunities by hematogenous dissemination as a consequence of a systemic 
disease with kidney as target organ. 
The final consequence of the interaction between host’s defense mechanism and colonizing 
microorganisms in patients with UC is the presence of bacteria in urine or bacteriuria. 
The majority of infectious agents causing catheter-associated bacteriuria originate in 
patient’s own intestinal flora, which at the same time can be regular inhabitants of the colon, 
or exogenous, as in healthcare-associated infections (HAIs). As in UTI’s pathogenesis, 
enterobactericeae can colonize periurethral areas of non-catheterized patients, especially 
women. Exogenous microorganisms can colonize UC through means of care personnel 
manipulation or less frequent circumstances, as in polluted products. 
5. Risk factor for bacteriuria development 
Asymptomatic bacteriuria is common but its prevalence among general public varies 
significantly with age, gender, and the presence of genitourinary tract alterations. 
Bacteriuria risk for catheterized patients is approximately 25% and its significance in 
relation to provide or not antimicrobial treatment in the asymptomatic patient is debatable 
considering that 80% of short-term catheterized patients receive antimicrobial treatment for 
a different purpose than that of a UTI. (14) 
In a multivariate analysis and observations of 1474 catheterized patients, Platt et al., found 
nine independent risk factors for catheter-associated bacteriuria development. (15) 
1. Period of catheterization 
2. Lack of urinometer usage 
3. Collector bag colonized by microorganisms 
4. Diabetes mellitus 
5. Lack of antibiotic usage 
6. Mishandling in UC procedures 
7. Female gender 
8. Abnormal creatinine 
9. Incorrect catheter care 
5.1 Period of catheterization 
According to UC usage standards, catheterization periods vary: 
1. Surgery: 1-7 days 
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2. Cardiac output measure: 7-30 days 
3. Urinary retention:  1-30 days 
4. Urinary incontinence:  >30 days 
Period of catheterization is the main risk factor for associated bacteriuria development. Once 
UC is inserted, bacteriuria increases at the rate of 3 to 10% per day of UC permanence 
(catheter day) and, it is estimated that by the thirtieth catheter day, 100% of catheterized 
patients will present bacteriuria. For this reason, it is important to divide the period of 
catheterization in: (i) Short-term, for less than 30 days; and (ii) Long-term, for more than 30 
days. In addition, bacteriuria may be asymptomatic or some symptoms may be identified 
having a real UTI. 
5.2 Short-term catheterization 
Between 15 to 25% of inpatients might have a UC for an average period of 2-4 days and 
approximately 10 to 13% of them will develop bacteriuria in comparison to 1% of non- 
catheterized inpatients that develop bacteriuria.  The most common infectious agent found 
in these patients is E. coli, besides Pseudomonas aeruginosa, Klebsiella pneumoniae, Proteus 
mirabilis, Enterobacter sp., Staphylococcus epidermidis, Staphylococcus aureus and Candida 
species. In general, only one microorganism is isolated in the urine culture but 15% can be 
polymicrobial.  Colony count can show a meaningful bacteriuria of equal or more than 105  
bacteria. In general, this bacteriuria, aside from the colony count, is accompanied with 
pyuria. Most short-term UC associated bacteriuria are asymptomatic, nonetheless, lower 
urinary symptoms and fever may be present even in 30% of these patients and less than 5% 
will develop bacteremia. The impact of short-term UC associated bacteriuria on mortality is 
not clear and results from studies have shown to be contradictory. 
5.3 Long-term catheterization 
Long-term catheterization is needed for urinary incontinence in women, lower urinary tract 
obstruction in men as a consequence of prostatic hyperplasia and prostate carcinoma, and to 
urinary obstruction in postrenal failure in women secondary to cervical carcinoma, aside 
from neurogenic bladder related  to spinal cord trauma both in men and women. 
Bacteriuria incidence tends to be similar to that observed in hospitals (3 to 10% per day), 
hence, most patients will have bacteriuria at the end of 30 catheter days. Bacteriuria 
prevalence is a consequence of: 
1. Bacteriuria incidence which is similar to that observed in short-term catheterization, by 
gram-negative and gram-positive bacteria, with an average permanence of a different 
infectious agent every two weeks. 
2. Some bacteria residing for weeks and months in the urinary tract, like E. coli and 
Providencia stuartii. 
Colony count is generally meaningful with 105 colonies or more and more than two 
infectious agents are present in more than 95% of long-term catheterization patients. 
The most common infectious agents identified in these patients are E. coli, P. aeruginosa, P. 
mirabilis, Providencia stuartii y Morganella morganii, the latter two in less frequency. Most 
frequent complications are symptomatic bacteriuria, obstruction, urinary stones, 
periurethral infection, chronic kidney disease, renal failure and cancer when catheter is used 
over several years. 
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4.4 Hematogenous or lymphatic dissemination 
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2. Cardiac output measure: 7-30 days 
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Clinical Management of Complicated Urinary Tract Infection 
 
230 
5.4 Therapy of asymtomatic bacteriuria 
There is no need for rutinary microbiological studies in catheterized patients presenting 
asymptomatic bacteriuria or funguria, or those who have had treatment for that condition. 
Recommendation A-1 from CDC’s (Control Diseases Centers) guidelines for bacteriuria 
prevention (16).  
Antimicrobial treatment can be considered for women who have persistent asymptomatic 
bacteriuria after catheter removal. Recommendation B-1 (17). 
6. Nosocomial urinary tract infection (NUTI) diagnosis 
Besides presenting symptoms or not, a urine test and a urine culture are necessary to 
confirm either bacteriuria or NUTI. In table 3, CDC and NHSN diagnosis criteria for UTIs 
are shown (26).   
7. Bacteriuria complications treatment 
Several clinical manifestations can be present in patients with asymptomatic bacteriuria 
associated with UC usage. 
 Cystitis is manifested through changes in the macroscopic characteristics of urine and it 
is combined with suprapubic pain, polakiuria, dysuria, urinary urgency, and vesical 
tenesmus, these latter symptoms are present when patients do not have sequelae of 
spinal shock. In the case a patient is catheterized due to spinal shock sequelae, the most 
recurrent symptom is associated with the change of macroscopic characteristics of urine 
(odor, color, and transparency). Urine culture and bacteria’s in vitro susceptibility to 
certain antibiotics should be considered for the choice of antibiotherapy, which can 
range from 7 to 10 days. 
 If the patient presents with  fever, it is strongly recommended to exclude any other 
plausible cause for this symptom; if fever seems to be secondary to pyelonephritis 
caused by UC, then a 14-21 day treatment is implemented depending on the severity of 
the infectious process and on the susceptibility of the infectious agent. 
 Candiduria is present in long-term catheterization patients that have had antibiotics 
previously. Candida presence in urine should be taken as possible hematogenous 
dissemination to kidney or other different organs. When candiduria is a result of 
candidemia or a disseminated candidiasis, it is recommended to exclude a systemic 
infection to determine the period of antimycotic treatment (18). Most of the times, 
candiduria is asymptomatic, but it can include complications such as a bladder or renal 
pelvis fungal bezoar, perinephric abscess and disseminated candidiasis. Treatment for 
asymptomatic candidiasis associated to UC is not clear, however, 40% of candiduria 
ends after UC removal and 20% does when UC is changed; this is a B-III 
recommendation (18). For asymptomatic patients who persist with candiduria and 
require catheter, several therapeutic strategies have been proposed. Bladder irrigation 
with 50 to 200 µg/mL of amphotericine B can clear funguria temporarily and it is not a 
frequent recommendation (recommendation C-III) (18); systemic use of fluconazole 200 
mg/d for 14 days has demonstrated microbiological cure. Antimycotic treatment in 
patients with asymptomatic candiduria is not totally defined, but treatment is 
recommended when undergoing genitourinary surgical procedures. Even with 
apparent microbiological cure by UC removal or with systemic treatment, relapse is 
common, even more when there is still UC use. 
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Urinary tract infection Clinical criteria Laboratory criteria 
Symptomatic NUTI  
At least one of the 
following:  
 
1. At least one of the 
following signs or 
symptoms, without any 
other cause; fever >38ºC, 
urinary urgency, frequency, 
dysuria or suprapubic pain 
and criteria 1 from 
laboratory 
2. At least one of the 
following signs or 
symptoms, without any 
other cause; fever >38ºC, 
urinary urgency, frequency, 
dysuria or suprapubic pain, 
and from laboratory criteria 
2, one of the given criteria. 
3. For children under 1, at 
least one of the following 
signs or symptoms, without 
any other cause; fever 
>38ºC or rectal 
hypothermia <37ºC, apnea, 
bradycardia, dysuria, 
lethargy or vomit, and the 
same 1 and 2 laboratory 
criteria respectively. 
1. Urine culture with less than 
two microorganisms and 
colony count of ≥105 
2. Positive leukocyte esterase; 
pyuria >10 leukocytes per 
hogh magnification field; >3 
erythrocytes per hight 
magnification field; positive 
urine Gram in a non-
cytospinned sample; two 
urine cultures with the 
same microorganism and a 
colony count of ≥102 in a 
patient with previous 
effective antibiotherapy and 
a count of ≤105; medical 
diagnosis or proper medical 
treatment for UTI. 
Asymptomatic 
bacteriuria 
At least one of the 
following: 
 
1. Patient with previous case 
of catheterization within the 
last 7 days and who has not 
fever, urinary urgency, 
dysuria or suprapubic pain, 
and laboratory criteria 1.  
2. Patient who has not had UC 
in the previous 7 days to 
the first urine cultura, and 
that has not presented 
fever, urinary urgency, 
frequency, dysuria or 
suprapubic pain, and 
laboratory criteria 3. 
 
3. Two positive urine cultures 
of ≥105 with less than 2 
microorganisms and 
showing the same 
microorganisms. 
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3. Two positive urine cultures 
of ≥105 with less than 2 
microorganisms and 
showing the same 
microorganisms. 
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Urinary tract infection Clinical criteria Laboratory criteria 
 
Other UTIs (kidney, 
urether, bladder, 
urethra, or 
retroperitoneum)   
At least one of the 
following: 
 
1. Abscess or evidence of 
infection at direct, 
intraoperative or 
histological examination. 
2. At least two of the 
following signs or 
symptoms, without any 
other cause; fever >38ºC, 
focused pain or pain in the 
implicated place, and at 
least one of the following; 
purulent drainage, or any of 
the laboratory criteria 2-5. 
3. For children under 1, at 
least one of the following 
signs or symptoms, without 
any other cause; fever 
>38ºC or rectal 
hypothermia <37ºC, apnea, 
bradycardia, dysuria, 
lethargy or vomit, and at 
least one of the following; 
purulent drainage, or any of 
the laboratory criteria 5-8.  
 
 
4. Positive culture from any 
fluid different from urine.  
5. Positive blood culture from 
suspected infection site. 
6. Compatible image with 
infection (CT scan, NMR, 
Scintigraphy) 
7. Medical diagnosis of 
infection 
8. Adequate medical 
treatment for infection. 
 
Comments: 
The culture taken from the tip of a UC is not laboratory criteria for NUTI diagnosis. 
Urine samples should be obtained using the proper technique, i.e. clean technique or catheterization. 
With children, samples must be taken from catheterization or suprapubic puncture; urine collected 
from perineal bag is not accepted. 
Circumcision-associated infections should be informed as such. 
 
Source: Bibliographic reference 26. 
Table 3. NUTI diagnosis criteria. 
8. Prevention guidelines 
Even though not all CAUTIs can be prevented, a great number can be avoided by proper 
catheter use. The following care recommendations should be implemented for short-term 
catheterization patients: 
Prevention is directed to three sources: 
1. Catheter colonization precautions. 
2. Once UC is inserted, bacteriuria prevention.  
3. Had bacteriuria developed, its complications should be avoided. 
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8.1 Urinary catheter colonization precautions 
The most successful approach to prevent catheter-associated bacteriuria is to implement 
catheter colonization safety measures. 
1. Use UC only when necessary. 
2. Use external devices: external urinary collectors such as condom catheters for men with 
urinary incontinence is a good alternative, these condoms have devices to connect them 
to a closed drainage system. Even though this system decreases UC use, the urine that 
remains in the condom can induce high bacteria concentration growth in penis skin and 
favor bacteriuria. Further complications can include penis skin maceration, penis ulcers 
and even penis gangrene when condom makes inadequate pressure in penis’ body. 
3. Intermittent catheterization: it is used in patients with sequelae of spinal shock or with 
spinal cord injury. UC insertion for urine voiding and its immediate removal every 4 to 
6 hours only increases bacteriuria in 1 to 3% per catheterization. For intermittent 
catheterization, clean are sterile techniques have been compared. In clean technique, 
catheter can be used again if sterilized at high temperatures before each use, and in 
sterile technique, catheter is new and sterile. There were no differences regarding UTI 
development in any of the two techniques, however, clean technique reduced costs. The 
most common complications are: bleeding, urethritis, fistula, stones,  and hydronephro-
sis. 
4. Suprapubic catheter (cystostomy):  many factors explain the frequency in its use. 
 Abdomen skin has lower bacteria concentration than periurethral area. 
 External obstruction of suprapubic catheters favor urine voiding through the 
urethra. 
 Urethral structures are not injured. 
Besides hematoma in catheter insertion site (abdominal wall), its infection and fistula, 
there are no other important complications. 
5. Gold-coated urethral catheter, polyurethane catheter or antimicrobial catheters have 
been used for long presurgical periods in patients with prostatic hyperplasia diagnosis 
and they have shown interesting results regarding less UTIs, but it cannot be proposed 
as universal recommendation since cost-effectiveness and superinfection evaluation has 
not been fully assessed. (19-22) 
6. Surgical recommendations: Especially in patients with cancer or intractable 
incontinence, bladder reconstruction procedures using colon or ileum segments, like in 
an ileal conduit diversion, bacteriuria is common, producing complications such as: 
acute and chronic pyelonephritis and renal failure secondary to vesicoureteral reflux.  
8.2 Bacteriuria prevention (23-25) 
Once UC is inserted, two strategies are recommended to prevent bacteriuria. 
 Use closed drainage systems: closed drainage systems in permanent catheterized 
patients must always remain closed. Junctures between catheters and collecting bag 
drainage tube must never be opened. Urine samples must be taken through syringe 
puncture and all aseptic measures should be observed during sample collection. 
 Remove catheter as soon as possible. Short-term catheterization has less risk of 
bacteriuria development. 
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Urinary tract infection Clinical criteria Laboratory criteria 
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urinary incontinence is a good alternative, these condoms have devices to connect them 
to a closed drainage system. Even though this system decreases UC use, the urine that 
remains in the condom can induce high bacteria concentration growth in penis skin and 
favor bacteriuria. Further complications can include penis skin maceration, penis ulcers 
and even penis gangrene when condom makes inadequate pressure in penis’ body. 
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6 hours only increases bacteriuria in 1 to 3% per catheterization. For intermittent 
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catheter can be used again if sterilized at high temperatures before each use, and in 
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sis. 
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 Abdomen skin has lower bacteria concentration than periurethral area. 
 External obstruction of suprapubic catheters favor urine voiding through the 
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 Urethral structures are not injured. 
Besides hematoma in catheter insertion site (abdominal wall), its infection and fistula, 
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been used for long presurgical periods in patients with prostatic hyperplasia diagnosis 
and they have shown interesting results regarding less UTIs, but it cannot be proposed 
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drainage tube must never be opened. Urine samples must be taken through syringe 
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8.3 Bacteriuria complications prevention 
Several clinical trials have demonstrated that despite catheterization period, asymptomatic 
bacteriuria need not antibiotic therapy. Nevertheless, some situations need a particular 
evaluation. 
1. In the case that isolated microorganisms might have high bacteremia incidence, e.g. 
Serratia marcescens 
2. Patients with high risk of serious complications: pregnant women, and neutropenic and 
transplanted patients 
3. Patients pending for urologic surgery 
4. Patients with prosthesis.  
In these situations, antibiotic therapy is recommended for asymptomatic bacteriuria since 
complication risks are greatly avoided by this means. 
Antibiotherapy after catheter removal has not proven to be successful either as to prevent 
UTI development or to favor microbiological cure. Likewise, it has been observed that 
catheterized patients with untreated asymptomatic bacteriuria clear it by just catheter 
removal. From prevention guidelines for CAUTIs, the following summary presents the main 
recommendations (16). 
8.4 Main recommendations for catheter-associated urinary tract infection prevention –
Summary— 
Category I. Strongly recommended to adopt 
 Personnel should be given training emphasizing on correct insertion techniques and 
catheter care measures.  
 Urinary catheters should be used only when necessary and left in place only for as long 
as necessary. 
 Promote handwashing and disinfection. 
 Insertion should be done by persons who know the correct aseptic technique using only 
sterile equipment. 
 Catheters should be appropriately assured to avoid urethral traction. 
 Closed drainage system should always remain sterile. 
 Use aseptic techniques for urine sample collection. 
 Urine flow drainage should be kept free.  
Category II. Moderately recommended to adopt 
 Periodic training should be provided to people in charge of catheters. 
 Small catheters should be chosen over catheters with larger diameters. 
 Avoid irrigation unless needed to prevent or control obstruction. 
 Daily meatal care with povidone-iodine should be avoided. 
 Catheters should not be changed at fixed intervals 
Category III. Weakly moderated to adopt 
 Alternative draining techniques should be considered before resorting to 
catheterization. 
 Substitute collecting system when sterile closed drainage has been violated. 
 Separate infected and uninfected catheterized patients. 
 Routine bacteriologic surveillance should be avoided. 
 




Urinary infection is the main nosocomial infection and is it associated to urinary catheter 
use. Urinary catheters favor bacteriuria development, which is more frequent when 
catheterization period exceeds 30 days. The most effective solution to decrease bacteriuria 
appearance is to use catheters only when strictly necessary. By reducing catheterization time 
and implementing closed drainage systems, bacteriuria risk can be highly controlled when 
catheterization is needed. Bacteriuria can be asymptomatic, thus not needing antibiotherapy. 
Should bacteriuria complications arise with urinary tract infection symptoms, 
antibiotherapy will highly depend on cystitis and pyelonephritis diagnosis, in either event, 
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1. PERSONNEL 
 Only persons (hospital team, family or patients) who know the correct insertion 
technique and catheter aseptic maintenance should handle catheters. Category  I 
 Periodic training should be provided to hospital personnel taking care of catheters 
focusing on correct techniques and possible complications during catheterization. 
Category II 
2. CATHETER USE 
 Urinary catheters should only be used when strictly necessary and removed as 
soon as possible. They should not be used for patient-care personnel convinience. 
Category I. 
 For selected patients, alternative urinary draining methods can be used, e.g. 
condom catheter, suprapubic catheter and intermittent catheterization. Category  
III. 
3. HANDWASHING 
 Handwashing is imperative just before and after catheter manipulation. Category I  
4. CATHETER INSERTION 
 Catheters must be inserted using proper aseptic technique and sterile equipment 
Category I. 
 Gloves, gauze, periurethral cleansing antiseptic solution, and single-use packet of 
lubricant should be used for insertion purposes. Category II. 
 Use as small a catheter as possible with good drainage consistency to avoid 
urethral trauma. Category II. 
 Urethral catheters should be properly secured after insertion to prevent movement 
and urethral traction. Category I. 
5. CLOSED STERILE DRAINAGE 
 A closed sterile drainage system should always be mantained. Category I. 
 Catheter and drainage tube should never be disconnected. Category I 
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8.3 Bacteriuria complications prevention 
Several clinical trials have demonstrated that despite catheterization period, asymptomatic 
bacteriuria need not antibiotic therapy. Nevertheless, some situations need a particular 
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1. In the case that isolated microorganisms might have high bacteremia incidence, e.g. 
Serratia marcescens 
2. Patients with high risk of serious complications: pregnant women, and neutropenic and 
transplanted patients 
3. Patients pending for urologic surgery 
4. Patients with prosthesis.  
In these situations, antibiotic therapy is recommended for asymptomatic bacteriuria since 
complication risks are greatly avoided by this means. 
Antibiotherapy after catheter removal has not proven to be successful either as to prevent 
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catheterized patients with untreated asymptomatic bacteriuria clear it by just catheter 
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 Catheters should not be changed at fixed intervals 
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 Substitute collecting system when sterile closed drainage has been violated. 
 Separate infected and uninfected catheterized patients. 
 Routine bacteriologic surveillance should be avoided. 
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 If aseptic technique breaks, catheter disconnects from collecting bag or draining 
tube breaks, collecting system should be replaced using aseptic technique after 
disinfecting catheter and tube juncture. Category III. 
6. IRRIGATION 
 Irrigation should be avoided unless obstruction anticipates. Category II 
 Catheter-tube juncture should be disinfected before disconnection. Category II 
 Irrigation solution and siringe must be disposable. Category I 
7. SAMPLE COLLECTION 
 Use sterile syringe Category I 
 Large urine volumes for special analysis can be obtained aseptically from drainage 
bag. Category I 
8. URINARY FLOW 
 Urine flow should be kept free. Category I 
 For unobstructed flow drainage Category I 
a. Disconnection between catheter and draining tube should be avoided. 
b. Draining bag should be cleared regularly using a separate collecting container for 
each patient.  
c. Poorly functioning or obstructed catheters need to be irrigated or replaced if 
necessary.  
d. Draining bag must be kept below patient’s bladder.  
9. MEATAL CARE WITH SOAP AND WATER OR WITH POVIDONE-IODINE  
 Daily cleansing with antiseptic solutions or soap and water do not reduce NUTI 
probability. Category II  
10. CATHETER CHANGE INTERVAL 
 Catheters should not be changed at fixed intervals. Category II 
11. SPATIAL SEPARATION OF CATHETERIZED PATIENTS  
 To diminish cross infection among uninfected and infected patients, they should be 
separarated Category III 
12. BACTERIOLOGIC SURVEILLANCE 
 Routine bacteriologic surveillance is not recommended for catheterized patients. 
Category III 
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1. Introduction  
Since they introduction in the treatment of erectile dysfunction (ED), phosphodiesterase 
type 5 (PDE-5) inhibitors have achieved widespread acceptance. Today PDE-5 inhibitors are 
considered as first-line oral pharmacotherapy in the management of ED (Hatzimouratidis et 
al., 2010). However, penile implants are still a popular choice, especially in patients who 
have failed to achieve erections by chemical enhancement, who prefer a permanent solution 
to their condition or in those who have considerable scar tissue in the penis resulting in 
erection deformalities (Mulcahy 1999). Despite its invasiveness, penile prostheses provide 
high satisfaction rates  (Montague & Angermeier 2001). 
The types of prosthesis most commonly implanted are the two-piece and the three-piece 
inflatable device, and the soft and malleable prosthesis. In the last few years the three-
piece inflatable device has been used for preference, as it improves the erection with the 
most acceptable functional and cosmetical results (Minervini et al., 2006; Bettocchi et al., 
2008). 
Engineering changes and designs revisions have reduced the mechanical malfunctions 
associated with inflatable penis prostheses to less than 5 % (Carson et al., 2000; Carson 2004). 
As penile prostheses are now expected to function for an average of 8-12 years post 
implantation, infection has become a more significant problem. The incidence of infection 
has been reported to range from 0.5 to 17.7% (Quesada & Light, 1993; Wilson & Delk, 1995) 
usually about 1-3 % in case of primary implantation, and about 10-13 % in case of revision or 
reimplantation (Abouassaly et al., 2004).  
The traditional treatment of penile prosthesis infection is systematic and local antibiotics 
application with the complete removal of the device followed by reinsertion within 2–12 
months. However, removal of the device can lead to corporeal fibrosis, making dilation of 
the corporeal bodies difficult and reinsertion of a new device more complicated (Brant et al., 
1996; Mulcahy, 1999). 
To reduce the risk of device associated infections and to avoid the difficulties associated 
with late reinsertions many modifications have been developed such as antibiotic or 
hydrophilic coated devices and immediate replacement of the infected prosthesis (salvage 
techniques). 
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The aim of this chapter is to summarize the different methods of prevention and treatment 
of penile prosthesis infections. 
2. Pathogenesis/epidemiology  
Staphylococcus species, especially Staphylococcus epidermidis are the most common infecting 
pathogens, isolated from 35 to 56% of infected penile prostheses patients (Carson , 2003). 
Gram-negative enteric bacteria including Proteus mirabilis, Pseudomonas aeruginosa, 
Escherichia coli and Serratia marcenses may also be pathogens, accounting for 20 % of 
infections (Abouassaly et al., 2004). Gram-negative bacteria can combine with anaerobic 
organisms in severe infections, such as Bacteroides species, and lead to gangrene of the penis. 
Fungi, mycobacteria and Neisseria gonorrhea have also been reported as etiological agents in 
penile prosthesis infections (Carson, 1989; Abouassaly et al., 2004). 
Penile prostheses get infected predominantly secondary to bacterial seeding at the time of 
surgery. Prosthetic materials attract bacteria and support subsequent biofilm formation. In a 
multicenter study culture positive bacteria were found in 70% of patients with clinically 
uninfected penile prostheses during revision surgery for mechanical malfunction. 
Saphylococcus species were cultured in 90 % of the cases (Henry et al., 2004), which have an 
enhanced ability to produce glycocalyx biofilm. 
Penile prosthesis infections can be divided into clinically apparent and subclinical infections. 
Clinical infections present with, penile pain, induration, erythema, fever, purulent drainage 
from the wound and extrusion. Subclinical infections most often manifest by chronic 
prosthesis-associated pain. 
3. Risk factors  
Known risk factors for penile prosthesis infection include urinary tract infection, 
infections elsewhere in the body and hematogenous spread (Carson & Robertson, 1988; 
Little & Rhodus, 1992). There is an increased incidence of infection among patients 
undergoing primary implantation with penile reconstruction or secondary prosthesis 
revision compared to primary implantation alone, probably due to the increased duration 
of surgery (Quesada & Light, 1993; Jarow, 1996). The role of diabetes mellitus and spinal 
chord injury, as risk factors of penile prosthesis infection are contradictory (Jarow, 1996; 
Cakan et al., 2003). 
4. Prevention  
4.1 General aspects 
Because in most cases bacterial contamination occurs at the time of surgery, it is essential to 
use appropriate preoperative preparations. Short preoperative hospital stays have been 
documented to maintain low virulence (Carson, 2003). It is important to eliminate skin 
infections and to have sterile urine prior to surgery. Washing the genital region with strong 
soap in the days before the procedure, preoperative shaving and an aggressive scrub of the 
operating area is recommended to decrease the risk of infection (Mulcahy, 1999; Gomelsky 
& Dmochowski, 2003). 
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During surgery adequate sterile technique, short operating time, minimal tissue 
devitalization along with effective wound closure can all decrease the rate of perioperative 
infections (Scott, 1987). 
4.2 Perioperative antibiotic prophylaxis 
Athough the effectiveness of prophylactic perioperative antibiotics for implantation of 
penile prosthesis has never been proven by prospective studies, their use has become 
established and favored by most urologists. Antibiotics should be administered 1-2 hours 
prior to surgery and continued for 36-48 hours postoperative. Most common pathogenic 
organisms most likely to produce infections must be targeted when choosing prophylactic 
antibiotics. Therefore traditional prophylaxis include a parenteral aminoglycoside for Gram-
negative and a first- or second generation cephalosporin or vancomycin for Gram-positive 
organisms coverage (Schwartz et al., 1996; Naber et al., 2001). Schwarz et al found in a 
randomized prospective trial of 20 patients that oral fluoroquinolone (ofloxacin) 
administered 2 hours before surgery achieved significantly higher intracavernosal levels 
and was more cost-effective than the combination of gentamicin and cefazolin (Schwartz et 
al., 1996). To estimate the safety and efficacy of this prophylaxis modality, further studies 
with similar settings, but bigger sample size should be performed. 
4.3 Antibiotic impregnation 
Early efforts in device impregnation focused on coating catheters with antibiotics. In 1995 
Raad et al reported that in in vitro studies catheters coated with a combination of rifampin 
and minocycline provided significantly better inhibitory activities against S. epidermidis, S. 
aureus and E. faecalis than catheters coated with either drug alone or vancomycin (Raad et 
al., 1995). After additional in vitro and in vivo studies in 2001 the US Food and Drug 
Administration approved the use of penile prosthesis coated with a combination of 
rifampin and minocycline called InhibiZone. The concentrations of the antibiotics, while 
adequate for decreasing colonization, provided only minimal serum levels of the agents. 
Coated inflatable penile prostheses are implanted in a fashion similar to those without 
antibiotic treatment except that the devices are not soaked prior to implantation (Carson, 
2004). 
In a retrospective study Carson et al reported 61,7% decrease in perioperative infection with 
InhibiZone compared to controls at 1 year post infection (Carson, 2004). The same group 
recently published their long-term clinical outcomes of almost 40,000 implants. There were 
significantly less revisions due to infections in the impregnated compared to the non-
impregnated group at up to 7.7 years of follow-up (1.1% vs 2.5%, respectively)(Carson et al., 
2011). In a subset of diabetic patients in the same series, the rate of infection-related 
revisions was significantly lower in the impregnated group compared to the controls at 7 
years (1,62 % vs 4,24 %)(Mulcahy & Carson, 2011). 
In 2007 Wilson et al. began a prospective randomized study comparing the infection rate of 
rifampin and minocycline coated implants with implants without impregnation (Wilson et 
al., 2007). After it became evident that the infection rate was less with the impregnated 
group they abandoned the other arm because of ethical considerations and compared they 
results with the previously published series of the same surgical team with noncoated 
implants (Wilson & Delk, 1995; Wilson et al. 1998). The use of antibiotic coated inflatable 
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The aim of this chapter is to summarize the different methods of prevention and treatment 
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Little & Rhodus, 1992). There is an increased incidence of infection among patients 
undergoing primary implantation with penile reconstruction or secondary prosthesis 
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operating area is recommended to decrease the risk of infection (Mulcahy, 1999; Gomelsky 
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penile prosthesis resulted in a statistically significant reduction in the infection rates 
compared with the historical data in nondiabetic virgin implant patients (p=0,0024), diabetic 
virgin implant patients (p=0,0141) and in revision patients in whom washout with antiseptic 
solutions was used (p= 0,0095). Revision without washout had the same infection rate (10%) 
as with noncoated implants.  
4.4 Hydrophilic coating 
In 2002 a hydrophilic penile prosthesis coating was developed which has been shown to 
decrease bacterial adherence in vitro and in animal models (Rajpurkar et al., 2004). This 
coating absorbs surgeon chosen intraoperative antibiotics that can elute into surrounding 
tissues over 24-72 h to further decrease infection (Hellstrom et al., 2003).  
Mansouri and colleagues compared the spectrum and durability, both in vitro and in vivo of 
the hydrophilic coated prosthesis dipped in vancomycin and the InhibiZone implants, and 
found that the antibiotic pre-impregnated prosthesis had a broader spectrum in vitro and a 
more durable antimicrobial activity in vitro and in an animal model than implants dipped in 
vancomycin (Mansouri et al. 2009). 
Clinical data on the hydrophilic coated inflatable penile prosthesis is limited. Wolter et al. 
presented their one-year experience with the device (Titan, Mentor Corporation, Santa 
Barbara, CA) (Wolter & Hellstrom 2004), the infection rate for 2357 coated penile prostheses 
was 1,06 % compared to 2,07 % in 482 uncoated penile prostheses implanted over the same 
time period. Although preliminary data using this device shows promise, long-term follow-
up and prospective studies are not yet available. 
5. Treatment  
Subclinical infections may be more common than clinically apparent infections. These 
infections are difficult to diagnose and even more challenging to treat. Parsons et al. 
recommend initial trial of oral antibiotic therapy using long-term antibiotics (ciprofloxacin 
500mg twice daily) (Parsons et al., 1993). Following initiation of antibiotics, pain suppression 
should suggest continuing antibiotics for 10–12 weeks. The authors reported a 60% success 
rate with conservative treatment of subclinical penile prosthesis infections. The use of oral 
cephalosporins (cefalexin and cephradine) has also been suggested for 10-12 weeks, 
although success rates are lower at 25-30% (Choong & Whitfield, 2000; Carson, 2003). If pain 
fails to resolve or rapidly returns after antibiotics, however, surgical intervention is 
appropriate. Parsons et al. have reported 90% success rate in treating these prostheses with 
an exchange protocol including systemic antibiotics for 24–48 h using vancomycin. The 
suspected infected prosthesis is then removed and a combination of vancomycin and 
protamine was used for antibiotic irrigation prior to reimplantation of a new prosthesis. 
Patients are maintained on vancomycin and parental antibiotics for 1 week (Parsons et al., 
1993; Carson, 2003). 
In case of clinically apparent infection surgical intervention along with antibiotics is of 
critical importance. The traditional treatment consists of the immediate removal of all the 
components followed by delayed reimplantation 2-12 months later (Gomelsky & 
Dmochowski, 2003; Mulcahy, 2003). The advantage of this solution is that the new implant 
is scheduled only when the infection has completely cleared. However, removal of the 
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device along with inflammation from the infectious process leads to corporeal fibrosis and 
scarring, which almost always results in penile shortening and may make dilation of the 
corporeal bodies very difficult, resulting reinsertion of a new device more complicated and 
sometimes impossible (Brant et al., 1996; Mulcahy, 1999). 
A salvage protocol was instituted in 1991 to avoid difficult reinsertion and maintain as 
much penile length as possible. The salvage procedure involves removing all parts of the 
infected prosthesis, washing the wound, and replacing the device at the same procedure. 
Mulcahy et al. recommend a sequence of irrigating solutions including kanamycin and 
bacitracin in normal saline followed by half-strength hydrogen peroxide, half-strength 
povidone-iodine solution, pressurized normal saline containing vancomycin and 
gentamicin, half-strength povidone-iodine, half-strength hydrogen peroxide, and finally 
another kanamycin/bacitracin solution (Mulcahy et al., 1995). Gloves, instruments, gowns, 
and drapes are changed and a new inflatable penile prosthesis is immediately implanted. 
Postoperatively, patients are treated with antibiotics (2x500 mg ciprofloxacin) for 4-6 weeks. 
Antibiotics can be modified based on culture and sensitivity results. The reported success 
rate of the salvage procedure is 84-91% (Brant et al., 1996; Mulcahy, 2003). To avoid 
complications of late reinsertion the salvage protocol is a treatment alternative of traditional 
delayed reimplantation, although in patients with life-threatening systemic conditions such 
as septicemia, or diabetic ketoacidosis, or in whom necrotizing infections with death of 
penile skin is occurring salvage procedure is not recommended (Brant et al., 1996; Mulcahy, 
1999).  
The delayed salvage procedure consists of placement of a drainage tube after removal of the 
prosthesis; antibiotic solution is irrigated through the drain and a new prosthesis is placed 
about 3 days later. However, Knoll et al could not find a statistically significant difference 
between immediate and delayed salvage procedure (Knoll, 1998), while there are the 
additional cost of the second surgical procedure. 
6. Further research  
Prospective studies and long-term follow up are needed to make stronger recommendations 
about the different methods in the prevention or treatment of penile prostheses infections, 
especially about the hydrophilic coated penile prosthesis. 
7. Conclusion 
The efforts to apply more effective methods of prevention and the new developments of 
prosthesis coatings resulted a significant reduction of the infectious complications of 
penile prosthesis implantation. Further improvements of surgical procedures and 
prosthesis materials and coatings can lead to further decrease of the infection rates in the 
future. 
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1. Introduction 
Calgranulins A (S100A8), B (S100A9) and C (S100A12) are members of the superfamily of 
EF-hand calcium binding proteins. The term calprotectin specifically refers to the 
Calgranulin A and B heterodimer that is formed by a non-covalent interaction. A 
distinguishing feature of calgranulins is their involvement in innate immunity and 
inflammation. As secreted proteins, calgranulins can directly inhibit microbial growth in the 
extracellular milieu, presumably through their ability to chelate zinc. Cells that actively 
express calgranulins are more resistant to bacterial adherence and invasion. Calgranulins 
also support optimal functioning of the cells that comprise the innate immune system. For 
example, granulocytes depend on the intracellular calgranulin A/B complex to adequately 
participate in cell adhesion, cytokinesis, cytokine secretion, and activation of the respiratory 
burst. Calgranulin A/B can down-regulate immune responses through inhibition of 
immunoglobulin production by lymphocytes and induction of myeloid derived suppressor 
cells. In addition, calgranulin induces apoptosis in cells that stimulate the inflammatory 
cascade. Calgranulin A expression may also be important in promoting the induction of a 
regulatory macrophage phenotype that down-regulates inflammation and facilitates a 
healing response.  
Under normal conditions, calgranulins support an optimal immune response, leading to 
resolution of infection and inflammation. When normal expression and/or secretion of 
calgranulins are perturbed, inflammation is exacerbated with adverse implications for host 
tissues.  As an example, dysregulation in the expression or secretion of calgranulins can 
have detrimental effects by promoting chronic active inflammation that leads to collateral 
tissue damage. Excessive amounts of calgranulin A/B in extracellular compartments of 
tissues correlates with a variety of inflammatory disorders. Expression and release of 
calgranulin A/B in the extracellular milieu can be triggered by IL-1α. Extracellular 
calgranulin A/B can then bind to and activate toll like receptor 4 (TLR 4), which in turn 
initiates further expression of pro-inflammatory mediators such as IL-1, IL-6, and IL-8.  The 
interaction of these cytokines and chemokines with calgranulin A can create an autocrine / 
paracine mediated pro-inflammatory feedback loop that does not necessarily resolve 
infection. In the urinary tract, over expression of calgranulin A is not specific for infection. 
Over expression of calgranulins has been reported in a variety of inflammatory disorders of 
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the urinary tract, including interstitial cystitis, interstitial nephritis, glomerulonephritis and 
neoplasia. This suggests that while calgranulin A may be a useful biomarker for chronic 
active inflammation, in general it may not be important in the defence against bacterial 
pathogens. Recent studies in rodent models of urinary tract infection (UTI) suggest that 
calgranulins are not required for innate defence against urogenital pathogens. Moreover, the 
exaggerated expression of these proteins during infection may be contributing to 
complicated urinary tract diseases such as struvite urolithiasis.   
This review will focus on the role of calgranulin A and B in innate immune responses with 
particular attention to diseases of the urinary tract. The interaction of calgranulins with 
various host cell signal transduction pathways important in innate immunity and 
inflammation of the urinary tract will be reviewed. Further, potential consequences of 
aberrant signalling that may contribute to perturbations of regulation of calgranulins will 
also be discussed.  
2. Classification and general function of calgranulins 
Calgranulins are members of the superfamily of EF-hand calcium binding proteins that are 
involved in innate immune and pro-inflammatory processes. In the literature, these proteins 
have been given a variety of names including S100A8, myeloid related protein 8 (MRP), and 
L1 light chain for calgranulin A. Calgranulin B is also known as MRP-14 and S100A9. 
Calgranulin C may be referred to as S100A12 and EN-RAGE (Nacken et al., 2003). The name 
calprotectin specifically refers to the Calgranulin A and B heterodimer that is formed by a 
non-covalent interaction. Calgranulin C does not appear to form a heterodimer complex 
with either Calgranulin A or B (Foell et al., 2007).  
Calgranulin C appears to be exclusively expressed in granulocytes (Vogl et al., 1999). 
However, calgranulins A and B are constitutively expressed in a variety of cells including 
granulocytes, monocytes, dendritic cells, epithelial cells, and keratinocytes (Foell et al., 2007; 
Frosch et al., 2004; Nacken et al., 2003). In healthy individuals, low concentrations of 
calprotectin can be detected in plasma, saliva, cerebrospinal fluid, urine and feces (Johne et 
al., 1997). Typically calgranulin gene expression is tightly regulated. However, during 
inflammation, expression is induced in cells such as macrophages and fibroblasts that do not 
normally produce calgranulins (Foell et al., 2007; Frosch et al.., 2004; Hsu et al., 2005; Nacken 
et al., 2003). Further, cells that constitutively express calgranulins are induced to secrete 
calprotectin into the extracellular milieu when stimulated (Kido et al., 2003). Therefore, 
calprotectin is considered a biomarker of inflammatory conditions such as rheumatoid 
arthritis, Crohn’s disease, and chorioamnionitis (Kostakis et al., 2010; Perere et al., 2010).  
Calprotectin deficiency has never been reported in humans, suggesting that this protein is 
essential for life. The need for calgranulin A was confirmed with a null mutation in mice, 
which resulted in early resorption of mouse embryos (Passey et al., 1999a). Null mutation of 
the S100A9 gene (calgranulin B) was not lethal in the mouse (Hobb et al., 2003). 
Interestingly, although the S100A9 -/- mouse expresses S100A8 (calgranulin A) mRNA, the 
protein is not detected in peripheral tissues.. Consequently, this mouse strain does not 
produce calprotectin, making it convenient for use in studying the role of calprotectin in 
various disease processes. Although the calgranulin genes are conserved among higher 
vertebrates, there are structural and functional differences among the various species 
(Nacken et al., 2003). For example, in rodents, calgranulin A is chemotactic for granulocytes 
but this is not the case in humans (Foell et al., 2007). Calgranulin C, which is not present in 
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rodents, is the potent granulocyte chemoattractant in humans (Yang et al., 2001) and is 
highly expressed in activated tissue macrophages localized within sites of inflammation 
(Perera et al., 2010). Calgranulin C also serves as a ligand for RAGE (Perera et al., 2010). 
Although, rodents possess RAGE, there is no evidence that either calgranulin A, B, or 
calprotectin act as a ligand for this receptor. To date, there are no published studies 
demonstrating a role for calgranulin C in urinary tract infection. Therefore, this review will 
focus on calgranulins A and B.   
2.1 The contribution of calgranulins to defense against infection 
The innate immune system comprises the first attack against invading microorganisms. Both 
intracellular and extracellular calgranulins play an integral role in modulating leukocyte 
activation, trafficking, and amplification of immune responses during infection. Intracellular 
calgranulins regulate cell adhesion, migration, phagocytosis, and bacterial killing through 
direct interactions with the cell cytoskeleton and plasma membrane components. 
Calprotectin and calgranulin B facilitate phagocyte transmigration by coordinating 
microtubule dynamics (Vogl, et al., 2004). Specifically, the calprotectin complex induces 
polymerization of microtubules that can be disrupted by phosphorylation of calgranulin B 
by p38 mitogen-activated protein kinase. With disruption of the calprotectin complex the 
microtubule depolymerizes. A similar mechanism in squamous epithelial cells increases 
their resistance to intracellular invasion by mucosal pathogens such as Porphyromonas 
gingivalis, Listeria monocytogenes, and Salmonella enterica serovar Typhimurium (Nisapakultorn 
et al., 2001a, 2001b; Zaia et al., 2009). In neutrophils, calgranulin B is a selective stimulator of 
MAC-1 mediated adhesion (Newton & Hogg, et al., 1995). Calgranulin B does not directly 
bind to MAC-1 but its stimulatory effects on 2 integrin / MAC-1 appear to be mediated 
through a G protein coupled receptor. Calgranulin A can inhibit MAC-1 affinity activation 
by dimerizing with calgranulin B. In addition to modulating leukocyte trafficking, 
calgranulins also enhance microbial killing through enhancing the generation of reactive 
oxygen species in phagocytes. In neutrophils, calgranulin A and the calprotectin complex 
activate NADPH oxidase by facilitating enzyme complex assembly at the plasma membrane 
(Kerkoff, et al., 2005). The calprotectin complex transfers arachidonic acid, an essential 
cofactor, to the enzyme complex while the calgranulin A subunit contributes to NADPH 
enzyme assembly by directly binding to the p67phox subunit (Kerkoff, et al., 2005). In 
macrophages, calgranulins contribute to the generation of nitric oxide mediated killing 
through induction of nitric oxide synthase gene expression (Pouliot et al., 2008). 
Active secretion of calgranulins from neutrophils can be induced through engagement of 
toll-like receptor/CD14 and nuclear factor  (Kido et al., 2003) or through protein kinase C 
in monocytes (Nacken et al., 2003). Calgranulins can be found in mucosal body fluids that 
are normally colonized with bacteria, such as the oral cavity. Moreover, calprotectin 
concentrations increase in mucosal fluids in response to certain infections such as 
Helicobacter pylori (Leach et al., 2008). It has been suggested that the increased expression of 
calprotectin at these sites confers resistance to bacterial invasion or dissemination into 
deeper tissues (Hsu et al., 2009). Increased expression of calprotectin in humans with 
chronic sinusitis directly correlates with resistance to bacterial infection (Hsu et al., 2009). In 
our rodent model of ureaplasmal induced urinary tract infection, some animals with 
asymptomatic bladder infection and baseline levels of calprotectin developed ascending 
renal infections. However, animals with bladder infections accompanied by high amounts of 
calprotectin did not develop ascending renal infection (Reyes et al., 2008, 2009). Therefore, 
suggesting that calprotectin may be somewhat protective in the urinary tract.  
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Calprotectin microbicidal activity towards Candida albicans, Staphylococcus aureus, 
Straphylococcus epidermis, Escherichia coli, and Klebisiella species has been demonstrated in vito 
(Brandtzaeg, et al., 1995). Further, calprotectin has been shown to be effective in inhibiting 
the growth of S. aureus within liver abscesses of mice (Corbin et al., 2008). The mechanism of 
action by calprotectin appears to be chelation of magnesium, manganese, and zinc, which 
are required for growth by bacteria (Corbin et al., 2008, Hsu et al., 2009).   
Extracellular calgranulins also augment immune defense mechanisms in a cytokine like 
manner. Calgranulin B enhances neutrophil microbial killing by stimulating degranulation 
of matrix metalloproteinase through p38 mitogen activated protein kinase (Simard et al., 
2010). Calprotectin stimulates production of interleukin-8 in airway epithelial cells (Ahmad 
et al, 2003). Calprotectin binding to microvascular endothelial cells promotes chemokine 
secretions, up regulation of cell adhesion molecules, and disruption of the endothelial 
barrier (Viemman et al., 2005, Eue et al., 2000), facilitating leukocyte migration into sites of 
infection. Calprotectin may also contribute to bacterial clearance from uroepithelium 
through its ability to enhance activation of toll-like receptor (TLR) 4 (Ehrchen, et al., 2009). 
Song et al. identified an additional alternative pathway in uroepithelium in which activation 
of TLR 4 by uropathogenic type 1 fimbriated E. coli or Klebsiella pneumoniae results in rapid 
activation of adenylate cyclase 3. The increased intracellular cAMP causes rapid expression 
and secretion of interleukin-6 that precedes cytokine production through the classical NF- 
mediated pathway (Song et al., 2007). This pathway may be critical for early defense against 
invading microbes. More importantly, cAMP blocks intracellular invasion of bacteria into 
uroepithelium and promotes expulsion of bacteria through inhibition of Rac-1 mediated 
mobilization of the cytoskeleton (Song et al., 2007). This is an intriguing concept, but it 
appears that calprotectin may not be contributing to this unique defense mechanism. 
Dessing et al., compared the ability of uropathogenic E. coli to establish acute ascending 
infection in wild type and calprotectin deficient mice (S100A9 -/-). In this study animals 
received an intraurethral inoculation of 108 organisms and were examined at 24 and 48 
hours post-inoculation. Despite significant increases in calprotectin in both the bladder and 
kidney tissues of wild type mice, they did not exhibit any difference in microbial load or 
lesion severity when compared S100A9 -/- mice. Therefore, suggesting that calprotectin is 
not critical for early clearance of bacteria from the urinary tract.  
2.2 Regulation of immunity by calgranulins 
Successful defense against infection depends on a well controlled inflammatory response 
that is able to remove the pathogen without extensive collateral damage of the surrounding 
host tissues. During an effective immune response the signal transduction pathways trigger 
production and /or release of pro-inflammatory mediators that potentiate removal of the 
pathogen, and simultaneously or sequentially activate anti-inflammatory factors and protect 
surrounding tissues from proteases and reactive oxygen species. Calgranulins participate in 
several of these processes most of which have been identified in macrophages (Lim et al. 
2009; Passey et al., 1999b; Xu et al., 2001). For example, bacterial lipopolysaccaride, IFN-γ, 
TNF-, and interleukin-10 all induce calgranulin gene expression in murine macrophages 
(Xu et al., 2001). Glucocorticoids also amplify calgranulin expression in macrophages that 
have been primed with lipopolysacarride (Hsu et al., 2005). Methylprednisolone treatment 
in rheumatoid arthritis patients significantly increases the number of calgranulin A and B 
expressing macrophages in synovium (Hsu et al., 2005).  
Secreted calgranulins also exhibit anti-inflammatory properties in neutrophils. Sroussi et al., 
have shown that both calgranulin A and B can repel human neutrophils in vitro, and that 
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calgranulin A can inhibit the recruitment of neutrophils in vivo (Sroussi et al., 2006, 2007). 
Recently, they have demonstrated that calgranulin A and B also inhibit neutrophil oxidative 
metabolism (Sroussi et al., 2010). Although the mechanism of action has not been elucidated, 
adenosine metabolites are known to be involved.  
Calgranulins that have undergone post-translational modifications can down-regulate 
inflammation or provide protection from granulocyte secreted products such as reactive 
oxygen species. Calgranulin A, in particular, is highly susceptible to oxidation by 
hydroxyapatite, hydrogen peroxide, and hypochlorite (Lim et al., 2009; Harrison et al, 1999). 
Calgranulins therefore act as sinks for reactive oxygen species, providing protection of the 
microenvironment from collateral damage. Both calgranulins A and B can be nitrosylated 
(addition of nitric oxide molecule) (Lim et al., 2008, 2009). Nitrosylated calgranulin A 
suppresses mast cell mediated activation, leukocyte adhesion, and extravasation into the 
microcirculation (Lim et al., 2008).  
Calgranulins A and B modulate various aspects of adaptive immunity. Calgranulin A has 
been reported to inhibit immunoglobulin G production in lymphocytes (Brun et al., 1995). 
Calgranulin B may down regulate responsiveness to toll-like receptor mediated stimulation 
in dendritic cells (Averill et al., 2011). During murine myeloid differentiation, increased 
expression of calgranulin B in embryonic stem cells favors development into myeloid 
derived suppressor cells over dendritic cells (Lim et al. 2009). Myeloid derived suppressor 
cells promote immune tolerance during infection and inflammation by suppression of T cell 
activation and promotion of a T helper type 2 cytokine phenotype involving expression of 
interleukin-4 and interleukin-13 (Delano et al., 2007; Ezernitchi et al., 2006; Haile et al., 2008). 
Moreover, calprotectin secreted by myeloid derived suppressor cells prolongs their 
immunosuppressive effects through an autocrine positive feedback loop (Lim et al., 2009).  
2.3 Pro-inflammatory effects of calgranulins 
Increases in extracellular calgranulin concentrations are associated with several inflammatory 
and auto-immune disorders including cystic fibrosis, chronic bronchitis, sepsis, pyelonephritis, 
oral candidiasis, periodontitis, Helicobacter pyloris infections, rheumatoid arthritis, systemic 
lupus erythematosus, Crohn’s disease, Sjogren’s syndrome, and atherosclerosis (Foell et al., 
2007; Johne et al., 1997; Perera et al., 2010). In the urinary tract calgranulins are found to be a 
major component of calcium oxalate, calcium phosphate, (Canales et al, 2008, 2010) and 
struvite uroliths (Bennett et al., 1994), all of which are associated with inflammation (Mushtaq 
et al., 2007; Reyes et al., 2009). In the case of calcium phosphate and calcium oxalate stones, 
renal injury with inflammation contributes to urolith formation (Khan, 2005). Struvite stones 
are sequela to severe inflammatory urinary tract infection caused by urease producing bacteria 
(Reyes et al., 2009). Due to their close association with inflammation, calgranulins are often 
used as diagnostic biomarkers for inflammatory disorders (Altwegg et al., 2007; Healy et al., 
2006). There is a growing body of evidence that calgranulins play more than a passive role in 
at least some of these disorders. For example, Croce et al. showed that the inflammatory 
response to vascular injury is attenuated in calprotectin deficient animals. Further, deletion of 
calprotectin in atherosclerosis prone ApoE-/- mice reduces their susceptibility to the disease 
(Croce et al, 2009).  Similar effects have been observed in CD40L over-expressing mice that 
spontaneously develop dermatitis, nephritis, auto-antibodies in serum, and auto-reactive CD8+ 
T cells (Loser et al., 2010). In these animals, genetic deletion of S100A9 alleviates the 
progression of the disease.  
One mechanism by which calprotectin amplifies inflammation is through direct activation of 
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increases expression of interleukin-17, which activates autoreactive CD8+ T cells (Loser et al., 
2010). In experimentally induced sepsis, calprotectin enhancement of TLR 4 activation 
induces exaggerated secretion of TNF- with endotoxic shock, which is not observed in 
S100A9 -/- mice. However, septic S100A9 -/- mice treated with recombinant calprotectin 
exhibit the same degree of endotoxic shock and mortality as their wild type counterparts. It 
is important to note that calprotectin mediated enhancement of TLR 4 pathway only occurs 
in systems that have already been immunologically activated. For example, in the case of the 
sepsis model, the initial activation of TLR 4 occurred by bacterial lipopolysaccaride. These 
results prompted us to re-evaluate our rat model of inflammation induced struvite 
urolithiasis secondary to experimental infection with Ureaplasma parvum (Reyes et al., 2008, 
2009). In this model, expression of calprotectin is only observed in animals with 
inflammation secondary to urinary tract infection. Therefore, we wondered if activation of 
TLR 4 may also be a aspect in this disease. An important feature of Ureaplasma parvum is that 
this pathogen does not activate TLR 4, but does activate TLRs 1, 2, and 6 in macrophages 
(Shimizu et al., 2008). Moreover, ureaplasmas do not induce pro-inflammatory cytokine 
expression in uroepithelium as shown in Figure 1.  
 
 
Fig. 1. Chemokine/cytokine profile of RT4 cell culture supernatants. 
In an unpublished study of women with first time urinary tract infection, we identified the 
predominant pathogens present. Escherichia coli was isolated from 59.8% of 82 samples that 
had high numbers (>300,000 CFU/ml clean catch urine), and from 64.8% of 54 urines with 
medium microbial loads (100,000 to 300,000 CFU/ml clean catch urine). The next most 
common isolates present in high numbers were Ureaplasma Spp (20.7%), Staphylococcus 
saprophyticus (7.3%), and Proteus mirabilis (7.3%). Escherichia fergusonii, Klebsiella pneumoniae, 
and Proteus vulgaris each accounted for 1.2% of remaining urines with >300,000 CFU/ml. At 
CFU 100,000 to 300,000/ml urine, S. saprophyticus was isolated from 7.4% of urines. K. 
pneumoniae, P. mirabilis, Staphylococcus aureus, S. epidermidis, S. haemolyticus, and Streptococcus 
agalactiae were isolated from 3.7% of urines, with Citrobacter koseri, Enterobacter aerogenes, and 
K. oxytoca each accounting for 2% of urine samples. We determined the cytokine/chemokine 
profile of RT4 cells. Test pathogens were chosen on the basis of predominance in our study 
patients. RT4 cells were sham inoculated with sterile carrier (control) or, U. urealyticum (Uu), 
E. coli (Ec), S. saprophyticus (Ss), S. agalactiae (Sa), or K. pneumoniae (Kp) at a multiplicity of 
infection of 100. At 24 hours post-inoculation, cell culture supernatants were harvested and 
evaluated for the presence of interleukin-8, interleukin-1α, and interleukin-1β. Values in the 
graph represent the mean ± sd (n = 4) of 2 independent experiments. Chemokine and 
cytokine concentrations were measured with a multiplex antibody assay as previously 
described (Reyes, et al. 2006).  
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Ureaplasmal infections are asymptomatic as long as their colonization is restricted to the 
urogenital mucosa. However, if these bacteria invade the deeper stromal layers, they induce 
an exaggerated host immune response that does not eliminate infection, but rather causes 
tremendous tissue damage at sites of colonization. In our rodent model of infection, 
invasion of bacteria into the submucosa triggered a smoldering inflammation within the 
submucosa that persisted. By two weeks post-inoculation, animals with ongoing 
submucosal infection developed struvite uroliths and an exaggerated pro-inflammatory 
cytokine profile in their urine. Since U. parvum is not capable of eliciting these responses in 
uroepithelium, we surmised that the initiator of uroepithelial cytokine production (see 
Figure 2) is a paracine factor originating from the inflamed submucosa.  On the other hand, 
animals in which the microbe is found only on the mucosal layer exhibited asymptomatic 
infection. In these animals, bladder uroepithelium appears quiescent and urine cytokine 
concentrations are comparable to uninfected controls as shown in Figure 2. This is similar to 































Fig. 2. Chemokine/cytokine profile in urine obtained from uninfected rats (Control), rats 
with asymptomatic urinary tract infection (UTI), or rats with struvite urolithiasis (Struvite).  
Values represent the mean ± sd of 5 biological replicates. Data was analyzed by ANOVA 
followed by Fishers PLSD test. 
 
 
Fig. 3. Induction of calgranulin A in U. parvum infected rat bladder tissues. Calgranulin 
concentrations in rat bladder tissue homogenates from sham inoculated controls, animals 
with asymptomatic (UTI), and complicated (Struvite) urinary tract infection were measured 
by ELISA (Reyes et al., 2009). Absorbance values obtained by ELISA were normalized to 
total protein concentration of tissue homogenates. Values represent the mean ± sd fold 
change (infected/control) in the calgranulin concentration from 5 biological replicates. Data 
were analyzed by unpaired student’s t test.  
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Fig. 2. Chemokine/cytokine profile in urine obtained from uninfected rats (Control), rats 
with asymptomatic urinary tract infection (UTI), or rats with struvite urolithiasis (Struvite).  
Values represent the mean ± sd of 5 biological replicates. Data was analyzed by ANOVA 
followed by Fishers PLSD test. 
 
 
Fig. 3. Induction of calgranulin A in U. parvum infected rat bladder tissues. Calgranulin 
concentrations in rat bladder tissue homogenates from sham inoculated controls, animals 
with asymptomatic (UTI), and complicated (Struvite) urinary tract infection were measured 
by ELISA (Reyes et al., 2009). Absorbance values obtained by ELISA were normalized to 
total protein concentration of tissue homogenates. Values represent the mean ± sd fold 
change (infected/control) in the calgranulin concentration from 5 biological replicates. Data 
were analyzed by unpaired student’s t test.  
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In our rodent model of U. parvum induced urinary tract infection, proteome analysis of 
bladder tissues revealed that concentrations of calgranulins A and B were seven fold higher 
in tissues from struvite positive animals (Reyes et al., 2009). Calgranulin A concentrations 
were confirmed by ELISA as shown in Figure 3. Moreover, the calgranulin A concentrations 
in bladder tissue homogenates directly correlated with urine pro-inflammatory cytokine 
concentrations, suggesting a link between calgranulin A, GRO/KC, IL-1α,and IL-1β. 
We also evaluated the distribution of calprotectin within the bladder tissues of animals 
infected with U. parvum for 72 hours and 2 weeks post-inoculation. Calprotectin within 
uroepithelium was detected in bladder tissues obtained from struvite positive animals at 2 
weeks post-inoculation (as shown in Figure 4). In these animals, calprotectin was also 
detected within endothelial cells that were surrounded by leukocyte infiltrates (Figure 4D).  
Despite the fact the uroepithelium of animals with asymptomatic urinary tract infection was 
colonized with U. parvum, these animals did not exhibit bladder inflammation or expression 
of calprotectin by uroepithelium (Figure 4B). We did not observe uroepithelial expression of 
calprotectin in the 72 hour group, even in animals with ongoing inflammation within the 
submucosa. Since calprotectin staining could be observed within neutrophils present in 
these tissues, we were confident that the lack of staining was not an artifact. 
 
 
Fig. 4. Distribution of calprotectin in bladder tissues of Fisher rats. Images are 400x 
magnification of representative bladder tissue sections obtained from sham inoculated 
control (A), asymptomatic urinary tract infection (B), and struvite positive animals (C and 
D). Thin white arrows are placed within the lumen and point to the uroepithelial surface in 
panels A, B, and C. Panel D shows the distribution of calprotectin (red) detected within the 
submucosa that was infiltrated with, some of which are concentrated around the blood 
vessel (identified by the block arrow).  Bladder tissue sections were processed as previously 
described (Reyes et al., 2009). Calprotectin was detected with monoclonal antibody (clone 
MAC 387, from Thermo Scientific, Fremont, CA., USA) followed by goat anti-rabbit 
conjugated to Alexa-660. Cell nuclei (blue) were labeled with DAPI stain. Images were 
captured with Olympus IX81 Spinning disk confocal microscope.  
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Danger-associated pattern molecules (DAMP) are endogenous ligands of toll like receptors. 
These molecules are often by-products of inflammation such as reactive oxygen species 
(Frantz et al., 2001) or tissue degradation products from the extracellular matrix (Okamura 
et al., 2001). Calprotectin is now considered a DAMP because of its ability to activate TLR4 
(Ehrchen et al., 2009). Since we observed a correlation between uroepithelial calprotectin 
expression and pro-inflammatory cytokines in the urine of struvite positive animals, we 
measured the amount and distribution of TLR 4 in the bladder tissues of rats infected for 72 
hours and 2 weeks post-inoculation.There were no appreciable differences in the amount of 
TLR 4 detected in bladder tissues from sham inoculated controls, or U. parvum infected 
animals at 72 hours post-inoculation. However, at 2 weeks post-inoculation, struvite 
positive animals exhibited more intense staining of TLR 4 in uroepithelium than uninfected 
controls or animals with asymptomatic urinary tract infection (see Figure 5). 
Since Ureaplasma does not directly activate TLR 4, the increased expression observed in 
struvite positive animals is most likely mediated by DAMPS. Our current study cannot 
confirm if this activation was initiated by calprotectin or other DAMPS that were detected in 
our proteome studies such as heat shock protein 60 (Chen et al., 2007) and a variety of 
extracellular matrix proteins. Nevertheless, the lack of TLR 4 activation in inflamed tissues 
from the 72 hour time point, coupled with the direct association of uroepithelial calprotectin 
expression and TLR 4 expression suggests that calprotectin is contributing to an adverse 
inflammatory response in the struvite group.   
 
 
Fig. 5. Distribution of TLR 4 in rat bladder tissues of Fisher rats. Images in panels A, B, and 
C are 200x magnification of representative bladder tissue sections obtained from sham 
inoculated control (A), asymptomatic urinary tract infection (B), and struvite positive 
animals (C and D). Thin white arrows are placed within the lumen and point to the 
uroepithelial surface. Panel D is a 400x magnification of panel C. Tissues were processed as 
previously described (Reyes et al., 2009). TLR 4 (red) was detected with rabbit polyclonal 
antibody (Abbiotec, LLC, San Diego, CA) followed by goat anti-rabbit conjugated to Alexa-
594. Cell nuclei (blue) were labeled with DAPI stain. Images were captured with Olympus 
IX81 Spinning disk confocal microscope.  
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2.4 Regulation of calgranulin gene expression in different cell populations 
In addition to participating in immune defence, calgranulins are involved in embryogenesis, 
growth, and differentiation. Therefore, it is not surprising that the expression of these 
proteins is tightly regulated in a cell and tissue specific manner, which can change in 
response to environmental cues. For example, most mucosal epithelial cells have a basal 
level of calgranulin expression that changes in response to the appropriate stimulus (Ross & 
Hertzberg, 2001, Hsu et al., 2005, 2009). The appropriate stimulus for one tissue type is not 
necessarily the same for another. For example, calgranulin expression in oral squamous 
epithelial cells increases in response to interleukin-1α, but bacterial lipopolysaccaride does 
not induce an effect (Ross & Hertzberg, 2001). This may pertain to the fact that the oral 
cavity is heavily colonized with bacteria. On the other hand, bronchiolar epithelium 
increases its calgranulin expression in response to lipopolysaccaride mediated activation of 
TLR4 (Henke et al., 2006). Uroepithelium has a low basal expression of calgranulins A and 
B, which is significantly up regulated in cancer and inflammation (Yao et al., 2007; Tyagi et 
al., 2008). It is not known what specific cytokines or factors induce up regulation of 
calgranulin gene expression in these cells, but the studies performed by our laboratory and 
Dressing et al., imply that uroepithelium would respond to both interleukin-1α and toll like 
receptor activation.  
Varieties of cell types that reside within bladder submucosa either repress or express 
calgranulins in response to changes within the tissue microenvironment. Cells pertinent to 
urinary tract infection are fibroblasts, dendritic cells, macrophages, and neutrophils 
(Cresswell, et al., 2001; Shafik, et al., 2004; Christmas & Botazzo, 1992; Shimizu et al., 2011). 
Fibroblasts do not participate in antimicrobial processes during urinary tract infection, but 
their response to mediators released by uroepithelial cells exposed to E. coli can influence 
their ability to migrate and remodel the extracellular matrix, which is particularly important 
in renal interstitial scarring (Kapoor et al., 2001). Furthermore, calgranulin expressing 
fibroblasts can be detected during the early stages of wound healing (Rahimi et al., 2005). 
Fibroblast growth factor-2 or interleukin-1β increases expression of calgranulins by 
fibroblasts. However, transforming growth factor-β, which promotes fibroblast migration in 
response to bacterial/urothelial products, can block calgranulin expression in these cells 
(Kapoor et al., 2001).  
Dendritic cells are important in immune surveillance and can express calgranulins in 
varying intensity depending on their level of maturation (Kumar et al., 2003; Koga et al., 
2008). Immature dendritic cells express higher amounts of calgranulins A and B than mature 
cells (Koga et al., 2008). Interleukin-10 promotes induction of tolerogenic dendritic cells, 
which then exhibit increased expression of calgranulins (Kumar et al., 2003). Further, 
calgranulin B may down regulate cytokine release in dendritic cells after toll-like receptor 
stimulation (Averill et al., 2011). 
Macrophages represent differentiated monocytes that have migrated into tissues in response 
to pro-inflammatory signals or part of a homeostatic process. When differentiation is 
complete these cells cease to express calgranulins unless they become activated (Nacken et 
al., 2003). It is important to note that not all activated macrophages express calgranulins. 
Presently, three macrophage phenotypes with distinctly different functions have been 
identified (Benoit et al., 2008; Mosser & Edwards, 2008). The phenotype is determined by the 
type of stimulus the cell receives during the process of activation. For example, 
macrophages exposed to interferon-γ in combination with TNF-α, and induction of TLR 
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transforms them into the classically activated or microbicidal macrophage (Benoit et al., 
2008; Mosser & Edwards, 2008). Classically activated macrophages are known for their 
enhanced microbial killing through induction of nitric oxide synthase, secretion of pro-
inflammatory cytokines (TNF, interleukin-1β, interleukin-6, and interleukin-12) and 
secretion of chemokines (CCL2, CCL5, and CXCL8) (Benoit et al., 2008). Resident 
macrophages that are exposed to interleukin-4 and/or interleukin-13 transform into a 
wound healing phenotype. Instead of participating in pro-inflammatory events, these cells 
primarily secrete extracellular matrix proteins and contribute to tissue remodelling. The 
third activated phenotype is referred to as the regulatory macrophage because these cells 
express high amounts of co-regulatory molecules that bind to T cell receptors. In addition, 
regulatory macrophages secrete high amounts of interleukin-10, and these cells are 
primarily involved in down-regulation of the inflammatory response (Mosser & Edwards, 
2008). Of the three phenotypes, only regulatory macrophages express calgranulins, in 
particular calgranulin A (Benoit et al., 2008; Hsu et al., 2009). Therefore, calgranulin A may 
be a useful molecular marker for the in situ identification of these cells. 
A common feature of regulatory macrophages is that they develop from simultaneous 
exposure to two stimuli (Mosser & Edwards, 2008). The first signal has little to no 
stimulatory function. Weak agonists known to induce a regulatory phenotype include 
immunoglobulin complexes, prostaglandins, apoptotic cells, glucocorticoids, interleukin-10, 
or G-protein coupled receptor ligands. The second signal involves TLR activation. It has 
been postulated that calgranulin expression by regulatory macrophages contributes to their 
immunosuppressive function (Hsu et al., 2009). Support for this argument is that regulatory 
macrophages exclusively express calgranulin A, which can reduce the damaging effects of 
inflammation by acting as a scavenger for reactive oxygen species. Furthermore, secreted 
calgranulin A also repels or inhibits recruitment of neutrophils (Hsu et al., 2009; Sroussi et 
al., 2010; Xu et al., 2001). Although regulatory macrophages may be highly beneficial during 
sterile inflammation, their presence at sites of infection may be potentially detrimental.  
Regulatory macrophages can be exploited by bacterial, parasitic, and viral pathogens. For 
example, during invasion of macrophages, Leishmania species can utilize immunoglobulin 
complexes to promote the induction of a regulatory phenotype (Moser & Edwards, 2008). 
Regulatory macrophages may also be inadvertently assisting microbial persistence in the 
urogenital tract. For example, Ureaplasmas are chronic and persistent colonizers of the 
human urogenital tract, and infections are often asymptomatic (Reyes et al., 2008, 2009; 
Volgmann et al., 2005). However, these organisms are also associated with pro-
inflammatory disorders including interstitial nephritis, urethritis, and overactive bladder 
(Latthe et al., 2008; Lee et al., 2010). As urease producers, Ureaplasmas promote development 
of struvite uroliths (Grenabo et al., 1988). During infection these microbes induce secretion 
of prostaglandin E2 and interleukin-10 in host cells (Aaltonen et al., 2007; Estrada-Gutierrez 
et al., 2010; Moser et al., 2009), which are recognized promoters of the regulatory 
macrophage phenotype (Moser & Edwards, 2008). Although this connection has yet to be 
demonstrated with this organism, it is an intriguing notion that Ureaplasmas may be 
benefiting from such a mechanism.  
3. Conclusion 
The biological function of calgranulins is complex, diverse and paradoxical. Therefore, 
extrapolations from studies outside of the context of urinary tract infection must be made 
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2.4 Regulation of calgranulin gene expression in different cell populations 
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response to environmental cues. For example, most mucosal epithelial cells have a basal 
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Hertzberg, 2001, Hsu et al., 2005, 2009). The appropriate stimulus for one tissue type is not 
necessarily the same for another. For example, calgranulin expression in oral squamous 
epithelial cells increases in response to interleukin-1α, but bacterial lipopolysaccaride does 
not induce an effect (Ross & Hertzberg, 2001). This may pertain to the fact that the oral 
cavity is heavily colonized with bacteria. On the other hand, bronchiolar epithelium 
increases its calgranulin expression in response to lipopolysaccaride mediated activation of 
TLR4 (Henke et al., 2006). Uroepithelium has a low basal expression of calgranulins A and 
B, which is significantly up regulated in cancer and inflammation (Yao et al., 2007; Tyagi et 
al., 2008). It is not known what specific cytokines or factors induce up regulation of 
calgranulin gene expression in these cells, but the studies performed by our laboratory and 
Dressing et al., imply that uroepithelium would respond to both interleukin-1α and toll like 
receptor activation.  
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calgranulins in response to changes within the tissue microenvironment. Cells pertinent to 
urinary tract infection are fibroblasts, dendritic cells, macrophages, and neutrophils 
(Cresswell, et al., 2001; Shafik, et al., 2004; Christmas & Botazzo, 1992; Shimizu et al., 2011). 
Fibroblasts do not participate in antimicrobial processes during urinary tract infection, but 
their response to mediators released by uroepithelial cells exposed to E. coli can influence 
their ability to migrate and remodel the extracellular matrix, which is particularly important 
in renal interstitial scarring (Kapoor et al., 2001). Furthermore, calgranulin expressing 
fibroblasts can be detected during the early stages of wound healing (Rahimi et al., 2005). 
Fibroblast growth factor-2 or interleukin-1β increases expression of calgranulins by 
fibroblasts. However, transforming growth factor-β, which promotes fibroblast migration in 
response to bacterial/urothelial products, can block calgranulin expression in these cells 
(Kapoor et al., 2001).  
Dendritic cells are important in immune surveillance and can express calgranulins in 
varying intensity depending on their level of maturation (Kumar et al., 2003; Koga et al., 
2008). Immature dendritic cells express higher amounts of calgranulins A and B than mature 
cells (Koga et al., 2008). Interleukin-10 promotes induction of tolerogenic dendritic cells, 
which then exhibit increased expression of calgranulins (Kumar et al., 2003). Further, 
calgranulin B may down regulate cytokine release in dendritic cells after toll-like receptor 
stimulation (Averill et al., 2011). 
Macrophages represent differentiated monocytes that have migrated into tissues in response 
to pro-inflammatory signals or part of a homeostatic process. When differentiation is 
complete these cells cease to express calgranulins unless they become activated (Nacken et 
al., 2003). It is important to note that not all activated macrophages express calgranulins. 
Presently, three macrophage phenotypes with distinctly different functions have been 
identified (Benoit et al., 2008; Mosser & Edwards, 2008). The phenotype is determined by the 
type of stimulus the cell receives during the process of activation. For example, 
macrophages exposed to interferon-γ in combination with TNF-α, and induction of TLR 
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transforms them into the classically activated or microbicidal macrophage (Benoit et al., 
2008; Mosser & Edwards, 2008). Classically activated macrophages are known for their 
enhanced microbial killing through induction of nitric oxide synthase, secretion of pro-
inflammatory cytokines (TNF, interleukin-1β, interleukin-6, and interleukin-12) and 
secretion of chemokines (CCL2, CCL5, and CXCL8) (Benoit et al., 2008). Resident 
macrophages that are exposed to interleukin-4 and/or interleukin-13 transform into a 
wound healing phenotype. Instead of participating in pro-inflammatory events, these cells 
primarily secrete extracellular matrix proteins and contribute to tissue remodelling. The 
third activated phenotype is referred to as the regulatory macrophage because these cells 
express high amounts of co-regulatory molecules that bind to T cell receptors. In addition, 
regulatory macrophages secrete high amounts of interleukin-10, and these cells are 
primarily involved in down-regulation of the inflammatory response (Mosser & Edwards, 
2008). Of the three phenotypes, only regulatory macrophages express calgranulins, in 
particular calgranulin A (Benoit et al., 2008; Hsu et al., 2009). Therefore, calgranulin A may 
be a useful molecular marker for the in situ identification of these cells. 
A common feature of regulatory macrophages is that they develop from simultaneous 
exposure to two stimuli (Mosser & Edwards, 2008). The first signal has little to no 
stimulatory function. Weak agonists known to induce a regulatory phenotype include 
immunoglobulin complexes, prostaglandins, apoptotic cells, glucocorticoids, interleukin-10, 
or G-protein coupled receptor ligands. The second signal involves TLR activation. It has 
been postulated that calgranulin expression by regulatory macrophages contributes to their 
immunosuppressive function (Hsu et al., 2009). Support for this argument is that regulatory 
macrophages exclusively express calgranulin A, which can reduce the damaging effects of 
inflammation by acting as a scavenger for reactive oxygen species. Furthermore, secreted 
calgranulin A also repels or inhibits recruitment of neutrophils (Hsu et al., 2009; Sroussi et 
al., 2010; Xu et al., 2001). Although regulatory macrophages may be highly beneficial during 
sterile inflammation, their presence at sites of infection may be potentially detrimental.  
Regulatory macrophages can be exploited by bacterial, parasitic, and viral pathogens. For 
example, during invasion of macrophages, Leishmania species can utilize immunoglobulin 
complexes to promote the induction of a regulatory phenotype (Moser & Edwards, 2008). 
Regulatory macrophages may also be inadvertently assisting microbial persistence in the 
urogenital tract. For example, Ureaplasmas are chronic and persistent colonizers of the 
human urogenital tract, and infections are often asymptomatic (Reyes et al., 2008, 2009; 
Volgmann et al., 2005). However, these organisms are also associated with pro-
inflammatory disorders including interstitial nephritis, urethritis, and overactive bladder 
(Latthe et al., 2008; Lee et al., 2010). As urease producers, Ureaplasmas promote development 
of struvite uroliths (Grenabo et al., 1988). During infection these microbes induce secretion 
of prostaglandin E2 and interleukin-10 in host cells (Aaltonen et al., 2007; Estrada-Gutierrez 
et al., 2010; Moser et al., 2009), which are recognized promoters of the regulatory 
macrophage phenotype (Moser & Edwards, 2008). Although this connection has yet to be 
demonstrated with this organism, it is an intriguing notion that Ureaplasmas may be 
benefiting from such a mechanism.  
3. Conclusion 
The biological function of calgranulins is complex, diverse and paradoxical. Therefore, 
extrapolations from studies outside of the context of urinary tract infection must be made 
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with caution. To date, there are only two published reports that refer to calgranulins during 
urinary tract infection. Based on these reports, we can only conclude that the antimicrobial 
properties of calgranulins are minimally effective in the urinary tract. More than likely, the 
pro-inflammatory properties of calgranulins contribute to complicated inflammatory 
diseases such as struvite urolithiasis, pyelonephritis, and possibly interstitial cystitis. The 
positive correlation between increased calgranulin expression and inflammation in tissues, 
support the argument that these proteins may serve as biomarkers for chronic complicated 
urinary tract infections. However, additional studies are required in order to determine 
which clinical settings would benefit from monitoring calgranulin concentrations during 
urinary tract infections. Of more immediate benefit may be the use of calgranulins as 
molecular markers in basic science research. For example, monitoring these proteins during 
maturation and activation of different cell types that comprise innate defense may provide 
new insights into mechanisms of immune dysregulation induced by various microbial 
pathogens of the urinary tract.  
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with caution. To date, there are only two published reports that refer to calgranulins during 
urinary tract infection. Based on these reports, we can only conclude that the antimicrobial 
properties of calgranulins are minimally effective in the urinary tract. More than likely, the 
pro-inflammatory properties of calgranulins contribute to complicated inflammatory 
diseases such as struvite urolithiasis, pyelonephritis, and possibly interstitial cystitis. The 
positive correlation between increased calgranulin expression and inflammation in tissues, 
support the argument that these proteins may serve as biomarkers for chronic complicated 
urinary tract infections. However, additional studies are required in order to determine 
which clinical settings would benefit from monitoring calgranulin concentrations during 
urinary tract infections. Of more immediate benefit may be the use of calgranulins as 
molecular markers in basic science research. For example, monitoring these proteins during 
maturation and activation of different cell types that comprise innate defense may provide 
new insights into mechanisms of immune dysregulation induced by various microbial 
pathogens of the urinary tract.  
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1. Introduction 
The bladder wall is coated with various mannosylated proteins which interfere with the 
binding of bacteria to the uroepithelium. As binding is an important factor in establishing 
pathogenicity for these organisms, its disruption results in reduced capacity for invasion of 
the tissues.[1a,b] Moreover, the unbound bacteria are more easily removed when voiding. 
The use of urinary catheters (or other physical trauma) may physically disturb this 
protective lining, thereby allowing bacteria to invade the exposed epithelium.[1a,b]Over 
ninety percent of all UTIs are ascending and starting with colonization of periuretheral 
area.[1c-d] The most common organism implicated in Urinary tract infections UTIs (80–85%) 
is E. coli,[1a,b] while Staphylococcus saprophyticus is the cause in 5–10%. [1a,b]  The genus 
Escherichia coli (E.coli) with five species is a member of Entrobacteriaceae family. This gram  
negative bacilli is associated with a variety of diseases, such as urinary tract nfections(UTIs), 
meningitis and so on. E.coli can produce adhesins (P pili, AAF/I,AAF/III,..) which bind to 
cells lining the bladder and upper urinary tract.[1c-d] During cystitis, uropathogenic 
Escherichia coli (UPEC) subvert innate defenses by invading superficial umbrella cells and 
rapidly increasing in numbers to form intracellular bacterial communities (IBCs).[1,2] By 
working together, bacteria in biofilms build themselves into structures that are more firmly 
anchored in infected cells and are more resistant to immune-system assaults and antibiotic 
treatments.[2a,b]  This is often the cause of chronic urinary tract infections. 
Bacteruria can be symptomatic or asymptomatic. There are no signs in asymptomatic 
Bacteruria but bacteria are isolated; in these cases treatment is necessary for pregnant 
women and patients who have instrument in genitourinary tract. Therefore, infection is 
defined by clinical parameters and special situations, no by identification of microbe 
solely.[1c-d] In complicated or questionable cases, confirmation via urinalysis, looking for 
the presence of nitrites, leukocytes, or leukocyte esterase, or via urine microscopy, looking 
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for the presence of red blood cells, white blood cells, and bacteria, may be useful.[1a,b] 
Urine culture shows a quantitative count of greater than or equal to 103 colony-forming 
units (CFU) per mL of a typical urinary tract organism along with antibiotic sensitivity is 
useful to select appropriate antibiotic .[1a,b] On the whole, diagnosis is based on symptoms 
and urine culture.[1c-d] 
 
 
Fig. 1. Multiple bacilli (rod-shaped bacteria have shown as black and bean-shaped) shown 
between white cells at urinary microscopy. This is called bacteriuria and pyuria, 
respectively. These changes are indicative of a UTI. See [1a,b] 
Accurately, estimate of its incidence is difficult because many cases have not been reported. 
According to the 1997 National Ambulatory Medical Care Survey and National Hospital 
Ambulatory Medical Care Survey, urinary tract infection accounted for nearly 7 million 
office visits and 1 million emergency department visits, resulting in 100,000 
hospitalizations.[1,3] The other investigate reported  over 1.7 million emergency department 
visits and more than 8.8 million office visits between 1999 and 2000.[1d] 
UTIs are frequently seen among women than men. Assessments show 50 percent of all 
women have an episode of UTI during their lifetime. Others are at risk for UTIs due to 
elderly, pregnancy, catheters, genitourinary tract abnormalities, underlying diseases (i.e. 
diabetes), renal stones and so on. Uncomplicated UTIs occur in young women in sexually 
active age, but complicated UTIs occur in individuals who have one or more structural 
abnormalities in genitourinary tract or have catheters indwelling. .[1a-d,4] Some of agents 
(abnormalities in urinary tract, renal stones, diabetes, genetic factors like receptors for 
bacterial pili, spinal cord injuries and etc.) which promote women for UTIs, also are 
common in men, and could add prostatitis and spermicides agents as other promoting 
factors in men. Albeit, the incidence of UTIs in men <65 year old is very low; but incidence 
of UTIs in men older than 65 increases dramatically, as UTIs ratio in female-to- male 
declines.[1a-d] 
Pediatrics UTIs create great morbidity and long standing problems, including impaired 
renal function and hypertension. Bacteria have been seen in approximately 1% of all babies’ 
and more in boys’ bladder, and bacteremia often is present. Risk of UTIs in non-circumcised 
males younger than 6 months is 12 times more than circumcised control group. According to 
statistics from 1990, the prevalence of urinary tract infections in pre-school and school girls 
was 1% to 3%, nearly 30-fold higher than that in boys.[1a,4] Also, the statistics from the 
same year show that approximately 5% of girls will develop at least one urinary tract 
infection in their school years.[1a] Children with recurrent UTIs may be treated with 
preventative antibiotics that decrease the rate of microbiological recurrence but not 
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symptomatic recurrence.[1a,5] These infections are often asymptomatic and it can be cause 
of most renal damages.[1a-d] 
Cranberries have enormous medical value. This was known to man from a very long time 
ago. The name cranberry derives from "craneberry", first named by early European settlers 
in America who felt the expanding flower, stem, calyx, and petals resembled the neck, head, 
and bill of a crane. Another name used in northeastern Canada is mossberry. The traditional 
English name for Vaccinium oxycoccos, fenberry, originated from plants found growing in 
fen (marsh) lands. In 17th century New England cranberries were sometimes called 
"bearberries" as bears were often seen feeding on them.[6] 
In North America, Native Americans were the first to use cranberries as food. Native 
Americans used cranberries in a variety of foods, especially for pemmican, wound medicine 
and dye. Calling the red berries Sassamanash, natives may have introduced cranberries to 
starving English settlers in Massachusetts who incorporated the berries into traditional 
Thanksgiving feasts. In the 1820s cranberries were shipped to Europe.[6,7] Cranberries 
became popular for wild harvesting in the Nordic countries and Russia. In Scotland, the 
berries were originally wild-harvested but with the loss of suitable habitat, the plants have 
become so scarce that this is no longer done. Cranberries are a group of evergreen dwarf 
shrubs or trailing vines in the genus Vaccinium subgenus Oxycoccos, or in some treatments, 
in the distinct genus Oxycoccos. They can be found in acidic bogs throughout the cooler 
regions of the Northern Hemisphere.[6] 
Vaccinium arctostaphylos L. genus that is relevant to the Ericaceae family has over 450 species 
which are found mostly in the cooler areas. A deciduous shrub grows to 3m by 2m. It is in 
flower from May to July, and the seeds ripen in September. The flowers are hermaphrodite 
(have both male and female organs) and are pollinated by Insects.[8,9] The plant prefers 
light (sandy) and medium (loamy) soils and requires well-drained soil. The plant prefers 
acid soils and can grow in very acid soil (pH 4-5). It can grow in semi-shade (light 
woodland) or no shade. It requires moist soil.[8,9] This kind of Cranberry (Vaccinium 
arctostaphylos L.) is growing in north and the parts of west of Iran. The local name of this 
herb is Qare-Qat (QΛre-QΛt).[8,9]   
Historically, cranberry beds were constructed in wetlands. Currently cranberry beds are 
constructed in upland areas that have a shallow water table. The topsoil is scraped off to 
form dykes around the bed perimeter.[6a] Clean sand is hauled in to a depth of four to eight 
inches. The surface is laser leveled flat to provide even drainage. Beds are frequently 
drained with socked tile in addition to the perimeter ditch. In addition to making it possible 
to hold water, the dykes allow equipment to service the beds without driving on the vines. 
Irrigation equipment is installed in the bed to provide irrigation for vine growth and for 
spring and autumn frost protection.[6a] 
Cranberries are related to bilberries, blueberries, and huckleberries, all in Vaccinium 
subgenus Vaccinium. These differ in having stouter, woodier stems forming taller shrubs, 
and in the bell-shaped flowers, the petals not being reflexed. Cranberries are susceptible to 
false blossom, a harmful but controllable phytoplasma disease common in the eastern 
production areas of Massachusetts and New Jersey. [6a] 
2. Urinary tract infections (UTI) 
UTIs are a serious health problem affecting millions of people each year. Infections of the 
urinary tract are the second most common type of infection in the body. The urinary tract 
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includes the kidneys, ureters, bladder and urethra. Any part of the urinary tract can become 
infected, but bladder and urethra infections are the most common. Women are especially 
prone to UTIs for reasons that are not yet well understood. One woman in five develops a 
UTI during her lifetime. A UTI is a bacterial infection that affects any part of the urinary 
tract.[10] The main causal agent is Escherichia coli. When bacteria get into the bladder or 
kidney and multiply in the urine, they may cause a UTI. The most common type of UTI is 
acute cystitis often referred to as a bladder infection. An infection of the upper urinary tract 
or kidney is known as pyelonephritis, and is potentially more serious. Although, they cause 
discomfort, urinary tract infections can usually be easily treated with a short course of 
antibiotics with all no significant difference between the classes of antibiotics commonly 
used.[10] UTIs are common in women and children and it causes some permanent side 
effect on kidneys. Since many years, peoples to treatment UTI utilize this herb and 
sometimes with appropriate antibiotics.[10]  
3. Chemistry of cranberry 
The chemical compositions of the different genius of Cranberry were studied widely. In the 
most genius of Cranberry some chemical compounds such as flavonoids, sugar, protein, total 
fat and some important fatty acids were identified. Raw cranberries have moderate levels of 
dietary fiber, Ca, Mg, Mn, P, K, Na, Vitamins C, A, K, Carotene, Lutein, Zeaxanthin and the 
essential dietary mineral, manganese, as well as a balanced profile of other essential 
micronutrients.[8] Cranberries also contain malic acid. By measure of the Oxygen Radical 
Absorbance Capacity with an ORAC score of 9,584 units per 100 g, cranberry ranks near the 
top of 277 commonly consumed foods.[6a,11,12] Raw cranberries are a source of polyphenol 
antioxidants, phytochemicals under active research for possible benefits to the 
cardiovascular system and immune system, and as anti-cancer agents.[6a,13,14]  
Cranberry juice contains a chemical component, a high molecular weight non-dialyzable 
material (NDM), as noted above, that is able to inhibit and even reverse the formation of 
plaque by Streptococcus mutans pathogens that cause tooth decay.[6a,15,16] Cranberry juice 
components also show efficacy against formation of kidney stones.[6a,17,18] Raw 
cranberries and cranberry juice are abundant food sources of flavonoids such as 
proanthocyanidins, flavonols and anthocyanidins (cyanidin, peonidin and quercetin). 
[6a,19,20] These compounds have shown promise as anti-cancer agents in in vitro studies. 
However, their effectiveness in humans has not been established, and may be limited by 
poor absorption into cells and rapid elimination from the blood.[6a] Since 2002, there has 
been an increasing focus on the potential role of cranberry polyphenolic constituents in 
preventing several types of cancer.[6a,21-26] In a 2001 University of Maine study that 
compared cranberries with twenty other fruits demonstrated that cranberries had the largest 
amount of both free and total phenols, with red grapes at a distant second place. [6a-27] 
Cranberry tannins have anti-clotting properties and may reduce urinary tract infections [6a-
28] and the amount of dental plaque-causing oral bacteria, thus being a prophylaxis for 
gingivitis.[6a-29]  
The main chemical compositions that extracted from Cranberry contain mineral compounds, 
flavonoids, benzoic acid, triterpenoids, anthocyanins, catechin, -hydroxybutiric acid, citric 
acid, glucuronic acid, quinic acids, ellagic acid, sugar(fructose, D-mannose), protein, total fat 
and some important fatty acids. In one study, the chemical composition of Vaccinium 
arctostaphylos L. essential oil were determined by utilize GC and GC/MS methods.[9,30] The 
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major determined volatiles in this type of Cranberry, are: hexadecanoic acid(27%), 
vitispirane(6.5%), -ionone(5.9%) and sandaracopimaradiene(4.8%).[9,30] L. Y. Foo et al. in 
2000 reported the proanthocyanidin fraction of Cranberry, isolated from the ethyl acetate 
extract that was investigated for ability to prevent adherence of E. coli to mannose-resistance 
adhesion by determining the ability to prevent agglutination of both isolated P-receptor 
resin-coated beads and human erythrocytes.[9,31] The characterization of Flavonols in 
Cranberry (Vaccinium macrocarpon) were investigated by N. Vorsa et al.[4]. In this report, the 
main Flavonols were extracted by acetone and ethylacetate and identified in this herb, such 
as: myricetin-3--xylopyranoside, quercetin-3--galactoside, quercetin-3--glucoside, 
quercetin-3--arabinopyranoside, quercetin-3--arabinofuranoside, 3’-methoxyquercetin-3- 
-xylopyranoside, quercetin-3-O-(6’’-p-coumaroyl)-galactoside and quercetin-3-O-(6’’-
benzoyl)-galactoside.[9,32] 
In 2004, two species, Vaccinium membranaceum and Vaccinium ovatum, native to Pacific 
Northwestern North America, were evaluated for their total, and individual, anthocyanin 
and polyphenolic compositions by Lee et al..[33,34] Vaccinium ovatum had greater total 
anthocyanin (ACY), total phenolics (TP), oxygen radical absorbing capacity (ORAC), and 
ferric reducing antioxidant potential (FRAP) than did V. membranaceum. The pH were also 
higher in V. ovatum. Berry extracts from each species were separated into three different 
fractions anthocyanin, polyphenolic, and sugar/ acids by solid-phase extraction.[33] The 
anthocyanin fractions of each species had the highest amount of ACY, TP, and antioxidant 
activity. Each species contained 15 anthocyanins (galactoside, glucoside, and arabinoside of 
delphinidin, cyanidin, petunidin, peonidin, and malvidin) but in different proportions. 
Their anthocyanin profiles were similar by high-performance liquid chromatography 
(HPLC) with photodiode array detection (LC-DAD) and high-performance liquid 
chromatography with photodiode array and mass spectrometry detections (LC-DAD-
MS).[33] Each species had a different polyphenolic profile. The polyphenolics of both 
species were mainly composed of cinnamic acid derivatives and flavonol glycosides. The 
major polyphenolic compound in V. membranaceum was neochlorogenic acid, and in V. 
ovatum, chlorogenic acid.[33] Some of the main compounds achieved, are: gallic acid, 
protocatechuic acid; neochlorogenic acid; cinnamic acid dervatives; catechin; chlorogenic 
acid; vanillic acid; caffeic acid; epicatechin; flavonol glycosides; delphinidin 3-galactoside; 
delphinidin 3-glucoside; delphinidin 3-arabinoside; cyanidin 3-galactoside; cyanidin 3-
glucoside; petunidin 3-galactoside; cyanidin 3-arabinoside; petunidin 3-glucoside; peonidin 
3-galactoside; petunidin 3-arabinoside; malvidin 3-galactoside; peonidin 3-glucoside; 
peonidin 3-arabinoside; malvidin 3-glucoside; malvidin 3-arabinoside.[33,34]  
In 2006, the chemical composition of the Qare-Qat or Iranian Vaccinium (V.arctostaphylos L.) 
had been investigated by Sedaghathoor etal.[30] It is a shrub that grows in the north of Iran. 
The fruits of Qare-Qat were collected from natural habitats and examined for chemical 
composition such as minerals. The results showed that the ripe fruit of V.arctostaphylos L. 
had 30.6% sugars, 15.5% protein, 1.5% total fat and 2% soluble solids. Dry matter, nitrogen 
and calcium contents of fruits were 22.3%, 2.5% and 1.4%, respectively.[30] Furthermore, 
about twelve compounds were identified as essential oil components of shoots of this plant. 
The major volatiles present in Vaccinium arctostaphylos L. shoots were hexadecanoic acid 
(27.0%), vitispirane (6.5%), Beta-ionone (5.9%) and sandaracopimaradiene (4.8%). Some of 
the essential oil components of this type of cranberry are: 2-Cyclopenten-1-one, 4-acetyl -
2,3,5,5-pentamethyl; Acetic acid 1-hydroxy-3,7-dimethyl-oct-6-enyl ester; Delta-3-Carene; 
Vitispirane; Naphthalene-1,2-dihydro-5,8-trimethyl; 1,3-Diacetylbenzene; β-Ionone; 2-
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includes the kidneys, ureters, bladder and urethra. Any part of the urinary tract can become 
infected, but bladder and urethra infections are the most common. Women are especially 
prone to UTIs for reasons that are not yet well understood. One woman in five develops a 
UTI during her lifetime. A UTI is a bacterial infection that affects any part of the urinary 
tract.[10] The main causal agent is Escherichia coli. When bacteria get into the bladder or 
kidney and multiply in the urine, they may cause a UTI. The most common type of UTI is 
acute cystitis often referred to as a bladder infection. An infection of the upper urinary tract 
or kidney is known as pyelonephritis, and is potentially more serious. Although, they cause 
discomfort, urinary tract infections can usually be easily treated with a short course of 
antibiotics with all no significant difference between the classes of antibiotics commonly 
used.[10] UTIs are common in women and children and it causes some permanent side 
effect on kidneys. Since many years, peoples to treatment UTI utilize this herb and 
sometimes with appropriate antibiotics.[10]  
3. Chemistry of cranberry 
The chemical compositions of the different genius of Cranberry were studied widely. In the 
most genius of Cranberry some chemical compounds such as flavonoids, sugar, protein, total 
fat and some important fatty acids were identified. Raw cranberries have moderate levels of 
dietary fiber, Ca, Mg, Mn, P, K, Na, Vitamins C, A, K, Carotene, Lutein, Zeaxanthin and the 
essential dietary mineral, manganese, as well as a balanced profile of other essential 
micronutrients.[8] Cranberries also contain malic acid. By measure of the Oxygen Radical 
Absorbance Capacity with an ORAC score of 9,584 units per 100 g, cranberry ranks near the 
top of 277 commonly consumed foods.[6a,11,12] Raw cranberries are a source of polyphenol 
antioxidants, phytochemicals under active research for possible benefits to the 
cardiovascular system and immune system, and as anti-cancer agents.[6a,13,14]  
Cranberry juice contains a chemical component, a high molecular weight non-dialyzable 
material (NDM), as noted above, that is able to inhibit and even reverse the formation of 
plaque by Streptococcus mutans pathogens that cause tooth decay.[6a,15,16] Cranberry juice 
components also show efficacy against formation of kidney stones.[6a,17,18] Raw 
cranberries and cranberry juice are abundant food sources of flavonoids such as 
proanthocyanidins, flavonols and anthocyanidins (cyanidin, peonidin and quercetin). 
[6a,19,20] These compounds have shown promise as anti-cancer agents in in vitro studies. 
However, their effectiveness in humans has not been established, and may be limited by 
poor absorption into cells and rapid elimination from the blood.[6a] Since 2002, there has 
been an increasing focus on the potential role of cranberry polyphenolic constituents in 
preventing several types of cancer.[6a,21-26] In a 2001 University of Maine study that 
compared cranberries with twenty other fruits demonstrated that cranberries had the largest 
amount of both free and total phenols, with red grapes at a distant second place. [6a-27] 
Cranberry tannins have anti-clotting properties and may reduce urinary tract infections [6a-
28] and the amount of dental plaque-causing oral bacteria, thus being a prophylaxis for 
gingivitis.[6a-29]  
The main chemical compositions that extracted from Cranberry contain mineral compounds, 
flavonoids, benzoic acid, triterpenoids, anthocyanins, catechin, -hydroxybutiric acid, citric 
acid, glucuronic acid, quinic acids, ellagic acid, sugar(fructose, D-mannose), protein, total fat 
and some important fatty acids. In one study, the chemical composition of Vaccinium 
arctostaphylos L. essential oil were determined by utilize GC and GC/MS methods.[9,30] The 
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major determined volatiles in this type of Cranberry, are: hexadecanoic acid(27%), 
vitispirane(6.5%), -ionone(5.9%) and sandaracopimaradiene(4.8%).[9,30] L. Y. Foo et al. in 
2000 reported the proanthocyanidin fraction of Cranberry, isolated from the ethyl acetate 
extract that was investigated for ability to prevent adherence of E. coli to mannose-resistance 
adhesion by determining the ability to prevent agglutination of both isolated P-receptor 
resin-coated beads and human erythrocytes.[9,31] The characterization of Flavonols in 
Cranberry (Vaccinium macrocarpon) were investigated by N. Vorsa et al.[4]. In this report, the 
main Flavonols were extracted by acetone and ethylacetate and identified in this herb, such 
as: myricetin-3--xylopyranoside, quercetin-3--galactoside, quercetin-3--glucoside, 
quercetin-3--arabinopyranoside, quercetin-3--arabinofuranoside, 3’-methoxyquercetin-3- 
-xylopyranoside, quercetin-3-O-(6’’-p-coumaroyl)-galactoside and quercetin-3-O-(6’’-
benzoyl)-galactoside.[9,32] 
In 2004, two species, Vaccinium membranaceum and Vaccinium ovatum, native to Pacific 
Northwestern North America, were evaluated for their total, and individual, anthocyanin 
and polyphenolic compositions by Lee et al..[33,34] Vaccinium ovatum had greater total 
anthocyanin (ACY), total phenolics (TP), oxygen radical absorbing capacity (ORAC), and 
ferric reducing antioxidant potential (FRAP) than did V. membranaceum. The pH were also 
higher in V. ovatum. Berry extracts from each species were separated into three different 
fractions anthocyanin, polyphenolic, and sugar/ acids by solid-phase extraction.[33] The 
anthocyanin fractions of each species had the highest amount of ACY, TP, and antioxidant 
activity. Each species contained 15 anthocyanins (galactoside, glucoside, and arabinoside of 
delphinidin, cyanidin, petunidin, peonidin, and malvidin) but in different proportions. 
Their anthocyanin profiles were similar by high-performance liquid chromatography 
(HPLC) with photodiode array detection (LC-DAD) and high-performance liquid 
chromatography with photodiode array and mass spectrometry detections (LC-DAD-
MS).[33] Each species had a different polyphenolic profile. The polyphenolics of both 
species were mainly composed of cinnamic acid derivatives and flavonol glycosides. The 
major polyphenolic compound in V. membranaceum was neochlorogenic acid, and in V. 
ovatum, chlorogenic acid.[33] Some of the main compounds achieved, are: gallic acid, 
protocatechuic acid; neochlorogenic acid; cinnamic acid dervatives; catechin; chlorogenic 
acid; vanillic acid; caffeic acid; epicatechin; flavonol glycosides; delphinidin 3-galactoside; 
delphinidin 3-glucoside; delphinidin 3-arabinoside; cyanidin 3-galactoside; cyanidin 3-
glucoside; petunidin 3-galactoside; cyanidin 3-arabinoside; petunidin 3-glucoside; peonidin 
3-galactoside; petunidin 3-arabinoside; malvidin 3-galactoside; peonidin 3-glucoside; 
peonidin 3-arabinoside; malvidin 3-glucoside; malvidin 3-arabinoside.[33,34]  
In 2006, the chemical composition of the Qare-Qat or Iranian Vaccinium (V.arctostaphylos L.) 
had been investigated by Sedaghathoor etal.[30] It is a shrub that grows in the north of Iran. 
The fruits of Qare-Qat were collected from natural habitats and examined for chemical 
composition such as minerals. The results showed that the ripe fruit of V.arctostaphylos L. 
had 30.6% sugars, 15.5% protein, 1.5% total fat and 2% soluble solids. Dry matter, nitrogen 
and calcium contents of fruits were 22.3%, 2.5% and 1.4%, respectively.[30] Furthermore, 
about twelve compounds were identified as essential oil components of shoots of this plant. 
The major volatiles present in Vaccinium arctostaphylos L. shoots were hexadecanoic acid 
(27.0%), vitispirane (6.5%), Beta-ionone (5.9%) and sandaracopimaradiene (4.8%). Some of 
the essential oil components of this type of cranberry are: 2-Cyclopenten-1-one, 4-acetyl -
2,3,5,5-pentamethyl; Acetic acid 1-hydroxy-3,7-dimethyl-oct-6-enyl ester; Delta-3-Carene; 
Vitispirane; Naphthalene-1,2-dihydro-5,8-trimethyl; 1,3-Diacetylbenzene; β-Ionone; 2-
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Pentadecanone; Sandaracopimaradiene; Hexadecanoic acid; Eicosane-2,6,10,14,18-
pentamethyl and Isopimaradiene.[30] 
Some of the physicochemical properties, like the logarithm of calculated Octanol-Water 
partitioning coefficients (logKow), total biodegradation and (TBd in mol/h) and median lethal 
concentration 50 (LC50) were calculated for some of the chemicals of the cranberry speciesby 
the EPI-suit v4.00 package.[35] See Table 1.  
The octanol-water partition coefficient (Kow) is a measure of the equilibrium concentration of 
a compound between octanol and water that indicates the potential for partitioning in to soil 
organic matter (i.e., a high Kow indicates a compound which will preferentially partition into 
soil organic matter rather than water). This coefficient is inversely related to the solubility of 
a compound in water. The logKow is used in models to estimate plant and soil invertebrate 
bioaccumulation factors. This parameter is also used in many environmental studies to help 
determine the environmental fate of chemicals.[9,35-38] 
Biodegradation is usually quantified by incubating a chemical compound in presence of a 
degrader, and measuring some factors like oxygen or production of CO2. The 
biodegradation studies demonstrate that microbial biosensors are a viable alternative means 
of reporting on potential biotransformation. However, a few chemicals are tested and large 
data sets for different chemicals need for quantitative structural relationship studies.[9,39] 
An LC50 value is the concentration of a material in air that will kill 50% of the test subjects 
(animals, typically mice or rats) when administered as a single exposure (typically 1 or 4 
hours). Also called the median lethal concentration and lethal concentration 50, this value 
gives an idea of the relative acute toxicity of an inhalant material. Typical units for LC50 
values are parts per million (ppm) of material in air, micrograms (10-6 = 0.000001 g) per liter 
of air and milligrams (10-3 = 0.001 gr) per cubic meter of air.[9,40] 
In accordance with the calculated data of the components 1-21 in cranberries, by EPI-suit 
v4.00 package (see Table-1), hexadecanoic acid (6.962), sandaracopimaradiene, 
isopimaradiene (6.445), 2-pentadecanone (5.658), δ-3-carene (4.611),  β-ionone (4,424), 
naphthalene-1,2-dihydro-5,8-trimethyl (3.303) and acetic acid 1-hydroxy-3,7-dimethyl-oct-6-
enyl ester (3.023) have the highest logarithm of octanol-water partition coefficient (logKow), 
respectively. Accordingly, the compounds have the lowest water solubility (Sw, mg.L-
1/25ºC). Neochlorogenic acid and Chlorogenic acid with -1.014 have the lowest amount of 
logKow. The compound with the highest lethal concentration (LC50, mg/L) was gallic acid. 
Meanwhile, sandaracopimaradiene, isopimaradiene had the lowest LC50 (0.04). The total 
biodegradation (TBd) of naphthalene-1,2-dihydro-5,8-trimethyl among and δ-3-carene 
among 1-21 were the highest and for β-ionone was the lowest (in mol/h×10-5).  
5. Urinary tract infections (UTI) and cranberry 
As discussed Cranberries have enormous medicinal value. These berries are not just good to 
eat; they also contain different kinds of chemicals that are nutritious. While the people in the 
17th century and there about knew generally the basic medicinal values of cranberries (the 
East Europeans even believed it to have the ability to cure cancer), research today has 
discovered other medicinal benefits that we can derive from cranberries.[41a-c] Cranberries 
have been found to be effective in battling urinary tract inflammation, oral disease, as well 
as even heart ailments. Here we will see how cranberries help prevent Urinary Tract 
Infection (UTI).[41a-c] While different food products or plants work in different ways, 
cranberries have their own way of reducing the risk of illness in the human body.[41a-c] 
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(in mg/L or ppm)
Total Biodegradation 
(in mol/h ×10–5) 
1 2-Cyclopenten-1-one, 4-acetyl -2,3,5,5-pentamethyl 1.531 344.87 5.2 
2 Acetic acid 1-hydroxy-3,7-dimethyl-oct-6-enyl ester 3.023 22.52 5.8 
3 δ-3-Carene 4.611 0.53 7.9 
5 Naphthalene-1,2-dihydro-5,8-trimethyl 3.303 11.44 8.1 
6 1,3-Diacetylbenzene 1.354 462.55 5.7 
7 β-Ionone 4.424 1.32 1.3 
8 2-Pentadecanone 5.658 0.11 3.1 
9 Sandaracopimaradiene 6.445 0.04 2.6 
10 Hexadecanoic acid 6.962 0.09 3.0 
12 Isopimaradiene 6.445 0.04 2.6 
13 Gallic acid 0.855 1218.82 5.4 
14 Protocatechuic acid 0.914 985.24 6.0 
15 Neochlorogenic acid -1.014 272.80 2.6 
16 Cinnamic acid 2.071 989.53 6.5 
17 Catechin 1.175 1115.68 3.2 
18 Chlorogenic acid -1.014 272.80 2.6 
19 Vanillic acid 1.219 593.19 5.5 
20 Caffeic acid 1.110 785.65 5.1 
21 Epicatechin 1.175 1115.68 3.2 
aThe values were calculated by EPI-suit v4.00 package.[35]    b Asterisk designates, Chemical may not be 
soluble.  
Table 1. The calculated logarithm of calculated Octanol-Water partitioning coefficients 
(logKow), water solubility at 25ºC (mg/L), median lethal concentration 50 (LC50) and total 
biodegradation and (TBd in mol/h) of some of the chemical components of some species of 
Cranberries.[35] 
One of the biggest and most widely health benefits of eating cranberries, in whatever form, 
either as whole fruit or juice or cocktail, is that it helps prevent urinary tract infection (UTI). 
While this was what our elders passed on to us as traditional oral medicinal knowledge, it is 
now recognized as official medical fact.[41a-c] 
Kidney stones are most often caused by high levels of ionized calcium (as in calcium salts) in 
the urine. Cranberries can help prevent this condition because they are rich in quinic acid, 
which increases the acidity of the urine. As a result, the levels of ionized calcium in the urine 
are lowered. The infection is basically caused by bacteria.[41a-c, 42] The bacteria latch on to 
the surface or lining of the cells of different body parts. Once they are attached to the lining 
of the specific body part in question, they feed off the cells or the surface or the lining they 
are attached to, and increase their numbers by reproducing, and in the process cause 
infections. In the case of UTI, this process happens in the lining of the urinary tract.[41a-c, 
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either as whole fruit or juice or cocktail, is that it helps prevent urinary tract infection (UTI). 
While this was what our elders passed on to us as traditional oral medicinal knowledge, it is 
now recognized as official medical fact.[41a-c] 
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the urine. Cranberries can help prevent this condition because they are rich in quinic acid, 
which increases the acidity of the urine. As a result, the levels of ionized calcium in the urine 
are lowered. The infection is basically caused by bacteria.[41a-c, 42] The bacteria latch on to 
the surface or lining of the cells of different body parts. Once they are attached to the lining 
of the specific body part in question, they feed off the cells or the surface or the lining they 
are attached to, and increase their numbers by reproducing, and in the process cause 
infections. In the case of UTI, this process happens in the lining of the urinary tract.[41a-c, 
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42] Initially, researchers went off-track when they figured that the cranberries’ ability to 
prevent UTI was because of its acidity. It has reported that cranberries prevent UTI by 
preventing the bacteria causing UTI from attaching itself to the surface of the urinary tract 
lining. Amy Howell published this discovery in the New England Journal of Medicine in 
1998.[41a-c-50] The research shows that cranberries are basically rich in proanthocyanidins. 
Proanthocyanidins  are tannins, a type of organic chemical compound, that have been 
condensed. This is how it works. The proanthocyanidins have their own specific way of 
functioning – they are blockers that block the bacteria from attaching themselves to the 
surface of the lining of the specific body part in question. In the case of UTI, the 
proanthocyanidins prevent the bacteria from getting glued to the lining of the urinary 
tract.[42-50] The most common side effects associated with excessive cranberry consumption 
are diarrhea and an increased risk of developing kidney stones. Regular cranberry 
consumption by women trying to prevent UTIs may result in vulvovaginal candidiasis. 
Alterations in the normal vaginal bacteria may lead to increased fungal growth.[42] 
In 1984 was surveyed the anti adhering of Cranberry on 77 strains of E. coli that in 75% 
samples it was verified.[38] In 1994, was examined the extraction of this herb for treating 153 
persons who involved to UTI.[39] In 1995, was showed that UTI in women is decreased for 
52% by Craberry extract prophylaxy.[9,40,51] In 2006, was investigated the effect of 
Cranberry in prevention on urinary tract infection in children, and prevention of nonspecific 
bacterial cell adhesion in immunoassays by use of Cranberry juice.[9,52,53] Sometimes 
peoples to treatment UTIs, utilize this herb with appropriate antibiotics.  
6. Experimental section 
In this study, were examined 61 isolated E. coli from urine sample of the patients that they 
had referred to the hospitals and laboratories of Sanandaj city. Dried fruit of Cranberry 
(Vaccinium arctostaphylos L.) was altered to powder and then was acquired aqueous 
extraction (1%) from it. This concentration was based on Boland’s study.[9] The most 
concentration of Cranberry in media was selected that had not any effect on bacteria on the 
media than media without plant extract. One control plate (Mueller-Hilton agar without 


















































Fig. 2. The chemical structures of Ciprofloxacin-1, Amikacin-2, Ampicillin-3 and 
Nitrofurantoin-4. 
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The other plate contained Mueller-Hilton agar accompanied Cranberry 1% extraction. A 
certain number of bacterias (1.5x108 CFU/ml) based on 0.5 Macfarland scale was cultured 
on the media. After this stage, the antibiotic disks (Ciprofloxacin-1, Amikacin-2, Ampicillin-
3, Tetracyclin, Co-trimoxazole, Nalidixic acid, Ceftazidime and Nitrofurantoin-4) were 
cultured. After 24 hours incubation in 37C was measured the zone around of the each disks 
and compared with standard schedule.[9,54] 
6.1 Results and discussions 
The results of the investigation were demonstrated in Table-1. The results were analyzed 
based on Ki test. The most susceptibility belonged to Amikacin-2 in frequency of the control 
group with 93.45%. The lowest frequency was 9.8% for Ampicillin-3. The other type of 
antibiotics the susceptibilities in control group were: Co-trimoxazol 39.34%, Ceftazidime 
51%, Nalidixic acid 54.1%, Nitrofurantoin 62.3%, Tetracyclin 72.13% and Ciprofloxacin-1 
73.8%. In test group, Nitrofurantoin-4 shows the most susceptibility (72.13%) and the lowest 
belongs to Ampicilline(18%). In addition, percentage of susceptibility for other antibiotics as 
Amikacin, Co-trimoxazole, Nalidix acid, Ceftazidime and Tetracyclin were: 28.87%, 34.42%, 
52.48%, 55% and 70.5%, respectively.[9] In accordance with the results, not only aqueous 
extract of Cranberry did not show any synergistic effect with any antibiotics, but also it 
showed sever antagonistic effect against Ciprofloxacine-1 and Amikacine-2 (P=0.00). See 
Table-2. However, in acidic pH Ampicillin-3 and Nitrofurantoin-4 had 10% increased in 
function, but in the whole statistical computation did not show any significant difference 
(see Table-2). Nitrofurantoin-4 shows better function in acidic pH. Ampicillin and 
Amoxicillin are resistant and absorbed much better in acidic pH. On the contrary, Co-
trimoxazole is more effective in alkaline pH.[9] In neutral  or acidic media it is changed to 
crystal form and precipitate.[9,54] In spite of the fact that there are no significant statistical 
difference between two plates (test plate and control plate), It was found that antagonistic 
effect between Cranberry and two antibiotic disks i.e. Ciprofloxacin-1 and Amikacin-2 
(P=0.00). The results show that use Cranberry with some antibiotics that explained here can 
diminish the medicinal effects of the antibiotics in UTIs treatments. The awareness about 
interfere and the suppression of the appropriate medicinal effect of antibiotics by Vaccinium 
arctostaphylos L. can be useful for treating UTIs.[9]  
Some of the physicochemical properties like: the logarithm of calculated Octanol-Water 
partitioning coefficients (logKow), total biodegradation and (TBd in mol/h and gr./h), water 
solubility (Sw, mg.L-1/25ºC) and median lethal concentration 50 (LC50) were calculated for 
the antibiotics (Ciprofloxacin, Amikacin, Ampicillin and Nitrofurantoin). The octanol-water 
partition coefficient (Kow) is a measure of the equilibrium concentration of a compound 
between octanol and water that indicates the potential for partitioning in to soil organic 
matter (i.e., a high Kow indicates a compound which will preferentially partition into soil 
organic matter rather than water).[35-40] The TBd is another useful and important factors in 
chemical and biochemical studies. It needs to use the effective and useful mathematical 
methods for making good concern between several data in chemistry and biochemistry. An 
LC50 value is the concentration of a material in air that will kill 50% of the test subjects 
(animals, typically mice or rats) when administered as a single exposure (typically 1 or 4 
hours). One of the other important physicochemical factors of compounds is water solubility 
(Sw, mg.L-1/25ºC). Some of the other calculated physicochemical properties of the antibiotics 
(Ciprofloxacin, Amikacin, Ampicillin and Nitrofurantoin) on UTIs that is created by 
Escherichia coli in Vitro and some of the chemical components of Cranberry were calculated. 
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42] Initially, researchers went off-track when they figured that the cranberries’ ability to 
prevent UTI was because of its acidity. It has reported that cranberries prevent UTI by 
preventing the bacteria causing UTI from attaching itself to the surface of the urinary tract 
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1998.[41a-c-50] The research shows that cranberries are basically rich in proanthocyanidins. 
Proanthocyanidins  are tannins, a type of organic chemical compound, that have been 
condensed. This is how it works. The proanthocyanidins have their own specific way of 
functioning – they are blockers that block the bacteria from attaching themselves to the 
surface of the lining of the specific body part in question. In the case of UTI, the 
proanthocyanidins prevent the bacteria from getting glued to the lining of the urinary 
tract.[42-50] The most common side effects associated with excessive cranberry consumption 
are diarrhea and an increased risk of developing kidney stones. Regular cranberry 
consumption by women trying to prevent UTIs may result in vulvovaginal candidiasis. 
Alterations in the normal vaginal bacteria may lead to increased fungal growth.[42] 
In 1984 was surveyed the anti adhering of Cranberry on 77 strains of E. coli that in 75% 
samples it was verified.[38] In 1994, was examined the extraction of this herb for treating 153 
persons who involved to UTI.[39] In 1995, was showed that UTI in women is decreased for 
52% by Craberry extract prophylaxy.[9,40,51] In 2006, was investigated the effect of 
Cranberry in prevention on urinary tract infection in children, and prevention of nonspecific 
bacterial cell adhesion in immunoassays by use of Cranberry juice.[9,52,53] Sometimes 
peoples to treatment UTIs, utilize this herb with appropriate antibiotics.  
6. Experimental section 
In this study, were examined 61 isolated E. coli from urine sample of the patients that they 
had referred to the hospitals and laboratories of Sanandaj city. Dried fruit of Cranberry 
(Vaccinium arctostaphylos L.) was altered to powder and then was acquired aqueous 
extraction (1%) from it. This concentration was based on Boland’s study.[9] The most 
concentration of Cranberry in media was selected that had not any effect on bacteria on the 
media than media without plant extract. One control plate (Mueller-Hilton agar without 


















































Fig. 2. The chemical structures of Ciprofloxacin-1, Amikacin-2, Ampicillin-3 and 
Nitrofurantoin-4. 
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The other plate contained Mueller-Hilton agar accompanied Cranberry 1% extraction. A 
certain number of bacterias (1.5x108 CFU/ml) based on 0.5 Macfarland scale was cultured 
on the media. After this stage, the antibiotic disks (Ciprofloxacin-1, Amikacin-2, Ampicillin-
3, Tetracyclin, Co-trimoxazole, Nalidixic acid, Ceftazidime and Nitrofurantoin-4) were 
cultured. After 24 hours incubation in 37C was measured the zone around of the each disks 
and compared with standard schedule.[9,54] 
6.1 Results and discussions 
The results of the investigation were demonstrated in Table-1. The results were analyzed 
based on Ki test. The most susceptibility belonged to Amikacin-2 in frequency of the control 
group with 93.45%. The lowest frequency was 9.8% for Ampicillin-3. The other type of 
antibiotics the susceptibilities in control group were: Co-trimoxazol 39.34%, Ceftazidime 
51%, Nalidixic acid 54.1%, Nitrofurantoin 62.3%, Tetracyclin 72.13% and Ciprofloxacin-1 
73.8%. In test group, Nitrofurantoin-4 shows the most susceptibility (72.13%) and the lowest 
belongs to Ampicilline(18%). In addition, percentage of susceptibility for other antibiotics as 
Amikacin, Co-trimoxazole, Nalidix acid, Ceftazidime and Tetracyclin were: 28.87%, 34.42%, 
52.48%, 55% and 70.5%, respectively.[9] In accordance with the results, not only aqueous 
extract of Cranberry did not show any synergistic effect with any antibiotics, but also it 
showed sever antagonistic effect against Ciprofloxacine-1 and Amikacine-2 (P=0.00). See 
Table-2. However, in acidic pH Ampicillin-3 and Nitrofurantoin-4 had 10% increased in 
function, but in the whole statistical computation did not show any significant difference 
(see Table-2). Nitrofurantoin-4 shows better function in acidic pH. Ampicillin and 
Amoxicillin are resistant and absorbed much better in acidic pH. On the contrary, Co-
trimoxazole is more effective in alkaline pH.[9] In neutral  or acidic media it is changed to 
crystal form and precipitate.[9,54] In spite of the fact that there are no significant statistical 
difference between two plates (test plate and control plate), It was found that antagonistic 
effect between Cranberry and two antibiotic disks i.e. Ciprofloxacin-1 and Amikacin-2 
(P=0.00). The results show that use Cranberry with some antibiotics that explained here can 
diminish the medicinal effects of the antibiotics in UTIs treatments. The awareness about 
interfere and the suppression of the appropriate medicinal effect of antibiotics by Vaccinium 
arctostaphylos L. can be useful for treating UTIs.[9]  
Some of the physicochemical properties like: the logarithm of calculated Octanol-Water 
partitioning coefficients (logKow), total biodegradation and (TBd in mol/h and gr./h), water 
solubility (Sw, mg.L-1/25ºC) and median lethal concentration 50 (LC50) were calculated for 
the antibiotics (Ciprofloxacin, Amikacin, Ampicillin and Nitrofurantoin). The octanol-water 
partition coefficient (Kow) is a measure of the equilibrium concentration of a compound 
between octanol and water that indicates the potential for partitioning in to soil organic 
matter (i.e., a high Kow indicates a compound which will preferentially partition into soil 
organic matter rather than water).[35-40] The TBd is another useful and important factors in 
chemical and biochemical studies. It needs to use the effective and useful mathematical 
methods for making good concern between several data in chemistry and biochemistry. An 
LC50 value is the concentration of a material in air that will kill 50% of the test subjects 
(animals, typically mice or rats) when administered as a single exposure (typically 1 or 4 
hours). One of the other important physicochemical factors of compounds is water solubility 
(Sw, mg.L-1/25ºC). Some of the other calculated physicochemical properties of the antibiotics 
(Ciprofloxacin, Amikacin, Ampicillin and Nitrofurantoin) on UTIs that is created by 
Escherichia coli in Vitro and some of the chemical components of Cranberry were calculated. 
 
 




Table 2. The comparison of the sensitivity of Escherichia coli to the antibiotics (1-4).[9] 
Effect Investigation of Aqueous Cranberry (Vaccinium arctostaphylos L.) Extract in  














(in mol/h ×10–5) 
Ciprofloxacin(1) -8×10- 4 11480 9303.95 2.8 
Amikacin(2) -8.7807 1×106 3.15×108 1.6 
Ampicillin(3) 1.4538 439.3 780.24 2.7 
Nitrofurantoin(4) -0.1675 1382.0 12523.00 3.9 
aThe values were calculated by EPI-suit v4.00 package.[35] b Asterisk designates, Chemical may not be 
soluble. 
Table 3. The calculated logarithm of calculated Octanol-Water partitioning coefficients 
(logKow), water solubility at 25ºC (mg/L), median lethal concentration 50 (LC50) and total 
biodegradation and (TBd in mol/h) of the antibiotics Ciprofloxacin(1), Amikacin(2), 
Ampicillin(3) and Nitrofurantoin(4).[9,35]   
[35-40] See Table-3. In accordance with the calculated data of the antibiotics (ciprofloxacin-1, 
Amikacin-2, Ampicillin-3 and Nitrofurantoin-4), by EPI-suit v4.00 package (see Table-3), 
ampicillin-3 (1.4538) has the highest logarithm of octanol-water partition coefficient (logKow). 
Accordingly, the compound has the lowest water solubility (Sw, mg.L-1/25ºC). Amikacin-2 
with -8.7807 has the lowest amount of logKow among selected antibiotics 1-4. The calculations 
show that the antibiotic with the highest lethal concentration (LC50, mg/L) was amikacin-2. 
Meanwhile, ampicillin-3 had the lowest LC50. The total biodegradation (TBd) of 
Nitrofurantoin-4 among the selected antibiotics 1-4 was the highest and for amikacin-2 was 
the lowest (in mol/h×10-5).  
7. Conclusion 
The chemical compositions of the different types of Craberry were investigated. It was 
determined that this type of medicinal herb was utilized for UTI treatments. Vaccinium 
arctostaphylos L. genus was used to investigate the synergistic effect of aqueous Cranberry 
(Vaccinium arctostaphylos L.) extract in accompanied with antibiotics (Ciprofloxacin-1, 
Amikacin-2, Ampicillin-3 and Nitrofurantoin-4) on UTIs created by Escherichia coli in 
Vitro. The results show that use Cranberry with some antibiotics that explained here can 
show some interference effects with the antibiotics and diminish the medicinal effects of 
the antibiotics (antagonist effect) in Urinary tract infections (UTI) treatments.[9] Some of 
the physicochemical properties, like the logarithm of calculated Octanol-Water 
partitioning coefficients (logKow), total biodegradation and (TBd in mol/h) and median 
lethal concentration 50 (LC50) were calculated for some of the chemicals of the cranberry 
species and antibiotics (Ciprofloxacin-1, Amikacin-2, Ampicillin-3 and Nitrofurantoin-
4).[9,35-40] 
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Urinary tract infection(UTI) is not uncommon cause of bacterial illness in children,4-8% of 
children have had an UTI from a population based study (Sureshkumar, Jones et al. 2009). 
The prevalence of UTIs is quite different between two gender and age with high incidence 
in girls(1% in male and 3% in female), except the male infants with an incidence of 0.7% 
compared to the 0.1~0.4% of  female infants (Foxman 2002),which is due to bacterias harbor 
in prepuce of youg infant,there was at least a tenfold increased risk for UTIs in 
noncircumcised compared with circumcised infant(Thomas, Wiswell et al.1986). The 
symptomatic UTIs raise a significant anxiety for parents and physician with concerning the 
potential of associated urinary tract disorders or abnormalities. Furthermore, UTIs recur 
more than 20% in young population, antimicrobial treatment and further investigation 
warrant in this circumstances. The most common cause of recurrent UTIs is related to the 
abnormal urinary tract, such as vesicoureteral reflux (VUR), duplex collecting system , 
spinal dysraphism with neurogenic bladder, Hinman’s syndrome …etc. However, the 
modalities of clinical survey are still controversial regarding the invasiveness and 
discomfort of examination, it may be need anesthesia. In addition, imaging for UTIs is 
bearing risk of radiation exposure, the recent reports advocate that the invasive examination 
such as voiding cystourethrography(VCUG) should be reserved for those with likelihood of 
VUR with renal damage or dysplasia from the less invasive studies, such as ultrasoud (US) 
(Preda, Jodal et al. 2011). Meanwhile, additional subject of management for congenital 
urinary abnormalities associated with UTIs is ongoing debate. This chapter will review the 
relevant literatures and examine the practical scenarios to cover the top-down approach of 
urinary tract infection in children, including pathogenesis, host-defense mechanism of the 
urinary tract, the comprehension of relationship between UTIs and congenital abnormalities 
or dysfunction, as well as the up-to-date of treatment concept. 
2. Pathogenesis of UTIs 
The etiology of UTIs is not well understood, and though to be related to gender, bowel habit, 
urinary incontinence and congenital abnormalities of urinary tract. The most frequent 
organism is Escherichia (E. Coli),which is originally an harmless flora in human intestine and 
has some properties as virulence factors (VFs) to overcome the new environment, with bearing 
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the ability to colonize and adhere to the uro-epithial cell through its fimbriase (P fimbriae, 
type-1 fimbria),the prevalence of P fimbriation from patients with severe UTIs such as 
urosepsis is high as 71% compared with 70% in pyelonephritis and 28% in other sources of 
infection (Brauner, Leissner et al.1987). The process of invasion acts as cytotoxic/endotoxic 
effect via lipopolysaccharide, aerobactin and enterochelin production, whereas the process of 
pyelonephritis occurring so call “Nephropathy” (Gally, Bogan et al. 1993; Olianti, Imperiale et 
al. 2004). Moreover,several gene polymorphisms such as toll-like receotor-2(TLR2) gene,TLR4 
gene,heat shock protein 72(HSPA1B) gene are closely associated with the hosts who were 
vulnerable to UTIs(Karoly, Fekete et al.2006; Tabel, Berdeli et al.2007). In addition,the micro-
organisms can alter the gene expression with changing their phenotype in order to adjust to 
host environment (Johnson 1991).At the point of host defence,urinary tract of human can 
fundamentally prevent ascending infection from micro-organisms. For instance, urine bolus 
excretes from renal calyces into bladder through the eccentric peristalsis of ureter, on the other 
hand, urine from bladder is not allow to reflux backward into ureter by the antireflux 
competence of submucosal tunnel subset between ureter and bladder. The regular empty of 
bladder can also prevent the pathogens stasis within lower urinary tract. For these reasons, 
most of UTIs in children are incidental and promptly recovery with appropriate antibiotics or 
correction of daily hygiene. However, a minority need to be paid attention on the risk of 
morbidities, including nephropathy from the chronic pyelonephritis, associated congenital 
abnormalities, or voiding disorders. 
3. Clinical manifestations 
Comparing to the adults the symptoms of UTIs in children are not specific owing to the 
limitation of the verbal expression, fever or chillness is the most general manifestation 
(National Collaborating Centre for Women’s and Children’s Health 2007) and followed with 
lethargic or irritable presentations. Low urinary tract syndrome such as dysuria, pain on 
micturiction, frequency, incontinence, suprapubic discomfort may be present.  
3.1 Acute pyelonephritis 
Acute pyelonephritis (APN) is considered if a febrile UTI associated with excess of CRP 
(Naber, Bergman et al. 2001; Huang, Huang et al. 2007).On the basis of Technetium-99m 
dimercaptosuccinic acid scintigraphy(DMSA), Nikfar et al. found procalcitonin 
concentration test could also be useful in the diagnosis of APN with 77% and 89% of 
sensitivity and specificity comparing to 80% and 65% of C-reative protein(CRP)(Nikfar, 
Khotaee et al. 2010). However, DMSA still  remains the standard tool for diagnosis of APN 
(Levitchenko, Lahy et al. 2001). At 6 months after APN, 88% of scars were observed by Parex 
et al., the overall of scars persisted in 27% after 3 years of follow-up. Additionally, increased 
number of scars from APN was related to high grade VUR (Parrex, Willi et al 2008). 
3.2 Acute lobar nephronia 
The progression of APN may cause acute and nonsuppurative renal infection with focal 
tissue edema and leukocytic infiltration that affect one or more lobules of kidney, so call 
acute lobar nephronia (ALN), which represents a focal mass effect in US or CT, histology 
may present with acute pyelonephritis and micro-abscesses (Rosenfield, Glickman et al 
1979). Klar et al. report 13 patients with 16 episodes of ALN in 210 hospitalized children 
with urinary tract infection, the most commen pathogen was E.coli (Klar, Hurvitz et al. 
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1996). It is crucial to differentiate ALN from renal abscess regard to their different 
pathogenesis and treatment, as the ALN needs antibiotics treated with duration at least 2-3 
weeks, whereas renal abscess may recquire drainage in addition to antibiotic control (Mark, 
Zaontz et al. 1984; Rothore, Barton et al. 1991)  
3.3 Cystitis 
Cystitis is rare in children and usually present with acute symptoms including 
suprapubic pain, dysuria, frequency or incontinence, the differentiation to the non-
infected lower urinary dysfunction (LUTD) should be made based on the urine 
finding.The uncommon inflammation of bladder caused by fungus, virus or allergy, 
sometimes masquerade as bladder tumor in US finding (Friedman, Friedman et al.1993; 
Rosenberg, Eggli et al.1994). 
4. Diagnosis and management strategies 
In addition to the clinical manifestations, the diagnosis of UTIs can be definitely based on 
the finding of urine sample either via clean mid-stream urine directly voided by child or 
collection of urine by sterile bag attached around the urethra in infants or young children 
who are unable to void voluntarily, otherwise, catheterization or suprapubic aspiration may 
be used. UTIs should be considered in an urine sample with pyuria or bacteria (National 
Collaborating Centre for Women’s and Children’s Health 2007). The threshold of diagnosis 
depends upon the access of urine sample collection, the less of false positive rate, the more 
invasive in the fashion of urine obtaining (Hellerstein 1982). As matter of fact, 80% of 
general pratitioners recommended the use of an urine bag reported by Kennedy et al., the 
remaining 20% recommended using a dean catch sample (Kennedy, Glynn et al. 2010). 
UTIs should be identified as simple or complicated infection by localization of infectious 
nidus (Figure 1) and whether a recurrent or atypical UTI(Box 1). In order to facilitate the 
diagnosis and treatment decision, the differentiation of upper urinary tract infection 
including kidney or ureter between lower urinary tract including bladder or urethra should 
be conducted based on the clinical symptoms and signs. 
Although the prediction rate of US for abnormalities has been questioned (Zamir, Sakran et 
al. 2004; Riccabona and Fotter 2009), notwithstanding, many congenital abnormalities of 
urinary tract have currently been detected by prenatal sonography. US is still considered an 
ideal tool to examine the urinary tract for children with first UTI for its noninvasiveness, 
reproducibility and lack of radiation exposure. The subtle architecture of kidney can be 
investigated in the context of APN including acute focal bacterial nephritis (ALN), renal 
abscess, pyohydronephrosis or stone associated infection (Klar, Hurvitz et al. 1996; 
Sureshkumar, Jones et al. 2009). Additionally, US can investigate the children with lower 
urinary tract dysfunction with estimation of residual urine, bladder outline and capacity 
(Uehling, Hahnfeld et al. 2000; Dacher and Savoye-Collet 2004). 
DMSA scintigraphy remains the important examination in the diagnosis of APN,defects in 
renal outline without any loss of renal volume can be found, whereas in scarring, the defect 
is associated with focal loss of renal mass (Piepsz A, Colarinha P et al. 2001). However, a 
100% of high negative diagnostic value for detection of renal scarring during the acute stage 
of infection was reported by Hitzel et al., therefore, the follow-up should be ongoing after 6 
months of acute pylonephritis to avoid the negative diagnostic value (Hitzel, Liard et al. 
2002). 
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Fig. 1. Algorithm for Investigation of Associated Abnormalities in Children with UTIs. 
_________________________________________________________________________________ 
Atypical (any of the following) 
 Septicaemia or patients who looks seriously ill (see NICE guideline [2]) 
 Poor urine flow 
 Abdominal or bladder mass 
 Raised creatinine concentration 
 Failure to respond to treatment with suitable antibiotics within 48 hours 
 Infection with non-Escherichia coli organisms 
Recurrent(any of the following) 
 Two or more episodes of urinary tract infection with acute pyelonephritis or upper 
urinary tract infection 
 One episode of urinary tract infection with acute pyelonephritis or upper urinary tract 
infection plus one or more episode of urinary tract infection with cystitis or lower 
urinary tract infection 
 Three or more episodes of urinary tract infection with cystitis or lower urinary tract 
infection 
_________________________________________________________________________________ 
Box 1. Main characteristics of patients with atypical or recurrent tract infection. Adapted 
from Rintaro et al.(2007).BJM 25:335:395-396; http://guidance.nice.org.uk/CG54 
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Magnetic resonance imaging (MRI, MRU) and enhanced CT are recently applied for 
depiction of APN and renal scarring. As the detection rate is questioning and availability is 
limited for requirement of sedation and injection of a potentially nephrotoxic medium while 
performaning the examination, which is reserved for children with doubtful diagnosis or 
suspicion of congenital abnormalities (Lonergan, Pennington et al. 1998; Kavanagh, Ryan et 
al. 2005). However, in UTIs with voiding dysfunction, MRI is practical to evaluate the spinal 
cord and facilitate the diagnosis of abnormalities associated with neurogenic bladder,such 
as spinal dysraphism with tethered cord (Siomou, Giapros et al. 2009). 
VCUG remains a reference examination for VUR, which requires urethral catheterization 
and radiation exposure, many parents are reluctant to the performance and it is reserved on 
an individual with likehood of VUR from otherwise noninvasive access, such as DMSA scan 
or US examination (Herz, Merguerian et al. 2010, Preda , Jodal et al. 2011). However, VCUG 
permits the effective grading of VUR when the treatment strategy is demanding. Moreover, 
in case with suspicion of urethral valves or VURD syndrome, VCUG is indispensable to 
search the urethra, bladder and even voiding function.  
5. Nosocomial infection of urinary tract 
Urinary tract infection in nosocomial infection is less common in children compared with 
adults, it encountered the 3rd to 5th most common infection in hospitalized children with 
incidence varied from 6-42% according to the different denominators (Ford-Jones, 
Mindorff et al. 1989; Weber, Sheridan et al. 1997; Orrett, Brook et al. 1999). E. coli is still 
the predominant pathogen followed by Candida species, Enterococcus, Pseudomonas species 
and Klebsiella species (Langley, Hanakowski et al. 2001; Prelog, Schieficker et al. 2007). 
Several risk factors include immunocompromise, broadly antibiotics use, or obstruction of 
urinary tract can cause nosocomial infection. However, instrustment of the urinary tract is 
still the most frequent risk for nosocomial urinary tract infection. Therefore, the 
surveillance of the use of urinary catheter is the main focus for the infection control in 
hospitalized children. 
6. Complex UTIs 
Most UTIs are simple and easy to be controlled by antibiotic treatment. Sureshkumar et al. 
reported female gender,encopresis,daytime urinary incontinence and renal anatomical 
problems are risk factors associated with UTIs(Sureshkumar,Jones et al.2009).Nonetheless, 
infants with febrile UTIs or children younger than 2 years of age are highly associated with 
congenital urinary tract abnormalities.Therefore, many different factors and scenario should 
be considered when children with recurrent or atypical UTIs,then anatomic or neurological 
evaluations warrant ongoing. 
6.1 VUR and associated abnormalities 
VUR encountered the most abnormalities with 25%to 50% of children with UTIs (Smellie, 
Normand et al. 1981; Downs 1999) which are also related to the hydronephrosis, renal 
dysplasia, duplex collecting system, or voiding dysfunction. Reflux nephropathy is the main 
concerning as 13~25% of patients develop end-stage renal disease from the inflammatory 
and immunological processes(Askari and Belman 1982; Craig, Irwig et al. 2000; Ardissino, 
Avolio et al. 2004). The risk of developing “Reflux nephropathy” is multiprediposing and 
related to the host susceptibility and virulence of bacteria(Matsuoka, Nakashima et al. 2006; 
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 Septicaemia or patients who looks seriously ill (see NICE guideline [2]) 
 Poor urine flow 
 Abdominal or bladder mass 
 Raised creatinine concentration 
 Failure to respond to treatment with suitable antibiotics within 48 hours 
 Infection with non-Escherichia coli organisms 
Recurrent(any of the following) 
 Two or more episodes of urinary tract infection with acute pyelonephritis or upper 
urinary tract infection 
 One episode of urinary tract infection with acute pyelonephritis or upper urinary tract 
infection plus one or more episode of urinary tract infection with cystitis or lower 
urinary tract infection 
 Three or more episodes of urinary tract infection with cystitis or lower urinary tract 
infection 
_________________________________________________________________________________ 
Box 1. Main characteristics of patients with atypical or recurrent tract infection. Adapted 
from Rintaro et al.(2007).BJM 25:335:395-396; http://guidance.nice.org.uk/CG54 
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Magnetic resonance imaging (MRI, MRU) and enhanced CT are recently applied for 
depiction of APN and renal scarring. As the detection rate is questioning and availability is 
limited for requirement of sedation and injection of a potentially nephrotoxic medium while 
performaning the examination, which is reserved for children with doubtful diagnosis or 
suspicion of congenital abnormalities (Lonergan, Pennington et al. 1998; Kavanagh, Ryan et 
al. 2005). However, in UTIs with voiding dysfunction, MRI is practical to evaluate the spinal 
cord and facilitate the diagnosis of abnormalities associated with neurogenic bladder,such 
as spinal dysraphism with tethered cord (Siomou, Giapros et al. 2009). 
VCUG remains a reference examination for VUR, which requires urethral catheterization 
and radiation exposure, many parents are reluctant to the performance and it is reserved on 
an individual with likehood of VUR from otherwise noninvasive access, such as DMSA scan 
or US examination (Herz, Merguerian et al. 2010, Preda , Jodal et al. 2011). However, VCUG 
permits the effective grading of VUR when the treatment strategy is demanding. Moreover, 
in case with suspicion of urethral valves or VURD syndrome, VCUG is indispensable to 
search the urethra, bladder and even voiding function.  
5. Nosocomial infection of urinary tract 
Urinary tract infection in nosocomial infection is less common in children compared with 
adults, it encountered the 3rd to 5th most common infection in hospitalized children with 
incidence varied from 6-42% according to the different denominators (Ford-Jones, 
Mindorff et al. 1989; Weber, Sheridan et al. 1997; Orrett, Brook et al. 1999). E. coli is still 
the predominant pathogen followed by Candida species, Enterococcus, Pseudomonas species 
and Klebsiella species (Langley, Hanakowski et al. 2001; Prelog, Schieficker et al. 2007). 
Several risk factors include immunocompromise, broadly antibiotics use, or obstruction of 
urinary tract can cause nosocomial infection. However, instrustment of the urinary tract is 
still the most frequent risk for nosocomial urinary tract infection. Therefore, the 
surveillance of the use of urinary catheter is the main focus for the infection control in 
hospitalized children. 
6. Complex UTIs 
Most UTIs are simple and easy to be controlled by antibiotic treatment. Sureshkumar et al. 
reported female gender,encopresis,daytime urinary incontinence and renal anatomical 
problems are risk factors associated with UTIs(Sureshkumar,Jones et al.2009).Nonetheless, 
infants with febrile UTIs or children younger than 2 years of age are highly associated with 
congenital urinary tract abnormalities.Therefore, many different factors and scenario should 
be considered when children with recurrent or atypical UTIs,then anatomic or neurological 
evaluations warrant ongoing. 
6.1 VUR and associated abnormalities 
VUR encountered the most abnormalities with 25%to 50% of children with UTIs (Smellie, 
Normand et al. 1981; Downs 1999) which are also related to the hydronephrosis, renal 
dysplasia, duplex collecting system, or voiding dysfunction. Reflux nephropathy is the main 
concerning as 13~25% of patients develop end-stage renal disease from the inflammatory 
and immunological processes(Askari and Belman 1982; Craig, Irwig et al. 2000; Ardissino, 
Avolio et al. 2004). The risk of developing “Reflux nephropathy” is multiprediposing and 
related to the host susceptibility and virulence of bacteria(Matsuoka, Nakashima et al. 2006; 
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Cendron 2008; Coulthard 2008). Although the management of VUR remains controversial, 
the ultimate goal is to prevent the further renal injury from reflux and repeat UTIs. Not 
more than 30% of spontaneous resolution rate for mild to moderate grade of VUR and less 
for high grade (Green field and Wan 1996; Kundson, Austin et al. 2007). Series of literatures  
reported  no significant benefits in control of renal scarring or recurrent UTIs with antibiotic 
use (Garin, Olavarria et al. 2006). Comparing with antibiotics alone, there is no any 
additional benefit of surgery except for a reduction of UTIs from a meta-analyses 
data(Wheeler, Vimalachandra et al. 2003). Surgical correction may at least mitigate the UTIs 
and process of nephropathy. In addition, several new antireflux techniques have been 
introduced with less invasiveness or high success rate from 70~98% (Lakshmanan and Fung 
2000; Chen, Yuan et al. 2004; Routh, Inman et al. 2010). 
Otherwise, the abnormalities associated with VUR such as duplex ureters with an 
obstruction of one renal moiety, ureterocele, ectopic opening of ureteral orifice that causes 
incontinence, or reflux associated with urethral valves, then surgical correction should be 
considered to prevent repeat UTIs and further renal damage. 
6.2 Voiding disorders 
Children with voiding dysfunction may present with UTIs or VUR as the consequence of 
urinary stasis and high bladder pressure (Whelan and McKenna 2004; Chen, Mao et al. 2004; 
Feldman and Bauer 2006). Twenty percent of children with high grade of VUR had lower 
urinary tract dysfunction by high bladder capacity and increased post-void residual 
urine(Sillén, Bradström et al. 2010)). Disorder of voiding can be categorized into the 
sequence of neurogenic abnormalities including spinal dysraphism with tethered cord 
syndrome, or cerebral palsy(Houle, Vernet et al. 1998; Rendeli, Ausili et al. 2007). In a series 
reported that urologic symptoms included VUR and renal failure were shown in 33% and 
14% of children with spinal dysraphism after a long term follow-up (Silveri, Capitanucci et 
al. 1997). The non-neurogenic disorders affect the voiding function in children including 
posterior urethral valves, Hinmain’s syndrome, prune belly syndrome(Chaichanamong Kol, 
Ikeda et al. 2008; Youssif, Dawood et al. 2009; Routh, Huang et al. 2010), which are highly 
associated with febrile UTI and chronic renal failure (Őborn and Herthelius 2010). The 
management of UTIs in children associated with voiding dysfunction is complex, the 
underlying disorders should be appraised when the symptoms are initially presented. The 
neurologic abnormalities or the urinary tract disorder required accurate evaluations and 
correction at different times in order to prevent irreversible damage of neurological and 
renal function. 
6.3 Renal abscess 
Perirenal or renal abscess and pyonephrosis are not common in UTIs of children, most occur 
in the urinary tract with obstruction, treatments depend on the individual scenario, 
subcutaneous drainage of the infection nidus under ultrasound or CT guide to preserve the 
kidney and antibiotics treatment is the main principle. 
6.4 Correction of bowel habit  
Several studies showed the relationship between bladder voiding and defecation in 
constipated children, urinary incontinence and UTIs are caused from the urinary outflow 
obstruction by bowel distention. Twenty nine to thirty four percent of children with chronic 
constipation or encopresis were associated with daytime or nighttime urinary incontinence, 
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moreover, 11% of these children were present with UTIs. Interestingly, treatment of the 
underlying bowel disorders resulted in improving of urinary incontinence in 63-89% of 
patients and disappearance of recurrent UTIs in children who had no urinary tract 
abnormalities (Loening-Baucke 1997;Sureshkumar, Jones 2009). 
6.5 Antibiotics treatment 
The empirical treatment with ampicilline and gentamycin may be provided once the UTIs 
were diagnosed and may switch to an appropriate antibiotics when the definitive results of 
urine culture and sensitivities are available. For upper urinary tract infection, oral antibiotics 
are not inferior to the parenteral antibiotics, low resisted antibiotics such as cephalosporin is 
recommended with course for 7-10 days. Parenteral antibiotics can be used in cases of oral 
antibiotics cannot be used, ceftriaxone or cefataxime for 4-7 days, depends upon the 
responding of infection control. For lower urinary tract infection, amxocillin, cephalosporin, 
trimethoprim or nitrofurantoin may be used for 3-7 days. Prophylasis of antibiotics is not 
recommended for prevention of recurrent UTIs ,which may increase the risk of drug 
resistance (Hsu, Tan et al. 2010; Nicolau 2011). 
6.6 Probiotics 
Many experimental and clinical use of probiotics for inflammatory bowel disease with 
promising results has been extensively reported (Alfaleh, Anabrees et al. 2008; Hedin, 
Mullard et al. 2010). The application for urinary tract infection is increasing. Certain strains 
isolated from lactic acid bacteria demonstrated  major antimicrobial activity against most of 
uropathogens in the pediatric urinary tract infection ( Lim, Lee et al. 2009). Currently, the 
benefits for inhibition of UTIs varied according to the types of strains(Abad and Safda 2009), 
further research on different strains and clinical administration are needed to be ongoing. 
7. Conclusion 
The prompt diagnosis and treatment of UTIs are considered importantly to prevent 
subsequent renal damage, particular in very young children. In order to avoid unnecessary 
examinations or delay in treatment, the abnormalities associated with UTIs should be 
evaluated under suggested treatment algorithm or guidelines when the clinical 
manifestations are initially occurred. Although many treatment guidelines or 
recommendations have been established and need to be adjusted based on the most 
evidence or consensus, however, the treatment of UTIs in children can be simple or complex 
according to the scenario of individual. 
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